{"9e12a2b4eefa75f174900eec51a572eef3af123c": [["IntroductionDespite being legal in 31 states, medicinal cannabis (MC) remains relatively understudied.", [["cannabis", "CHEMICAL", 56, 64], ["MC", "CHEMICAL", 66, 68]]], ["It is known that just over 1% of adult Americans use MC [1] and that the vast majority of them are seeking relief from severe pain or muscle spasms [2, 3] .", [["muscle", "ANATOMY", 134, 140], ["MC", "CHEMICAL", 53, 55], ["pain", "DISEASE", 126, 130], ["muscle spasms", "DISEASE", 134, 147], ["muscle", "ORGAN", 134, 140], ["severe pain", "PROBLEM", 119, 130], ["muscle spasms", "PROBLEM", 134, 147], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["muscle", "ANATOMY", 134, 140], ["spasms", "OBSERVATION", 141, 147]]], ["There is evidence that MC is effective in relieving chronic pain [4, 5] , chemotherapy induced nausea [6, 7] , and spasticity in Multiple Sclerosis [4, 8, 9] .", [["MC", "CHEMICAL", 23, 25], ["pain", "DISEASE", 60, 64], ["nausea", "DISEASE", 95, 101], ["spasticity", "DISEASE", 115, 125], ["Multiple Sclerosis", "DISEASE", 129, 147], ["MC", "SIMPLE_CHEMICAL", 23, 25], ["relieving chronic pain", "PROBLEM", 42, 64], ["chemotherapy induced nausea", "PROBLEM", 74, 101], ["spasticity in Multiple Sclerosis", "PROBLEM", 115, 147], ["MC", "OBSERVATION_MODIFIER", 23, 25], ["effective", "OBSERVATION_MODIFIER", 29, 38], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["pain", "OBSERVATION", 60, 64], ["spasticity", "OBSERVATION_MODIFIER", 115, 125], ["Multiple", "OBSERVATION_MODIFIER", 129, 137], ["Sclerosis", "OBSERVATION", 138, 147]]], ["Several studies have suggested that use of MC is associated with reduced need for narcotic and non-narcotic pain medications [10] [11] [12] .IntroductionSpinal cord injury (SCI) is often attended by pain and spasticity [13] [14] [15] .", [["IntroductionSpinal cord", "ANATOMY", 141, 164], ["MC", "CHEMICAL", 43, 45], ["pain", "DISEASE", 108, 112], ["IntroductionSpinal cord injury", "DISEASE", 141, 171], ["SCI", "DISEASE", 173, 176], ["pain", "DISEASE", 199, 203], ["spasticity", "DISEASE", 208, 218], ["IntroductionSpinal cord", "MULTI-TISSUE_STRUCTURE", 141, 164], ["Several studies", "TEST", 0, 15], ["narcotic", "TREATMENT", 82, 90], ["non-narcotic pain medications", "TREATMENT", 95, 124], ["IntroductionSpinal cord injury", "PROBLEM", 141, 171], ["pain", "PROBLEM", 199, 203], ["spasticity", "PROBLEM", 208, 218], ["cord", "ANATOMY", 160, 164], ["injury", "OBSERVATION", 165, 171]]], ["Between 64 and 88% of people with SCI live with chronic pain [16] [17] [18] [19] , and as pain is associated with poor social functioning, community participation, and overall quality of life, it is frequently listed among the top health concerns of individuals living with SCI [20] [21] [22] .", [["SCI", "DISEASE", 34, 37], ["chronic pain", "DISEASE", 48, 60], ["pain", "DISEASE", 90, 94], ["SCI", "DISEASE", 274, 277], ["people", "ORGANISM", 22, 28], ["individuals", "ORGANISM", 250, 261], ["people", "SPECIES", 22, 28], ["chronic pain", "PROBLEM", 48, 60], ["pain", "PROBLEM", 90, 94]]], ["While MC might effectively address the pain and spasticity of SCI, its potential uses and benefits have been inadequately studied.", [["MC", "CHEMICAL", 6, 8], ["pain", "DISEASE", 39, 43], ["spasticity", "DISEASE", 48, 58], ["SCI", "DISEASE", 62, 65], ["the pain", "PROBLEM", 35, 43], ["spasticity of SCI", "PROBLEM", 48, 65]]], ["Three trials have investigated cannabis' effects on pain in SCI.", [["cannabis", "CHEMICAL", 31, 39], ["pain", "DISEASE", 52, 56], ["SCI", "DISEASE", 60, 63], ["pain in SCI", "PROBLEM", 52, 63], ["SCI", "ANATOMY", 60, 63]]], ["Rintala et al. [23] found that MC was ineffective for relief of sub-lesional neuropathic pain, Wilsey et al. [24] demonstrated efficacy for short-term (not chronic) pain relief, and while Wade et al. [25] showed that MC yields significant improvements in pain, spasticity, and spasms, their subjects had a mix of neurological disorders and there was no sub-group analysis of the 4 participants with SCI.IntroductionSeveral authors have interrogated utilization patterns of recreational and medicinal cannabis among people with SCI.", [["neurological", "ANATOMY", 313, 325], ["MC", "CHEMICAL", 31, 33], ["neuropathic pain", "DISEASE", 77, 93], ["pain", "DISEASE", 165, 169], ["MC", "CHEMICAL", 217, 219], ["pain", "DISEASE", 255, 259], ["spasticity", "DISEASE", 261, 271], ["spasms", "DISEASE", 277, 283], ["neurological disorders", "DISEASE", 313, 335], ["SCI", "DISEASE", 399, 402], ["cannabis", "CHEMICAL", 500, 508], ["SCI", "DISEASE", 527, 530], ["MC", "SIMPLE_CHEMICAL", 31, 33], ["MC", "SIMPLE_CHEMICAL", 217, 219], ["people", "ORGANISM", 515, 521], ["participants", "SPECIES", 381, 393], ["people", "SPECIES", 515, 521], ["sub-lesional neuropathic pain", "PROBLEM", 64, 93], ["short-term (not chronic) pain relief", "PROBLEM", 140, 176], ["pain", "PROBLEM", 255, 259], ["spasticity", "PROBLEM", 261, 271], ["spasms", "PROBLEM", 277, 283], ["neurological disorders", "PROBLEM", 313, 335], ["SCI", "PROBLEM", 399, 402], ["sub", "OBSERVATION_MODIFIER", 64, 67], ["lesional", "OBSERVATION_MODIFIER", 68, 76], ["neuropathic", "OBSERVATION_MODIFIER", 77, 88], ["significant", "OBSERVATION_MODIFIER", 227, 238], ["improvements", "OBSERVATION_MODIFIER", 239, 251], ["pain", "OBSERVATION", 255, 259]]], ["Drossel et al. surveyed 244 community dwelling individuals with SCI, finding that just under one-quarter used cannabis and that many sought relief from pain (70.4%) and spasticity (46.3%) [26] .", [["SCI", "DISEASE", 64, 67], ["cannabis", "CHEMICAL", 110, 118], ["pain", "DISEASE", 152, 156], ["spasticity", "DISEASE", 169, 179], ["SCI", "PROBLEM", 64, 67], ["pain", "PROBLEM", 152, 156], ["spasticity", "TEST", 169, 179]]], ["Andresen et al. reported that among 48 active cannabis users with SCI in Denmark, pain and spasticity were the second and third most cited reasons for use and nearly 60% described their symptom relief as \"good\" or \"very good\" [27] .", [["cannabis", "CHEMICAL", 46, 54], ["SCI", "DISEASE", 66, 69], ["pain", "DISEASE", 82, 86], ["spasticity", "DISEASE", 91, 101], ["pain", "PROBLEM", 82, 86], ["spasticity", "PROBLEM", 91, 101]]], ["In a survey of 147 individuals with SCI, Cardenas et al. [28] found that just under 20% were current MC users and that while it afforded substantial pain relief, most reported that it lasted just hours.", [["SCI", "DISEASE", 36, 39], ["pain", "DISEASE", 149, 153], ["SCI", "PROBLEM", 36, 39], ["substantial pain relief", "PROBLEM", 137, 160]]], ["Hawley et al. described common reasons for, methods of, and side effects of cannabis use among 27 people living with SCI [29] .IntroductionWhile each of these studies has substantively contributed to the literature, all four groups surveyed subjects from limited geographic areas, introducing potential biases based on attitudes toward, legal status of, and availability of cannabis.", [["cannabis", "CHEMICAL", 76, 84], ["SCI", "DISEASE", 117, 120], ["cannabis", "CHEMICAL", 374, 382], ["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104], ["these studies", "TEST", 153, 166]]], ["Further, none of the authors examined how attitudes toward cannabis use may affect individuals' utilization patterns nor how MC users compare its perceived efficacy to that of prescription medications.", [["cannabis", "CHEMICAL", 59, 67], ["prescription medications", "TREATMENT", 176, 200]]], ["These represent important persistent gaps in the literature.IntroductionWe developed an on-line survey addressing adults living with SCI's use and knowledge of MC and their perceptions of its risks and benefits (Appendix A).", [["SCI", "DISEASE", 133, 136], ["adults", "ORGANISM", 114, 120], ["important", "OBSERVATION_MODIFIER", 16, 25], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["gaps", "OBSERVATION", 37, 41]]], ["The first paper to have been published from this data set interrogated attitudes toward recreational and medicinal cannabis among individuals living with SCI [30] .", [["cannabis", "CHEMICAL", 115, 123], ["SCI", "DISEASE", 154, 157]]], ["Most respondents felt that cannabis is safe for use, has potential therapeutic benefits, and ought to be legalized, however substantial pluralities expressed concerns about health-related and social risks of use, and a majority thought cannabis use was attended by legal risks.", [["cannabis", "CHEMICAL", 27, 35], ["cannabis", "CHEMICAL", 236, 244]]], ["In this paper, we sought to answer three main questions: (a) which characteristics among individuals with SCI are associated with being a never user (NU), a past user (PU), or a current user (CU) of MC; (b) why and for which conditions do people with SCI choose to use MC, and; (c) how do current and past MC users with SCI describe its efficacy.", [["SCI", "DISEASE", 106, 109], ["SCI", "DISEASE", 251, 254], ["SCI", "DISEASE", 320, 323], ["people", "ORGANISM", 239, 245], ["people", "SPECIES", 239, 245]]], ["In attempting to understand what motivates or dissuades people with SCI from using MC and whether cannabis offers people with SCI substantial relief from bothersome symptoms, we hoped to provide a foundation for further efficacy research and advocacy work.Survey developmentThis study utilized a cross sectional multi-center survey methodology that has been described in our prior publication [30] .", [["SCI", "DISEASE", 68, 71], ["cannabis", "CHEMICAL", 98, 106], ["SCI", "DISEASE", 126, 129], ["people", "ORGANISM", 56, 62], ["people", "ORGANISM", 114, 120], ["people", "SPECIES", 56, 62], ["people", "SPECIES", 114, 120], ["SCI substantial relief", "TREATMENT", 126, 148], ["bothersome symptoms", "PROBLEM", 154, 173], ["This study", "TEST", 274, 284]]], ["The authors reviewed existing surveys and manuscripts [1, 3, 26, 27, 31] addressing perceived risks and benefits of MC use, utilization patterns among MC users, and primary reasons for use of MC.", [["MC", "CHEMICAL", 116, 118], ["MC", "CHEMICAL", 192, 194]]], ["We also used established pain and quality of life questionnaires taken from the International Spinal Cord Injury Pain and Quality of Life Basic Data Sets [32, 33] .", [["pain", "DISEASE", 25, 29], ["Pain", "DISEASE", 113, 117], ["established pain and quality of life questionnaires", "TREATMENT", 13, 64], ["the International Spinal Cord Injury Pain", "PROBLEM", 76, 117], ["Spinal Cord", "ANATOMY", 94, 105]]], ["We then received input from experts in the areas of neuropathic pain, MC use, and spinal cord injury medicine seeking to understand how MC users obtain and administer the agent, their risk of attendant substance abuse, and the evolution of attitudes toward MC use.", [["spinal cord", "ANATOMY", 82, 93], ["neuropathic pain", "DISEASE", 52, 68], ["MC", "CHEMICAL", 70, 72], ["cord injury", "DISEASE", 89, 100], ["substance abuse", "DISEASE", 202, 217], ["MC", "CHEMICAL", 257, 259], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 82, 93], ["neuropathic pain", "PROBLEM", 52, 68], ["spinal cord injury medicine", "TREATMENT", 82, 109], ["the agent", "TREATMENT", 167, 176], ["neuropathic", "OBSERVATION_MODIFIER", 52, 63], ["pain", "OBSERVATION", 64, 68], ["spinal cord", "ANATOMY", 82, 93], ["injury", "OBSERVATION", 94, 100]]], ["Based on this preliminary work, we developed a survey with four primary foci: (a) participants' attitudes toward and utilization of recreational and MC; (b) their experiences with other controlled and illicit substances; (c) their perceptions of the risks and benefits of MC use, and; (d) their knowledge of recreational and MC.", [["MC", "CHEMICAL", 272, 274], ["participants", "SPECIES", 82, 94], ["foci", "OBSERVATION", 72, 76]]], ["We solicited feedback on the survey's content and usability from Thomas Jefferson University's SCI Consumer Ethics Advisory Board-a group composed exclusively of individuals living with SCI -then submitted the instrument for IRB approval.", [["SCI", "DISEASE", 186, 189], ["individuals", "ORGANISM", 162, 173], ["IRB approval", "TREATMENT", 225, 237]]], ["For the purposes of the survey, \"medicinal cannabis\" was defined as cannabis used to treat a medical condition or symptom, regardless of how it was obtained or who had recommended it.Survey developmentOf note, this manuscript, while drawing upon the same dataset used in a previous publication, sought to answer an entirely different and unique set of questions.", [["cannabis", "CHEMICAL", 43, 51], ["cannabis", "CHEMICAL", 68, 76], ["a medical condition", "PROBLEM", 91, 110], ["symptom", "PROBLEM", 114, 121]]], ["The final subject pool included participants from 39 states in the United States.", [["participants", "SPECIES", 32, 44]]], ["Inclusion criteria included being an adult with SCI and being able to access and complete an internet-based survey.", [["SCI", "DISEASE", 48, 51]]], ["There were no stated exclusion criteria.", [["no", "UNCERTAINTY", 11, 13]]], ["Consent to participate was obtained by having potential subjects read an explanation of the study-including express permission to stop at any pointthen click a link to access it.", [["the study", "TEST", 88, 97]]], ["Given our final \"n\" of 353, our formal response rate was 15.25%.Data analysisSurvey responses were reviewed for completeness and each section's results were analyzed based on number of responses.", [["our formal response rate", "TEST", 28, 52], ["each section's results", "TEST", 129, 151]]], ["For purposes of analysis, participants' data were grouped into three user categories of current MC user (CU), past MC user (PU), or never used MC (NU).", [["participants", "SPECIES", 26, 38], ["analysis", "TEST", 16, 24]]], ["For certain analyses-particularly when attempting to delineate factors associated with never use of cannabis-responses from current and past users were combined and defined as \"present or past user of MC.\"", [["cannabis", "CHEMICAL", 100, 108], ["certain analyses", "TEST", 4, 20]]], ["For other analyses, the three groups were treated separately.", [["other analyses", "TEST", 4, 18]]], ["Individual survey items were evaluated for which test would be appropriate.", [["Individual survey items", "TEST", 0, 23]]], ["The three choices were Chi Square, distribution-free exact statistics, or t-tests for continuous data.ResultsA total of 353 people with SCI responded to the survey and 274 (77.60%) were completed in their entirety.", [["SCI", "DISEASE", 136, 139], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["continuous data", "TEST", 86, 101], ["SCI", "PROBLEM", 136, 139], ["the survey", "TEST", 153, 163]]], ["A sizable minority (37.20%) of participants reported \"working for pay,\" 43.60% were retired, 74.20% lived in either a suburban or an urban area, and with 11 (3.1%) exceptions, all respondents reported living in a private residence.ResultsThe majority (85.10%) identified trauma (sports, assault, motor vehicle crash, fall, or \"birth injury or other traumatic cause\") as the etiology of their spinal cord injury or dysfunction, 4.10% required ongoing or \"as needed\" ventilatory assistance, and just over half (52%) had cervical level injuries.", [["spinal cord", "ANATOMY", 392, 403], ["cervical", "ANATOMY", 518, 526], ["trauma", "DISEASE", 271, 277], ["motor vehicle crash", "DISEASE", 296, 315], ["birth injury", "DISEASE", 327, 339], ["traumatic", "DISEASE", 349, 358], ["cord injury", "DISEASE", 399, 410], ["cervical level injuries", "DISEASE", 518, 541], ["participants", "ORGANISM", 31, 43], ["spinal cord", "ORGAN", 392, 403], ["cervical", "ORGAN", 518, 526], ["participants", "SPECIES", 31, 43], ["trauma", "PROBLEM", 271, 277], ["fall", "PROBLEM", 317, 321], ["\"birth injury", "PROBLEM", 326, 339], ["other traumatic cause\"", "PROBLEM", 343, 365], ["their spinal cord injury", "PROBLEM", 386, 410], ["dysfunction", "PROBLEM", 414, 425], ["ventilatory assistance", "TREATMENT", 465, 487], ["cervical level injuries", "PROBLEM", 518, 541], ["sizable", "OBSERVATION_MODIFIER", 2, 9], ["minority", "OBSERVATION", 10, 18], ["spinal cord", "ANATOMY", 392, 403], ["injury", "OBSERVATION", 404, 410], ["cervical", "ANATOMY", 518, 526], ["injuries", "OBSERVATION", 533, 541]]], ["While 18% reported having American Spinal Injury Association (ASIA) Impairment Scale (AIS) A injuries, most respondents (53.60%) were unable to classify their injuries.ResultsOne hundred eight participants (30.40%) reported currently using MC, 42 (11.80%) reported past use, and 130 (36.60%) had never used MC.", [["Spinal Injury", "DISEASE", 35, 48], ["injuries", "DISEASE", 93, 101], ["injuries", "DISEASE", 159, 167], ["MC", "CHEMICAL", 240, 242], ["MC", "CHEMICAL", 307, 309], ["participants", "ORGANISM", 193, 205], ["participants", "SPECIES", 193, 205], ["American Spinal Injury", "PROBLEM", 26, 48], ["Impairment Scale (AIS)", "PROBLEM", 68, 90], ["A injuries", "PROBLEM", 91, 101], ["Spinal", "ANATOMY", 35, 41], ["Injury", "OBSERVATION", 42, 48]]], ["Seventy-five individuals (21.10%) did not answer the question and were excluded from related analyses.", [["individuals", "ORGANISM", 13, 24]]], ["Current and past users were no more Table 2 ) and more likely to believe that cannabis is a \"gateway drug\" (CU + PU = 7.40%; NU = 22.50%; \u03c7 2 = 12.80, p = 0.00), a \"very dangerous\" drug (CU + PU = 1.30%; NU = 7.00%; \u03c7 2 = 5.90, p = 0.026), and that it is safer to take prescription pain killers than to use MC (CU + PU = 4.00%; NU = 11.80%; \u03c7 2 = 5.91, p = 0.021).", [["cannabis", "CHEMICAL", 78, 86], ["pain", "DISEASE", 282, 286], ["MC", "CHEMICAL", 307, 309], ["PU", "TEST", 113, 115], ["NU", "TEST", 125, 127], ["p", "TEST", 151, 152], ["PU", "TEST", 192, 194], ["NU", "TEST", 204, 206], ["p", "TEST", 228, 229], ["pain killers", "TREATMENT", 282, 294], ["PU", "TEST", 316, 318], ["NU", "TEST", 328, 330]]], ["There was widespread agreement among participants that cannabis could have medicinal effects (CU + PU = 96.00%; NU = 95.30%; \u03c7 2 = 0.07, p = 1.00) and that its use carries either no or only slight health risks (CU + PU = 91.20%; NU = 83.60%; \u03c7 2 = 3.61, p = 0.067).", [["cannabis", "CHEMICAL", 55, 63], ["participants", "SPECIES", 37, 49], ["medicinal effects", "PROBLEM", 75, 92], ["PU", "TEST", 99, 101], ["NU", "TEST", 112, 114], ["PU", "TEST", 216, 218], ["NU", "TEST", 229, 231], ["p", "TEST", 254, 255]]], ["There were no significant differences in perceptions of social or legal risks between the user groups.ResultsTo assess subjects' reports of pain, health, and quality of life, we utilized a 10-point Likert scale, grouping answers 0-3 as \"low interference,\" 4-6 as \"some interference,\" and 7-10 as \"extreme interference.\"", [["pain", "DISEASE", 140, 144], ["pain", "PROBLEM", 140, 144], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["In comparing responses of current and past MC users (combined n = 124) with those of never users (n = 117), there were no significant differences in pain's interference with day-to-day activities (\u03c7 2 = 6.76, p = 0.034), mood (\u03c7 2 = 2.14, p = 0.344), or ability to sleep (\u03c7 2 = 0.70, p = 0.704), in assessments of life satisfaction (\u03c7 2 = 2.576, p = 0.276) or in satisfaction with physical (\u03c7 2 = 0.32, p = 0.854) or emotional health (\u03c7 2 = 0.26, p = 0.880) ( Table 3) .ResultsAmong current (n = 92) and past users (n = 27), mean age of first MC use was 43.12 years.", [["MC", "CHEMICAL", 43, 45], ["pain", "DISEASE", 149, 153], ["significant differences in pain", "PROBLEM", 122, 153], ["mood", "TEST", 221, 225], ["p", "TEST", 239, 240], ["p", "TEST", 346, 347], ["p", "TEST", 403, 404], ["no", "UNCERTAINTY", 119, 121], ["significant", "OBSERVATION_MODIFIER", 122, 133]]], ["A large majority (65.50%) of current and past users reported using or having used MC at least 3-5 days per week (29.40% reported \"several times a day\"), and while 64.3% have or had used MC for 5 years or fewer (30.20% <1 year), 10.9% have or had used it for greater than 20 years.", [["MC", "CHEMICAL", 82, 84], ["MC", "CHEMICAL", 186, 188], ["large", "OBSERVATION_MODIFIER", 2, 7], ["majority", "OBSERVATION_MODIFIER", 8, 16]]], ["There were no demographic or injury-specific differences between current and past MC users and never MC users.ResultsMost current (n = 99) and past users (n = 30) inhaled MC (CU = 63.60%; PU = 53.30%) or used sprays or tinctures (CU = 11.10%; PU = 23.30%).", [["MC", "CHEMICAL", 82, 84], ["MC", "CHEMICAL", 101, 103], ["MC", "CHEMICAL", 171, 173], ["injury", "PROBLEM", 29, 35], ["PU", "TEST", 188, 190], ["tinctures", "TREATMENT", 219, 228], ["CU", "TEST", 230, 232], ["PU", "TEST", 243, 245], ["no", "UNCERTAINTY", 11, 13], ["injury", "OBSERVATION", 29, 35]]], ["Sixty-four percent use or used MC because it \"helps with [their] condition,\" 48% in hopes that MC would help reduce their use of other prescription medications, 34% because prescription medications had failed, 22.70% because it had been recommended by a physician, and 22.70% because it had been recommended by a friend.", [["MC", "CHEMICAL", 31, 33], ["MC", "CHEMICAL", 95, 97], ["other prescription medications", "TREATMENT", 129, 159], ["prescription medications", "TREATMENT", 173, 197]]], ["Current and past users reported using MC to address pain (65.30%), spasms (63.30%), sleeplessness (32.70%), and anxiety (24.00%).", [["MC", "CHEMICAL", 38, 40], ["pain", "DISEASE", 52, 56], ["spasms", "DISEASE", 67, 73], ["sleeplessness", "DISEASE", 84, 97], ["anxiety", "DISEASE", 112, 119], ["pain", "PROBLEM", 52, 56], ["spasms", "PROBLEM", 67, 73], ["sleeplessness", "PROBLEM", 84, 97], ["anxiety", "PROBLEM", 112, 119]]], ["When asked whether their dose of MC had changed over the duration of treatment, 37.20% responded that it had not, 30 .20% answered that their use had changed depending on their condition, and 10.90% reported a need for an initial dose escalation followed by dose stabilization.", [["MC", "CHEMICAL", 33, 35], ["treatment", "TREATMENT", 69, 78], ["an initial dose escalation", "TREATMENT", 219, 245], ["dose stabilization", "TREATMENT", 258, 276]]], ["When asked if MC affects or had affected their overall condition or symptoms (99 CU and 30 PU), 63.60% reported that it offers or had offered \"great relief\" and 30.20% that it offers or had offered \"a little relief.\"", [["symptoms", "PROBLEM", 68, 76]]], ["Only 6.30% of subjects reported that MC use had either made no difference in their condition or symptoms or made them worse (\u03c7 2 = 13.70, p = 0.001).", [["MC", "CHEMICAL", 37, 39], ["symptoms", "PROBLEM", 96, 104]]], ["Over 60% of respondents reported that using MC had allowed them to reduce or discontinue use of other medications (61.20% total; CU = 66.70%; PU = 43.30%; \u03c7 2 = 5.28, p = 0.032) and only 35.20% answered that they had symptoms or conditions that had not been helped at all by MC (CU = 31.60%; PU = 46.70%; \u03c7 2 = 2.28, p = 0.19).", [["MC", "CHEMICAL", 44, 46], ["other medications", "TREATMENT", 96, 113], ["CU", "TEST", 129, 131], ["PU", "TEST", 142, 144], ["\u03c7", "TEST", 155, 156], ["p", "TEST", 167, 168], ["symptoms", "PROBLEM", 217, 225], ["CU", "TEST", 279, 281], ["PU", "TEST", 292, 294], ["p", "TEST", 317, 318]]], ["When asked to describe effects of MC versus those of prescription medications, 37.20% reported that prescription medications had produced \"much worse\" effects than MC (CU = 42.40%; PU = 20.0%; \u03c7 2 = 4.96, p = 0.031) and an additional 18.60% reported that other medications' effects had been \"somewhat worse\" than MCs' (CU = 20.20%; PU = 13.3%; \u03c7 2 = 0.72, p = 0.593).", [["MCs", "ANATOMY", 313, 316], ["MC", "CHEMICAL", 34, 36], ["MC", "CHEMICAL", 164, 166], ["prescription medications", "TREATMENT", 53, 77], ["prescription medications", "TREATMENT", 100, 124], ["CU", "TEST", 168, 170], ["PU", "TEST", 181, 183], ["p", "TEST", 205, 206], ["other medications", "TREATMENT", 255, 272], ["CU", "TEST", 319, 321], ["PU", "TEST", 332, 334], ["p", "TEST", 356, 357]]], ["Just over 34% reported having suffered no undesirable effects from MC (CU = 32.30%; PU = 40.00%).ResultsWhen subjects were asked to identify MCs' and prescription medications' positive or desirable effects, the top five for each were identical (Table 4 ).", [["MCs", "ANATOMY", 141, 144], ["MC", "DISEASE", 67, 69], ["MCs", "CELL", 141, 144], ["CU", "TEST", 71, 73], ["PU", "TEST", 84, 86], ["prescription medications", "TREATMENT", 150, 174]]], ["However, a higher percentage of respondents noted beneficial effects of MC than noted beneficial effects of prescription medications.", [["MC", "CHEMICAL", 72, 74], ["prescription medications", "TREATMENT", 108, 132]]], ["Subjects were also asked to list negative side effects of MC and prescription medications.", [["MC", "CHEMICAL", 58, 60], ["Subjects", "ORGANISM", 0, 8], ["MC", "SIMPLE_CHEMICAL", 58, 60], ["MC", "TREATMENT", 58, 60], ["prescription medications", "TREATMENT", 65, 89]]], ["Their rank orders were different, and higher percentages of respondents listed negative effects of prescription medications than listed negative effects of MC (Table 5 ).", [["MC", "CHEMICAL", 156, 158], ["prescription medications", "TREATMENT", 99, 123]]], ["Subjects were asked to select from a list of 33 possible effects that could be ascribed to MC and/or prescription medications and that could be considered either positive, negative, or neutral.", [["MC", "CHEMICAL", 91, 93], ["Subjects", "ORGANISM", 0, 8], ["prescription medications", "TREATMENT", 101, 125]]], ["On average, MC was assigned 7.6 positive effects while prescription medications were assigned 5.35 (t = 3.9, df = 234; p = .000).", [["MC", "TEST", 12, 14], ["prescription medications", "TREATMENT", 55, 79], ["t", "TEST", 100, 101], ["df", "TEST", 109, 111], ["p", "TEST", 119, 120]]], ["Medicinal cannabis was assigned an average of 6.0 negative effects while prescription medications were assigned 9.9 (t = \u22123.76, df = 203; p = .001).ResultsWhen asked to compare the relative efficacy of MC with that of other medications in providing symptom relief (98 CU and 30 PU), 63.3% reported that cannabis works better than prescription medications, 17.20% reported the opposite, and 10.20% answered that only cannabis offered them relief (\u03c7 2 = 7.93, p = 0.047).", [["cannabis", "CHEMICAL", 10, 18], ["MC", "CHEMICAL", 202, 204], ["cannabis", "CHEMICAL", 303, 311], ["cannabis", "CHEMICAL", 416, 424], ["prescription medications", "TREATMENT", 73, 97], ["t", "TEST", 117, 118], ["df", "TEST", 128, 130], ["p", "TEST", 138, 139], ["other medications", "TREATMENT", 218, 235], ["symptom relief", "PROBLEM", 249, 263], ["prescription medications", "TREATMENT", 330, 354]]], ["When asked if they suffer or had suffered from symptoms or conditions that had not been helped by MC, 35.20% replied \"yes\" (CU = 31.60%; PU = 46.70%; NS) and 64.80% replied \"no\" (CU = 68.40%; PU = 53.30%; NS).", [["symptoms", "PROBLEM", 47, 55], ["CU", "TEST", 124, 126], ["PU", "TEST", 137, 139], ["NS", "TREATMENT", 150, 152], ["PU", "TEST", 192, 194], ["NS", "TREATMENT", 205, 207]]], ["A minority of respondents (16.70%) said it had never controlled their symptoms, but none answered that it had lost effect, that side effects were limiting, that it was unaffordable, that it was difficult to ensure a supply, or that its use was illegal.", [["their symptoms", "PROBLEM", 64, 78]]], ["In free text responses, past MC users cited fear of physician repercussions, drops in blood pressure, variability in effect, social stigma, loss of employment, and risk of losing federally funded housing as reasons for having stopped.DiscussionThis study is the first to examine how personal beliefs influence MC use and to compare its perceived efficacy and tolerability to that of prescription medications.", [["blood", "ANATOMY", 86, 91], ["loss of employment", "DISEASE", 140, 158], ["MC", "CHEMICAL", 310, 312], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["blood pressure", "TEST", 86, 100], ["This study", "TEST", 244, 254], ["prescription medications", "TREATMENT", 383, 407]]], ["A number of our findings are notable.DiscussionFirst, there seem to be demonstrable differences between current and past MC users and those who have never used MC.", [["MC", "CHEMICAL", 121, 123], ["MC", "CHEMICAL", 160, 162], ["notable", "OBSERVATION_MODIFIER", 29, 36]]], ["In contrast to Drossel et al., in which subjects who used MC were more likely to report pain interference with life than were non-MC users [26] , our groups did not differ in pain interference or in self-assessments of emotional or physical health.", [["pain", "DISEASE", 88, 92], ["pain", "DISEASE", 175, 179], ["pain interference", "PROBLEM", 88, 105], ["pain interference", "PROBLEM", 175, 192]]], ["However, current and past users were less concerned than never users with a number of perceived risks of cannabis use, notably that it is a \"gateway\" or a \"very dangerous\" drug.", [["cannabis", "CHEMICAL", 105, 113]]], ["Clinicians in states with legal MC must understand that some patients who may find it beneficial may hold both solid (legal risks) and less well established (safety relative to that of other medications) fears about its use, and that those concerns may make them less likely to consider treatment with MC.DiscussionSecond, our data seem to indicate that MC has variable efficacy.", [["MC", "CHEMICAL", 302, 304], ["MC", "CHEMICAL", 354, 356], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["medications", "TREATMENT", 191, 202]]], ["Past users were less likely than CUs to report having been able to reduce use of other medications while they were taking MC and to endorse that prescription medications' side effects were worse than MCs'.", [["MCs", "ANATOMY", 200, 203], ["MC", "CHEMICAL", 122, 124], ["MCs", "CELL", 200, 203], ["MCs", "CELL_TYPE", 200, 203], ["other medications", "TREATMENT", 81, 98], ["prescription medications", "TREATMENT", 145, 169]]], ["Further, fully 16% of them stopped using MC because they found it ineffective.", [["MC", "CHEMICAL", 41, 43]]], ["There was no requirement in this survey that MC be purchased from a medical distributor, and there is variable efficacy of cannabis products taken from the same plant.", [["cannabis", "CHEMICAL", 123, 131], ["cannabis products", "TREATMENT", 123, 140], ["no", "UNCERTAINTY", 10, 12], ["requirement", "OBSERVATION_MODIFIER", 13, 24]]], ["Therefore, it is expected that there would be considerable variation in the quality, potency, and chemical components of the cannabis our subjects utilized.", [["cannabis", "CHEMICAL", 125, 133], ["considerable", "OBSERVATION_MODIFIER", 46, 58], ["variation", "OBSERVATION_MODIFIER", 59, 68]]], ["Even so, these data suggest that there may simply be people who are more or less likely to respond to and benefit from MC therapy, and that ongoing monitoring and evaluation by clinicians is essential to effective prescribing.", [["MC", "CHEMICAL", 119, 121], ["people", "ORGANISM", 53, 59], ["MC", "SIMPLE_CHEMICAL", 119, 121], ["people", "SPECIES", 53, 59], ["MC therapy", "TREATMENT", 119, 129], ["ongoing monitoring", "TEST", 140, 158], ["evaluation", "TEST", 163, 173]]], ["Future work may also focus on which individuals with SCI are more or less likely to respond to MC therapy.DiscussionThird [26, 27, 29] , only Cardenas et al. [28] and Andresen interrogated its perceived efficacy in relieving pain.", [["SCI", "DISEASE", 53, 56], ["MC", "CHEMICAL", 95, 97], ["pain", "DISEASE", 225, 229], ["individuals", "ORGANISM", 36, 47], ["SCI", "PROBLEM", 53, 56], ["MC therapy", "TREATMENT", 95, 105], ["relieving pain", "PROBLEM", 215, 229]]], ["None of these studies asked subjects to directly compare MCs' perceived efficacy and tolerability with that of prescription medications.", [["MCs", "CELL", 57, 60], ["these studies", "TEST", 8, 21], ["prescription medications", "TREATMENT", 111, 135]]], ["Among our subjects, over 90% of CU and PU reported \"a little\" or \"great\" relief from symptoms with MC and 61.20% claimed that MC had allowed them to reduce or discontinue use of other medications.", [["MC", "CHEMICAL", 99, 101], ["MC", "CHEMICAL", 126, 128], ["symptoms", "PROBLEM", 85, 93], ["other medications", "TREATMENT", 178, 195]]], ["Further, large majorities of these subjects (73.4%) reported that cannabis is more effective (or exclusively effective) and better tolerated than other medications they had been offered.", [["cannabis", "CHEMICAL", 66, 74], ["other medications", "TREATMENT", 146, 163], ["large", "OBSERVATION_MODIFIER", 9, 14], ["more effective", "OBSERVATION_MODIFIER", 78, 92]]], ["While gabapentinoids [34] [35] [36] , Botulinum Toxin A [37] , and antidepressants [38, 39] have been shown to have modest effects on chronic pain in individuals with SCI, the medical community's ability to adequately relieve SCI-related pain remains limited.", [["gabapentinoids [34] [35] [36", "CHEMICAL", 6, 34], ["Botulinum Toxin A", "CHEMICAL", 38, 55], ["antidepressants", "CHEMICAL", 67, 82], ["chronic pain", "DISEASE", 134, 146], ["SCI", "DISEASE", 167, 170], ["SCI", "DISEASE", 226, 229], ["pain", "DISEASE", 238, 242], ["gabapentinoids", "CHEMICAL", 6, 20], ["gabapentinoids [34] [35] [36]", "SIMPLE_CHEMICAL", 6, 35], ["Botulinum Toxin A", "SIMPLE_CHEMICAL", 38, 55], ["Botulinum Toxin A", "TREATMENT", 38, 55], ["antidepressants", "TEST", 67, 82], ["chronic pain", "PROBLEM", 134, 146], ["SCI", "PROBLEM", 167, 170], ["SCI", "PROBLEM", 226, 229], ["related pain", "PROBLEM", 230, 242], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["pain", "OBSERVATION", 142, 146]]], ["Our findings support the notion that MC may have an important role-either as adjuvant therapy or as monotherapy-in treating a number of common symptoms experienced by individuals living with SCI.", [["MC", "CHEMICAL", 37, 39], ["SCI", "DISEASE", 191, 194], ["MC", "SIMPLE_CHEMICAL", 37, 39], ["adjuvant therapy", "TREATMENT", 77, 93], ["monotherapy", "TREATMENT", 100, 111], ["common symptoms", "PROBLEM", 136, 151]]], ["There is certainly a need for expedited clinical trials evaluating efficacy of MC in chronic SCI, and no justification for cannabis' continued classification as a Schedule 1 drug, a designation indicating that it has no accepted medical use.", [["MC", "CHEMICAL", 79, 81], ["SCI", "DISEASE", 93, 96], ["cannabis", "CHEMICAL", 123, 131], ["expedited clinical trials", "TREATMENT", 30, 55], ["MC in chronic SCI", "PROBLEM", 79, 96], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["SCI", "OBSERVATION", 93, 96]]], ["Finally, we were taken by former users' stated reasons for having discontinued using MC.", [["MC", "CHEMICAL", 85, 87]]], ["While some of them seem to have found MC less effective than did current users, very few of them reported having stopped using it due to lack of effect.", [["MC", "PROBLEM", 38, 40]]], ["Rather, they relayed stories of fear of continued use, of variable and unpredictable effects (potentially addressed through regulation), of stigma, and of loss of employment and government-subsidized housing.", [["variable and unpredictable effects", "PROBLEM", 58, 92], ["stigma", "PROBLEM", 140, 146]]], ["It seems, then, that some individuals with SCI-related symptoms may benefit from MC treatment but are dissuaded from using it by their fears of facing potentially drastic repercussions.Study limitationsThis study has several important limitations.", [["SCI", "DISEASE", 43, 46], ["MC", "CHEMICAL", 81, 83], ["SCI", "PROBLEM", 43, 46], ["symptoms", "PROBLEM", 55, 63], ["MC treatment", "TREATMENT", 81, 93], ["Study limitations", "TEST", 185, 202], ["This study", "TEST", 202, 212]]], ["First, we did not ask participants which medications they had taken in the past and/or currently take.", [["participants", "SPECIES", 22, 34], ["medications", "TREATMENT", 41, 52]]], ["As a result, it is difficult to assess the adequacy of attempts to control subjects' symptoms (particularly pain and spasticity) before they initiated MC use, and to determine whether they are using MC as adjuvant or monotherapy.", [["pain", "DISEASE", 108, 112], ["spasticity", "DISEASE", 117, 127], ["MC", "CHEMICAL", 199, 201], ["subjects' symptoms", "PROBLEM", 75, 93], ["pain", "PROBLEM", 108, 112], ["spasticity", "PROBLEM", 117, 127], ["adjuvant", "TREATMENT", 205, 213], ["monotherapy", "TREATMENT", 217, 228]]], ["Second, we did not assess how much MC participants used.", [["participants", "SPECIES", 38, 50]]], ["Hence, it is impossible to use this work to estimate appropriate or effective dosing of MC.", [["MC", "CHEMICAL", 88, 90]]], ["While we did not inquire about annual family income or ethnicity, we know that over 60% of our participants had college or advanced degrees.", [["participants", "ORGANISM", 95, 107], ["participants", "SPECIES", 95, 107]]], ["Depending on duration of injury, between 10.90 and 43.70% of individuals with SCI have completed a college degree [40] .", [["SCI", "DISEASE", 78, 81], ["injury", "PROBLEM", 25, 31], ["SCI", "PROBLEM", 78, 81]]], ["It is certainly possible that people who have completed more school have different attitudes toward cannabis use, though we were unable to find literature to substantiate this.", [["cannabis", "CHEMICAL", 100, 108], ["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["certainly possible", "UNCERTAINTY", 6, 24]]], ["Further, the very topic of this survey may have attracted participants with a history of or a strong interest in using MC.", [["participants", "SPECIES", 58, 70]]], ["While 30.40% of our subjects were CU of MC, just under 10% of adult Americans report having using cannabis in the past year [41] .", [["MC", "DISEASE", 40, 42], ["cannabis", "CHEMICAL", 98, 106]]], ["Finally, our low response rate is a clear limitation, as only 15.25% of individuals to whom the survey was emailed responded, and under one-third of them were active MC users.", [["individuals", "ORGANISM", 72, 83], ["active", "OBSERVATION_MODIFIER", 159, 165]]], ["This being said, this study provides evidence that some individuals with SCI and associated symptoms find relief with MC, that they find MCs' side effects largely tolerable and less onerous than those of prescription medications, and that some people with SCI may avoid using or discontinue use of MC not because it is ineffective, but, rather, due to perceived and real repercussions of continued use.Data archivingThe datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.Data archivingAuthor contributions MS was responsible for researching and developing the survey, submitting the project to the IRB, coordinating survey distribution, and drafting the manuscript.", [["MCs", "ANATOMY", 137, 140], ["SCI", "DISEASE", 73, 76], ["SCI", "DISEASE", 256, 259], ["MCs", "CELL", 137, 140], ["people", "ORGANISM", 244, 250], ["people", "SPECIES", 244, 250], ["this study", "TEST", 17, 27], ["SCI", "PROBLEM", 73, 76], ["associated symptoms", "PROBLEM", 81, 100], ["prescription medications", "TREATMENT", 204, 228], ["the current study", "TEST", 459, 476]]], ["MC assisted with survey development, was primarily responsible for data analysis, and helped draft the manuscript.", [["MC", "CHEMICAL", 0, 2], ["data analysis", "TEST", 67, 80]]], ["TR was responsible for researching and developing the survey, helping analyze the data, and drafting the manuscript.", [["the data", "TEST", 78, 86]]], ["KG was responsible for researching and developing the survey, helping analyze the data, and drafting the manuscript.", [["the data", "TEST", 78, 86]]], ["AB was responsible for researching and developing the survey, helping analyze the data, and drafting the manuscript.", [["the data", "TEST", 78, 86]]], ["DG was responsible for researching and developing the survey, helping analyze the data, and drafting the manuscript.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Statement of ethics This study was reviewed by the Thomas JeffersonUniversity Institutional Review Board and deemed exempt.", [["DG", "SIMPLE_CHEMICAL", 0, 2], ["ethical standards", "TREATMENT", 132, 149], ["This study", "TEST", 249, 259]]], ["We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were following during the course of this research.Statement of ethics This study was reviewed by the Thomas JeffersonPublisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["human", "ORGANISM", 104, 109], ["volunteers", "ORGANISM", 110, 120], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["governmental regulations", "TREATMENT", 49, 73], ["This study", "TEST", 191, 201]]]], "fabd054d3637c4c87ecc506058d771ae30274560": [["IntroductionAfter outbreak of severe acute respiratory syndrome (SARS) December 2019.", [["acute respiratory syndrome", "DISEASE", 37, 63], ["SARS", "DISEASE", 65, 69], ["severe acute respiratory syndrome", "PROBLEM", 30, 63], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63]]], ["It is found that the causative agent of this pandemic was caused by a novel coronavirus SARS-CoV-2 (CSG of the International, 2020).", [["SARS", "DISEASE", 88, 92], ["coronavirus SARS-CoV-2", "ORGANISM", 76, 98], ["coronavirus", "SPECIES", 76, 87], ["this pandemic", "PROBLEM", 40, 53], ["a novel coronavirus SARS", "PROBLEM", 68, 92]]], ["This novel infectious disease is encountered by over 210 countries and territories around the world (worldometers.info, 2020), leading to a newly emerging global crisis.IntroductionUp till now, SARS-CoV-2 has spread internationally with over 9.1 million patients diagnosed and over 471,000 deaths worldwide (worldometers.info, 2020) by June 22, 2020.", [["infectious disease", "DISEASE", 11, 29], ["deaths", "DISEASE", 290, 296], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 254, 262], ["SARS-CoV", "SPECIES", 194, 202], ["This novel infectious disease", "PROBLEM", 0, 29], ["a newly emerging global crisis", "PROBLEM", 138, 168], ["IntroductionUp", "TREATMENT", 169, 183], ["SARS", "PROBLEM", 194, 198], ["infectious", "OBSERVATION", 11, 21], ["global", "OBSERVATION_MODIFIER", 155, 161], ["crisis", "OBSERVATION", 162, 168]]], ["Whereas the USA, UK, Spain and Italy have become the most unfortunate countries exposed to this overwhelming disease in the region of the Americas and the European region respectively.", [["this overwhelming disease", "PROBLEM", 91, 116], ["overwhelming", "OBSERVATION_MODIFIER", 96, 108], ["disease", "OBSERVATION", 109, 116], ["region", "ANATOMY_MODIFIER", 124, 130], ["Americas", "ANATOMY_MODIFIER", 138, 146]]], ["The US has taken over 2.37 million confirmed cases with over 120,000 deaths (CDC, 2020), while Italy had reported the percentage of patients in intensive care who are actively infected was consistently between 9% and 11% from March 1 up until Match 11 (Remuzzi, A. , & Remuzzi, G., 2020).IntroductionAt a glance, the spread of COVID-19 and its overwhelming virulence have turned into an unstoppable crisis which has already reached the required epidemiological standard for it to be declared a pandemic, with infected cases exceeding 100,000 in 100 countries in just three months and only 12 days to reach the next 100,000 (Callaway.", [["deaths", "DISEASE", 69, 75], ["COVID-19", "CHEMICAL", 327, 335], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["The US", "TEST", 0, 6], ["actively infected", "PROBLEM", 167, 184], ["COVID", "TEST", 327, 332], ["an unstoppable crisis", "PROBLEM", 384, 405], ["infected", "OBSERVATION", 176, 184]]], ["E, 2020) .IntroductionIt is of paramount importance to implement a series of medical interventions to overcome the challenges brought by COVID-19 and govern this grievous plague efficiently.", [["medical interventions", "TREATMENT", 77, 98]]], ["While awaiting the development of vaccination, prompt and precise medical treatment plays a crucial role in this demanding situation.", [["vaccination", "TREATMENT", 34, 45], ["precise medical treatment", "TREATMENT", 58, 83]]], ["However, there are no specific therapies approved officially by the U.S. Food and Drug Administration (FDA) to treat COVID-19 (Tim, Jennifer, & Tony, 2020) .", [["COVID", "DISEASE", 117, 122], ["COVID-19", "CHEMICAL", 117, 125], ["COVID", "TEST", 117, 122], ["no", "UNCERTAINTY", 19, 21]]], ["Consequently, identifying effective therapies to combat the disease is a pressing need.", [["effective therapies", "TREATMENT", 26, 45], ["the disease", "PROBLEM", 56, 67]]], ["Either antiviral treatment or cellular therapy may lead to the complete or partial success of a cure for the patients, depending on its level of effectiveness.", [["cellular", "ANATOMY", 30, 38], ["cellular", "CELL", 30, 38], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["antiviral treatment", "TREATMENT", 7, 26], ["cellular therapy", "TREATMENT", 30, 46]]], ["Thus, the effectiveness of treatment is critically responsible for the overall improvement of this pandemic disease and deserves to be studied extensively to enhance the clinical intervention.IntroductionBased on the mortality rate of COVID-19 is about 6% globally, learning more about the effectiveness and differences between drug therapies help to contribute to a more successful treatment.", [["treatment", "TREATMENT", 27, 36], ["this pandemic disease", "PROBLEM", 94, 115], ["the clinical intervention", "TREATMENT", 166, 191], ["the mortality rate", "TEST", 213, 231], ["COVID", "TEST", 235, 240], ["drug therapies", "TREATMENT", 328, 342], ["a more successful treatment", "TREATMENT", 365, 392]]], ["This literature review will summarise and discuss different types of therapies, including compassionate uses of antiviral drugs (which are now undergoing their clinical trials owing to a lack of clinical experience) and on in-vitro activity against this novel virus.", [["therapies", "TREATMENT", 69, 78], ["antiviral drugs", "TREATMENT", 112, 127], ["this novel virus", "PROBLEM", 249, 265]]], ["Besides, we will also explore cellular and immunotherapy to highlight their therapeutic potentials.", [["cellular", "ANATOMY", 30, 38], ["cellular", "CELL", 30, 38], ["cellular and immunotherapy", "TREATMENT", 30, 56]]], ["This review would give an insight of feasible development of potent medications and provide a framework for possible intervention strategies in a foreseeable future.SARS-CoV-2Fig.", [["SARS", "DISEASE", 165, 169], ["2Fig", "DNA", 174, 178], ["potent medications", "TREATMENT", 61, 79], ["intervention strategies", "TREATMENT", 117, 140]]], ["Basic structure of coronaviruses.", [["coronaviruses", "ORGANISM", 19, 32], ["coronaviruses", "PROBLEM", 19, 32], ["coronaviruses", "OBSERVATION", 19, 32]]], ["(Seah, Su, & Lingam, 2020) Structure of SARS-CoV-2 SARS-CoV-2 belongs to Betacoronavirus, the same genus as contagious Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in coronavirus family.", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 126, 164], ["SARS-CoV)", "DISEASE", 166, 175], ["Respiratory Syndrome coronavirus", "DISEASE", 196, 228], ["SARS-CoV-2 SARS-CoV-2", "ORGANISM", 40, 61], ["Betacoronavirus", "ORGANISM", 73, 88], ["SARS-CoV", "ORGANISM", 166, 174], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 184, 228], ["MERS-CoV", "ORGANISM", 230, 238], ["coronavirus", "ORGANISM", 243, 254], ["coronavirus", "SPECIES", 243, 254], ["SARS-CoV", "SPECIES", 40, 48], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 119, 174], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 184, 228], ["MERS-CoV", "SPECIES", 230, 238], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["Betacoronavirus", "PROBLEM", 73, 88], ["contagious Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)", "PROBLEM", 108, 175], ["the Middle East Respiratory Syndrome coronavirus", "PROBLEM", 180, 228], ["contagious", "OBSERVATION_MODIFIER", 108, 118], ["Severe", "OBSERVATION_MODIFIER", 119, 125], ["Acute", "OBSERVATION_MODIFIER", 126, 131], ["Respiratory Syndrome", "OBSERVATION", 132, 152], ["Middle", "ANATOMY_MODIFIER", 184, 190], ["Respiratory Syndrome", "OBSERVATION", 196, 216]]], ["Their genome is composed of a positive-sense single-stranded RNA (+ssRNA).", [["positive-sense single-stranded RNA", "DNA", 30, 64], ["a positive-sense single-stranded RNA", "PROBLEM", 28, 64]]], ["SARS-CoV-2 comprises of four structural proteins which aid in assembling and infection --the transmembrane spike glycoprotein (S), membrane protein (M), envelop protein (E) and nucleocapsid protein (N) (Tortorici, & Veesler, 2019) .", [["transmembrane", "ANATOMY", 93, 106], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 77, 86], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["envelop protein (E)", "GENE_OR_GENE_PRODUCT", 153, 172], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 177, 197], ["structural proteins", "PROTEIN", 29, 48], ["transmembrane spike glycoprotein", "PROTEIN", 93, 125], ["S", "PROTEIN", 127, 128], ["membrane protein", "PROTEIN", 131, 147], ["M", "PROTEIN", 149, 150], ["envelop protein", "PROTEIN", 153, 168], ["E", "PROTEIN", 170, 171], ["nucleocapsid protein", "PROTEIN", 177, 197], ["N", "PROTEIN", 199, 200], ["SARS", "PROBLEM", 0, 4], ["four structural proteins", "PROBLEM", 24, 48], ["infection", "PROBLEM", 77, 86], ["the transmembrane spike glycoprotein (S", "TEST", 89, 128], ["membrane protein", "TEST", 131, 147], ["envelop protein", "TEST", 153, 168], ["nucleocapsid protein", "TEST", 177, 197], ["infection", "OBSERVATION", 77, 86]]], ["Among these proteins, viral attachment and entry into host cells are mediated by the S protein.", [["cells", "ANATOMY", 59, 64], ["host cells", "CELL", 54, 64], ["host cells", "CELL_TYPE", 54, 64], ["S protein", "PROTEIN", 85, 94], ["viral attachment", "PROBLEM", 22, 38], ["viral attachment", "OBSERVATION", 22, 38]]], ["It is surfaceexposed and can be cleaved by host proteases into S1 and S2 subunits (Yuan et al., 2017) .", [["S1", "GENE_OR_GENE_PRODUCT", 63, 65], ["S2", "GENE_OR_GENE_PRODUCT", 70, 72], ["host proteases", "PROTEIN", 43, 57], ["S1", "PROTEIN", 63, 65], ["S2 subunits", "PROTEIN", 70, 81]]], ["The cleavage allows initiation of the membrane fusion via a large scale irreversible conformational changes (Walls et al., 2017; Belouzard, Chu, & Whittaker, 2009 ).", [["membrane", "ANATOMY", 38, 46], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["The cleavage", "PROBLEM", 0, 12], ["the membrane fusion", "TREATMENT", 34, 53], ["a large scale irreversible conformational changes", "PROBLEM", 58, 107], ["membrane fusion", "OBSERVATION", 38, 53], ["large", "OBSERVATION_MODIFIER", 60, 65]]], ["The S1 subunit consists of the receptor-binding domain(s) (RBD) that can undergo hinge-like conformational movements, leading to a transient hidden or exposure of receptor binding determinants and thus mediates the engagement of a host receptor (Wrapp et al., 2020) .", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S1 subunit", "PROTEIN", 4, 14], ["receptor-binding domain", "PROTEIN", 31, 54], ["RBD", "PROTEIN", 59, 62], ["hinge", "PROTEIN", 81, 86], ["receptor binding determinants", "PROTEIN", 163, 192], ["hinge-like conformational movements", "PROBLEM", 81, 116], ["a transient hidden", "PROBLEM", 129, 147]]], ["Therefore, it has been suggested that the critical RBD(s) is responsible for the determination of cell tropism, host range and zoonotic transmission of coronaviruses (Graham, & Baric, 2010) .", [["cell", "ANATOMY", 98, 102], ["RBD", "GENE_OR_GENE_PRODUCT", 51, 54], ["cell", "CELL", 98, 102], ["coronaviruses", "ORGANISM", 152, 165], ["RBD", "PROTEIN", 51, 54], ["cell tropism", "PROBLEM", 98, 110], ["cell tropism", "OBSERVATION", 98, 110]]], ["Subsequently, the S1 subunit stabilizes the profusion conformation of the membrane-bound S2 subunit which contains the fusion machinery (Gui et al., 2017; Walls et al., 2019) .", [["membrane", "ANATOMY", 74, 82], ["S1", "GENE_OR_GENE_PRODUCT", 18, 20], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["S2", "GENE_OR_GENE_PRODUCT", 89, 91], ["S1 subunit", "PROTEIN", 18, 28], ["membrane-bound S2 subunit", "PROTEIN", 74, 99], ["profusion conformation", "OBSERVATION", 44, 66], ["bound", "ANATOMY_MODIFIER", 83, 88], ["S2", "ANATOMY", 89, 91]]], ["Hence, the intricate processes of host receptor binding and proteolytic cleavage of the S protein are essetial for the viral entry into susceptible targets.", [["S protein", "PROTEIN", 88, 97], ["host receptor binding", "PROBLEM", 34, 55], ["proteolytic cleavage of the S protein", "TREATMENT", 60, 97], ["host receptor binding", "OBSERVATION", 34, 55]]], ["The comprehension of structure and function of the S protein help to formulate a timely strategy for a specific drug such as monoclonal antibody drugs, as well as the development of vaccines in a foreseeable future.SARS-CoV-2The life cycle of SARS-C0V-2 Upon entering the host cell with the aid of S protein, SARS-CoV-2 releases its RNA genome into the cytoplasm, it translates into structural proteins and two polyproteins, pp1a and pp1ab, they are then split into small products via viral proteinase cleavage (Perlman, & Netland, 2009 ).", [["cell", "ANATOMY", 277, 281], ["cytoplasm", "ANATOMY", 353, 362], ["SARS", "DISEASE", 215, 219], ["SARS", "DISEASE", 243, 247], ["SARS-C0V-2", "CELL", 243, 253], ["host cell", "CELL", 272, 281], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 309, 319], ["cytoplasm", "ORGANISM_SUBSTANCE", 353, 362], ["pp1a", "GENE_OR_GENE_PRODUCT", 425, 429], ["pp1ab", "GENE_OR_GENE_PRODUCT", 434, 439], ["S protein", "PROTEIN", 51, 60], ["S protein", "PROTEIN", 298, 307], ["SARS-CoV-2", "PROTEIN", 309, 319], ["RNA genome", "DNA", 333, 343], ["structural proteins", "PROTEIN", 383, 402], ["polyproteins", "PROTEIN", 411, 423], ["pp1a", "PROTEIN", 425, 429], ["pp1ab", "PROTEIN", 434, 439], ["viral proteinase", "PROTEIN", 485, 501], ["the S protein", "TREATMENT", 47, 60], ["a specific drug", "TREATMENT", 101, 116], ["monoclonal antibody drugs", "TREATMENT", 125, 150], ["vaccines", "TREATMENT", 182, 190], ["SARS", "TEST", 243, 247], ["C0V", "TEST", 248, 251], ["S protein", "TEST", 298, 307], ["SARS", "TEST", 309, 313], ["CoV", "TEST", 314, 317], ["pp1ab", "TREATMENT", 434, 439], ["viral proteinase cleavage", "TREATMENT", 485, 510], ["host cell", "OBSERVATION", 272, 281], ["viral proteinase", "OBSERVATION", 485, 501]]], ["Afterwards, the viral genome begins to replicate, the positive-strand genome undergoes discontinuous transcription to synthesize the subgeneric negative-strand templates, templates for mRNA synthesis are thus generated, while the full-length negative-strand template is served as a genomic RNA template.", [["viral genome", "DNA", 16, 28], ["positive-strand genome", "DNA", 54, 76], ["subgeneric negative-strand templates", "DNA", 133, 169], ["full-length negative-strand template", "DNA", 230, 266], ["genomic RNA template", "DNA", 282, 302], ["the viral genome", "PROBLEM", 12, 28], ["mRNA synthesis", "PROBLEM", 185, 199], ["strand template", "TREATMENT", 251, 266], ["a genomic RNA template", "TREATMENT", 280, 302], ["viral genome", "OBSERVATION", 16, 28], ["strand templates", "OBSERVATION", 153, 169]]], ["Followed by the formation of viral nucleocapsids via a combination of genomic RNA and N protein in the cytoplasm, as well as the insertion of the newly formed envelope glycoproteins into the membrane of the endoplasmic reticulum (ER) or Golgi, the viral particles are then budded into the lumen of ER-Golgi intermediate compartment (ERGIC).", [["nucleocapsids", "ANATOMY", 35, 48], ["cytoplasm", "ANATOMY", 103, 112], ["membrane", "ANATOMY", 191, 199], ["endoplasmic reticulum", "ANATOMY", 207, 228], ["ER", "ANATOMY", 230, 232], ["Golgi", "ANATOMY", 237, 242], ["lumen", "ANATOMY", 289, 294], ["ER-Golgi intermediate compartment", "ANATOMY", 298, 331], ["ERGIC", "ANATOMY", 333, 338], ["cytoplasm", "ORGANISM_SUBSTANCE", 103, 112], ["membrane", "CELLULAR_COMPONENT", 191, 199], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 207, 228], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["Golgi", "CELLULAR_COMPONENT", 237, 242], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 289, 294], ["ER", "GENE_OR_GENE_PRODUCT", 298, 300], ["Golgi", "CELLULAR_COMPONENT", 301, 306], ["intermediate compartment", "CELLULAR_COMPONENT", 307, 331], ["genomic RNA", "RNA", 70, 81], ["N protein", "PROTEIN", 86, 95], ["envelope glycoproteins", "PROTEIN", 159, 181], ["ER", "PROTEIN", 230, 232], ["ER", "PROTEIN", 298, 300], ["viral nucleocapsids", "PROBLEM", 29, 48], ["genomic RNA and N protein in the cytoplasm", "PROBLEM", 70, 112], ["the insertion of the newly formed envelope glycoproteins", "TREATMENT", 125, 181], ["the viral particles", "PROBLEM", 244, 263], ["viral nucleocapsids", "OBSERVATION", 29, 48], ["envelope glycoproteins", "OBSERVATION", 159, 181], ["membrane", "ANATOMY_MODIFIER", 191, 199], ["endoplasmic reticulum", "ANATOMY", 207, 228], ["viral particles", "OBSERVATION", 248, 263], ["lumen", "ANATOMY_MODIFIER", 289, 294], ["Golgi", "OBSERVATION", 301, 306], ["intermediate compartment", "OBSERVATION", 307, 331]]], ["It is then followed by the release of virions through exocytosis.", [["virions", "ANATOMY", 38, 45]]], ["Finally, the vesicles containing virions fuse with the plasma membrane to infect other host cells (Stertz et al, 2007) .", [["vesicles", "ANATOMY", 13, 21], ["virions", "ANATOMY", 33, 40], ["plasma membrane", "ANATOMY", 55, 70], ["cells", "ANATOMY", 92, 97], ["vesicles", "CELLULAR_COMPONENT", 13, 21], ["virions", "CELLULAR_COMPONENT", 33, 40], ["plasma membrane", "CELLULAR_COMPONENT", 55, 70], ["cells", "CELL", 92, 97], ["host cells", "CELL_TYPE", 87, 97], ["the vesicles containing virions fuse", "PROBLEM", 9, 45], ["the plasma membrane", "TREATMENT", 51, 70], ["vesicles", "ANATOMY", 13, 21], ["virions fuse", "OBSERVATION", 33, 45], ["host cells", "OBSERVATION", 87, 97]]], ["It must be pointed out that the above process is a replication basis of SARS-CoV, the exact pathophysiological mechanisms underlying the emergence of SARS-CoV-2 still awaits exploration.", [["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 150, 154], ["SARS-CoV", "ORGANISM", 72, 80], ["SARS-CoV-2", "ORGANISM", 150, 160], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 150, 158], ["SARS", "PROBLEM", 72, 76], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["exploration", "TEST", 174, 185]]], ["SARS-CoV-2 mutations impact the viral pathogenicity Noteworthily, the pathogenicity of SARS-CoV-2 are found to be influenced by patient-derived mutations.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2", "ORGANISM", 87, 97], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["SARS-CoV", "SPECIES", 87, 95], ["SARS", "TEST", 0, 4], ["the viral pathogenicity", "PROBLEM", 28, 51], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["viral pathogenicity", "OBSERVATION", 32, 51]]], ["It is identified that 19 of the 33 mutations are novel in the collection of 11 viral isolates, in which 6 mutations are localized in spike protein .", [["spike protein", "PROTEIN", 133, 146], ["the 33 mutations", "PROBLEM", 28, 44], ["viral isolates", "TEST", 79, 93], ["spike protein", "PROBLEM", 133, 146]]], ["This indicates that the polymorphism of SARS-CoV-2 is much more than expected and the site of mutation may highly affect the viral pathogenesis.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["SARS-CoV-2", "DNA", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["the polymorphism of SARS", "PROBLEM", 20, 44], ["CoV", "TEST", 45, 48], ["mutation", "PROBLEM", 94, 102], ["the viral pathogenesis", "PROBLEM", 121, 143], ["viral", "OBSERVATION", 125, 130]]], ["Strikingly, two viral isolates at 24 hours post-infection (p.i.) have reported a nearly 270-fold difference in viral load.", [["a nearly 270-fold difference in viral load", "PROBLEM", 79, 121], ["viral load", "OBSERVATION", 111, 121]]], ["In addition, an unexpected tri-nucleotide mutation was observed in one viral isolate, which resulted in viral positivity for a sustainable period of 45 days .", [["tri-nucleotide", "GENE_OR_GENE_PRODUCT", 27, 41], ["an unexpected tri-nucleotide mutation", "PROBLEM", 13, 50], ["one viral isolate", "PROBLEM", 67, 84], ["viral positivity", "PROBLEM", 104, 120], ["tri-nucleotide mutation", "OBSERVATION", 27, 50], ["viral positivity", "OBSERVATION", 104, 120]]], ["Further studies should be directed towards the mutational impact of tri-nucleotide on the viral pathogenicity.SARS-CoV-2Ahough this non-peer-reviewed journal cannot be served as a clinical guideline, it has provided a significant insight for therapies development by taking the impact of the accumulating mutations into account to prevent potential pitfalls.SARS-CoV-2The similarity between SARS-CoV and MERS-CoV SARS-CoV-2 shares more than 85% of its identity with SARS-CoV (Wu et al., 2020) .", [["tri-nucleotide", "CHEMICAL", 68, 82], ["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 358, 362], ["SARS", "DISEASE", 391, 395], ["SARS", "DISEASE", 466, 470], ["tri-nucleotide", "CHEMICAL", 68, 82], ["tri-nucleotide", "SIMPLE_CHEMICAL", 68, 82], ["SARS-CoV", "ORGANISM", 391, 399], ["MERS-CoV SARS-CoV-2", "ORGANISM", 404, 423], ["SARS-CoV", "ORGANISM", 466, 474], ["CoV SARS-CoV", "SPECIES", 409, 421], ["SARS-CoV", "SPECIES", 391, 399], ["MERS-CoV", "SPECIES", 404, 412], ["SARS-CoV", "SPECIES", 466, 474], ["Further studies", "TEST", 0, 15], ["the viral pathogenicity", "PROBLEM", 86, 109], ["therapies development", "TREATMENT", 242, 263], ["the accumulating mutations", "PROBLEM", 288, 314], ["potential pitfalls", "PROBLEM", 339, 357], ["SARS", "TEST", 358, 362], ["CoV", "TEST", 363, 366], ["SARS", "TEST", 391, 395], ["CoV", "TEST", 396, 399], ["MERS", "TEST", 404, 408], ["CoV SARS", "TEST", 409, 417], ["CoV", "TEST", 418, 421], ["viral pathogenicity", "OBSERVATION", 90, 109]]], ["What is more, a greater similarity of (>90%) sequence identity is observed in the RNA-dependent RNA poymerase (RdRp) between them.", [["RNA-dependent RNA poymerase", "GENE_OR_GENE_PRODUCT", 82, 109], ["RNA-dependent RNA poymerase", "PROTEIN", 82, 109], ["RdRp", "PROTEIN", 111, 115]]], ["This poses a suggestion of RdRp inhibitors being the candidate drug for COVID-19 (Liu, Morse, Lalonde, & Xu, 2020).", [["COVID-19", "CHEMICAL", 72, 80], ["COVID-19", "CHEMICAL", 72, 80], ["RdRp inhibitors", "TREATMENT", 27, 42], ["COVID", "TEST", 72, 77], ["RdRp inhibitors", "OBSERVATION", 27, 42]]], ["Revealingly, the same receptor of SARS-CoV, angiotensin-converting enzyme 2 (ACE2) is also used by SARS-CoV-2 (Hoffmann et al., 2020), which is highly expressed in a small subset of cells in the lung called type 2 alveolar cells .", [["cells", "ANATOMY", 182, 187], ["lung", "ANATOMY", 195, 199], ["type 2 alveolar cells", "ANATOMY", 207, 228], ["SARS", "DISEASE", 34, 38], ["angiotensin", "CHEMICAL", 44, 55], ["SARS-CoV", "ORGANISM", 34, 42], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 44, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["SARS-CoV-2", "ORGANISM", 99, 109], ["cells", "CELL", 182, 187], ["lung", "ORGAN", 195, 199], ["type 2 alveolar cells", "CELL", 207, 228], ["SARS-CoV, angiotensin-converting enzyme 2", "PROTEIN", 34, 75], ["ACE2", "PROTEIN", 77, 81], ["lung called type 2 alveolar cells", "CELL_TYPE", 195, 228], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 99, 107], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["angiotensin", "TEST", 44, 55], ["converting enzyme", "TEST", 56, 73], ["ACE2", "TEST", 77, 81], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["small", "OBSERVATION_MODIFIER", 166, 171], ["subset of cells", "OBSERVATION", 172, 187], ["lung", "ANATOMY", 195, 199], ["alveolar cells", "OBSERVATION", 214, 228]]], ["Interestingly, SARS-CoV-2 conserves 8 binding-residues of 14 these amino acids in SARS-CoV, which are responsible for direct interaction with ACE2 (Fehr, & Perlman, 2015) .", [["amino acids", "CHEMICAL", 67, 78], ["amino acids", "CHEMICAL", 67, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["amino acids", "AMINO_ACID", 67, 78], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["ACE2", "PROTEIN", 142, 146], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["these amino acids", "TEST", 61, 78], ["SARS", "PROBLEM", 82, 86], ["CoV", "PROBLEM", 87, 90]]], ["To note, there is a nearly 10-to 20-fold higher affinity in the SARS-CoV-2 S protein binding to ACE2 than that of SARS-CoV, implying an increased ease in spreading between humans (Wrapp et al., 2020) .", [["SARS", "DISEASE", 64, 68], ["SARS", "DISEASE", 114, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 114, 122], ["humans", "ORGANISM", 172, 178], ["ACE2", "PROTEIN", 96, 100], ["humans", "SPECIES", 172, 178], ["SARS-CoV", "SPECIES", 114, 122], ["humans", "SPECIES", 172, 178], ["the SARS", "TEST", 60, 68], ["CoV", "TEST", 69, 72], ["ACE2", "TEST", 96, 100], ["SARS", "PROBLEM", 114, 118], ["CoV", "PROBLEM", 119, 122], ["an increased ease", "PROBLEM", 133, 150], ["SARS", "OBSERVATION", 64, 68], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["ease", "OBSERVATION_MODIFIER", 146, 150]]], ["This indicates that SARS-CoV-2 is highly similar to the receptor-binding domain in S protein of SARS-CoV.SARS-CoV-2In contrast, SARS-CoV-2 is less related to MERS-CoV; only 50% of its genetic sequence identity is shared with SARS-CoV-2 .", [["SARS", "DISEASE", 20, 24], ["SARS", "DISEASE", 105, 109], ["SARS", "DISEASE", 128, 132], ["SARS", "DISEASE", 225, 229], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["SARS-CoV", "ORGANISM", 96, 104], ["SARS-CoV-2In", "ORGANISM", 105, 117], ["SARS-CoV-2", "ORGANISM", 128, 138], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 158, 166], ["SARS-CoV-2", "ORGANISM", 225, 235], ["receptor-binding domain", "PROTEIN", 56, 79], ["S protein", "PROTEIN", 83, 92], ["MERS-CoV", "DNA", 158, 166], ["SARS-CoV", "SPECIES", 96, 104], ["SARS-CoV", "SPECIES", 128, 136], ["MERS-CoV", "SPECIES", 158, 166], ["SARS-CoV", "SPECIES", 225, 233], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["CoV", "PROBLEM", 101, 104], ["SARS", "TEST", 105, 109], ["CoV-2In contrast", "TEST", 110, 126], ["SARS", "PROBLEM", 128, 132], ["SARS", "OBSERVATION", 20, 24]]], ["Moreover, the primary receptor of MERS-CoV present in the lower respiratory tract, dipeptidyl peptidase 4 (DPP4), is not exploited by SARS-CoV-2 .", [["lower respiratory tract", "ANATOMY", 58, 81], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["lower", "ORGANISM_SUBDIVISION", 58, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 83, 105], ["DPP4", "GENE_OR_GENE_PRODUCT", 107, 111], ["SARS-CoV-2", "ORGANISM", 134, 144], ["MERS-CoV", "PROTEIN", 34, 42], ["dipeptidyl peptidase 4", "PROTEIN", 83, 105], ["DPP4", "PROTEIN", 107, 111], ["MERS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 134, 142], ["CoV", "PROBLEM", 39, 42], ["dipeptidyl peptidase", "TREATMENT", 83, 103], ["lower", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81]]], ["Nonetheless, MERS-CoV shares highly similar pathological characteristics with COVID-19, including viral cytopathic-like changes of giant cells multinucleation along with atypical enlarged pneumocytes in the intra-alveolar spaces , suggesting to some extent the epidemiological characteristics of SARS-CoV-2 is similar to that of MERS-CoV.", [["giant cells", "ANATOMY", 131, 142], ["pneumocytes", "ANATOMY", 188, 199], ["intra-alveolar spaces", "ANATOMY", 207, 228], ["SARS", "DISEASE", 296, 300], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["giant cells", "CELL", 131, 142], ["pneumocytes", "CELL", 188, 199], ["intra-alveolar spaces", "PATHOLOGICAL_FORMATION", 207, 228], ["SARS-CoV-2", "ORGANISM", 296, 306], ["MERS-CoV", "ORGANISM", 329, 337], ["MERS", "PROTEIN", 13, 17], ["COVID-19", "DNA", 78, 86], ["giant cells", "CELL_TYPE", 131, 142], ["atypical enlarged pneumocytes", "CELL_TYPE", 170, 199], ["MERS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 296, 304], ["MERS-CoV", "SPECIES", 329, 337], ["COVID", "TEST", 78, 83], ["viral cytopathic", "PROBLEM", 98, 114], ["giant cells multinucleation", "PROBLEM", 131, 158], ["atypical enlarged pneumocytes in the intra-alveolar spaces", "PROBLEM", 170, 228], ["SARS", "PROBLEM", 296, 300], ["CoV", "TEST", 301, 304], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["cytopathic", "OBSERVATION_MODIFIER", 104, 114], ["giant cells multinucleation", "OBSERVATION", 131, 158], ["atypical", "OBSERVATION_MODIFIER", 170, 178], ["enlarged", "OBSERVATION_MODIFIER", 179, 187], ["pneumocytes", "OBSERVATION", 188, 199], ["intra-alveolar", "ANATOMY_MODIFIER", 207, 221], ["suggesting to", "UNCERTAINTY", 231, 244], ["some extent", "OBSERVATION_MODIFIER", 245, 256], ["SARS", "OBSERVATION", 296, 300]]], ["General principles of the same Coronaviridae family may govern its biological activities.SARS-CoV-2Besides, these three CoVs all show a similar innate immune response.", [["SARS", "DISEASE", 89, 93], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 31, 44], ["SARS-CoV-2Besides", "ORGANISM", 89, 106], ["CoVs", "GENE_OR_GENE_PRODUCT", 120, 124], ["Coronaviridae family", "PROTEIN", 31, 51], ["CoVs", "DNA", 120, 124], ["SARS-CoV-2Besides", "SPECIES", 89, 106], ["SARS", "TEST", 89, 93]]], ["A highly proinflammatory condition was observed in patients with SARS-CoV-2 infection who needed intensive care unit (ICU).", [["SARS-CoV-2 infection", "DISEASE", 65, 85], ["patients", "ORGANISM", 51, 59], ["CoV-2", "ORGANISM", 70, 75], ["patients", "SPECIES", 51, 59], ["A highly proinflammatory condition", "PROBLEM", 0, 34], ["SARS", "PROBLEM", 65, 69], ["CoV-2 infection", "PROBLEM", 70, 85], ["highly", "OBSERVATION_MODIFIER", 2, 8], ["proinflammatory", "OBSERVATION_MODIFIER", 9, 24]]], ["They showed increased plasma levels of many innate cytokines .", [["plasma", "ANATOMY", 22, 28], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["innate cytokines", "PROTEIN", 44, 60], ["increased plasma levels", "PROBLEM", 12, 35], ["many innate cytokines", "PROBLEM", 39, 60], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["plasma levels", "OBSERVATION", 22, 35], ["innate cytokines", "OBSERVATION", 44, 60]]], ["Both SARS and MERS also have this noticeable growth, signifying a potential similar cytokine storm-mediated disease severity (Mahallawi, Khabour, Zhang, Makhdoum, & Suliman, 2018; Wong et al., 2004) .", [["SARS", "DISEASE", 5, 9], ["cytokine", "PROTEIN", 84, 92], ["this noticeable growth", "PROBLEM", 29, 51], ["mediated disease severity", "PROBLEM", 99, 124], ["SARS", "OBSERVATION", 5, 9], ["cytokine storm", "OBSERVATION", 84, 98]]], ["Altogether, identifying the similarity of pathological and immunological characteristics with SARS-CoV and MERS-CoV could facilitate our knowledge of pathophysiological mechanisms underlying the emergence of SARS-CoV-2.", [["SARS", "DISEASE", 208, 212], ["SARS-CoV", "ORGANISM", 94, 102], ["MERS-CoV", "ORGANISM", 107, 115], ["SARS-CoV-2", "ORGANISM", 208, 218], ["SARS-CoV", "SPECIES", 94, 102], ["MERS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 208, 216], ["SARS", "PROBLEM", 94, 98], ["CoV", "PROBLEM", 112, 115], ["pathophysiological mechanisms", "PROBLEM", 150, 179]]], ["The genetics similarity with SARS-CoV also aids in the interpretation of the resulting inflammatory response that may trigger the onset of severe pneumonia (Fehr, & Perlman, 2015) .", [["SARS", "DISEASE", 29, 33], ["pneumonia", "DISEASE", 146, 155], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "SPECIES", 29, 37], ["the resulting inflammatory response", "PROBLEM", 73, 108], ["severe pneumonia", "PROBLEM", 139, 155], ["inflammatory", "OBSERVATION", 87, 99], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["pneumonia", "OBSERVATION", 146, 155]]], ["By comprehending these similarities with the precedential SARS-CoV and MERS-CoV, it is believed that it increases the likelihood for the physicians to design efficient therapeutic measures for the COVID-19 patients and reduce fatality.SARS-CoV-2Cytokine storm While the pathogenesis of SARS-CoV-2 is still elusive and there is uncertainty with respect to its mechanism of viral transmission, the similar mechanisms of other pathogenic CoV provide useful information to enhance our recognition of COVID-19.", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 235, 239], ["SARS", "DISEASE", 286, 290], ["CoV", "ORGANISM", 63, 66], ["MERS-CoV", "ORGANISM", 71, 79], ["patients", "ORGANISM", 206, 214], ["SARS-CoV-2Cytokine", "GENE_OR_GENE_PRODUCT", 235, 253], ["SARS-CoV-2", "ORGANISM", 286, 296], ["CoV", "ORGANISM", 435, 438], ["COVID-19", "DNA", 496, 504], ["patients", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 286, 294], ["the precedential SARS", "TEST", 41, 62], ["the COVID", "TEST", 193, 202], ["SARS", "PROBLEM", 286, 290], ["viral transmission", "PROBLEM", 372, 390], ["COVID", "TEST", 496, 501], ["viral", "OBSERVATION", 372, 377]]], ["Since SARS-CoV-2 requires the same receptor as SARS-CoV (ACE2) for viral entry, aerosol and fomites transmission of SARS-CoV-2 is plausible (van Doremalen, et al, 2020).", [["SARS", "DISEASE", 116, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 47, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["SARS-CoV-2", "ORGANISM", 116, 126], ["SARS-CoV", "PROTEIN", 47, 55], ["ACE2", "PROTEIN", 57, 61], ["SARS-CoV", "SPECIES", 116, 124], ["SARS", "PROBLEM", 6, 10], ["CoV (ACE2)", "TREATMENT", 52, 62], ["viral entry", "TREATMENT", 67, 78], ["aerosol", "TREATMENT", 80, 87]]], ["Upon entry into alveolar epithelial cells via exploitation of ACE2, the virus replicates rapidly by infecting pneumocytes and macrophages (Shieh et al, 2005) .", [["alveolar epithelial cells", "ANATOMY", 16, 41], ["pneumocytes", "ANATOMY", 110, 121], ["macrophages", "ANATOMY", 126, 137], ["alveolar epithelial cells", "CELL", 16, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["pneumocytes", "CELL", 110, 121], ["macrophages", "CELL", 126, 137], ["alveolar epithelial cells", "CELL_TYPE", 16, 41], ["ACE2", "PROTEIN", 62, 66], ["pneumocytes", "CELL_TYPE", 110, 121], ["macrophages", "CELL_TYPE", 126, 137], ["ACE2", "PROBLEM", 62, 66], ["the virus", "PROBLEM", 68, 77], ["alveolar", "ANATOMY_MODIFIER", 16, 24], ["epithelial cells", "OBSERVATION", 25, 41], ["virus", "OBSERVATION", 72, 77], ["infecting", "OBSERVATION_MODIFIER", 100, 109], ["pneumocytes", "OBSERVATION", 110, 121], ["macrophages", "OBSERVATION_MODIFIER", 126, 137]]], ["This triggers the antigen presentation in CoV infection, leading to a strong cellular and humoral immune response.", [["cellular", "ANATOMY", 77, 85], ["infection", "DISEASE", 46, 55], ["CoV", "ORGANISM", 42, 45], ["cellular", "CELL", 77, 85], ["CoV", "SPECIES", 42, 45], ["CoV infection", "PROBLEM", 42, 55], ["a strong cellular and humoral immune response", "PROBLEM", 68, 113], ["CoV infection", "OBSERVATION", 42, 55], ["humoral immune response", "OBSERVATION", 90, 113]]], ["Ultimately, the cytokine storm and pulmonary tissue damage Besides, as mentioned above, this deadly cytokine storm-mediated condition is also observed in SARS and MERS (Mahallawi et al., 2018; Wong et al., 2004 ).", [["pulmonary tissue", "ANATOMY", 35, 51], ["SARS", "DISEASE", 154, 158], ["pulmonary tissue", "TISSUE", 35, 51], ["cytokine", "PROTEIN", 16, 24], ["cytokine", "PROTEIN", 100, 108], ["the cytokine storm", "TREATMENT", 12, 30], ["pulmonary tissue damage", "PROBLEM", 35, 58], ["cytokine storm", "OBSERVATION", 16, 30], ["pulmonary tissue", "ANATOMY", 35, 51], ["damage", "OBSERVATION", 52, 58]]], ["An increased level of IL-6, IFN-\u03b1, and CCL5, CXCL8, CXCL10 in serum was observed in patients with severe MERS-CoV infection in contrast to those with the mild-moderate disease (Min et al, 2016) .", [["serum", "ANATOMY", 62, 67], ["MERS-CoV infection", "DISEASE", 105, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["CCL5", "GENE_OR_GENE_PRODUCT", 39, 43], ["CXCL8", "GENE_OR_GENE_PRODUCT", 45, 50], ["CXCL10", "GENE_OR_GENE_PRODUCT", 52, 58], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["patients", "ORGANISM", 84, 92], ["MERS-CoV", "ORGANISM", 105, 113], ["IL-6", "PROTEIN", 22, 26], ["IFN", "PROTEIN", 28, 31], ["CCL5", "PROTEIN", 39, 43], ["CXCL8", "PROTEIN", 45, 50], ["CXCL10", "PROTEIN", 52, 58], ["patients", "SPECIES", 84, 92], ["MERS-CoV", "SPECIES", 105, 113], ["An increased level of IL", "TEST", 0, 24], ["IFN", "TEST", 28, 31], ["CCL5", "TEST", 39, 43], ["CXCL8", "TEST", 45, 50], ["CXCL10 in serum", "TEST", 52, 67], ["severe MERS", "PROBLEM", 98, 109], ["CoV infection in contrast", "PROBLEM", 110, 135], ["the mild-moderate disease", "PROBLEM", 150, 175], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["CCL5", "ANATOMY", 39, 43], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["MERS", "OBSERVATION", 105, 109], ["CoV infection", "OBSERVATION", 110, 123], ["mild", "OBSERVATION_MODIFIER", 154, 158], ["moderate", "OBSERVATION_MODIFIER", 159, 167], ["disease", "OBSERVATION", 168, 175]]], ["Also, the dead has a distinctively higher level of IL-18, IP-10, MG, and MCP1 than in those of the survivors of severe SARS-CoV infected patients (Huang et al, 2005) .", [["SARS-CoV infected", "DISEASE", 119, 136], ["IL-18", "GENE_OR_GENE_PRODUCT", 51, 56], ["IP-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["MG", "GENE_OR_GENE_PRODUCT", 65, 67], ["MCP1", "GENE_OR_GENE_PRODUCT", 73, 77], ["SARS-CoV", "ORGANISM", 119, 127], ["patients", "ORGANISM", 137, 145], ["IL-18", "PROTEIN", 51, 56], ["MG", "PROTEIN", 65, 67], ["MCP1", "PROTEIN", 73, 77], ["patients", "SPECIES", 137, 145], ["SARS-CoV", "SPECIES", 119, 127], ["IL", "TEST", 51, 53], ["IP", "TEST", 58, 60], ["MG", "TEST", 65, 67], ["MCP1", "TEST", 73, 77], ["severe SARS", "PROBLEM", 112, 123], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["SARS", "OBSERVATION", 119, 123], ["CoV", "OBSERVATION_MODIFIER", 124, 127], ["infected", "OBSERVATION_MODIFIER", 128, 136]]], ["Likewise, the immune response of some patients against the SARS-CoV-2 causes an elevation of IL-6 (Huang et al., 2020).", [["SARS", "DISEASE", 59, 63], ["patients", "ORGANISM", 38, 46], ["SARS-CoV-2", "ORGANISM", 59, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 93, 97], ["IL", "PROTEIN", 93, 95], ["patients", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 59, 67], ["the SARS", "TEST", 55, 63], ["CoV", "TEST", 64, 67], ["an elevation of IL", "PROBLEM", 77, 95], ["elevation", "OBSERVATION_MODIFIER", 80, 89]]], ["The data have strongly emphasized that these three CoVs share the common immunopathological events which provoke a vigorous attack by the immune system to the host body, giving rise to ARDS and MOF.", [["immune system", "ANATOMY", 138, 151], ["body", "ANATOMY", 164, 168], ["ARDS", "DISEASE", 185, 189], ["MOF", "DISEASE", 194, 197], ["CoVs", "GENE_OR_GENE_PRODUCT", 51, 55], ["immune system", "ANATOMICAL_SYSTEM", 138, 151], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["the common immunopathological events", "PROBLEM", 62, 98], ["ARDS", "PROBLEM", 185, 189], ["MOF", "PROBLEM", 194, 197], ["ARDS", "OBSERVATION", 185, 189]]], ["Furthermore, a model of ex-vivo human lung tissue revealed that SARS-CoV-2 generated 3.2 folds higher amounts of infectious viral particles than that of SARS-CoV within 48h p.i..", [["lung tissue", "ANATOMY", 38, 49], ["SARS", "DISEASE", 153, 157], ["human", "ORGANISM", 32, 37], ["lung tissue", "TISSUE", 38, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["SARS-CoV", "ORGANISM", 153, 161], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["SARS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 153, 161], ["ex-vivo human lung tissue", "TEST", 24, 49], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["infectious viral particles", "PROBLEM", 113, 139], ["SARS", "PROBLEM", 153, 157], ["lung", "ANATOMY", 38, 42], ["infectious", "OBSERVATION_MODIFIER", 113, 123], ["viral particles", "OBSERVATION_MODIFIER", 124, 139]]], ["Surprisingly, despite the more efficient replication, SARS-CoV-2 did not trigger significant levels of interferons in infected human lung tissues (Chu et al., 2020) .", [["lung tissues", "ANATOMY", 133, 145], ["SARS-CoV-2", "ORGANISM", 54, 64], ["interferons", "GENE_OR_GENE_PRODUCT", 103, 114], ["human", "ORGANISM", 127, 132], ["lung tissues", "TISSUE", 133, 145], ["interferons", "PROTEIN", 103, 114], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["SARS-CoV", "TEST", 54, 62], ["interferons in infected human lung tissues", "PROBLEM", 103, 145], ["interferons", "OBSERVATION", 103, 114], ["infected human", "OBSERVATION", 118, 132], ["lung", "ANATOMY", 133, 137]]], ["The preliminary data have explained the high person-to-person transmissibility of this novel virus.", [["person", "SPECIES", 45, 51], ["person", "SPECIES", 55, 61], ["The preliminary data", "TEST", 0, 20], ["this novel virus", "PROBLEM", 82, 98]]], ["Moreover, its low degree of innate immune activation accounts for the false-negative in patients who have mild or even asymptomatic infections, which promotes the COVID-19's spread by \"stealth transmission\".", [["infections", "DISEASE", 132, 142], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["innate immune activation", "PROBLEM", 28, 52], ["the false", "TEST", 66, 75], ["mild or even asymptomatic infections", "PROBLEM", 106, 142], ["the COVID", "TEST", 159, 168], ["low degree", "OBSERVATION_MODIFIER", 14, 24], ["innate immune activation", "OBSERVATION", 28, 52], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["asymptomatic", "OBSERVATION_MODIFIER", 119, 131], ["infections", "OBSERVATION", 132, 142]]], ["In short, SARS-CoV-2 acts as a ninja which is not easily detected while maintaining its potency.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["short", "OBSERVATION_MODIFIER", 3, 8]]], ["If the mechanism that renders these viral characteristics of high transmissibility and symptomatic infection can be elucidated in the future researches, more precise treatment strategies and infection controls can be developed for COVID-19 patients, especially for those who immunocompromised.SARS-CoV-2Although advancement in drug improvement occurs frequently, de novo drug development is costly and timely.", [["infection", "DISEASE", 99, 108], ["infection", "DISEASE", 191, 200], ["SARS", "DISEASE", 293, 297], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["high transmissibility", "PROBLEM", 61, 82], ["symptomatic infection", "PROBLEM", 87, 108], ["precise treatment strategies", "TREATMENT", 158, 186], ["infection controls", "PROBLEM", 191, 209], ["immunocompromised", "PROBLEM", 275, 292], ["symptomatic", "OBSERVATION_MODIFIER", 87, 98], ["infection", "OBSERVATION", 99, 108]]], ["Inventing a new drug from scratch would cost too much time, which in this case, cost too many lives.", [["new", "OBSERVATION_MODIFIER", 12, 15]]], ["Instead, repurposing existing drugs for a new disease is always the preferred first step since animal and safety trials are not required which could shorten the time to roll out the drug and reduce its cost.", [["repurposing existing drugs", "TREATMENT", 9, 35], ["a new disease", "PROBLEM", 40, 53]]], ["A possible way for drug exploration with considerable interest is to test if the (Agostini et al., 2018) .", [["drug exploration", "TEST", 19, 35]]], ["The mechanism of naturally developed resistance mutation still remains unknown.", [["resistance mutation", "PROBLEM", 37, 56], ["resistance mutation", "OBSERVATION", 37, 56]]], ["Because of this, we cannot rule out the possibility of remdesivir resistance, since the same study had shown that remdesivir was more sensitive towards the mutated MHV that lacked proofreading capability (Agostini et al., 2018) .", [["remdesivir", "CHEMICAL", 55, 65], ["remdesivir", "CHEMICAL", 114, 124], ["remdesivir", "CHEMICAL", 55, 65], ["remdesivir", "CHEMICAL", 114, 124], ["remdesivir", "SIMPLE_CHEMICAL", 55, 65], ["remdesivir", "SIMPLE_CHEMICAL", 114, 124], ["MHV", "ORGANISM", 164, 167], ["MHV", "SPECIES", 164, 167], ["remdesivir resistance", "PROBLEM", 55, 76], ["the same study", "TEST", 84, 98]]], ["This implies there is a likelihood for either a mutation that enhances proofreading or strengthens replication fidelity that ends up in the emergence of drug resistance (Kirchdoerfer, & Ward, 2019) .", [["a mutation", "PROBLEM", 46, 56]]], ["Further studies should be conducted to understand such resistance mutations for improving the effectiveness of remdesivir.SARS-CoV-2Nonetheless, remdesivir has been widely applied to over a hundred patients infected with SARS-CoV-2 in the US, Europe, and Japan through Expanded Access or Compassionate Use programs (Bender, 2020) .", [["remdesivir", "CHEMICAL", 111, 121], ["SARS", "DISEASE", 122, 126], ["remdesivir", "CHEMICAL", 145, 155], ["SARS", "DISEASE", 221, 225], ["remdesivir", "CHEMICAL", 111, 121], ["remdesivir", "SIMPLE_CHEMICAL", 111, 121], ["remdesivir", "SIMPLE_CHEMICAL", 145, 155], ["patients", "ORGANISM", 198, 206], ["SARS-CoV-2", "ORGANISM", 221, 231], ["patients", "SPECIES", 198, 206], ["SARS-CoV", "SPECIES", 221, 229], ["Further studies", "TEST", 0, 15], ["such resistance mutations", "PROBLEM", 50, 75], ["remdesivir", "TREATMENT", 111, 121], ["SARS", "PROBLEM", 122, 126], ["remdesivir", "TREATMENT", 145, 155], ["SARS", "PROBLEM", 221, 225], ["CoV", "TEST", 226, 229]]], ["Presently, evaluation of remdesivir efficacy in patients have been conducted by randomized, controlled, and double-blind clinical trials.", [["remdesivir", "CHEMICAL", 25, 35], ["remdesivir", "SIMPLE_CHEMICAL", 25, 35], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["evaluation", "TEST", 11, 21], ["remdesivir efficacy", "TREATMENT", 25, 44]]], ["More recently, remdesivir showed clinical improvement in 36 of 53 (68%) patients with COVID-19 in a preliminary report (Grein et al., 2020) .", [["remdesivir", "CHEMICAL", 15, 25], ["remdesivir", "CHEMICAL", 15, 25], ["remdesivir", "SIMPLE_CHEMICAL", 15, 25], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["COVID", "TEST", 86, 91]]], ["The mortality was 13% over a median follow-up of 18 days, compared to the 28-day mortality of another randomised, controlled trial of lopinavir-ritonavir in patients, which was 22% .", [["lopinavir-ritonavir", "CHEMICAL", 134, 153], ["lopinavir", "CHEMICAL", 134, 143], ["ritonavir", "CHEMICAL", 144, 153], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 134, 153], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["lopinavir", "TREATMENT", 134, 143], ["ritonavir", "TREATMENT", 144, 153]]], ["Although this trial is conducted in a small size of the cohort and there is a lack of viral load data to confirm the antiviral effects of the drug, the mortality and clinical improvement shown in this cohort are optimistic.", [["viral load data", "PROBLEM", 86, 101], ["the drug", "TREATMENT", 138, 146], ["small", "OBSERVATION_MODIFIER", 38, 43], ["size", "OBSERVATION_MODIFIER", 44, 48]]], ["In May, report from big size of cohort revealed improved therapeutic effects with speed up recovery from COVID-19 although it only mildly reduced mortality.", [["COVID-19", "CHEMICAL", 105, 113], ["COVID", "TEST", 105, 110], ["mildly reduced mortality", "PROBLEM", 131, 155], ["improved", "OBSERVATION_MODIFIER", 48, 56], ["therapeutic", "OBSERVATION_MODIFIER", 57, 68], ["mildly", "OBSERVATION_MODIFIER", 131, 137], ["reduced", "OBSERVATION_MODIFIER", 138, 145], ["mortality", "OBSERVATION", 146, 155]]], ["Therefore, FDA has fast approved this drug for treating COVID-19.ChloroquineIn vitro data have shown its influential antiviral activity against a clinical isolate of SARS-CoV-2.", [["ChloroquineIn", "CHEMICAL", 65, 78], ["SARS", "DISEASE", 166, 170], ["COVID-19", "CHEMICAL", 56, 64], ["ChloroquineIn", "CHEMICAL", 65, 78], ["ChloroquineIn", "SIMPLE_CHEMICAL", 65, 78], ["SARS-CoV-2", "ORGANISM", 166, 176], ["SARS-CoV", "SPECIES", 166, 174], ["COVID", "TEST", 56, 61], ["ChloroquineIn vitro data", "TEST", 65, 89], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174]]], ["Similar to remdesivir, chloroquine has a high selection index (SI) and inhibits SARS-CoV-2 at a low micromolar concentration (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50), suggesting a decent chance of it becoming a potential treatment candidate .ChloroquineAs an antimalarial drug, chloroquine has been used for over 70 years.", [["remdesivir", "CHEMICAL", 11, 21], ["chloroquine", "CHEMICAL", 23, 34], ["ChloroquineAs", "CHEMICAL", 245, 258], ["chloroquine", "CHEMICAL", 281, 292], ["remdesivir", "CHEMICAL", 11, 21], ["chloroquine", "CHEMICAL", 23, 34], ["ChloroquineAs", "CHEMICAL", 245, 258], ["chloroquine", "CHEMICAL", 281, 292], ["remdesivir", "SIMPLE_CHEMICAL", 11, 21], ["chloroquine", "SIMPLE_CHEMICAL", 23, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["ChloroquineAs", "SIMPLE_CHEMICAL", 245, 258], ["chloroquine", "SIMPLE_CHEMICAL", 281, 292], ["remdesivir", "TREATMENT", 11, 21], ["chloroquine", "TREATMENT", 23, 34], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["a low micromolar concentration", "TREATMENT", 94, 124], ["EC50", "TEST", 126, 130], ["\u03bcM", "TEST", 138, 140], ["CC50", "TEST", 142, 146], ["SI", "TEST", 157, 159], ["ChloroquineAs", "TREATMENT", 245, 258], ["an antimalarial drug", "TREATMENT", 259, 279], ["chloroquine", "TREATMENT", 281, 292]]], ["It is chosen from the tens of thousands of existing drugs because of the reported antiviral effects in patients with SARS-CoV (Vincent et al, 2005) .", [["SARS-CoV", "DISEASE", 117, 125], ["patients", "ORGANISM", 103, 111], ["SARS-CoV", "ORGANISM", 117, 125], ["patients", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 117, 125], ["existing drugs", "TREATMENT", 43, 57], ["SARS", "PROBLEM", 117, 121], ["antiviral", "OBSERVATION", 82, 91]]], ["Chloroquine had become less relevant as the SARS outbreak died and there were no new cases of CoVs until now.", [["Chloroquine", "CHEMICAL", 0, 11], ["SARS", "DISEASE", 44, 48], ["CoVs", "DISEASE", 94, 98], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["CoVs", "CANCER", 94, 98], ["Chloroquine", "TREATMENT", 0, 11], ["CoVs", "PROBLEM", 94, 98], ["less relevant", "OBSERVATION_MODIFIER", 23, 36], ["no", "UNCERTAINTY", 78, 80], ["new", "OBSERVATION_MODIFIER", 81, 84]]], ["Recognising that the current SARS-CoV-2 is similar to SARS-CoV genetically, chloroquine was considered again as a therapeutic measure for the novel pandemic.ChloroquinePrincipally, several antiviral functions are involved in the use of chloroquine.", [["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 54, 58], ["chloroquine", "CHEMICAL", 76, 87], ["ChloroquinePrincipally", "CHEMICAL", 157, 179], ["chloroquine", "CHEMICAL", 236, 247], ["chloroquine", "CHEMICAL", 76, 87], ["ChloroquinePrincipally", "CHEMICAL", 157, 179], ["chloroquine", "CHEMICAL", 236, 247], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "ORGANISM", 54, 62], ["chloroquine", "SIMPLE_CHEMICAL", 76, 87], ["ChloroquinePrincipally", "SIMPLE_CHEMICAL", 157, 179], ["chloroquine", "SIMPLE_CHEMICAL", 236, 247], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58], ["chloroquine", "TREATMENT", 76, 87], ["the novel pandemic", "PROBLEM", 138, 156], ["ChloroquinePrincipally", "TREATMENT", 157, 179], ["several antiviral functions", "TREATMENT", 181, 208], ["chloroquine", "TREATMENT", 236, 247], ["antiviral functions", "OBSERVATION", 189, 208]]], ["A well-known function is that chloroquine can act as an inhibitor to the endosomal acidification to block CoV replication.", [["endosomal", "ANATOMY", 73, 82], ["chloroquine", "CHEMICAL", 30, 41], ["chloroquine", "CHEMICAL", 30, 41], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["endosomal", "CELLULAR_COMPONENT", 73, 82], ["CoV", "GENE_OR_GENE_PRODUCT", 106, 109], ["chloroquine", "TREATMENT", 30, 41], ["an inhibitor", "TREATMENT", 53, 65], ["the endosomal acidification", "PROBLEM", 69, 96], ["block CoV replication", "TREATMENT", 100, 121]]], ["A previous study declared as the viral entry is mediated by fusion competent SARS-CoV S protein in a pH-dependent manner, they require endosomal acidification for entry (Simmons et al, 2004 ).", [["endosomal", "ANATOMY", 135, 144], ["-CoV S protein", "GENE_OR_GENE_PRODUCT", 81, 95], ["endosomal", "CELLULAR_COMPONENT", 135, 144], ["fusion competent SARS-CoV S protein", "PROTEIN", 60, 95], ["A previous study", "TEST", 0, 16], ["the viral entry", "PROBLEM", 29, 44], ["endosomal acidification", "PROBLEM", 135, 158], ["endosomal acidification", "OBSERVATION", 135, 158]]], ["The endosomal acid proteases are used to cleave the S protein, whereby activating fusion Taken together, the multiple mechanisms of chloroquine can potentially achieve a promising therapeutic effect against SARS-CoV-2 infection.", [["endosomal", "ANATOMY", 4, 13], ["chloroquine", "CHEMICAL", 132, 143], ["SARS-CoV-2 infection", "DISEASE", 207, 227], ["chloroquine", "CHEMICAL", 132, 143], ["chloroquine", "SIMPLE_CHEMICAL", 132, 143], ["SARS-CoV-2", "ORGANISM", 207, 217], ["endosomal acid proteases", "PROTEIN", 4, 28], ["S protein", "PROTEIN", 52, 61], ["SARS-CoV-2", "SPECIES", 207, 217], ["The endosomal acid proteases", "TREATMENT", 0, 28], ["activating fusion", "TREATMENT", 71, 88], ["chloroquine", "TREATMENT", 132, 143], ["SARS", "PROBLEM", 207, 211], ["CoV-2 infection", "PROBLEM", 212, 227], ["acid proteases", "OBSERVATION", 14, 28], ["infection", "OBSERVATION", 218, 227]]], ["The reduction of SARS-CoV infectivity and cell spread was attained in the presence of 1-10 \u03bcM chloroquine, which is clinically achievable in the plasma of malaria-infected patients (Ducharme, & Farinotti, 1996) .", [["cell", "ANATOMY", 42, 46], ["plasma", "ANATOMY", 145, 151], ["SARS", "DISEASE", 17, 21], ["chloroquine", "CHEMICAL", 94, 105], ["malaria-infected", "DISEASE", 155, 171], ["chloroquine", "CHEMICAL", 94, 105], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["cell", "CELL", 42, 46], ["chloroquine", "SIMPLE_CHEMICAL", 94, 105], ["plasma", "ORGANISM_SUBSTANCE", 145, 151], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21], ["CoV infectivity", "PROBLEM", 22, 37], ["cell spread", "PROBLEM", 42, 53], ["chloroquine", "TREATMENT", 94, 105], ["malaria", "PROBLEM", 155, 162], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["SARS", "OBSERVATION", 17, 21], ["CoV infectivity", "OBSERVATION_MODIFIER", 22, 37], ["cell spread", "OBSERVATION", 42, 53], ["malaria", "OBSERVATION", 155, 162], ["infected", "OBSERVATION_MODIFIER", 163, 171]]], ["The EC90 value of this drug against the SARS-CoV-2 in Vero E6 cells was 6.90 \u03bcM, which is the plasma concentration achievable for rheumatoid arthritis treatment .ChloroquineThese data support that chloroquine can interfere with SARS-CoV-2 in a feasible and rather effective dosage.ChloroquineDue to the numerous pros as mentioned above, preliminary trials of chloroquine have been conducted in many countries.", [["Vero E6 cells", "ANATOMY", 54, 67], ["plasma", "ANATOMY", 94, 100], ["SARS", "DISEASE", 40, 44], ["rheumatoid arthritis", "DISEASE", 130, 150], ["Chloroquine", "CHEMICAL", 162, 173], ["chloroquine", "CHEMICAL", 197, 208], ["ChloroquineDue", "CHEMICAL", 281, 295], ["chloroquine", "CHEMICAL", 359, 370], ["Chloroquine", "CHEMICAL", 162, 173], ["chloroquine", "CHEMICAL", 197, 208], ["ChloroquineDue", "CHEMICAL", 281, 295], ["chloroquine", "CHEMICAL", 359, 370], ["SARS-CoV-2", "ORGANISM", 40, 50], ["Vero E6 cells", "CELL", 54, 67], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["Chloroquine", "SIMPLE_CHEMICAL", 162, 173], ["chloroquine", "SIMPLE_CHEMICAL", 197, 208], ["ChloroquineDue", "SIMPLE_CHEMICAL", 281, 295], ["chloroquine", "SIMPLE_CHEMICAL", 359, 370], ["Vero E6 cells", "CELL_LINE", 54, 67], ["SARS-CoV", "SPECIES", 40, 48], ["Vero E6", "SPECIES", 54, 61], ["the SARS", "TEST", 36, 44], ["CoV", "TEST", 45, 48], ["Vero E6 cells", "TEST", 54, 67], ["the plasma concentration", "TREATMENT", 90, 114], ["rheumatoid arthritis treatment", "TREATMENT", 130, 160], ["Chloroquine", "TREATMENT", 162, 173], ["chloroquine", "TREATMENT", 197, 208], ["CoV", "TEST", 233, 236], ["ChloroquineDue", "TREATMENT", 281, 295], ["chloroquine", "TREATMENT", 359, 370], ["rheumatoid arthritis", "OBSERVATION", 130, 150]]], ["70% of COVID-19 patients were con- ).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 7, 12]]], ["Yet, currently, there is no published scientific journal reporting the precise data from the clinical trials, which poses a difficulty in interpreting results.", [["no", "UNCERTAINTY", 25, 27]]], ["Likewise, although the inhibitory effect of chloroquine was observed in the pneumonia patients with COVID-19, no specific data were available for result interpretation, even though a significant effect in terms of clinical outcome and viral clearance has been shown when compared to controls groups (Gao, Tian, & Yang, 2020) .", [["chloroquine", "CHEMICAL", 44, 55], ["pneumonia", "DISEASE", 76, 85], ["chloroquine", "CHEMICAL", 44, 55], ["COVID-19", "CHEMICAL", 100, 108], ["chloroquine", "SIMPLE_CHEMICAL", 44, 55], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["chloroquine", "TREATMENT", 44, 55], ["the pneumonia", "PROBLEM", 72, 85], ["COVID", "TEST", 100, 105], ["specific data", "TEST", 113, 126], ["viral clearance", "TEST", 235, 250], ["pneumonia", "OBSERVATION", 76, 85]]], ["In light of the foregoing, it is imperative high-quality data from worldwide clinical trials are necessitated for chloroquine to become an approved therapy.", [["chloroquine", "CHEMICAL", 114, 125], ["chloroquine", "CHEMICAL", 114, 125], ["chloroquine", "SIMPLE_CHEMICAL", 114, 125], ["chloroquine", "TREATMENT", 114, 125], ["an approved therapy", "TREATMENT", 136, 155]]], ["Given the fact that chloroquine exerts remarkable inhibitory antiviral effects on the susceptible cells, it is highly recommended to be considered as the treatment candidate for both prophylactic and therapeutic use.ChloroquineHydroxychloroquine Hydroxychloroquine (HCQ) was also suggested as candidate drug.", [["cells", "ANATOMY", 98, 103], ["chloroquine", "CHEMICAL", 20, 31], ["ChloroquineHydroxychloroquine", "CHEMICAL", 216, 245], ["Hydroxychloroquine", "CHEMICAL", 246, 264], ["HCQ", "CHEMICAL", 266, 269], ["chloroquine", "CHEMICAL", 20, 31], ["ChloroquineHydroxychloroquine", "CHEMICAL", 216, 245], ["Hydroxychloroquine", "CHEMICAL", 246, 264], ["HCQ", "CHEMICAL", 266, 269], ["chloroquine", "SIMPLE_CHEMICAL", 20, 31], ["cells", "CELL", 98, 103], ["ChloroquineHydroxychloroquine", "SIMPLE_CHEMICAL", 216, 245], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 246, 264], ["HCQ", "SIMPLE_CHEMICAL", 266, 269], ["susceptible cells", "CELL_TYPE", 86, 103], ["chloroquine", "TREATMENT", 20, 31], ["the susceptible cells", "TREATMENT", 82, 103], ["ChloroquineHydroxychloroquine Hydroxychloroquine (HCQ)", "TREATMENT", 216, 270]]], ["It is a derivative of CQ by introducing a hydroxyl group into CQ.", [["CQ", "CHEMICAL", 22, 24], ["hydroxyl", "CHEMICAL", 42, 50], ["CQ", "CHEMICAL", 62, 64], ["CQ", "CHEMICAL", 22, 24], ["hydroxyl", "CHEMICAL", 42, 50], ["CQ", "SIMPLE_CHEMICAL", 22, 24], ["hydroxyl", "SIMPLE_CHEMICAL", 42, 50], ["CQ", "SIMPLE_CHEMICAL", 62, 64], ["a derivative of CQ", "TREATMENT", 6, 24], ["a hydroxyl group into CQ", "TREATMENT", 40, 64]]], ["Hence it is not surprising that it shares (Savarino et al., 2003) almost the same pharmacological properties as CQ (Browning, 2014 .", [["CQ", "CHEMICAL", 112, 114], ["CQ", "SIMPLE_CHEMICAL", 112, 114], ["not surprising", "UNCERTAINTY", 12, 26]]], ["This drug is only approved for human use by prescription for the parasitic treatment, and for preventing heartworm disease in animals (Campbell, 1989) .", [["heartworm disease", "DISEASE", 105, 122], ["human", "ORGANISM", 31, 36], ["heartworm", "ORGANISM_SUBDIVISION", 105, 114], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["the parasitic treatment", "TREATMENT", 61, 84], ["heartworm disease", "PROBLEM", 105, 122]]], ["Since the drug called Heartgard containing ivermectin is available in veterinary clinics (Campbell, 1989) , Momekov have raised a concern about that a trend of self-medication for COVID-19 may be evoked ( Side effects raised by these drugs such as QT prolongation should also be monitored and cautioned.ChloroquineFurther investigations of the efficacy of antiviral drugs in wide clinical applications should be undertaken to combat this deadly pandemic as soon as possible.Convalescent Plasma TherapyThe therapeutic value is highlighted in immunotherapy as like as antiviral therapy.", [["ivermectin", "CHEMICAL", 43, 53], ["COVID-19", "CHEMICAL", 180, 188], ["QT prolongation", "DISEASE", 248, 263], ["ChloroquineFurther", "CHEMICAL", 303, 321], ["ivermectin", "CHEMICAL", 43, 53], ["COVID-19", "CHEMICAL", 180, 188], ["ChloroquineFurther", "CHEMICAL", 303, 321], ["Heartgard", "SIMPLE_CHEMICAL", 22, 31], ["ivermectin", "SIMPLE_CHEMICAL", 43, 53], ["COVID-19", "SIMPLE_CHEMICAL", 180, 188], ["Plasma", "ORGANISM_SUBSTANCE", 487, 493], ["ivermectin", "TREATMENT", 43, 53], ["self-medication", "TREATMENT", 160, 175], ["COVID", "TREATMENT", 180, 185], ["Side effects", "PROBLEM", 205, 217], ["these drugs", "TREATMENT", 228, 239], ["QT prolongation", "TREATMENT", 248, 263], ["ChloroquineFurther investigations", "TREATMENT", 303, 336], ["antiviral drugs", "TREATMENT", 356, 371], ["wide clinical applications", "TREATMENT", 375, 401], ["Convalescent Plasma Therapy", "TREATMENT", 474, 501], ["The therapeutic value", "TEST", 501, 522], ["immunotherapy", "TREATMENT", 541, 554], ["antiviral therapy", "TREATMENT", 566, 583], ["Plasma Therapy", "OBSERVATION", 487, 501]]], ["While awaiting the approved specific antiviral agents for COVID-19 via clinical trials, convalescent plasma (CP) therapy is also approached as a potential candidate.", [["plasma", "ANATOMY", 101, 107], ["COVID-19", "CHEMICAL", 58, 66], ["CP", "CHEMICAL", 109, 111], ["COVID-19", "CHEMICAL", 58, 66], ["convalescent", "ORGANISM", 88, 100], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["CP", "MULTI-TISSUE_STRUCTURE", 109, 111], ["antiviral agents", "TREATMENT", 37, 53], ["COVID", "TEST", 58, 63], ["convalescent plasma (CP) therapy", "TREATMENT", 88, 120]]], ["It is a classic adaptive immunotherapy which provides the plasma from recovered patients with a high neutralising antibody titer to a susceptible person.", [["plasma", "ANATOMY", 58, 64], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["person", "SPECIES", 146, 152], ["a classic adaptive immunotherapy", "TREATMENT", 6, 38], ["a high neutralising antibody titer", "PROBLEM", 94, 128]]], ["Upon circulation of the blood, the antibodies reach the target tissue and confer an- (Halstead, 2015) .", [["blood", "ANATOMY", 24, 29], ["tissue", "ANATOMY", 63, 69], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["tissue", "TISSUE", 63, 69], ["antibodies", "PROTEIN", 35, 45], ["the blood", "TEST", 20, 29], ["the antibodies", "TEST", 31, 45], ["blood", "ANATOMY", 24, 29]]], ["This was observed in SARS-CoV infection in vitro (Wang et al., 2014) .", [["SARS-CoV infection", "DISEASE", 21, 39], ["SARS-CoV", "ORGANISM", 21, 29], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "PROBLEM", 21, 25], ["CoV infection", "PROBLEM", 26, 39], ["CoV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39]]], ["Nonetheless, ADE may be unlikely to happen in COVID-19 as the proposed use of CP would rely on preparations with high titers of neutralizing antibody and timely transfusion (Duan et al., 2020) .", [["CP", "CHEMICAL", 78, 80], ["COVID-19", "CHEMICAL", 46, 54], ["neutralizing antibody", "PROTEIN", 128, 149], ["CP", "PROBLEM", 78, 80], ["neutralizing antibody", "TREATMENT", 128, 149], ["may be unlikely", "UNCERTAINTY", 17, 32]]], ["Furthermore, given the advanced blood banking techniques, the risks of the above contraindications and inadvertently TTI can be minimized via screening the suspected pathogens and matching the blood type of donors and recipients.Convalescent Plasma TherapyOverall, given the experience and current preliminary data on the use of CP therapy suggest its safety use in SARS-CoV-2 infection (worldometers.info, 2020).", [["blood", "ANATOMY", 32, 37], ["blood", "ANATOMY", 193, 198], ["CP", "CHEMICAL", 329, 331], ["SARS-CoV-2 infection", "DISEASE", 366, 386], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["donors", "ORGANISM", 207, 213], ["recipients", "ORGANISM", 218, 228], ["Plasma", "ORGANISM_SUBSTANCE", 242, 248], ["SARS-CoV-2", "ORGANISM", 366, 376], ["SARS-CoV", "SPECIES", 366, 374], ["the advanced blood banking techniques", "TREATMENT", 19, 56], ["the above contraindications", "TREATMENT", 71, 98], ["inadvertently TTI", "PROBLEM", 103, 120], ["the suspected pathogens", "PROBLEM", 152, 175], ["donors and recipients", "TREATMENT", 207, 228], ["Convalescent Plasma TherapyOverall", "TREATMENT", 229, 263], ["CP therapy", "TREATMENT", 329, 339], ["SARS", "PROBLEM", 366, 370], ["CoV-2 infection", "PROBLEM", 371, 386], ["infection", "OBSERVATION", 377, 386]]], ["This treatment would be a boon for critically ill patients to improve their survival rate.", [["critically ill", "DISEASE", 35, 49], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["This treatment", "TREATMENT", 0, 14], ["critically ill patients", "TREATMENT", 35, 58]]], ["It is also beneficial if administered at an early stage of the disease, more randomized clinical studies should be conducted for a risk-benefit assessment in individual variables.", [["the disease", "PROBLEM", 59, 70], ["clinical studies", "TEST", 88, 104], ["benefit assessment", "TEST", 136, 154], ["disease", "OBSERVATION", 63, 70]]], ["Moreover, SARS-CoV-2 specific hyperimmune serum such as Takeda's TAK-888 (Takeda, 2020) and Kamada's anti-COVID-19 IgG (Weinreb, 2020) are now developing, these have undoubtedly provided additional options for COVID-19 rescue.Natural Killer cell therapyNatural killer (NK) cells are innate cytotoxic lymphocytes essential for host-rejection of both tumours and virus-infected cells.", [["serum", "ANATOMY", 42, 47], ["Killer cell therapyNatural killer (NK) cells", "ANATOMY", 234, 278], ["lymphocytes", "ANATOMY", 300, 311], ["tumours", "ANATOMY", 349, 356], ["cells", "ANATOMY", 376, 381], ["TAK-888", "CHEMICAL", 65, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["hyperimmune", "ORGANISM", 30, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["TAK-888", "SIMPLE_CHEMICAL", 65, 72], ["Killer cell therapyNatural killer (NK) cells", "CELL", 234, 278], ["innate cytotoxic lymphocytes", "CELL", 283, 311], ["tumours", "CANCER", 349, 356], ["cells", "CELL", 376, 381], ["IgG", "PROTEIN", 115, 118], ["Natural Killer cell therapyNatural killer (NK) cells", "CELL_TYPE", 226, 278], ["innate cytotoxic lymphocytes", "CELL_TYPE", 283, 311], ["virus-infected cells", "CELL_TYPE", 361, 381], ["hyperimmune", "SPECIES", 30, 41], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["hyperimmune serum", "TEST", 30, 47], ["Kamada's anti-COVID", "TREATMENT", 92, 111], ["COVID", "TREATMENT", 210, 215], ["Natural Killer cell therapyNatural killer (NK) cells", "TREATMENT", 226, 278], ["innate cytotoxic lymphocytes", "PROBLEM", 283, 311], ["both tumours", "PROBLEM", 344, 356], ["virus", "PROBLEM", 361, 366], ["infected cells", "PROBLEM", 367, 381], ["Killer cell", "OBSERVATION", 234, 245], ["cytotoxic lymphocytes", "OBSERVATION", 290, 311], ["tumours", "OBSERVATION", 349, 356], ["infected cells", "OBSERVATION", 367, 381]]], ["Therefore, NK cell therapy is a common therapeutic approach for solid tumours and haematological malignancies, whereas recently NK cells are evolutionarily designed to detect and eliminate virus-infected cells, which can be developed into a practical treatment for COVID-19.", [["NK cell", "ANATOMY", 11, 18], ["solid tumours", "ANATOMY", 64, 77], ["haematological malignancies", "ANATOMY", 82, 109], ["NK cells", "ANATOMY", 128, 136], ["cells", "ANATOMY", 204, 209], ["haematological malignancies", "DISEASE", 82, 109], ["NK cell", "CELL", 11, 18], ["solid tumours", "CANCER", 64, 77], ["haematological malignancies", "CANCER", 82, 109], ["NK cells", "CELL", 128, 136], ["cells", "CELL", 204, 209], ["NK cells", "CELL_TYPE", 128, 136], ["virus-infected cells", "CELL_TYPE", 189, 209], ["NK cell therapy", "TREATMENT", 11, 26], ["solid tumours", "PROBLEM", 64, 77], ["haematological malignancies", "PROBLEM", 82, 109], ["NK cells", "PROBLEM", 128, 136], ["virus-infected cells", "PROBLEM", 189, 209], ["a practical treatment", "TREATMENT", 239, 260], ["COVID", "TEST", 265, 270], ["NK cell therapy", "OBSERVATION", 11, 26], ["haematological malignancies", "OBSERVATION", 82, 109], ["infected cells", "OBSERVATION", 195, 209]]], ["It is presumed that NK cell lyses antibody-coated virus-infected cells via ADCC, a key effector function (Hammer, R\u00fcckert, & Romagnano, 2018) .Natural Killer cell therapyNormally stimulation and effector function of NK cell relies on the integration of signals derived from activating and inhibitory receptors.", [["NK cell", "ANATOMY", 20, 27], ["cells", "ANATOMY", 65, 70], ["Killer cell", "ANATOMY", 151, 162], ["NK cell", "ANATOMY", 216, 223], ["NK cell", "CELL", 20, 27], ["cells", "CELL", 65, 70], ["ADCC", "CELL", 75, 79], ["Killer cell", "CELL", 151, 162], ["NK cell", "CELL", 216, 223], ["NK cell lyses antibody-coated virus-infected cells", "CELL_TYPE", 20, 70], ["NK cell", "CELL_TYPE", 216, 223], ["inhibitory receptors", "PROTEIN", 289, 309], ["NK cell lyses antibody", "TEST", 20, 42], ["coated virus", "PROBLEM", 43, 55], ["infected cells", "PROBLEM", 56, 70], ["ADCC", "TEST", 75, 79], ["Natural Killer cell therapyNormally stimulation", "TREATMENT", 143, 190], ["presumed that", "UNCERTAINTY", 6, 19], ["NK cell lyses", "OBSERVATION", 20, 33], ["infected cells", "OBSERVATION", 56, 70], ["Killer cell", "OBSERVATION", 151, 162], ["NK cell", "OBSERVATION", 216, 223]]], ["The surface of normal cells has expressed major histocompatibility complex (MHC) class I molecules to act as ligands for inhibitory receptors and conduce to the self-tolerance of NK cells.", [["surface", "ANATOMY", 4, 11], ["cells", "ANATOMY", 22, 27], ["NK cells", "ANATOMY", 179, 187], ["surface", "CELLULAR_COMPONENT", 4, 11], ["cells", "CELL", 22, 27], ["NK cells", "CELL", 179, 187], ["normal cells", "CELL_TYPE", 15, 27], ["major histocompatibility complex (MHC) class I molecules", "PROTEIN", 42, 98], ["inhibitory receptors", "PROTEIN", 121, 141], ["NK cells", "CELL_TYPE", 179, 187], ["inhibitory receptors", "TREATMENT", 121, 141], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["normal cells", "OBSERVATION", 15, 27], ["NK cells", "OBSERVATION", 179, 187]]], ["Whereas to evade T-cell recognition, viruses reduce ex-pression of the MHC I molecules and result in a low inhibitory signal of NK cells.", [["T-cell", "ANATOMY", 17, 23], ["NK cells", "ANATOMY", 128, 136], ["T-cell", "CELL", 17, 23], ["NK cells", "CELL", 128, 136], ["MHC I molecules", "PROTEIN", 71, 86], ["NK cells", "CELL_TYPE", 128, 136], ["viruses", "PROBLEM", 37, 44], ["a low inhibitory signal of NK cells", "PROBLEM", 101, 136], ["NK cells", "OBSERVATION", 128, 136]]], ["Plus, DNA damage response (DDR) activated by the virus increases cellular stress.", [["cellular", "ANATOMY", 65, 73], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["cellular", "CELL", 65, 73], ["DNA damage response", "PROBLEM", 6, 25], ["the virus increases cellular stress", "PROBLEM", 45, 80], ["cellular stress", "OBSERVATION", 65, 80]]], ["Altogether these shift the balance of the signal towards NK cell activation, followed by stimulation of NK cells to remove virusinfected cells directly via ADCC or indirectly through secretion of pro-inflammatory cytokines at the times before replicating virion assembly and spreading of virus (Lanier, 2008) .", [["NK cell", "ANATOMY", 57, 64], ["NK cells", "ANATOMY", 104, 112], ["cells", "ANATOMY", 137, 142], ["virion", "ANATOMY", 255, 261], ["NK cell", "CELL", 57, 64], ["NK cells", "CELL", 104, 112], ["virusinfected cells", "CELL", 123, 142], ["NK cells", "CELL_TYPE", 104, 112], ["virusinfected cells", "CELL_TYPE", 123, 142], ["pro-inflammatory cytokines", "PROTEIN", 196, 222], ["NK cell activation", "TREATMENT", 57, 75], ["stimulation of NK cells", "TREATMENT", 89, 112], ["virusinfected cells", "PROBLEM", 123, 142], ["ADCC", "TREATMENT", 156, 160], ["pro-inflammatory cytokines", "PROBLEM", 196, 222], ["replicating virion assembly", "TREATMENT", 243, 270], ["virus", "PROBLEM", 288, 293]]], ["Apart from the positive signaling, this defense mechanism also requires a cell to cell contact to initiate.", [["cell", "ANATOMY", 74, 78], ["cell", "ANATOMY", 82, 86], ["cell", "CELL", 74, 78], ["cell", "CELL", 82, 86], ["the positive signaling", "PROBLEM", 11, 33], ["positive signaling", "OBSERVATION", 15, 33]]], ["Therefore, it is necessary to form a lytic synapse between the target cells and NK cells.Natural Killer cell therapyThe actin cytoskeleton is reorganized followed by polarization of microtubule organizing centre and secretory lysosome toward the lytic synapse.", [["cells", "ANATOMY", 70, 75], ["NK cells", "ANATOMY", 80, 88], ["Killer cell", "ANATOMY", 97, 108], ["cytoskeleton", "ANATOMY", 126, 138], ["microtubule", "ANATOMY", 182, 193], ["secretory lysosome", "ANATOMY", 216, 234], ["lytic synapse", "ANATOMY", 246, 259], ["cells", "CELL", 70, 75], ["NK cells", "CELL", 80, 88], ["Killer cell", "CELL", 97, 108], ["actin", "GENE_OR_GENE_PRODUCT", 120, 125], ["cytoskeleton", "CELLULAR_COMPONENT", 126, 138], ["microtubule", "CELLULAR_COMPONENT", 182, 193], ["organizing centre", "CELLULAR_COMPONENT", 194, 211], ["secretory lysosome", "CELLULAR_COMPONENT", 216, 234], ["lytic synapse", "CELLULAR_COMPONENT", 246, 259], ["target cells", "CELL_TYPE", 63, 75], ["NK cells", "CELL_TYPE", 80, 88], ["actin", "PROTEIN", 120, 125], ["microtubule organizing centre", "PROTEIN", 182, 211], ["a lytic synapse", "PROBLEM", 35, 50], ["Natural Killer cell therapy", "TREATMENT", 89, 116], ["lytic", "OBSERVATION", 37, 42], ["target cells", "OBSERVATION", 63, 75], ["NK cells", "OBSERVATION", 80, 88], ["Killer cell therapy", "OBSERVATION", 97, 116], ["actin cytoskeleton", "OBSERVATION", 120, 138], ["reorganized", "OBSERVATION_MODIFIER", 142, 153], ["secretory lysosome", "OBSERVATION", 216, 234], ["lytic synapse", "OBSERVATION", 246, 259]]], ["After docking to the plasma membrane of NK cells at the synapse, the secretory lysosome, eventually, is fused with the target cell plasma membrane to liberate its cytotoxic granules (Paul, & Lal, 2017) .", [["plasma membrane", "ANATOMY", 21, 36], ["NK cells", "ANATOMY", 40, 48], ["synapse", "ANATOMY", 56, 63], ["secretory lysosome", "ANATOMY", 69, 87], ["cell plasma membrane", "ANATOMY", 126, 146], ["granules", "ANATOMY", 173, 181], ["plasma membrane", "CELLULAR_COMPONENT", 21, 36], ["NK cells", "CELL", 40, 48], ["synapse", "CELLULAR_COMPONENT", 56, 63], ["secretory lysosome", "CELLULAR_COMPONENT", 69, 87], ["cell plasma membrane", "CELLULAR_COMPONENT", 126, 146], ["granules", "ORGANISM_SUBSTANCE", 173, 181], ["NK cells", "CELL_TYPE", 40, 48], ["the plasma membrane of NK cells", "TREATMENT", 17, 48], ["the target cell plasma membrane", "TREATMENT", 115, 146], ["NK cells", "OBSERVATION", 40, 48], ["secretory lysosome", "OBSERVATION", 69, 87], ["cytotoxic granules", "OBSERVATION", 163, 181]]], ["Perforin, a membrane pore-forming molecule which can permeabilise the cells (Tay, & Welsh, 1997) .", [["membrane pore", "ANATOMY", 12, 25], ["cells", "ANATOMY", 70, 75], ["Perforin", "CHEMICAL", 0, 8], ["Perforin", "GENE_OR_GENE_PRODUCT", 0, 8], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["cells", "CELL", 70, 75], ["Perforin", "PROTEIN", 0, 8], ["membrane pore-forming molecule", "PROTEIN", 12, 42], ["a membrane pore-forming molecule", "TREATMENT", 10, 42]]], ["This allows the entry of a serine protease, granzyme, into the target cells and activate caspase molecules to induce apoptosis of target cells (Orange, & Biron, 1996) and influenza virus (Monteiro, Harvey, & Trinchieri, 1998) ; however, it is not demonstrated in lymphocytic choriomeningitis virus (LCMV) (Orange, & Biron, 1996) .", [["cells", "ANATOMY", 70, 75], ["cells", "ANATOMY", 137, 142], ["influenza virus", "DISEASE", 171, 186], ["lymphocytic choriomeningitis virus", "DISEASE", 263, 297], ["serine", "CHEMICAL", 27, 33], ["granzyme", "GENE_OR_GENE_PRODUCT", 44, 52], ["cells", "CELL", 70, 75], ["caspase", "GENE_OR_GENE_PRODUCT", 89, 96], ["cells", "CELL", 137, 142], ["influenza virus", "ORGANISM", 171, 186], ["lymphocytic choriomeningitis virus", "ORGANISM", 263, 297], ["LCMV", "ORGANISM", 299, 303], ["serine protease", "PROTEIN", 27, 42], ["granzyme", "PROTEIN", 44, 52], ["target cells", "CELL_TYPE", 63, 75], ["caspase molecules", "PROTEIN", 89, 106], ["target cells", "CELL_TYPE", 130, 142], ["influenza virus", "SPECIES", 171, 186], ["lymphocytic choriomeningitis virus", "SPECIES", 263, 297], ["lymphocytic choriomeningitis virus", "SPECIES", 263, 297], ["LCMV", "SPECIES", 299, 303], ["a serine protease", "TREATMENT", 25, 42], ["granzyme", "TREATMENT", 44, 52], ["caspase molecules", "TEST", 89, 106], ["apoptosis of target cells", "PROBLEM", 117, 142], ["influenza virus", "PROBLEM", 171, 186], ["lymphocytic choriomeningitis virus", "PROBLEM", 263, 297], ["not demonstrated", "UNCERTAINTY", 243, 259], ["lymphocytic choriomeningitis", "OBSERVATION", 263, 291]]], ["The above infections have shown the NK cell response is dependent upon the endogenous IL-12, conclusively suggesting that the IFN-\u03b3 production by NK cells is an outcome of IL-12 during viral in-fection.", [["NK cell", "ANATOMY", 36, 43], ["NK cells", "ANATOMY", 146, 154], ["infections", "DISEASE", 10, 20], ["NK cell", "CELL", 36, 43], ["IL-12", "GENE_OR_GENE_PRODUCT", 86, 91], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 126, 131], ["NK cells", "CELL", 146, 154], ["IL-12", "GENE_OR_GENE_PRODUCT", 172, 177], ["endogenous IL-12", "PROTEIN", 75, 91], ["IFN", "PROTEIN", 126, 129], ["NK cells", "CELL_TYPE", 146, 154], ["IL", "PROTEIN", 172, 174], ["The above infections", "PROBLEM", 0, 20], ["the endogenous IL", "TEST", 71, 88], ["the IFN", "TEST", 122, 129], ["NK cells", "PROBLEM", 146, 154], ["IL", "TEST", 172, 174], ["viral in-fection", "PROBLEM", 185, 201], ["infections", "OBSERVATION", 10, 20], ["NK cell response", "OBSERVATION", 36, 52]]], ["It would be reasonable to consider NK cell therapy for treating COVID-19, particularly for those who are unrelieved by antiviral medicine.", [["NK cell", "ANATOMY", 35, 42], ["NK cell", "CELL", 35, 42], ["NK cell therapy", "TREATMENT", 35, 50], ["COVID", "TEST", 64, 69], ["antiviral medicine", "TREATMENT", 119, 137]]], ["On these grounds, to clarify the immune-mediated component of NK cells of COVID-19, efforts to develop an animal model would be appreciated.", [["NK cells", "ANATOMY", 62, 70], ["NK cells", "CELL", 62, 70], ["COVID-19", "CELL", 74, 82], ["NK cells", "CELL_TYPE", 62, 70], ["NK cells", "PROBLEM", 62, 70], ["COVID", "TEST", 74, 79], ["NK cells", "OBSERVATION", 62, 70]]], ["Be alert, cytokine storm induced by the exaggerated production of IFN-\u03b3 may be involved in the immunopathological damage in patients with COVID-19.", [["COVID-19", "CHEMICAL", 138, 146], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["patients", "ORGANISM", 124, 132], ["cytokine", "PROTEIN", 10, 18], ["IFN", "PROTEIN", 66, 69], ["\u03b3", "PROTEIN", 70, 71], ["patients", "SPECIES", 124, 132], ["the immunopathological damage", "PROBLEM", 91, 120], ["COVID", "TEST", 138, 143]]], ["Therefore, NK cell therapy may not be suitable for those patients who are suffered from cytokine storm syndrome, especially the critical illness individuals as aforementioned in this review .", [["NK cell", "ANATOMY", 11, 18], ["NK cell", "CELL", 11, 18], ["patients", "ORGANISM", 57, 65], ["cytokine", "PROTEIN", 88, 96], ["patients", "SPECIES", 57, 65], ["NK cell therapy", "TREATMENT", 11, 26], ["cytokine storm syndrome", "PROBLEM", 88, 111], ["the critical illness individuals", "PROBLEM", 124, 156], ["NK cell therapy", "OBSERVATION", 11, 26], ["cytokine storm syndrome", "OBSERVATION", 88, 111]]], ["The therapeutic value of this therapy, alternatively, may be reflected in immunocompromised patients with COVID-19.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["this therapy", "TREATMENT", 25, 37], ["COVID", "TEST", 106, 111], ["may be", "UNCERTAINTY", 54, 60], ["immunocompromised", "OBSERVATION", 74, 91]]], ["In view of this, a thorough risk-benefit assessment must be committed to investigating the potential immune impact, particularly dose-response relationship should be taken into account during the clinical trial.Natural Killer cell therapyUnlike the antiviral drugs, NK cell therapy is fully dependent on harnessing the human immune system to fight the virus.", [["Killer cell", "ANATOMY", 219, 230], ["NK cell", "ANATOMY", 266, 273], ["Killer cell", "CELL", 219, 230], ["NK cell", "CELL", 266, 273], ["human", "ORGANISM", 319, 324], ["immune system", "ANATOMICAL_SYSTEM", 325, 338], ["human", "SPECIES", 319, 324], ["human", "SPECIES", 319, 324], ["benefit assessment", "TEST", 33, 51], ["Natural Killer cell therapy", "TREATMENT", 211, 238], ["the antiviral drugs", "TREATMENT", 245, 264], ["NK cell therapy", "TREATMENT", 266, 281], ["the virus", "PROBLEM", 348, 357], ["Killer cell therapy", "OBSERVATION", 219, 238], ["antiviral drugs", "OBSERVATION", 249, 264]]], ["Since NK cells can be differentiated from induced pluripotent stem cells (iPSCs) and gained from umbilical cord blood, they are a promising source of allogeneic NK cells and are potential to be true off-the-shelf cellular therapies, whereby providing NK cells with a patient-specific basis.", [["NK cells", "ANATOMY", 6, 14], ["pluripotent stem cells", "ANATOMY", 50, 72], ["iPSCs", "ANATOMY", 74, 79], ["umbilical cord blood", "ANATOMY", 97, 117], ["NK cells", "ANATOMY", 161, 169], ["cellular", "ANATOMY", 213, 221], ["NK cells", "ANATOMY", 251, 259], ["NK cells", "CELL", 6, 14], ["pluripotent stem cells", "CELL", 50, 72], ["iPSCs", "CELL", 74, 79], ["cord blood", "ORGANISM_SUBSTANCE", 107, 117], ["NK cells", "CELL", 161, 169], ["cellular", "CELL", 213, 221], ["NK cells", "CELL", 251, 259], ["patient", "ORGANISM", 267, 274], ["NK cells", "CELL_TYPE", 6, 14], ["induced pluripotent stem cells", "CELL_TYPE", 42, 72], ["iPSCs", "CELL_TYPE", 74, 79], ["allogeneic NK cells", "CELL_TYPE", 150, 169], ["NK cells", "CELL_TYPE", 251, 259], ["patient", "SPECIES", 267, 274], ["NK cells", "PROBLEM", 6, 14], ["induced pluripotent stem cells", "PROBLEM", 42, 72], ["umbilical cord blood", "PROBLEM", 97, 117], ["allogeneic NK cells", "TREATMENT", 150, 169], ["cellular therapies", "TREATMENT", 213, 231], ["pluripotent stem cells", "OBSERVATION", 50, 72], ["umbilical cord", "ANATOMY", 97, 111], ["allogeneic NK cells", "OBSERVATION", 150, 169]]], ["Allogeneic induced NK therapy does not require a treatment involving patient-specific cells that spend weeks to synthesize, and it can be applied repeatedly, with the potential to improve clinical benefit based on optimisation of dose and schedule.", [["NK", "ANATOMY", 19, 21], ["cells", "ANATOMY", 86, 91], ["NK", "CELL", 19, 21], ["patient", "ORGANISM", 69, 76], ["cells", "CELL", 86, 91], ["patient", "SPECIES", 69, 76], ["Allogeneic induced NK therapy", "TREATMENT", 0, 29], ["a treatment", "TREATMENT", 47, 58], ["optimisation of dose and schedule", "TREATMENT", 214, 247], ["NK therapy", "OBSERVATION", 19, 29]]], ["In addition, NK cells are capable in recognising various infected cells without the reliance of the presentation of a single antigen, it is superior to T-cell based therapy as it omits some of the resistance mechanisms (Amorosi, 2019) .", [["NK cells", "ANATOMY", 13, 21], ["cells", "ANATOMY", 66, 71], ["T-cell", "ANATOMY", 152, 158], ["NK cells", "CELL", 13, 21], ["cells", "CELL", 66, 71], ["T-cell", "CELL", 152, 158], ["NK cells", "CELL_TYPE", 13, 21], ["infected cells", "CELL_TYPE", 57, 71], ["NK cells", "PROBLEM", 13, 21], ["a single antigen", "PROBLEM", 116, 132], ["T-cell based therapy", "TREATMENT", 152, 172], ["NK cells", "OBSERVATION", 13, 21], ["infected cells", "OBSERVATION", 57, 71]]], ["Most importantly, a clinical and manufacturing collaboration is designed to extend the therapeutic use of CYNK-001 to COVID-19 (GlobeNewswire, 2020).", [["CYNK-001", "CHEMICAL", 106, 114], ["COVID-19", "CHEMICAL", 118, 126], ["CYNK", "TEST", 106, 110], ["COVID", "TEST", 118, 123]]], ["If this allogeneic, off-the-shelf, placental-derived NK therapy shows a satisfactory result, it is feasibly to become a potential novel treatment for COVID-19.Natural Killer cell therapyLastly, for both CP immunotherapy and NK cellular therapy, CP/NK must be manufactured and be utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin.Current challenges of clinical trials and future prospect of therapeutic interventionsThe novel COVID-19 situation has escalated into an unprecedented worldwide crisis in the last few months.", [["placental", "ANATOMY", 35, 44], ["NK", "ANATOMY", 53, 55], ["Killer cell", "ANATOMY", 167, 178], ["NK cellular", "ANATOMY", 224, 235], ["NK", "ANATOMY", 248, 250], ["CP", "CHEMICAL", 245, 247], ["placental", "CELL", 35, 44], ["NK", "CELL", 53, 55], ["Killer cell", "CELL", 167, 178], ["NK cellular", "CELL", 224, 235], ["NK", "CELL", 248, 250], ["human", "ORGANISM", 396, 401], ["human", "SPECIES", 396, 401], ["human", "SPECIES", 396, 401], ["this allogeneic", "TREATMENT", 3, 18], ["NK therapy", "TREATMENT", 53, 63], ["a potential novel treatment", "TREATMENT", 118, 145], ["COVID", "TEST", 150, 155], ["Natural Killer cell therapyLastly", "TREATMENT", 159, 192], ["both CP immunotherapy", "TREATMENT", 198, 219], ["NK cellular therapy", "TREATMENT", 224, 243], ["CP", "PROBLEM", 245, 247], ["NK", "PROBLEM", 248, 250], ["clinical trials", "TREATMENT", 431, 446], ["therapeutic interventions", "TREATMENT", 470, 495], ["The novel COVID", "TEST", 495, 510], ["Killer cell", "OBSERVATION", 167, 178], ["unprecedented", "OBSERVATION_MODIFIER", 546, 559], ["worldwide", "OBSERVATION_MODIFIER", 560, 569], ["crisis", "OBSERVATION", 570, 576]]], ["With the concerted efforts and commitment to researches, many therapeutic regimens have been explored and advocated in the absence of definitive management protocols.", [["many therapeutic regimens", "TREATMENT", 57, 82], ["definitive management protocols", "TREATMENT", 134, 165]]], ["Some therapies may be devel- an urgent unmet that need to determine the optimal treatment including specific antiviral therapy, modulating rationale of the immune system, as well as the capability of supporting failed organ systems.", [["immune system", "ANATOMY", 156, 169], ["organ", "ANATOMY", 218, 223], ["organ", "ORGAN", 218, 223], ["Some therapies", "TREATMENT", 0, 14], ["the optimal treatment", "TREATMENT", 68, 89], ["specific antiviral therapy", "TREATMENT", 100, 126]]], ["However, it is a pity that some of the studies have not been further analysed since they lack scientific rationale, insufficient provision of information regarding active ingredients and the applicability to mainstream medical practice is finite (Lythgoe, & Middleton, 2020) .", [["the studies", "TEST", 35, 46], ["active ingredients", "TREATMENT", 164, 182]]], ["These indeed pose an obstacle towards a successful intervention for COVID-19, if no improvement for these limitations is done, the postponed development of efficient therapy, in particular, concerning the area of investigations on unmet medical need and life-threatening diseases, will lead to a delay in patients' access to treatment in hospitals.", [["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["a successful intervention", "TREATMENT", 38, 63], ["COVID", "TEST", 68, 73], ["efficient therapy", "TREATMENT", 156, 173], ["life-threatening diseases", "PROBLEM", 254, 279], ["treatment in hospitals", "TREATMENT", 325, 347]]], ["Hence it is essential to overcome the challenges to achieve satisfactory and undisrupted access to treatment in hospitals.", [["treatment in hospitals", "TREATMENT", 99, 121]]], ["The upcoming preliminary data may not be sufficient to warrant CP therapy as an official therapy but to provide supportive evidence in proving its competence and feasibility.", [["The upcoming preliminary data", "TEST", 0, 29], ["CP therapy", "TREATMENT", 63, 73], ["an official therapy", "TREATMENT", 77, 96]]], ["It is estimated that there is still a distance for plasma-based therapy to reach the standard authorised treatment for COVID-19.", [["plasma", "ANATOMY", 51, 57], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["plasma-based therapy", "TREATMENT", 51, 71], ["the standard authorised treatment", "TREATMENT", 81, 114], ["COVID", "TEST", 119, 124]]], ["Whereas there are 5 trials involving NK cell for investigations (Lythgoe, & Middleton, 2020) , compare to the above treatment strategies, it is relatively far away to be developed as an intervention strategy in COVID- 19 .", [["NK cell", "ANATOMY", 37, 44], ["NK cell", "CELL", 37, 44], ["NK cell", "CELL_TYPE", 37, 44], ["investigations", "TEST", 49, 63], ["the above treatment strategies", "TREATMENT", 106, 136], ["an intervention strategy", "TREATMENT", 183, 207], ["COVID", "TEST", 211, 216]]], ["Lastly, ivermectin is still under investigation with a pending clinical trial, potential role in COVID-19 must be fully confirmed before deployment of global use (Table 1) .", [["ivermectin", "CHEMICAL", 8, 18], ["ivermectin", "CHEMICAL", 8, 18], ["ivermectin", "SIMPLE_CHEMICAL", 8, 18], ["ivermectin", "TREATMENT", 8, 18], ["COVID", "TEST", 97, 102]]], ["Further clinical trials are expected to be conducted to obtain high-quality data for assessing potentials therapies objectively, so as to assure its effectiveness is satisfactory for COVID-19 qualified therapy.", [["potentials therapies", "TREATMENT", 95, 115], ["COVID-19 qualified therapy", "TREATMENT", 183, 209]]], ["It is believed that there are more international collaboration and the globalisation of clinical trials with larger sample size which have a reliable scientific rationale and statistical rigour for providing conclusive results.Current challenges of clinical trials and future prospect of therapeutic interventionsBy and large, many clinical trials are focusing on antiviral treatments with certain amounts of them targeting in antimalarial drugs, this stands for some point of view that repositioning and repurposing the existing drugs are the main trends in the future therapeutic strategies.", [["larger sample size", "PROBLEM", 109, 127], ["clinical trials", "TREATMENT", 249, 264], ["therapeutic interventionsBy", "TREATMENT", 288, 315], ["antiviral treatments", "TREATMENT", 364, 384], ["antimalarial drugs", "TREATMENT", 427, 445], ["repositioning", "TREATMENT", 487, 500], ["repurposing the existing drugs", "TREATMENT", 505, 535], ["therapeutic strategies", "TREATMENT", 570, 592], ["size", "OBSERVATION_MODIFIER", 123, 127], ["large", "OBSERVATION_MODIFIER", 320, 325]]], ["The repurposed drugs raise considerable interest in being the optimal therapeutic option in managing CoV infections, owing to their advantage of easy availability, known pharmacokinetic properties, sides effects and also well-established regimens (Pillaiyar, Meenakshisundaram, & Manickam, 2020) .", [["CoV infections", "DISEASE", 101, 115], ["CoV", "ORGANISM", 101, 104], ["CoV", "SPECIES", 101, 104], ["The repurposed drugs", "TREATMENT", 0, 20], ["CoV infections", "PROBLEM", 101, 115]]], ["It is forecasted that developmental antiviral treatments would be the fastest approved therapeutic intervention for COVID-19, efforts should also be directed toward evaluating immunotherapies and cellular therapies that are effective against viruses similar to SARS-CoV-2.ConclusionThe recent COVID-19 outbreak has been deemed a global misfortune, especially the COVID-19 cases on the Diamond Princess Cruise Ship, which have raised ethical consideration concerning the psychological fragility and quality of life of the isolated passengers and crew members (Nakazawa, Ino, & Akabayashi, 2020).", [["cellular", "ANATOMY", 196, 204], ["SARS", "DISEASE", 261, 265], ["cellular", "CELL", 196, 204], ["SARS-CoV-2", "ORGANISM", 261, 271], ["SARS-CoV", "SPECIES", 261, 269], ["developmental antiviral treatments", "TREATMENT", 22, 56], ["therapeutic intervention", "TREATMENT", 87, 111], ["COVID", "TREATMENT", 116, 121], ["immunotherapies", "TREATMENT", 176, 191], ["cellular therapies", "TREATMENT", 196, 214], ["viruses", "PROBLEM", 242, 249], ["CoV", "TEST", 266, 269], ["the psychological fragility", "PROBLEM", 466, 493]]], ["Apart from feeling their desperation and fear for tomorrow etched in the worried lines of their face, it is realized that the spread of COVID-19 cannot be fully restricted by quarantine alone.", [["COVID-19", "CHEMICAL", 136, 144], ["COVID-19", "CHEMICAL", 136, 144], ["worried lines", "CELL_LINE", 73, 86], ["COVID-19", "DNA", 136, 144], ["COVID", "TREATMENT", 136, 141]]], ["Such pathogenic COVID-19 is, therefore, demanding efficient therapeutic interventions to precisely treat the sufferers and prevent the new spread.", [["Such pathogenic COVID", "TEST", 0, 21], ["therapeutic interventions", "TREATMENT", 60, 85], ["the new spread", "PROBLEM", 131, 145], ["new", "OBSERVATION_MODIFIER", 135, 138], ["spread", "OBSERVATION_MODIFIER", 139, 145]]], ["Although there are no specific therapies approved by the FDA for COVID-19, many potential therapies are now under development given the similarities and epidemiological characteristics of SARS-CoV.", [["SARS-CoV", "DISEASE", 188, 196], ["COVID-19", "CHEMICAL", 65, 73], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 188, 196], ["SARS-CoV", "SPECIES", 188, 196], ["specific therapies", "TREATMENT", 22, 40], ["COVID", "TEST", 65, 70], ["many potential therapies", "TREATMENT", 75, 99], ["SARS", "PROBLEM", 188, 192], ["no", "UNCERTAINTY", 19, 21]]], ["It has been confirmed that SARS-CoV-2 is genetically similar to SARS-CoV and share the same receptor ACE2.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["SARS-CoV", "ORGANISM", 64, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["ACE2", "PROTEIN", 101, 105], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 64, 72], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["SARS", "OBSERVATION", 27, 31]]], ["Cytokine storm is also observed in all SARS-CoV-2, SARS-CoV and MERS-CoV infections, therefore several antiviral treatments for SARS-CoV and MERS-COV infection have been considered for the COVID-19 rescue.", [["infections", "DISEASE", 73, 83], ["SARS", "DISEASE", 128, 132], ["infection", "DISEASE", 150, 159], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV", "ORGANISM", 51, 59], ["MERS-CoV", "ORGANISM", 64, 72], ["SARS-CoV", "ORGANISM", 128, 136], ["MERS-COV", "ORGANISM", 141, 149], ["Cytokine", "PROTEIN", 0, 8], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 128, 136], ["Cytokine storm", "PROBLEM", 0, 14], ["all SARS", "TEST", 35, 43], ["CoV", "TEST", 44, 47], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["MERS", "PROBLEM", 64, 68], ["CoV infections", "PROBLEM", 69, 83], ["several antiviral treatments", "TREATMENT", 95, 123], ["SARS", "PROBLEM", 128, 132], ["CoV", "PROBLEM", 133, 136], ["MERS", "PROBLEM", 141, 145], ["COV infection", "PROBLEM", 146, 159], ["the COVID", "TEST", 185, 194], ["storm", "OBSERVATION", 9, 14], ["CoV", "ANATOMY", 69, 72], ["infections", "OBSERVATION", 73, 83]]], ["Among the various treatment methods, remdesivir is one of the most promising antiviral therapeutics by acting an inhibitor of RdRp to terminate viral RNA synthesis.", [["remdesivir", "CHEMICAL", 37, 47], ["remdesivir", "CHEMICAL", 37, 47], ["remdesivir", "SIMPLE_CHEMICAL", 37, 47], ["RdRp", "GENE_OR_GENE_PRODUCT", 126, 130], ["RdRp", "PROTEIN", 126, 130], ["viral RNA", "RNA", 144, 153], ["the various treatment methods", "TREATMENT", 6, 35], ["antiviral therapeutics", "TREATMENT", 77, 99], ["an inhibitor of RdRp", "TREATMENT", 110, 130], ["viral RNA synthesis", "PROBLEM", 144, 163], ["viral RNA synthesis", "OBSERVATION", 144, 163]]], ["While CQ and HCQ exert multiple mechanisms to inhibit the viral entry, viral receptor glycosylation, post-translational modification of the viral protein, couple with immunomodulating activities, reflecting they have robust therapeutic values of COVID-19 treatments with pharmaceutical drugs, in which a synergistic effect was demonstrated in the combination of HCQ and azithromycin.", [["CQ", "CHEMICAL", 6, 8], ["HCQ", "CHEMICAL", 13, 16], ["HCQ", "CHEMICAL", 362, 365], ["azithromycin", "CHEMICAL", 370, 382], ["CQ", "CHEMICAL", 6, 8], ["HCQ", "CHEMICAL", 13, 16], ["HCQ", "CHEMICAL", 362, 365], ["azithromycin", "CHEMICAL", 370, 382], ["CQ", "SIMPLE_CHEMICAL", 6, 8], ["HCQ", "SIMPLE_CHEMICAL", 13, 16], ["COVID-19", "SIMPLE_CHEMICAL", 246, 254], ["HCQ", "SIMPLE_CHEMICAL", 362, 365], ["azithromycin", "SIMPLE_CHEMICAL", 370, 382], ["viral receptor", "PROTEIN", 71, 85], ["viral protein", "PROTEIN", 140, 153], ["CQ", "PROBLEM", 6, 8], ["HCQ", "TREATMENT", 13, 16], ["the viral entry", "PROBLEM", 54, 69], ["viral receptor glycosylation", "TREATMENT", 71, 99], ["the viral protein", "PROBLEM", 136, 153], ["COVID-19 treatments", "TREATMENT", 246, 265], ["pharmaceutical drugs", "TREATMENT", 271, 291], ["HCQ", "TREATMENT", 362, 365], ["azithromycin", "TREATMENT", 370, 382], ["viral protein", "OBSERVATION", 140, 153]]], ["Ivermectin is an anti-parasitic drug which shows a potential antiviral ability against SARS-CoV-2 in vitro, its true inhibitory effect is yet to be determined.", [["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV", "SPECIES", 87, 95], ["Ivermectin", "TREATMENT", 0, 10], ["an anti-parasitic drug", "TREATMENT", 14, 36], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["vitro", "TREATMENT", 101, 106]]], ["Besides, the neutralizing effect of antibodies is shown in CP therapy to suppress viral load and improve the immune system, which heightens its value in immunotherapy for COVID-19.", [["immune system", "ANATOMY", 109, 122], ["CP", "CHEMICAL", 59, 61], ["antibodies", "PROTEIN", 36, 46], ["the neutralizing effect of antibodies", "PROBLEM", 9, 46], ["CP therapy", "TREATMENT", 59, 69], ["viral load", "PROBLEM", 82, 92], ["COVID", "TEST", 171, 176]]], ["Likewise, superior effector functions in NK cell therapy to enhance immunity also features its possible role in cellular therapy for COVID-19 pneumonia.", [["NK cell", "ANATOMY", 41, 48], ["cellular", "ANATOMY", 112, 120], ["pneumonia", "DISEASE", 142, 151], ["NK cell", "CELL", 41, 48], ["cellular", "CELL", 112, 120], ["NK cell therapy", "TREATMENT", 41, 56], ["cellular therapy", "TREATMENT", 112, 128], ["COVID", "TEST", 133, 138], ["pneumonia", "PROBLEM", 142, 151], ["NK cell therapy", "OBSERVATION", 41, 56], ["pneumonia", "OBSERVATION", 142, 151]]], ["While urgent, the impact of patient-derived mutation should be taken into account to prevent unexpected risk.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["patient-derived mutation", "TREATMENT", 28, 52]]], ["Nevertheless, the present review is limited by the non-stopping changing of the COVID-19, ever-updating statistics and the continued unravelling of new study findings.", [["the COVID", "TEST", 76, 85], ["new study findings", "TEST", 148, 166]]], ["Although researches are in progress to evaluate the clinical impacts of each therapy, the documented clinical data on different treatment approaches for SARS-CoV-2 are under demand.ConclusionUndoubtedly, the novel COVID-19 pandemic is one of the biggest humanity challenges.", [["SARS", "DISEASE", 153, 157], ["each therapy", "TREATMENT", 72, 84], ["different treatment approaches", "TREATMENT", 118, 148], ["SARS", "PROBLEM", 153, 157]]], ["Lessons from the 2003 SARS outbreak have already warned us not to exclude the possibility of new outbreaks of SARS (Savarino et al., 2003) .", [["SARS", "DISEASE", 22, 26], ["SARS", "DISEASE", 110, 114], ["SARS", "PROBLEM", 110, 114]]], ["There is no time for us to sacrifice the lives of today; instead, it is now the time for us to demand a concerted endeavor for COVID-19 rescue.", [["COVID-19", "CHEMICAL", 127, 135], ["COVID", "TREATMENT", 127, 132], ["no", "UNCERTAINTY", 9, 11]]], ["Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or ex vivo human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating the development of the therapeutic intervention.", [["lung tissues", "ANATOMY", 135, 147], ["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["human", "ORGANISM", 129, 134], ["lung tissues", "TISSUE", 135, 147], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["SARS", "PROBLEM", 70, 74], ["CoV-2 pathogenesis", "PROBLEM", 75, 93], ["the novel viruses", "PROBLEM", 204, 221], ["the therapeutic intervention", "TREATMENT", 263, 291], ["lung", "ANATOMY", 135, 139]]], ["Also, clinical trials should be focused on the determinants of therapies safety and efficacy.", [["therapies safety", "TREATMENT", 63, 79]]]], "PMC7166516": [["AbbreviationsAn investigation was performed to determine the cause of increased morbidity and mortality in calves <21 days of age on a large commercial dairy farm.", [["calves", "ORGANISM", 107, 113], ["calves", "SPECIES", 107, 113], ["An investigation", "TEST", 13, 29], ["increased morbidity", "PROBLEM", 70, 89], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["morbidity", "OBSERVATION", 80, 89], ["large", "OBSERVATION_MODIFIER", 135, 140]]], ["Historically, affected calves suffered from anorexia, diarrhea, abnormal gait, seizures, and death between 3 and 14 days of age.", [["anorexia", "DISEASE", 44, 52], ["diarrhea", "DISEASE", 54, 62], ["abnormal gait", "DISEASE", 64, 77], ["seizures", "DISEASE", 79, 87], ["death", "DISEASE", 93, 98], ["calves", "ORGANISM", 23, 29], ["calves", "SPECIES", 23, 29], ["anorexia", "PROBLEM", 44, 52], ["diarrhea", "PROBLEM", 54, 62], ["abnormal gait", "PROBLEM", 64, 77], ["seizures", "PROBLEM", 79, 87], ["death", "PROBLEM", 93, 98], ["anorexia", "OBSERVATION", 44, 52]]], ["Serum chemistry determinations and measurement of the sodium content of milk replacer and water used on the farm identified salt poisoning as the cause of the clinical signs.", [["Serum", "ANATOMY", 0, 5], ["sodium", "CHEMICAL", 54, 60], ["poisoning", "DISEASE", 129, 138], ["sodium", "CHEMICAL", 54, 60], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["sodium", "SIMPLE_CHEMICAL", 54, 60], ["milk replacer", "ORGANISM_SUBSTANCE", 72, 85], ["salt", "SIMPLE_CHEMICAL", 124, 128], ["Serum chemistry determinations", "TEST", 0, 30], ["the sodium content of milk replacer", "TREATMENT", 50, 85], ["salt poisoning", "PROBLEM", 124, 138], ["the clinical signs", "PROBLEM", 155, 173]]], ["The use of high salinity water to mix milk replacer, mixing of oral electrolyte powder directly into liquid feed, adding additional milk replacer powder to the same volume of water for daily cold weather feedings, and limited access to water contributed to the salt poisoning.", [["oral", "ANATOMY", 63, 67], ["poisoning", "DISEASE", 266, 275], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["oral", "ORGANISM_SUBDIVISION", 63, 67], ["salt", "SIMPLE_CHEMICAL", 261, 265], ["high salinity water to mix milk replacer", "TREATMENT", 11, 51], ["oral electrolyte powder", "TREATMENT", 63, 86], ["additional milk replacer powder", "TREATMENT", 121, 152], ["daily cold weather feedings", "TREATMENT", 185, 212], ["the salt poisoning", "PROBLEM", 257, 275]]], ["Morbidity and mortality rates decreased after switching to an entirely whole\u2010milk diet, mixing oral electrolyte powder in water according to label instructions, and providing adlibitum access to normal salinity water.AbbreviationsSodium is the major cation in extracellular fluid, and under normal conditions serves as a marker of total body water.", [["oral", "ANATOMY", 95, 99], ["extracellular fluid", "ANATOMY", 260, 279], ["body", "ANATOMY", 337, 341], ["AbbreviationsSodium", "CHEMICAL", 217, 236], ["oral", "ORGANISM_SUBDIVISION", 95, 99], ["adlibitum", "SIMPLE_CHEMICAL", 175, 184], ["AbbreviationsSodium", "SIMPLE_CHEMICAL", 217, 236], ["cation", "SIMPLE_CHEMICAL", 250, 256], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 260, 273], ["fluid", "ORGANISM_SUBSTANCE", 274, 279], ["body", "ORGANISM_SUBDIVISION", 337, 341], ["Morbidity", "PROBLEM", 0, 9], ["mortality rates", "PROBLEM", 14, 29], ["an entirely whole\u2010milk diet", "TREATMENT", 59, 86], ["mixing oral electrolyte powder", "TREATMENT", 88, 118], ["AbbreviationsSodium", "PROBLEM", 217, 236], ["total body water", "TREATMENT", 331, 347], ["major", "OBSERVATION_MODIFIER", 244, 249], ["cation", "OBSERVATION_MODIFIER", 250, 256], ["extracellular", "OBSERVATION_MODIFIER", 260, 273], ["fluid", "OBSERVATION", 274, 279]]], ["Its osmotic effect is important in establishing concentration gradients that drive fluid shifts between the extracellular and intracellular fluid compartments.", [["fluid", "ANATOMY", 83, 88], ["extracellular", "ANATOMY", 108, 121], ["intracellular fluid compartments", "ANATOMY", 126, 158], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["intracellular fluid compartments", "CELLULAR_COMPONENT", 126, 158], ["Its osmotic effect", "PROBLEM", 0, 18], ["fluid shifts between the extracellular and intracellular fluid compartments", "PROBLEM", 83, 158], ["osmotic effect", "OBSERVATION", 4, 18], ["fluid shifts", "OBSERVATION", 83, 95], ["extracellular", "ANATOMY_MODIFIER", 108, 121], ["intracellular", "ANATOMY_MODIFIER", 126, 139], ["fluid compartments", "OBSERVATION", 140, 158]]], ["Active and passive transport mechanisms in the body facilitate these processes.", [["body", "ANATOMY", 47, 51], ["body", "ORGANISM_SUBDIVISION", 47, 51]]], ["Maintenance of sodium homeostasis is critical to maintaining cellular hydration and preventing rapid fluxes of water between compartments.1, 2", [["cellular", "ANATOMY", 61, 69], ["sodium", "CHEMICAL", 15, 21], ["sodium", "CHEMICAL", 15, 21], ["sodium", "SIMPLE_CHEMICAL", 15, 21], ["cellular", "CELL", 61, 69], ["water", "SIMPLE_CHEMICAL", 111, 116], ["sodium homeostasis", "TREATMENT", 15, 33], ["cellular hydration", "TREATMENT", 61, 79], ["rapid fluxes of water between compartments", "TREATMENT", 95, 137], ["sodium homeostasis", "OBSERVATION", 15, 33], ["cellular hydration", "OBSERVATION", 61, 79], ["rapid", "OBSERVATION_MODIFIER", 95, 100], ["fluxes", "OBSERVATION", 101, 107]]]], "71d3406258973d7ea61a630bf16f5cfa04f78a13": [["Summary A f\u00e6cal suspension from a patient with gastroenteritis, which contained large numbers of coronavirus particles when examined by electron microscopy, was inoculated into human embryo intestinal-organ cultures and primary human embryo-kidney monolayers.", [["embryo intestinal-organ cultures", "ANATOMY", 183, 215], ["embryo-kidney monolayers", "ANATOMY", 234, 258], ["gastroenteritis", "DISEASE", 47, 62], ["patient", "ORGANISM", 34, 41], ["coronavirus", "ORGANISM", 97, 108], ["human", "ORGANISM", 177, 182], ["embryo intestinal-organ cultures", "CELL", 183, 215], ["human", "ORGANISM", 228, 233], ["embryo-kidney monolayers", "CELL", 234, 258], ["human embryo intestinal-organ cultures", "CELL_LINE", 177, 215], ["primary human embryo-kidney monolayers", "CELL_LINE", 220, 258], ["patient", "SPECIES", 34, 41], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 228, 233], ["A f\u00e6cal suspension", "TREATMENT", 8, 26], ["gastroenteritis", "PROBLEM", 47, 62], ["large numbers of coronavirus particles", "PROBLEM", 80, 118], ["electron microscopy", "TEST", 136, 155], ["organ cultures", "TEST", 201, 215], ["primary human embryo-kidney monolayers", "PROBLEM", 220, 258], ["gastroenteritis", "OBSERVATION", 47, 62], ["large", "OBSERVATION_MODIFIER", 80, 85], ["coronavirus particles", "OBSERVATION", 97, 118], ["intestinal", "ANATOMY", 190, 200], ["organ", "ANATOMY", 201, 206], ["kidney", "ANATOMY", 241, 247]]], ["In the organ cultures, the villous epithelium became detached and large numbers of coronavirus particles were seen by electron microscopy both in the medium and in thin sections of the intestinal epithelial cells, where the virus appeared to be multiplying.", [["organ cultures", "ANATOMY", 7, 21], ["villous epithelium", "ANATOMY", 27, 45], ["sections", "ANATOMY", 169, 177], ["intestinal epithelial cells", "ANATOMY", 185, 212], ["organ cultures", "CELL", 7, 21], ["villous epithelium", "TISSUE", 27, 45], ["coronavirus", "ORGANISM", 83, 94], ["intestinal epithelial cells", "CELL", 185, 212], ["intestinal epithelial cells", "CELL_TYPE", 185, 212], ["the organ cultures", "TEST", 3, 21], ["the villous epithelium", "PROBLEM", 23, 45], ["large numbers of coronavirus particles", "PROBLEM", 66, 104], ["electron microscopy", "TEST", 118, 137], ["the virus", "PROBLEM", 220, 229], ["organ", "ANATOMY", 7, 12], ["villous epithelium", "ANATOMY", 27, 45], ["large", "OBSERVATION_MODIFIER", 66, 71], ["numbers", "OBSERVATION_MODIFIER", 72, 79], ["coronavirus particles", "OBSERVATION", 83, 104], ["intestinal epithelial cells", "ANATOMY", 185, 212], ["virus", "OBSERVATION", 224, 229]]], ["In organ cultures and in human embryo-kidney cells, intracytoplasmic virus was demonstrated by indirect immunofluorescence with convalescent serum from the patient.", [["organ cultures", "ANATOMY", 3, 17], ["embryo-kidney cells", "ANATOMY", 31, 50], ["serum", "ANATOMY", 141, 146], ["organ cultures", "CELL", 3, 17], ["human", "ORGANISM", 25, 30], ["embryo-kidney cells", "CELL", 31, 50], ["intracytoplasmic virus", "ORGANISM", 52, 74], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["patient", "ORGANISM", 156, 163], ["human embryo-kidney cells", "CELL_TYPE", 25, 50], ["human", "SPECIES", 25, 30], ["patient", "SPECIES", 156, 163], ["human", "SPECIES", 25, 30], ["organ cultures", "TEST", 3, 17], ["intracytoplasmic virus", "PROBLEM", 52, 74], ["indirect immunofluorescence", "TEST", 95, 122], ["convalescent serum", "TEST", 128, 146], ["organ", "ANATOMY", 3, 8], ["kidney cells", "ANATOMY", 38, 50], ["intracytoplasmic virus", "OBSERVATION", 52, 74]]], ["Coronavirus particles have been seen in samples from three outbreaks of non-bacterial gastroenteritis in humans.", [["samples", "ANATOMY", 40, 47], ["gastroenteritis", "DISEASE", 86, 101], ["humans", "ORGANISM", 105, 111], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["Coronavirus particles", "PROBLEM", 0, 21], ["non-bacterial gastroenteritis in humans", "PROBLEM", 72, 111], ["three", "OBSERVATION_MODIFIER", 53, 58], ["outbreaks", "OBSERVATION_MODIFIER", 59, 68], ["non-bacterial", "OBSERVATION_MODIFIER", 72, 85], ["gastroenteritis", "OBSERVATION", 86, 101]]], ["Faecal samples from the first two outbreaks were inoculated into organ and cell cultures and the coronavirus seen in a faecal sample from the second outbreak is believed to have been propagated.Electron MicroscopyAn extract of faeces from one Bristol patient (case X) collected the day after the onset of symptoms was examined by electron microscopy and large numbers of coronavirus particles with typical projections were seen (fig. la).", [["Faecal samples", "ANATOMY", 0, 14], ["organ", "ANATOMY", 65, 70], ["cell cultures", "ANATOMY", 75, 88], ["faecal sample", "ANATOMY", 119, 132], ["faeces", "ANATOMY", 227, 233], ["Faecal samples", "ORGANISM_SUBSTANCE", 0, 14], ["organ", "ORGAN", 65, 70], ["cell cultures", "CELL", 75, 88], ["coronavirus", "ORGANISM", 97, 108], ["faeces", "ORGANISM_SUBSTANCE", 227, 233], ["patient", "ORGANISM", 251, 258], ["coronavirus", "ORGANISM", 371, 382], ["patient", "SPECIES", 251, 258], ["Faecal samples", "TEST", 0, 14], ["cell cultures", "TEST", 75, 88], ["the coronavirus", "PROBLEM", 93, 108], ["a faecal sample", "TEST", 117, 132], ["symptoms", "PROBLEM", 305, 313], ["electron microscopy", "TEST", 330, 349], ["coronavirus particles", "PROBLEM", 371, 392], ["organ", "ANATOMY", 65, 70], ["cell cultures", "OBSERVATION", 75, 88], ["large", "OBSERVATION_MODIFIER", 354, 359], ["coronavirus particles", "OBSERVATION", 371, 392]]], ["The particles were pleomorphic with an overall diameter ranging from 120 to 230 nm with fringes about 20 nm wide.", [["particles", "OBSERVATION_MODIFIER", 4, 13], ["pleomorphic", "OBSERVATION", 19, 30], ["overall", "OBSERVATION_MODIFIER", 39, 46], ["diameter", "OBSERVATION_MODIFIER", 47, 55], ["ranging", "OBSERVATION_MODIFIER", 56, 63], ["120 to 230 nm", "OBSERVATION_MODIFIER", 69, 82], ["20 nm", "OBSERVATION_MODIFIER", 102, 107]]], ["No internal structure was seen in any of the particles, but some showed the collapsed appearance previously observed with coronaviruses.7Electron MicroscopyThe particles described here were very similar in appearance to some of those described by Mathan et al.5 in faeces of both normal people and patients with sprue in India, including the occasional bizarreshaped particle.", [["sprue", "DISEASE", 312, 317], ["faeces", "ORGANISM_SUBSTANCE", 265, 271], ["people", "ORGANISM", 287, 293], ["patients", "ORGANISM", 298, 306], ["people", "SPECIES", 287, 293], ["patients", "SPECIES", 298, 306], ["internal structure", "PROBLEM", 3, 21], ["the collapsed appearance", "PROBLEM", 72, 96], ["coronaviruses", "PROBLEM", 122, 135], ["Electron Microscopy", "TEST", 137, 156], ["sprue in India", "PROBLEM", 312, 326], ["the occasional bizarreshaped particle", "PROBLEM", 338, 375], ["internal", "OBSERVATION_MODIFIER", 3, 11], ["structure", "OBSERVATION", 12, 21], ["collapsed", "OBSERVATION", 76, 85], ["coronaviruses", "OBSERVATION", 122, 135], ["particles", "OBSERVATION_MODIFIER", 160, 169]]], ["The morphology of the particles is distinct from that of the oncornaviruses, arenaviruses, and orthomyxoviruses, but identical with that of the coronaviruses.8Electron MicroscopyAttempted Propagation 0-05 ml of a 10% faecal emulsion from patient X was inoculated into human embryo intestinal-organ culture.", [["oncornaviruses", "ANATOMY", 61, 75], ["faecal", "ANATOMY", 217, 223], ["embryo intestinal-organ culture", "ANATOMY", 274, 305], ["oncornaviruses", "GENE_OR_GENE_PRODUCT", 61, 75], ["coronaviruses", "ORGANISM", 144, 157], ["faecal", "ORGANISM_SUBSTANCE", 217, 223], ["patient", "ORGANISM", 238, 245], ["human", "ORGANISM", 268, 273], ["embryo intestinal", "MULTI-TISSUE_STRUCTURE", 274, 291], ["patient", "SPECIES", 238, 245], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["arenaviruses", "PROBLEM", 77, 89], ["orthomyxoviruses", "PROBLEM", 95, 111], ["the coronaviruses", "PROBLEM", 140, 157], ["a 10% faecal emulsion", "TREATMENT", 211, 232], ["organ culture", "TEST", 292, 305], ["morphology", "OBSERVATION_MODIFIER", 4, 14], ["particles", "OBSERVATION_MODIFIER", 22, 31], ["distinct", "OBSERVATION_MODIFIER", 35, 43], ["coronaviruses", "OBSERVATION", 144, 157], ["intestinal", "ANATOMY", 281, 291], ["organ", "ANATOMY", 292, 297]]], ["After 2 days' incubation, the columnar epithelium of the villi of the inoculated cultures could be seen macroscopically to have become detached.", [["columnar epithelium", "ANATOMY", 30, 49], ["villi", "ANATOMY", 57, 62], ["cultures", "ANATOMY", 81, 89], ["columnar epithelium", "TISSUE", 30, 49], ["villi", "MULTI-TISSUE_STRUCTURE", 57, 62], ["the inoculated cultures", "TEST", 66, 89], ["columnar", "ANATOMY_MODIFIER", 30, 38], ["epithelium", "ANATOMY_MODIFIER", 39, 49], ["villi", "ANATOMY", 57, 62], ["detached", "OBSERVATION", 135, 143]]], ["Electron microscopy of the fluids from duodenal, jejunal, and ileal organ cultures all showed very large numbers of coronavirus particles (fig. lb) similar to those seen in the faeces.Electron MicroscopyThe detachment of villous epithelium was thought to result from the multiplication of virus, as it did not occur in uninoculated cultures, nor in those inoculated with faecal suspension heated to 5 6\u00b0C for 30 minutes, and there was no bacterial contamination.", [["fluids", "ANATOMY", 27, 33], ["duodenal", "ANATOMY", 39, 47], ["jejunal", "ANATOMY", 49, 56], ["ileal organ cultures", "ANATOMY", 62, 82], ["faeces", "ANATOMY", 177, 183], ["villous epithelium", "ANATOMY", 221, 239], ["cultures", "ANATOMY", 332, 340], ["duodenal", "MULTI-TISSUE_STRUCTURE", 39, 47], ["jejunal", "MULTI-TISSUE_STRUCTURE", 49, 56], ["ileal organ cultures", "CELL", 62, 82], ["coronavirus", "ORGANISM", 116, 127], ["faeces", "ORGANISM_SUBDIVISION", 177, 183], ["villous epithelium", "TISSUE", 221, 239], ["uninoculated cultures", "CELL_LINE", 319, 340], ["Electron microscopy of the fluids from duodenal, jejunal, and ileal organ cultures", "TEST", 0, 82], ["coronavirus particles", "PROBLEM", 116, 137], ["Electron Microscopy", "TEST", 184, 203], ["villous epithelium", "PROBLEM", 221, 239], ["the multiplication of virus", "PROBLEM", 267, 294], ["uninoculated cultures", "TEST", 319, 340], ["faecal suspension", "TREATMENT", 371, 388], ["bacterial contamination", "PROBLEM", 438, 461], ["duodenal", "ANATOMY", 39, 47], ["jejunal", "ANATOMY", 49, 56], ["ileal organ", "ANATOMY", 62, 73], ["coronavirus particles", "OBSERVATION", 116, 137], ["faeces", "OBSERVATION", 177, 183], ["detachment", "OBSERVATION", 207, 217], ["villous epithelium", "OBSERVATION", 221, 239], ["virus", "OBSERVATION", 289, 294], ["no", "UNCERTAINTY", 435, 437], ["bacterial contamination", "OBSERVATION", 438, 461]]], ["The villous epithelium was not shed nor were particles seen in fluids from organ cultures inoculated with faeces from the earlier Weston outbreak which contained as many coronavirus particles as the fseces from patient X. Fluids collected 2 days after inoculation with faecal emulsion from patient X were passed into further organ cultures, and again the villous epithelium became detached, although to a lesser extent, and coronavirus particles in smaller numbers were seen on electron microscopy.Electron MicroscopySections of organ cultures 18 hours after the inoculation of faecal emulsion from patient X showed virus particles with a mean diameter of about 62 nm within cytoplasmic vesicles of the columnar epithelial cells (fig. 2a) .", [["villous epithelium", "ANATOMY", 4, 22], ["organ cultures", "ANATOMY", 75, 89], ["faeces", "ANATOMY", 106, 112], ["organ cultures", "ANATOMY", 325, 339], ["villous epithelium", "ANATOMY", 355, 373], ["organ cultures", "ANATOMY", 529, 543], ["faecal", "ANATOMY", 578, 584], ["cytoplasmic vesicles", "ANATOMY", 675, 695], ["columnar epithelial cells", "ANATOMY", 703, 728], ["villous epithelium", "TISSUE", 4, 22], ["organ cultures", "CELL", 75, 89], ["faeces", "ORGANISM_SUBDIVISION", 106, 112], ["coronavirus", "ORGANISM", 170, 181], ["patient", "ORGANISM", 211, 218], ["patient", "ORGANISM", 290, 297], ["organ cultures", "CELL", 325, 339], ["villous epithelium", "TISSUE", 355, 373], ["coronavirus", "ORGANISM", 424, 435], ["organ cultures", "CELL", 529, 543], ["patient", "ORGANISM", 599, 606], ["cytoplasmic", "ORGANISM_SUBSTANCE", 675, 686], ["vesicles", "CELLULAR_COMPONENT", 687, 695], ["columnar epithelial cells", "CELL", 703, 728], ["columnar epithelial cells", "CELL_TYPE", 703, 728], ["patient", "SPECIES", 211, 218], ["patient", "SPECIES", 290, 297], ["patient", "SPECIES", 599, 606], ["organ cultures", "TEST", 75, 89], ["faeces", "PROBLEM", 106, 112], ["the earlier Weston outbreak", "PROBLEM", 118, 145], ["many coronavirus particles", "PROBLEM", 165, 191], ["Fluids", "TREATMENT", 222, 228], ["faecal emulsion", "TREATMENT", 269, 284], ["further organ cultures", "TEST", 317, 339], ["the villous epithelium", "PROBLEM", 351, 373], ["coronavirus particles in smaller numbers", "PROBLEM", 424, 464], ["electron microscopy", "TEST", 478, 497], ["organ cultures", "TEST", 529, 543], ["the inoculation", "TEST", 559, 574], ["faecal emulsion", "TEST", 578, 593], ["virus particles", "PROBLEM", 616, 631], ["a mean diameter", "TEST", 637, 652], ["villous epithelium", "OBSERVATION", 4, 22], ["fluids", "OBSERVATION", 63, 69], ["coronavirus particles", "OBSERVATION", 170, 191], ["villous epithelium", "ANATOMY", 355, 373], ["detached", "OBSERVATION", 381, 389], ["lesser extent", "OBSERVATION_MODIFIER", 405, 418], ["coronavirus particles", "OBSERVATION", 424, 445], ["smaller", "OBSERVATION_MODIFIER", 449, 456], ["organ", "ANATOMY", 529, 534], ["faecal", "ANATOMY", 578, 584], ["mean diameter", "OBSERVATION_MODIFIER", 639, 652], ["62 nm", "OBSERVATION_MODIFIER", 662, 667], ["cytoplasmic vesicles", "OBSERVATION", 675, 695], ["columnar epithelial cells", "OBSERVATION", 703, 728]]], ["Evidence of multiplication was provided by the presence of crescents of thickened vesicle membrane, which had underlying densely staining material, bulging into the vesicles (fig. 2a ).", [["crescents", "ANATOMY", 59, 68], ["vesicle membrane", "ANATOMY", 82, 98], ["vesicles", "ANATOMY", 165, 173], ["vesicle membrane", "CELLULAR_COMPONENT", 82, 98], ["vesicles", "CELLULAR_COMPONENT", 165, 173], ["multiplication", "PROBLEM", 12, 26], ["crescents of thickened vesicle membrane", "PROBLEM", 59, 98], ["underlying densely staining material", "PROBLEM", 110, 146], ["bulging into the vesicles", "PROBLEM", 148, 173], ["multiplication", "OBSERVATION", 12, 26], ["crescents", "OBSERVATION", 59, 68], ["thickened", "OBSERVATION", 72, 81], ["vesicle membrane", "OBSERVATION", 82, 98], ["densely", "OBSERVATION_MODIFIER", 121, 128], ["staining material", "OBSERVATION", 129, 146], ["bulging", "OBSERVATION", 148, 155], ["vesicles", "ANATOMY", 165, 173]]], ["Furthermore, inclusion bodies containing tubular structures with a mean diameter of 32 nm were seen (fig. 2b ).", [["bodies", "ANATOMY", 23, 29], ["tubular structures", "ANATOMY", 41, 59], ["tubular structures", "MULTI-TISSUE_STRUCTURE", 41, 59], ["inclusion bodies containing tubular structures", "PROBLEM", 13, 59], ["a mean diameter", "TEST", 65, 80], ["bodies", "ANATOMY_MODIFIER", 23, 29], ["tubular", "ANATOMY_MODIFIER", 41, 48], ["mean", "OBSERVATION_MODIFIER", 67, 71], ["diameter", "OBSERVATION_MODIFIER", 72, 80], ["32 nm", "OBSERVATION_MODIFIER", 84, 89]]], ["All these appearances have been previously described in sections of cells infected with coronaviruses.9 10 The nuclei were normal, and budding from the cell surface which is described for many other viruses, but not for coronaviruses, was not seen.", [["sections", "ANATOMY", 56, 64], ["cells", "ANATOMY", 68, 73], ["nuclei", "ANATOMY", 111, 117], ["cell surface", "ANATOMY", 152, 164], ["cells", "CELL", 68, 73], ["coronaviruses", "ORGANISM", 88, 101], ["nuclei", "CELLULAR_COMPONENT", 111, 117], ["budding", "CELLULAR_COMPONENT", 135, 142], ["cell surface", "CELLULAR_COMPONENT", 152, 164], ["coronaviruses", "PROBLEM", 88, 101], ["many other viruses", "PROBLEM", 188, 206], ["coronaviruses", "PROBLEM", 220, 233], ["nuclei", "ANATOMY", 111, 117], ["normal", "OBSERVATION", 123, 129], ["cell surface", "OBSERVATION", 152, 164], ["viruses", "OBSERVATION", 199, 206], ["not for", "UNCERTAINTY", 212, 219], ["coronaviruses", "OBSERVATION", 220, 233], ["not seen", "UNCERTAINTY", 239, 247]]], ["Control cells showed none of these changes.", [["cells", "ANATOMY", 8, 13], ["Control cells", "CELL", 0, 13]]], ["Fsecal emulsion from patient X was also inoculated into primary human embryo-kidney monolayers.Electron MicroscopyBoth these cells and sections of inoculated organ cultures showed immunofluorescence with convalescent serum from patient X and fluorescein-conjugated antihuman globulin.", [["embryo-kidney monolayers", "ANATOMY", 70, 94], ["cells", "ANATOMY", 125, 130], ["sections", "ANATOMY", 135, 143], ["organ cultures", "ANATOMY", 158, 172], ["serum", "ANATOMY", 217, 222], ["fluorescein", "CHEMICAL", 242, 253], ["fluorescein", "CHEMICAL", 242, 253], ["patient", "ORGANISM", 21, 28], ["human", "ORGANISM", 64, 69], ["embryo-kidney monolayers", "CELL", 70, 94], ["cells", "CELL", 125, 130], ["organ cultures", "CELL", 158, 172], ["serum", "ORGANISM_SUBSTANCE", 217, 222], ["patient", "ORGANISM", 228, 235], ["fluorescein", "SIMPLE_CHEMICAL", 242, 253], ["antihuman globulin", "SIMPLE_CHEMICAL", 265, 283], ["primary human embryo-kidney monolayers", "CELL_LINE", 56, 94], ["antihuman globulin", "PROTEIN", 265, 283], ["patient", "SPECIES", 21, 28], ["human", "SPECIES", 64, 69], ["patient", "SPECIES", 228, 235], ["human", "SPECIES", 64, 69], ["Fsecal emulsion", "PROBLEM", 0, 15], ["inoculated organ cultures", "TEST", 147, 172], ["immunofluorescence", "TEST", 180, 198], ["convalescent serum", "TEST", 204, 222], ["fluorescein", "TEST", 242, 253], ["conjugated antihuman globulin", "TREATMENT", 254, 283], ["kidney", "ANATOMY", 77, 83], ["monolayers", "OBSERVATION", 84, 94], ["organ", "ANATOMY", 158, 163]]], ["In the monolayers, after 2 days' incubation, small particulate areas of fluorescence were seen in the cytoplasm of some of the cells (fig. 3a ), which progressed after a further 4 days' incubation to large inclusion-like masses ( fig. 3b ).", [["monolayers", "ANATOMY", 7, 17], ["cytoplasm", "ANATOMY", 102, 111], ["cells", "ANATOMY", 127, 132], ["monolayers", "CELL", 7, 17], ["cytoplasm", "ORGANISM_SUBSTANCE", 102, 111], ["cells", "CELL", 127, 132], ["small particulate areas of fluorescence", "PROBLEM", 45, 84], ["large inclusion-like masses", "PROBLEM", 200, 227], ["monolayers", "OBSERVATION_MODIFIER", 7, 17], ["small", "OBSERVATION_MODIFIER", 45, 50], ["particulate", "OBSERVATION_MODIFIER", 51, 62], ["areas", "OBSERVATION_MODIFIER", 63, 68], ["fluorescence", "OBSERVATION", 72, 84], ["cells", "ANATOMY", 127, 132], ["large", "OBSERVATION_MODIFIER", 200, 205], ["inclusion", "OBSERVATION", 206, 215], ["masses", "OBSERVATION", 221, 227]]], ["This appearance has been described in coronavirus-infected cells.llElectron MicroscopyNo fluorescence was seen in uninoculated cultures,Electron MicroscopyIn the organ cultures 12 hours after inoculation, fluorescence was seen only in the epithelium of the villi and not in other cells-similar to the appearance of pig intestine infected with TGE.", [["organ cultures", "ANATOMY", 162, 176], ["epithelium", "ANATOMY", 239, 249], ["villi", "ANATOMY", 257, 262], ["cells", "ANATOMY", 280, 285], ["intestine", "ANATOMY", 319, 328], ["coronavirus", "ORGANISM", 38, 49], ["organ cultures", "CELL", 162, 176], ["epithelium", "TISSUE", 239, 249], ["villi", "MULTI-TISSUE_STRUCTURE", 257, 262], ["cells", "CELL", 280, 285], ["pig", "ORGANISM", 315, 318], ["intestine", "ORGAN", 319, 328], ["pig", "SPECIES", 315, 318], ["pig", "SPECIES", 315, 318], ["coronavirus", "PROBLEM", 38, 49], ["fluorescence", "PROBLEM", 89, 101], ["uninoculated cultures", "TEST", 114, 135], ["Electron Microscopy", "TEST", 136, 155], ["the organ cultures", "TEST", 158, 176], ["inoculation", "PROBLEM", 192, 203], ["fluorescence", "TEST", 205, 217], ["pig intestine", "PROBLEM", 315, 328], ["fluorescence", "OBSERVATION", 89, 101], ["organ", "ANATOMY", 162, 167], ["epithelium", "ANATOMY_MODIFIER", 239, 249], ["villi", "ANATOMY", 257, 262], ["pig intestine", "ANATOMY", 315, 328], ["infected", "OBSERVATION", 329, 337]]], ["11 The increase in the amount of fluorescence between the 2nd and 4th days in human embryo-kidney cells suggests multiplication and not phagocytosis.", [["embryo-kidney cells", "ANATOMY", 84, 103], ["human", "ORGANISM", 78, 83], ["embryo-kidney cells", "CELL", 84, 103], ["human embryo-kidney cells", "CELL_TYPE", 78, 103], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["the 2nd and 4th days in human embryo-kidney cells", "TREATMENT", 54, 103], ["multiplication", "PROBLEM", 113, 127], ["phagocytosis", "PROBLEM", 136, 148], ["increase", "OBSERVATION_MODIFIER", 7, 15], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["fluorescence", "OBSERVATION", 33, 45], ["human embryo", "ANATOMY", 78, 90], ["kidney", "ANATOMY", 91, 97], ["multiplication", "OBSERVATION", 113, 127], ["not", "UNCERTAINTY", 132, 135], ["phagocytosis", "OBSERVATION_MODIFIER", 136, 148]]], ["More work is required to elucidate the relationship of this virus to gastroenteritis, and to the animal intestinal coronaviruses.", [["intestinal", "ANATOMY", 104, 114], ["gastroenteritis", "DISEASE", 69, 84], ["intestinal coronaviruses", "DISEASE", 104, 128], ["intestinal coronaviruses", "ORGANISM", 104, 128], ["this virus", "PROBLEM", 55, 65], ["gastroenteritis", "PROBLEM", 69, 84], ["the animal intestinal coronaviruses", "PROBLEM", 93, 128], ["gastroenteritis", "OBSERVATION", 69, 84], ["intestinal", "ANATOMY", 104, 114], ["coronaviruses", "OBSERVATION", 115, 128]]], ["Sharpel and Mebusl2 have found antibodies to calf coronavirus in human sera.Electron MicroscopyThese particles cannot be identified as coronaviruses on morphology alone, but the typical electron microscopic appearance in cell sections is very suggestive.Electron MicroscopyDefinite characterisation of the particles as coronaviruses must await further work.", [["sera", "ANATOMY", 71, 75], ["cell sections", "ANATOMY", 221, 234], ["Sharpel", "GENE_OR_GENE_PRODUCT", 0, 7], ["Mebusl2", "GENE_OR_GENE_PRODUCT", 12, 19], ["calf coronavirus", "ORGANISM", 45, 61], ["human", "ORGANISM", 65, 70], ["sera", "ORGANISM_SUBSTANCE", 71, 75], ["cell sections", "MULTI-TISSUE_STRUCTURE", 221, 234], ["coronaviruses", "ORGANISM", 319, 332], ["Sharpel", "PROTEIN", 0, 7], ["Mebusl2", "PROTEIN", 12, 19], ["antibodies", "PROTEIN", 31, 41], ["calf", "SPECIES", 45, 49], ["coronavirus", "SPECIES", 50, 61], ["human", "SPECIES", 65, 70], ["calf coronavirus", "SPECIES", 45, 61], ["human", "SPECIES", 65, 70], ["antibodies to calf coronavirus in human sera", "PROBLEM", 31, 75], ["Electron Microscopy", "TEST", 76, 95], ["cell sections", "TEST", 221, 234], ["coronaviruses", "PROBLEM", 319, 332], ["calf coronavirus", "ANATOMY", 45, 61], ["particles", "OBSERVATION", 101, 110], ["cannot be identified", "UNCERTAINTY", 111, 131], ["cell sections", "OBSERVATION", 221, 234], ["very suggestive", "UNCERTAINTY", 238, 253]]]], "PMC3486865": [["IntroductionInfluenza A viruses (IVs), which belong to the orthomyxoviridae family, consist of eight negative RNA strands.", [["Influenza A viruses", "DISEASE", 12, 31], ["Influenza A viruses", "ORGANISM", 12, 31], ["IVs", "CANCER", 33, 36], ["orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 59, 75], ["orthomyxoviridae family", "PROTEIN", 59, 82], ["negative RNA strands", "RNA", 101, 121], ["Influenza A viruses", "SPECIES", 12, 31], ["RNA strands", "OBSERVATION", 110, 121]]], ["Hemagglutinin (HA) and neuraminidase (NA) are two glycoproteins that are encoded by the IV genome, expressed from segments 4 and 6, respectively.", [["Hemagglutinin", "CHEMICAL", 0, 13], ["HA", "CHEMICAL", 15, 17], ["NA", "CHEMICAL", 38, 40], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 13], ["HA", "GENE_OR_GENE_PRODUCT", 15, 17], ["neuraminidase (NA)", "GENE_OR_GENE_PRODUCT", 23, 41], ["Hemagglutinin", "PROTEIN", 0, 13], ["HA", "PROTEIN", 15, 17], ["neuraminidase", "PROTEIN", 23, 36], ["NA", "PROTEIN", 38, 40], ["glycoproteins", "PROTEIN", 50, 63], ["IV genome", "DNA", 88, 97], ["Hemagglutinin (HA)", "TREATMENT", 0, 18], ["neuraminidase (NA)", "TREATMENT", 23, 41], ["two glycoproteins", "TREATMENT", 46, 63], ["IV genome", "OBSERVATION_MODIFIER", 88, 97], ["segments 4", "ANATOMY_MODIFIER", 114, 124]]], ["The selection due to various host immune systems and anti-flu drugs accelerate the mutation rates of viral proteins, especially for these two membrane proteins [1], [2].", [["membrane", "ANATOMY", 142, 150], ["anti-flu drugs", "SIMPLE_CHEMICAL", 53, 67], ["membrane", "CELLULAR_COMPONENT", 142, 150], ["viral proteins", "PROTEIN", 101, 115], ["membrane proteins", "PROTEIN", 142, 159], ["The selection", "TREATMENT", 0, 13], ["various host immune systems", "TREATMENT", 21, 48], ["anti-flu drugs", "TREATMENT", 53, 67], ["viral proteins", "PROBLEM", 101, 115], ["these two membrane proteins", "TEST", 132, 159]]], ["There are 17 HA subtypes and 10 NA subtypes, designated H1-H17 and N1-N10, respectively.", [["H1-H17", "CELL", 56, 62], ["N1-N10", "CELL", 67, 73], ["H1-H17 and N1-N10", "DNA", 56, 73], ["17 HA subtypes", "PROBLEM", 10, 24], ["10 NA subtypes", "PROBLEM", 29, 43], ["17 HA subtypes", "OBSERVATION_MODIFIER", 10, 24], ["10 NA subtypes", "OBSERVATION_MODIFIER", 29, 43]]], ["Over 118 combinations of IVs can be isolated from wild birds, which are also the natural reservoir of these viruses (except the H17N10 virus, which, until recently, was isolated only from bat) [3]\u2013[5].", [["IVs", "GENE_OR_GENE_PRODUCT", 25, 28], ["birds", "ORGANISM", 55, 60], ["H17N10 virus", "ORGANISM", 128, 140], ["IVs", "TREATMENT", 25, 28], ["these viruses", "PROBLEM", 102, 115], ["the H17N10 virus", "PROBLEM", 124, 140], ["viruses", "OBSERVATION", 108, 115]]], ["The species jumping ability of IVs can result in the infections of poultry and mammals, such as chicken, swine, equine or whale species, with different virulence levels [6]\u2013[9].", [["infections", "DISEASE", 53, 63], ["IVs", "GENE_OR_GENE_PRODUCT", 31, 34], ["chicken", "ORGANISM", 96, 103], ["swine", "ORGANISM", 105, 110], ["equine", "ORGANISM", 112, 118], ["chicken", "SPECIES", 96, 103], ["swine", "SPECIES", 105, 110], ["equine", "SPECIES", 112, 118], ["poultry", "SPECIES", 67, 74], ["chicken", "SPECIES", 96, 103], ["swine", "SPECIES", 105, 110], ["IVs", "TREATMENT", 31, 34], ["the infections of poultry and mammals", "PROBLEM", 49, 86], ["whale species", "PROBLEM", 122, 135], ["different virulence levels", "PROBLEM", 142, 168], ["infections", "OBSERVATION", 53, 63]]], ["The H1N1, H2N2 and H3N2 viruses have been responsible for tens of millions deaths during the deadly history of human influenza epidemics.", [["deaths", "DISEASE", 75, 81], ["influenza epidemics", "DISEASE", 117, 136], ["H2N2", "ORGANISM", 10, 14], ["H3N2 viruses", "ORGANISM", 19, 31], ["human", "ORGANISM", 111, 116], ["H2N2 and H3N2", "SPECIES", 10, 23], ["human", "SPECIES", 111, 116], ["H3N2 viruses", "SPECIES", 19, 31], ["human", "SPECIES", 111, 116], ["The H1N1", "PROBLEM", 0, 8], ["H2N2", "PROBLEM", 10, 14], ["H3N2 viruses", "PROBLEM", 19, 31], ["human influenza epidemics", "PROBLEM", 111, 136], ["H1N1", "OBSERVATION", 4, 8], ["H3N2 viruses", "OBSERVATION", 19, 31], ["influenza", "OBSERVATION", 117, 126]]], ["Furthermore, the H5N1, H7N7, H7N2, H7N3 and H9N2 viruses have been isolated from sporadic human infections and deaths [10]\u2013[13].", [["infections", "DISEASE", 96, 106], ["deaths", "DISEASE", 111, 117], ["H7N7", "ORGANISM", 23, 27], ["H7N2, H7N3", "ORGANISM", 29, 39], ["H9N2 viruses", "ORGANISM", 44, 56], ["human", "ORGANISM", 90, 95], ["H9N2", "SPECIES", 44, 48], ["human", "SPECIES", 90, 95], ["H7N7", "SPECIES", 23, 27], ["H7N2", "SPECIES", 29, 33], ["H7N3", "SPECIES", 35, 39], ["H9N2 viruses", "SPECIES", 44, 56], ["human", "SPECIES", 90, 95], ["the H5N1", "TEST", 13, 21], ["H7N7", "PROBLEM", 23, 27], ["H7N2", "TEST", 29, 33], ["H7N3", "PROBLEM", 35, 39], ["H9N2 viruses", "PROBLEM", 44, 56], ["sporadic human infections", "PROBLEM", 81, 106]]], ["It is worth noting that the H5N1 virus is the most severe for human and avian species, with sudden onset and high mortality.", [["H5N1 virus", "ORGANISM", 28, 38], ["human", "ORGANISM", 62, 67], ["H5N1 virus", "SPECIES", 28, 38], ["human", "SPECIES", 62, 67], ["H5N1 virus", "SPECIES", 28, 38], ["human", "SPECIES", 62, 67], ["the H5N1 virus", "PROBLEM", 24, 38], ["human and avian species", "PROBLEM", 62, 85], ["high mortality", "PROBLEM", 109, 123], ["H5N1", "OBSERVATION", 28, 32], ["high", "OBSERVATION_MODIFIER", 109, 113], ["mortality", "OBSERVATION", 114, 123]]], ["The mortality rate in hundreds of patients who were hospitalized for H5N1 infections was roughly 59.05%, much higher than the mortality rates of the Spanish Flu or the 2009 influenza pandemic (H1N1) [11], [14], [15].IntroductionAs a requirement for infection, the homotrimeric HAs play a key role in binding to the host sialic acid (SA) receptors and membrane fusion.", [["membrane", "ANATOMY", 351, 359], ["H5N1 infections", "DISEASE", 69, 84], ["Flu", "CHEMICAL", 157, 160], ["influenza pandemic", "DISEASE", 173, 191], ["H1N1", "DISEASE", 193, 197], ["infection", "DISEASE", 249, 258], ["sialic acid", "CHEMICAL", 320, 331], ["sialic acid", "CHEMICAL", 320, 331], ["patients", "ORGANISM", 34, 42], ["homotrimeric HAs", "GENE_OR_GENE_PRODUCT", 264, 280], ["sialic acid (SA) receptors", "GENE_OR_GENE_PRODUCT", 320, 346], ["membrane", "CELLULAR_COMPONENT", 351, 359], ["host sialic acid (SA) receptors", "PROTEIN", 315, 346], ["patients", "SPECIES", 34, 42], ["H5N1", "SPECIES", 69, 73], ["H5N1 infections", "PROBLEM", 69, 84], ["infection", "PROBLEM", 249, 258], ["the host sialic acid (SA) receptors", "TREATMENT", 311, 346], ["membrane fusion", "TREATMENT", 351, 366], ["infection", "OBSERVATION", 249, 258], ["membrane fusion", "OBSERVATION", 351, 366]]], ["The nascent HA of all subtypes consists of conserved structures, including the signal peptide, the cytoplasm domain, the transmembrane domain and the extracellular domain [16].", [["cytoplasm", "ANATOMY", 99, 108], ["transmembrane", "ANATOMY", 121, 134], ["extracellular", "ANATOMY", 150, 163], ["cytoplasm", "ORGANISM_SUBSTANCE", 99, 108], ["transmembrane", "CELLULAR_COMPONENT", 121, 134], ["extracellular", "CELLULAR_COMPONENT", 150, 163], ["cytoplasm domain", "PROTEIN", 99, 115], ["transmembrane domain", "PROTEIN", 121, 141], ["extracellular domain", "PROTEIN", 150, 170], ["the signal peptide", "TEST", 75, 93], ["the transmembrane domain", "TEST", 117, 141], ["all subtypes", "OBSERVATION_MODIFIER", 18, 30], ["cytoplasm domain", "OBSERVATION", 99, 115]]], ["The mature HA monomer can be cleaved by proteases into the global HA1 and stalk HA2 subunits [17].", [["HA", "GENE_OR_GENE_PRODUCT", 11, 13], ["proteases", "PROTEIN", 40, 49], ["global HA1 and stalk HA2 subunits", "PROTEIN", 59, 92], ["The mature HA monomer", "PROBLEM", 0, 21], ["stalk HA2 subunits", "TREATMENT", 74, 92], ["mature", "OBSERVATION_MODIFIER", 4, 10], ["HA monomer", "OBSERVATION_MODIFIER", 11, 21]]], ["When IVs are located in the host digestive tract or respiratory tract cell, the receptor binding domains (RBDs) at the tip of HA1 bind to the SA\u03b12-3Gal or SA\u03b12-6Gal receptors, which are essential for endocytosis [18], [19].", [["digestive tract", "ANATOMY", 33, 48], ["respiratory tract cell", "ANATOMY", 52, 74], ["IVs", "GENE_OR_GENE_PRODUCT", 5, 8], ["digestive tract", "ORGAN", 33, 48], ["respiratory tract cell", "CELL", 52, 74], ["RBDs", "GENE_OR_GENE_PRODUCT", 106, 110], ["\u03b12-3Gal", "GENE_OR_GENE_PRODUCT", 144, 151], ["SA\u03b12-6Gal receptors", "GENE_OR_GENE_PRODUCT", 155, 174], ["IVs", "PROTEIN", 5, 8], ["receptor binding domains", "PROTEIN", 80, 104], ["RBDs", "PROTEIN", 106, 110], ["HA1", "PROTEIN", 126, 129], ["\u03b12", "PROTEIN", 144, 146], ["3Gal", "PROTEIN", 147, 151], ["\u03b12", "PROTEIN", 157, 159], ["6Gal receptors", "PROTEIN", 160, 174], ["IVs", "TREATMENT", 5, 8], ["respiratory tract cell", "PROBLEM", 52, 74], ["the receptor binding domains (RBDs", "PROBLEM", 76, 110], ["HA1 bind", "PROBLEM", 126, 134], ["the SA", "TEST", 138, 144], ["endocytosis", "PROBLEM", 200, 211], ["host", "ANATOMY_MODIFIER", 28, 32], ["digestive tract", "ANATOMY", 33, 48], ["respiratory", "OBSERVATION", 52, 63], ["tract cell", "OBSERVATION", 64, 74], ["tip", "OBSERVATION_MODIFIER", 119, 122]]], ["HA unfold and expose the interior HA2 subunits in the acid environment, then the fusion peptides in HA2 insert themselves into the host membrane (viral membrane fusion) [20], [21].IntroductionHomotetrameric NA is a type II membrane protein, whereas HA is a type I membrane protein.", [["membrane", "ANATOMY", 136, 144], ["membrane", "ANATOMY", 152, 160], ["membrane", "ANATOMY", 264, 272], ["NA", "CHEMICAL", 207, 209], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["Homotetrameric NA", "SIMPLE_CHEMICAL", 192, 209], ["type II", "GENE_OR_GENE_PRODUCT", 215, 222], ["membrane", "CELLULAR_COMPONENT", 223, 231], ["HA", "GENE_OR_GENE_PRODUCT", 249, 251], ["type I", "GENE_OR_GENE_PRODUCT", 257, 263], ["membrane", "CELLULAR_COMPONENT", 264, 272], ["interior HA2 subunits", "PROTEIN", 25, 46], ["HA2", "PROTEIN", 100, 103], ["type II membrane protein", "PROTEIN", 215, 239], ["HA", "PROTEIN", 249, 251], ["type I membrane protein", "PROTEIN", 257, 280], ["HA unfold", "PROBLEM", 0, 9], ["the interior HA2 subunits", "TREATMENT", 21, 46], ["the acid environment", "TREATMENT", 50, 70], ["the fusion peptides", "TREATMENT", 77, 96], ["HA2 insert", "TREATMENT", 100, 110], ["viral membrane fusion", "TREATMENT", 146, 167], ["acid environment", "OBSERVATION", 54, 70], ["host membrane", "OBSERVATION", 131, 144], ["viral membrane fusion", "OBSERVATION", 146, 167]]], ["The nascent NA consists of four parts: the cytoplasm tail (in amino-terminus), the transmembrane domain, the stalk domain and the global domain [22].", [["cytoplasm tail", "ANATOMY", 43, 57], ["transmembrane", "ANATOMY", 83, 96], ["NA", "CHEMICAL", 12, 14], ["amino", "CHEMICAL", 62, 67], ["cytoplasm tail", "CELLULAR_COMPONENT", 43, 57], ["transmembrane", "CELLULAR_COMPONENT", 83, 96], ["cytoplasm tail", "PROTEIN", 43, 57], ["amino-terminus", "PROTEIN", 62, 76], ["transmembrane domain", "PROTEIN", 83, 103], ["stalk domain", "PROTEIN", 109, 121], ["global domain", "PROTEIN", 130, 143], ["The nascent NA", "TEST", 0, 14], ["cytoplasm tail", "OBSERVATION", 43, 57]]], ["Different subtypes of NA are composed of 450\u223c480 amino acids, displaying low sequence similarity.", [["NA", "CHEMICAL", 22, 24], ["amino acids", "CHEMICAL", 49, 60], ["amino acids", "CHEMICAL", 49, 60], ["NA", "MULTI-TISSUE_STRUCTURE", 22, 24], ["amino acids", "AMINO_ACID", 49, 60], ["NA", "TEST", 22, 24], ["amino acids", "TEST", 49, 60]]], ["Although there is variable homology among the various NA subtype sequences, especially in the N1 and N2 subtypes with the deletion of 4\u223c30 amino acids in the stalk domain [23], NA subtypes display stable topologies: a six-bladed \u03b2-propeller fold makes an enzymatic activity domain that functions in the release of progeny virions [24], [25].IntroductionHA and NA have a distribution ratio of 4\u22361 on the influenza viral envelop and maintain the basic functions of host recognition, infection and viral diffusion [26].", [["amino acids", "CHEMICAL", 139, 150], ["NA", "CHEMICAL", 360, 362], ["infection", "DISEASE", 481, 490], ["amino acids", "CHEMICAL", 139, 150], ["amino acids", "AMINO_ACID", 139, 150], ["HA", "GENE_OR_GENE_PRODUCT", 353, 355], ["NA", "SIMPLE_CHEMICAL", 360, 362], ["influenza viral", "ORGANISM", 403, 418], ["NA subtype sequences", "DNA", 54, 74], ["stalk domain", "PROTEIN", 158, 170], ["enzymatic activity domain", "PROTEIN", 255, 280], ["variable homology among the various NA subtype sequences", "PROBLEM", 18, 74], ["the deletion", "TEST", 118, 130], ["amino acids", "TEST", 139, 150], ["the stalk domain", "TEST", 154, 170], ["NA subtypes", "TEST", 177, 188], ["a six-bladed \u03b2-propeller fold", "TREATMENT", 216, 245], ["IntroductionHA", "PROBLEM", 341, 355], ["a distribution ratio", "TEST", 368, 388], ["the influenza viral envelop", "PROBLEM", 399, 426], ["host recognition", "TEST", 463, 479], ["infection", "PROBLEM", 481, 490], ["viral diffusion", "PROBLEM", 495, 510], ["N2 subtypes", "OBSERVATION", 101, 112], ["stable", "OBSERVATION_MODIFIER", 197, 203], ["enzymatic activity", "OBSERVATION", 255, 273]]], ["Various studies have reported that some of the factors that influence HA include the number of the basic residues in the HA0 cleavage site, the mutation of key residues in the RBD, the changing of antigenic sites or N-glycosylation sites (glycosites) and the variation of the topology of N-glycan structures [15], [27].", [["N", "CHEMICAL", 216, 217], ["N", "CHEMICAL", 288, 289], ["HA", "GENE_OR_GENE_PRODUCT", 70, 72], ["HA0", "GENE_OR_GENE_PRODUCT", 121, 124], ["HA0 cleavage site", "PROTEIN", 121, 138], ["RBD", "PROTEIN", 176, 179], ["antigenic sites", "PROTEIN", 197, 212], ["N-glycosylation sites", "PROTEIN", 216, 237], ["Various studies", "TEST", 0, 15], ["influence HA", "PROBLEM", 60, 72], ["the basic residues", "PROBLEM", 95, 113], ["the HA0 cleavage site", "PROBLEM", 117, 138], ["the mutation of key residues in the RBD", "PROBLEM", 140, 179], ["antigenic sites", "TREATMENT", 197, 212], ["N-glycosylation sites", "TREATMENT", 216, 237], ["RBD", "ANATOMY", 176, 179]]], ["Meanwhile, the factors that influence NA include deletion of the stalk domain, the mutations drug-resistance, as well as the changing of antigen sites or glycosites and the variation of the topology of N-glycan structures [28].", [["NA", "CHEMICAL", 38, 40], ["N", "CHEMICAL", 202, 203], ["NA", "SIMPLE_CHEMICAL", 38, 40], ["stalk domain", "PROTEIN", 65, 77], ["antigen sites", "PROTEIN", 137, 150], ["deletion of the stalk domain", "PROBLEM", 49, 77], ["the mutations drug-resistance", "PROBLEM", 79, 108], ["antigen sites", "TREATMENT", 137, 150], ["glycosites", "PROBLEM", 154, 164]]], ["As a kind of glycan-binding protein (GBP), HA works with NA, which functions as an exoglycosidase, cooperatively.", [["NA", "CHEMICAL", 57, 59], ["glycan-binding protein", "GENE_OR_GENE_PRODUCT", 13, 35], ["GBP", "GENE_OR_GENE_PRODUCT", 37, 40], ["NA", "SIMPLE_CHEMICAL", 57, 59], ["exoglycosidase", "GENE_OR_GENE_PRODUCT", 83, 97], ["glycan-binding protein", "PROTEIN", 13, 35], ["GBP", "PROTEIN", 37, 40], ["HA", "PROTEIN", 43, 45], ["exoglycosidase", "PROTEIN", 83, 97], ["HA", "PROBLEM", 43, 45]]], ["Only by achieving a dynamic equilibrium between attaching to the host and releasing progeny virions can the IVs gain a long-term mechanism for infection and diffusion.IntroductionThe existence of N-glycosylation is necessary for viral membrane glycoproteins.", [["virions", "ANATOMY", 92, 99], ["membrane", "ANATOMY", 235, 243], ["infection", "DISEASE", 143, 152], ["N", "CHEMICAL", 196, 197], ["IVs", "GENE_OR_GENE_PRODUCT", 108, 111], ["IVs", "PROTEIN", 108, 111], ["viral membrane glycoproteins", "PROTEIN", 229, 257], ["infection and diffusion", "PROBLEM", 143, 166], ["N-glycosylation", "TREATMENT", 196, 211], ["viral membrane glycoproteins", "PROBLEM", 229, 257], ["infection", "OBSERVATION", 143, 152]]], ["The biosynthesis and modification of nascent secretory or membrane proteins occurs in the endoplasmic reticulum and Golgi, N-linked glycans encode crucial information for the folding, maturation, transport or degradation of proteins [29].", [["membrane", "ANATOMY", 58, 66], ["endoplasmic reticulum", "ANATOMY", 90, 111], ["Golgi", "ANATOMY", 116, 121], ["N", "CHEMICAL", 123, 124], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 90, 111], ["Golgi", "CELLULAR_COMPONENT", 116, 121], ["nascent secretory or membrane proteins", "PROTEIN", 37, 75], ["N-linked glycans", "PROTEIN", 123, 139], ["The biosynthesis", "TREATMENT", 0, 16], ["nascent secretory or membrane proteins", "PROBLEM", 37, 75], ["nascent secretory", "OBSERVATION", 37, 54], ["membrane proteins", "OBSERVATION", 58, 75], ["endoplasmic reticulum", "ANATOMY", 90, 111]]], ["To escape both the host's humoral and cellular immune systems, the potential glycosites in viral envelope proteins can provide the identical glycans as those of the host's cells to mask the antigenic sites [28], [30].", [["cellular", "ANATOMY", 38, 46], ["cells", "ANATOMY", 172, 177], ["cellular", "CELL", 38, 46], ["cells", "CELL", 172, 177], ["viral envelope proteins", "PROTEIN", 91, 114], ["host's cells", "CELL_TYPE", 165, 177], ["cellular immune systems", "TREATMENT", 38, 61], ["the potential glycosites", "PROBLEM", 63, 87], ["viral envelope proteins", "TREATMENT", 91, 114], ["the host's cells", "TREATMENT", 161, 177], ["cellular immune", "OBSERVATION", 38, 53]]], ["Additionally, glycosylation also impacts the sensitivity of HA to temperature, the protection of cleavage sites and the stalk domain, and even the receptor-binding preferences [31]\u2013[33].", [["cleavage sites", "PROTEIN", 97, 111], ["stalk domain", "PROTEIN", 120, 132], ["glycosylation", "TREATMENT", 14, 27], ["HA", "PROBLEM", 60, 62], ["cleavage sites", "TREATMENT", 97, 111]]], ["As the ideal model for the influence of N-glycosylation in pathogen-host interaction, the present studies show that the envelope glycoproteins of IVs appear to only have N-glycosylation, with no O-glycosylation and GPI-anchors [34]; hence, the glycosites discussed in this paper only pertain to N-glycosylation site.IntroductionCurrent studies have analyzed the evolutionary dynamics of N-glycosylation sites of select subtypes or HA/NA as a whole [35]\u2013[37].", [["N", "CHEMICAL", 40, 41], ["N", "CHEMICAL", 170, 171], ["O", "CHEMICAL", 195, 196], ["N", "CHEMICAL", 295, 296], ["N", "CHEMICAL", 387, 388], ["IVs", "GENE_OR_GENE_PRODUCT", 146, 149], ["GPI", "SIMPLE_CHEMICAL", 215, 218], ["envelope glycoproteins", "PROTEIN", 120, 142], ["IVs", "PROTEIN", 146, 149], ["GPI", "PROTEIN", 215, 218], ["N-glycosylation site", "PROTEIN", 295, 315], ["N-glycosylation sites", "PROTEIN", 387, 408], ["N-glycosylation", "TREATMENT", 40, 55], ["the present studies", "TEST", 86, 105], ["the envelope glycoproteins of IVs", "TREATMENT", 116, 149], ["glycosylation", "TREATMENT", 172, 185], ["GPI", "TEST", 215, 218], ["the glycosites", "TREATMENT", 240, 254], ["IntroductionCurrent studies", "TEST", 316, 343], ["HA", "PROBLEM", 431, 433]]], ["Although most influenza evolution can be accounted for by genetic drift, there is also evidence of adaptive evolution of mutations which are under positive selection [38], [39].", [["most influenza evolution", "PROBLEM", 9, 33], ["adaptive evolution of mutations", "PROBLEM", 99, 130], ["influenza", "OBSERVATION", 14, 23]]], ["We have extended previous studies of basic similarity alignment scoring of similarity to analyze the position-specific glycosites that are under selective pressure in IVs [40].", [["previous studies", "TEST", 17, 33], ["specific glycosites", "PROBLEM", 110, 129], ["selective pressure in IVs", "TREATMENT", 145, 170]]], ["Here we present a detailed investigation of the distribution and the evolutionary pattern of the glycosites in the envelope glycoproteins of IVs, especially in the H5N1 virus.Protein sequence data from all subtypes of HA and NA ::: Materials and MethodsThe amino acid sequences of HA and NA were obtained from the NCBI (National Center for Biotechnology Information) Influenza Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU, accessed 15th March 2012) [5].", [["amino acid", "CHEMICAL", 257, 267], ["amino acid", "CHEMICAL", 257, 267], ["IVs", "GENE_OR_GENE_PRODUCT", 141, 144], ["H5N1 virus", "ORGANISM", 164, 174], ["amino acid", "AMINO_ACID", 257, 267], ["envelope glycoproteins", "PROTEIN", 115, 137], ["IVs", "PROTEIN", 141, 144], ["H5N1 virus", "SPECIES", 164, 174], ["H5N1 virus", "SPECIES", 164, 174], ["the glycosites", "PROBLEM", 93, 107], ["IVs", "TREATMENT", 141, 144], ["the H5N1 virus", "PROBLEM", 160, 174], ["Protein sequence data", "TEST", 175, 196], ["HA", "PROBLEM", 218, 220], ["Methods", "TREATMENT", 246, 253], ["The amino acid sequences", "TEST", 253, 277], ["HA", "PROBLEM", 281, 283], ["NA", "TEST", 288, 290], ["H5N1 virus", "OBSERVATION", 164, 174]]], ["To fully understand the distributed regularity of the glycosites in each subtype, we downloaded the 29 sets of HA and NA with the customized definition \u201c>{serotype} {strain} {segname}\u201d using the following combinations: H1Nx\u223cH17Nx and HyN1\u223cHyN10 (where x and y represent \u201cany\u201d by default), in addition to the HA and NA from the H5N1 virus.Protein sequence data from all subtypes of HA and NA ::: Materials and MethodsAll the sequence alignments of the various HAs and NAs were performed using Clustal 2.0.", [["NA", "CHEMICAL", 315, 317], ["H5N1 virus", "ORGANISM", 327, 337], ["HyN1", "PROTEIN", 234, 238], ["N10", "PROTEIN", 241, 244], ["H5N1 virus", "SPECIES", 327, 337], ["H5N1 virus", "SPECIES", 327, 337], ["HA", "PROBLEM", 111, 113], ["NA", "TEST", 118, 120], ["the customized definition", "TEST", 126, 151], ["the HA", "PROBLEM", 304, 310], ["NA", "TEST", 315, 317], ["the H5N1 virus", "PROBLEM", 323, 337], ["Protein sequence data", "TEST", 338, 359], ["HA", "PROBLEM", 381, 383], ["Methods", "TREATMENT", 409, 416], ["Clustal", "TEST", 492, 499], ["H5N1", "OBSERVATION", 327, 331]]], ["Repetitive, incomplete and mixed sequences were removed.", [["Repetitive, incomplete and mixed sequences", "PROBLEM", 0, 42]]], ["For the purpose of convenience, one representative sequence with the generally longest length from each subtype was chosen for further description (Table S1 and S2).Protein sequence data from all subtypes of HA and NA ::: Materials and MethodsTo assess the relationship between the distributed regularity of the glycosites in the envelope glycoproteins and the evolutionary position of various HAs and NAs, firstly, the preliminary trees for each HA and NA subtype were constructed using all available sequences; secondly ten representative sequences from discrepant clades, with consideration of host source and areas, were picked up (excluding H14, H17 and N10 due to limited records).", [["S2", "PROTEIN", 161, 163], ["envelope glycoproteins", "PROTEIN", 330, 352], ["Protein sequence data", "TEST", 165, 186], ["HA", "PROBLEM", 208, 210], ["Methods", "TREATMENT", 236, 243], ["the envelope glycoproteins", "PROBLEM", 326, 352], ["each HA and NA subtype", "TEST", 442, 464], ["all available sequences", "TEST", 488, 511], ["S2", "ANATOMY", 161, 163], ["distributed", "OBSERVATION_MODIFIER", 282, 293], ["regularity", "OBSERVATION_MODIFIER", 294, 304], ["envelope glycoproteins", "OBSERVATION", 330, 352], ["position", "OBSERVATION_MODIFIER", 374, 382]]], ["The phylogenetic trees of the HA and NA were constructed by MEGA5.05 with N-J methods and a p-distance model with a bootstrap value of 1000 [41], [42].Prediction and statistical analysis of potential glycosites ::: Materials and MethodsAs is known, N-X-T/S (X cannot be a proline) is the glycosite motif.", [["N-X-T", "CHEMICAL", 249, 254], ["proline", "CHEMICAL", 272, 279], ["proline", "CHEMICAL", 272, 279], ["glycosite motif", "PROTEIN", 288, 303], ["NA", "TEST", 37, 39], ["N-J methods", "TREATMENT", 74, 85], ["a p-distance model", "TREATMENT", 90, 108], ["a bootstrap value", "TEST", 114, 131], ["MethodsAs", "TEST", 229, 238], ["the glycosite motif", "TREATMENT", 284, 303], ["phylogenetic trees", "OBSERVATION", 4, 22]]], ["Although some researchers have concluded that not all the potential glycosites would be glycosylated in mature glycoproteins, Kelley WM et al. argued that the 14-sugar glycans would be transferred to all the glycosites in nascent proteins and be truncated and modified in the subsequent process [42].Prediction and statistical analysis of potential glycosites ::: Materials and MethodsDue to the fixed pattern of glycosite, many programs and software provide the prediction of glycosites [43], such as the \u201cNetNGlyc 1.0 Server\u201d (www.cbs.dtu.dk/services/NetNGlyc).", [["14-sugar", "CHEMICAL", 159, 167], ["glycosites", "SIMPLE_CHEMICAL", 68, 78], ["nascent proteins", "PROTEIN", 222, 238], ["glycosylated in mature glycoproteins", "PROBLEM", 88, 124], ["Materials", "TREATMENT", 364, 373], ["MethodsDue", "TREATMENT", 378, 388]]], ["By submitting the alignment files to a prediction server, we obtained a series scores for the potential glycosites.", [["a series scores", "TEST", 70, 85]]], ["In consideration of experimental error, those occasional glycosites, which may result from the genomic sequencing or translated by different genetic codes, were excluded.", [["experimental error", "PROBLEM", 20, 38], ["those occasional glycosites", "PROBLEM", 40, 67], ["consideration of", "UNCERTAINTY", 3, 19], ["experimental error", "OBSERVATION", 20, 38]]], ["For example, the 429NLS in the HA of A/duck/Hunan/3315/2006(H5N1) only appears in H5 set once, and it is also embedded inside of HA trimer [44].", [["A/duck/Hunan/3315/2006(H5N1", "ORGANISM", 37, 64], ["429NLS", "DNA", 17, 23], ["H5", "PROTEIN", 82, 84], ["A/duck/Hunan/3315/2006(H5N1)", "SPECIES", 37, 65], ["H5N1", "PROBLEM", 60, 64]]], ["Statistics of the position, pattern and the levels of conservation in various subtypes were used for further discussion (Table S1, File S2).The comparison of 3D structures of HA and NA ::: Materials and MethodsThe available structures of HA and NA would help us to explore the distinctive function of various glycosites.", [["NA", "CHEMICAL", 245, 247], ["HA", "SIMPLE_CHEMICAL", 238, 240], ["NA", "SIMPLE_CHEMICAL", 245, 247], ["Methods", "TREATMENT", 203, 210], ["HA", "PROBLEM", 238, 240], ["position", "OBSERVATION_MODIFIER", 18, 26]]], ["Therefore, we collected the structures of various HA or NA subtypes from the PDB (Protein Data Bank, http://www.rcsb.org/pdb/home/home.do).", [["various HA", "PROBLEM", 42, 52], ["NA subtypes", "PROBLEM", 56, 67], ["PDB", "ANATOMY", 77, 80]]], ["To obtain the whole multimer, these monomer structures were processed with a VMD 1.9 transformation matrix using a Tcl script [45].", [["a VMD 1.9 transformation matrix", "TREATMENT", 75, 106]]], ["The code for each representative structure of the various subtypes of HA and NA and the corresponding source of IVs are shown in Table S2.The comparison of 3D structures of HA and NA ::: Materials and MethodsMost coordinate files of envelope glycoproteins are obtained from X-ray crystallography or NMR.", [["NA", "CHEMICAL", 77, 79], ["NA", "MULTI-TISSUE_STRUCTURE", 77, 79], ["IVs", "CANCER", 112, 115], ["IVs", "PROTEIN", 112, 115], ["envelope glycoproteins", "PROTEIN", 233, 255], ["HA", "PROBLEM", 70, 72], ["NA", "PROBLEM", 77, 79], ["IVs", "PROBLEM", 112, 115], ["envelope glycoproteins", "PROBLEM", 233, 255], ["X-ray crystallography", "TEST", 274, 295], ["NMR", "TEST", 299, 302]]], ["Furthermore, complete larger glycans are too \ufb02exible to yield sufficient electron density [46].", [["electron", "SIMPLE_CHEMICAL", 73, 81], ["complete larger glycans", "PROBLEM", 13, 36]]], ["Isolation and purification of membrane glycoproteins by particular enzyme treatments lead to the lack of partial domains [47].", [["membrane", "ANATOMY", 30, 38], ["membrane glycoproteins", "GENE_OR_GENE_PRODUCT", 30, 52], ["membrane glycoproteins", "PROTEIN", 30, 52], ["Isolation", "TREATMENT", 0, 9], ["purification of membrane glycoproteins", "TREATMENT", 14, 52], ["particular enzyme treatments", "TREATMENT", 56, 84], ["membrane glycoproteins", "OBSERVATION", 30, 52]]], ["Most recorded structures of HAs are lacking the HA0 cleavage site and partial HA2; while those of the NAs are lacking the stem domain.Co-evolution of glycosites in the H5N1 virus ::: Materials and MethodsThe H5N1 virus can be divided into 10 clades, according to the evolutionary position of the HAs defined by the WHO (World Health Organization) in 2008.", [["HAs", "GENE_OR_GENE_PRODUCT", 28, 31], ["H5N1 virus", "ORGANISM", 168, 178], ["H5N1 virus", "ORGANISM", 208, 218], ["HA0 cleavage site", "DNA", 48, 65], ["HA2", "PROTEIN", 78, 81], ["stem domain", "PROTEIN", 122, 133], ["H5N1 virus", "SPECIES", 168, 178], ["H5N1 virus", "SPECIES", 168, 178], ["H5N1 virus", "SPECIES", 208, 218], ["the HA0 cleavage site", "PROBLEM", 44, 65], ["partial HA2", "PROBLEM", 70, 81], ["glycosites", "PROBLEM", 150, 160], ["Materials", "TREATMENT", 183, 192], ["Methods", "TREATMENT", 197, 204], ["The H5N1 virus", "TREATMENT", 204, 218], ["partial", "OBSERVATION_MODIFIER", 70, 77], ["HA2", "OBSERVATION_MODIFIER", 78, 81], ["stem domain", "OBSERVATION", 122, 133], ["H5N1", "OBSERVATION", 168, 172], ["H5N1", "OBSERVATION", 208, 212]]], ["These clades are numbered 0 to 9 [48], [49].", [["These clades", "TEST", 0, 12]]], ["Clades 0\u223c2 are responsible for all the human infections, resulting in 359 deaths since 2003 [11].", [["infections", "DISEASE", 45, 55], ["deaths", "DISEASE", 74, 80], ["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["the human infections", "PROBLEM", 35, 55], ["infections", "OBSERVATION", 45, 55]]], ["Many clades have not been reported for the last four years, while the dominant H5N1 viruses are concentrated in clade 0\u223c2.", [["H5N1 viruses", "ORGANISM", 79, 91], ["H5N1 viruses", "SPECIES", 79, 91], ["the dominant H5N1 viruses", "PROBLEM", 66, 91], ["dominant", "OBSERVATION_MODIFIER", 70, 78], ["H5N1 viruses", "OBSERVATION", 79, 91]]], ["Clade 2.1, clade 2.2 and clade 2.3 have further evolved into third- or fourth-order clades, and these newly formed viruses have become geographic strains.Co-evolution of glycosites in the H5N1 virus ::: Materials and MethodsFor the purpose of investigating the co-evolution relationship between the glycosite patterns of HA and NA, we reconstructed a phylogeny tree of HAs and determined ten clades.", [["H5N1 virus", "ORGANISM", 188, 198], ["H5N1 virus", "SPECIES", 188, 198], ["H5N1 virus", "SPECIES", 188, 198], ["Clade", "TEST", 0, 5], ["these newly formed viruses", "PROBLEM", 96, 122], ["geographic strains", "PROBLEM", 135, 153], ["glycosites", "PROBLEM", 170, 180], ["Methods", "TREATMENT", 217, 224], ["HA", "PROBLEM", 321, 323], ["viruses", "OBSERVATION", 115, 122], ["H5N1", "OBSERVATION", 188, 192]]], ["When discrete monophyletic groups with a common node meet a bootstrap value of \u226560 at the clade-defining node and average percentage pairwise nucleotide distances between and within clades of >1.5% and <1.5%, respectively, they could split into the second-, third-, or even fourth-order clades [50].", [["node", "ANATOMY", 48, 52], ["node", "ANATOMY", 105, 109], ["node", "MULTI-TISSUE_STRUCTURE", 48, 52], ["node", "MULTI-TISSUE_STRUCTURE", 105, 109], ["a bootstrap value", "TEST", 58, 75], ["monophyletic", "OBSERVATION_MODIFIER", 14, 26], ["common node", "ANATOMY", 41, 52], ["node", "OBSERVATION", 105, 109]]], ["The statistics of the glycosites of each HA, as well as the corresponding NA, were recorded according to their clades (Files S3, S4 and Figure S1).Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsAs shown in Figure 1A, the current 17 HA subtypes were concentrated in two evolutionary groups.", [["HA", "GENE_OR_GENE_PRODUCT", 41, 43], ["S4", "PROTEIN", 129, 131], ["each HA", "PROBLEM", 36, 43], ["the corresponding NA", "TEST", 56, 76], ["HA", "PROBLEM", 176, 178], ["ResultsAs", "TEST", 217, 226], ["S4", "ANATOMY", 129, 131]]], ["One large group, represented by H1 and H5, contained H2, H6, H8, H9, H11, H12, H13 and H16; Another large group was represented by H3, and contained H4, H7, H10, H14 and H15.", [["H2, H6, H8, H9, H11, H12, H13 and H16", "CHEMICAL", 53, 90], ["H4, H7, H10, H14 and H15", "CHEMICAL", 149, 173], ["H8", "GENE_OR_GENE_PRODUCT", 61, 63], ["H11", "GENE_OR_GENE_PRODUCT", 69, 72], ["H12", "GENE_OR_GENE_PRODUCT", 74, 77], ["H13", "GENE_OR_GENE_PRODUCT", 79, 82], ["H3", "GENE_OR_GENE_PRODUCT", 131, 133], ["H4", "GENE_OR_GENE_PRODUCT", 149, 151], ["H7", "GENE_OR_GENE_PRODUCT", 153, 155], ["H14", "GENE_OR_GENE_PRODUCT", 162, 165], ["H15", "GENE_OR_GENE_PRODUCT", 170, 173], ["H1", "PROTEIN", 32, 34], ["H5", "PROTEIN", 39, 41], ["H11", "PROTEIN", 69, 72], ["H12", "PROTEIN", 74, 77], ["H16", "PROTEIN", 87, 90], ["H3", "PROTEIN", 131, 133], ["H4", "PROTEIN", 149, 151], ["H7", "PROTEIN", 153, 155], ["H10", "PROTEIN", 157, 160], ["H14", "PROTEIN", 162, 165], ["H15", "PROTEIN", 170, 173], ["H2", "PROBLEM", 53, 55], ["H8", "PROBLEM", 61, 63], ["H9", "PROBLEM", 65, 67], ["H11", "PROBLEM", 69, 72], ["H12", "TEST", 74, 77], ["H13", "TEST", 79, 82], ["H4", "PROBLEM", 149, 151], ["H7", "PROBLEM", 153, 155], ["H14", "TEST", 162, 165], ["large", "OBSERVATION_MODIFIER", 4, 9], ["group", "OBSERVATION", 10, 15], ["H11", "ANATOMY", 69, 72], ["H12", "ANATOMY", 74, 77], ["large", "OBSERVATION_MODIFIER", 100, 105]]], ["Although each subtype of HA had a lower similarity to each other and the distribution of the glycosites differed in sequential numbering, we found that the sequence alignment of all HA subtypes indicated that partial glycosites appeared in similar domains.", [["HA", "GENE_OR_GENE_PRODUCT", 25, 27], ["glycosites", "GENE_OR_GENE_PRODUCT", 93, 103], ["glycosites", "DNA", 93, 103], ["HA", "PROBLEM", 25, 27], ["all HA subtypes", "PROBLEM", 178, 193], ["partial glycosites", "PROBLEM", 209, 227], ["HA", "OBSERVATION", 25, 27], ["partial", "OBSERVATION_MODIFIER", 209, 216], ["glycosites", "OBSERVATION", 217, 227], ["similar domains", "OBSERVATION", 240, 255]]], ["Furthermore, the structure alignment of available HAs also showed that various HA subtypes had a highly conserved structure, and the distribution of glycosites was also regular (Figure S2).Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsBy analyzing the position of glycosites and their conservative rates, we conclude that two types of glycosites appear in HAs: one with a high level of conservation in all HA subtypes and another with various conservative rates in different HA subtypes.", [["glycosites", "GENE_OR_GENE_PRODUCT", 366, 376], ["various HA subtypes", "PROBLEM", 71, 90], ["HA", "PROBLEM", 218, 220], ["glycosites", "TREATMENT", 295, 305], ["all HA subtypes", "PROBLEM", 433, 448], ["distribution", "OBSERVATION_MODIFIER", 133, 145]]], ["Two highly conserved glycosites are located near the HA0 cleavage site (e.g., the 27NNST in H1 or the 30NGT in H8) and the fusion peptide of the HA2 (e.g., the 498NGT in H1 or 500NGS in H5) respectively in all subtypes, and these two glycosites play necessary role in viral life cycle for protecting the HA0 cleavage sites and fusion peptide [34], [51].", [["glycosites", "GENE_OR_GENE_PRODUCT", 21, 31], ["HA0", "GENE_OR_GENE_PRODUCT", 304, 307], ["HA0 cleavage site", "DNA", 53, 70], ["27NNST", "DNA", 82, 88], ["H1", "DNA", 92, 94], ["HA2", "PROTEIN", 145, 148], ["H1", "PROTEIN", 170, 172], ["H5", "PROTEIN", 186, 188], ["HA0 cleavage sites", "DNA", 304, 322], ["NGT in H8", "TREATMENT", 104, 113], ["the fusion peptide", "TREATMENT", 119, 137], ["the HA2", "PROBLEM", 141, 148], ["NGT in H1", "TREATMENT", 163, 172], ["viral life cycle", "TREATMENT", 268, 284], ["the HA0 cleavage sites", "TREATMENT", 300, 322], ["fusion peptide", "TREATMENT", 327, 341], ["glycosites", "OBSERVATION", 21, 31], ["cleavage", "OBSERVATION_MODIFIER", 57, 65], ["site", "OBSERVATION_MODIFIER", 66, 70], ["fusion", "OBSERVATION", 123, 129]]], ["In addition, another highly conserved glycosite appears at C-terminal part of the HA1 sequence, which is near the connection of the global and stalk domains, except in H7 and H15 sequences [52].", [["C", "CHEMICAL", 59, 60], ["glycosite", "GENE_OR_GENE_PRODUCT", 38, 47], ["C-terminal part", "PROTEIN", 59, 74], ["HA1 sequence", "PROTEIN", 82, 94], ["global and stalk domains", "PROTEIN", 132, 156], ["H7", "PROTEIN", 168, 170], ["H15", "PROTEIN", 175, 178], ["glycosite", "OBSERVATION", 38, 47], ["terminal", "ANATOMY_MODIFIER", 61, 69], ["global", "OBSERVATION_MODIFIER", 132, 138]]], ["Three to ten characteristic glycosites were distinctive in each subtype.", [["glycosites", "CANCER", 28, 38], ["ten characteristic", "OBSERVATION_MODIFIER", 9, 27], ["glycosites", "OBSERVATION", 28, 38], ["distinctive", "OBSERVATION_MODIFIER", 44, 55], ["each subtype", "OBSERVATION_MODIFIER", 59, 71]]], ["Their conservative rates were influenced by different internal evolution branches, ranked from 0.5% (e.g., 292NGS with 2.85% in H3) to 100% (e.g., 38NGT with 99.94% in H3), distributed mainly in the global domain.", [["H3", "PROTEIN", 128, 130], ["H3", "PROTEIN", 168, 170], ["global domain", "PROTEIN", 199, 212], ["NGS", "TEST", 110, 113], ["NGT", "TEST", 149, 152], ["branches", "OBSERVATION_MODIFIER", 73, 81], ["global domain", "OBSERVATION", 199, 212]]], ["It is worth mentioning that some highly conserved glycosites were near to cysteines (Figure 1).", [["cysteines", "CHEMICAL", 74, 83], ["glycosites", "GENE_OR_GENE_PRODUCT", 50, 60], ["some highly conserved glycosites", "PROBLEM", 28, 60]]], ["Kozlov et al. hypothesized that ERp53, which is involved in the formation of disulfide bonds during the folding of nascent proteins, would form a complex with calreticulin/calnexin, which depends on precursor N-glycans [53].Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsOne most obvious characteristics of glycosites was that the increasing samples or cross-species reports would lead to more glycosites.", [["samples", "ANATOMY", 372, 379], ["disulfide", "CHEMICAL", 77, 86], ["ERp53", "GENE_OR_GENE_PRODUCT", 32, 37], ["calreticulin", "GENE_OR_GENE_PRODUCT", 159, 171], ["calnexin", "GENE_OR_GENE_PRODUCT", 172, 180], ["ERp53", "PROTEIN", 32, 37], ["nascent proteins", "PROTEIN", 115, 131], ["calreticulin", "PROTEIN", 159, 171], ["calnexin", "PROTEIN", 172, 180], ["disulfide bonds", "PROBLEM", 77, 92], ["nascent proteins", "PROBLEM", 115, 131], ["calreticulin/calnexin", "TREATMENT", 159, 180], ["HA", "PROBLEM", 253, 255], ["glycosites", "PROBLEM", 337, 347], ["the increasing samples or cross-species", "PROBLEM", 357, 396], ["glycosites", "OBSERVATION", 337, 347], ["increasing", "OBSERVATION_MODIFIER", 361, 371]]], ["There are many factors contributing to the existence of numerous glycosites in H1, H3 and H5 subtypes.", [["H3", "GENE_OR_GENE_PRODUCT", 83, 85], ["H3", "PROTEIN", 83, 85], ["numerous glycosites in H1", "PROBLEM", 56, 81], ["H3", "PROBLEM", 83, 85], ["numerous", "OBSERVATION_MODIFIER", 56, 64], ["glycosites", "OBSERVATION", 65, 75], ["H1", "ANATOMY", 79, 81]]], ["Because the RNA virus is rapidly mutating, long-term cross-species infections have resulted in the accumulation of adaptive mutations and glycosites.", [["infections", "DISEASE", 67, 77], ["the RNA virus", "PROBLEM", 8, 21], ["long-term cross-species infections", "PROBLEM", 43, 77], ["adaptive mutations and glycosites", "PROBLEM", 115, 148], ["RNA virus", "OBSERVATION", 12, 21], ["accumulation of", "OBSERVATION", 99, 114], ["adaptive mutations", "OBSERVATION", 115, 133]]], ["Due to the selection pressure of different host immune systems, a disadvantageous mutation would be eliminated while a virus with the gains and losses of glycosites would be conserved.", [["glycosites", "GENE_OR_GENE_PRODUCT", 154, 164], ["a disadvantageous mutation", "PROBLEM", 64, 90], ["a virus", "PROBLEM", 117, 124], ["losses of glycosites", "PROBLEM", 144, 164], ["host immune systems", "OBSERVATION", 43, 62]]], ["For example, the HAs from avian H1N1 or H3N2 virus had less glycosites than those of the seasonal human H1N1 or H3N2 virus (e.g., 286NAS in A/Memphis/28/1983 (H1N1).", [["HAs", "ORGANISM", 17, 20], ["avian H1N1", "ORGANISM", 26, 36], ["H3N2 virus", "ORGANISM", 40, 50], ["human H1N1", "ORGANISM", 98, 108], ["H3N2 virus", "ORGANISM", 112, 122], ["Memphis/28/1983 (H1N1", "ORGANISM", 142, 163], ["avian H1N1 or H3N2 virus", "SPECIES", 26, 50], ["human", "SPECIES", 98, 103], ["H1N1 or H3N2 virus", "SPECIES", 104, 122], ["H3N2 virus", "SPECIES", 40, 50], ["human H1N1 or H3N2 virus", "SPECIES", 98, 122], ["A/Memphis/28/1983 (H1N1)", "SPECIES", 140, 164], ["avian H1N1", "PROBLEM", 26, 36], ["H3N2 virus", "PROBLEM", 40, 50], ["the seasonal human H1N1", "PROBLEM", 85, 108], ["H3N2 virus", "PROBLEM", 112, 122], ["H1N1", "PROBLEM", 159, 163], ["H1N1", "OBSERVATION", 32, 36], ["H3N2", "OBSERVATION", 40, 44]]], ["Figure 2A and File 5S).Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsThe H3 set had the most glycosites (16, as shown in File S6) among all HA subtypes, which were mainly contributed by H3N2 and H3N8 virus.", [["H3", "GENE_OR_GENE_PRODUCT", 104, 106], ["H3N2", "ORGANISM", 217, 221], ["H3N8 virus", "ORGANISM", 226, 236], ["Figure 2A and File 5S", "DNA", 0, 21], ["H3", "PROTEIN", 104, 106], ["S6", "PROTEIN", 157, 159], ["H3N8 virus", "SPECIES", 226, 236], ["HA", "PROBLEM", 52, 54], ["all HA subtypes", "PROBLEM", 167, 182], ["H3N2", "PROBLEM", 217, 221], ["H3N8 virus", "PROBLEM", 226, 236]]], ["The earliest H3 record had only one moderate conservative glycosite (79NCT, e.g. A/equine/Miami/1/1963 (H3N8)) except for six highly conserved glycosites, which is also conserved in most seasonal human H3N2 virus and mammalian H3N8 virus (e.g. A/Denmark/22/2011 (H3N2) or A/equine/Yokohama/aq79/2011 (H3N8)), but not in subsequent avian H3N1\u223c H3N9 virus (e.g. A/duck/Zhejiang/5/2011 (H3N3) or A/duck/Saitama/2/2009 (H3N8).", [["Miami/1/1963 (H3N8)", "ORGANISM", 90, 109], ["glycosites", "GENE_OR_GENE_PRODUCT", 143, 153], ["seasonal", "ORGANISM", 187, 195], ["human H3N2 virus", "ORGANISM", 196, 212], ["mammalian H3N8 virus", "ORGANISM", 217, 237], ["A/Denmark/22/2011 (H3N2)", "ORGANISM", 244, 268], ["A/equine/Yokohama/aq79/2011 (H3N8)", "ORGANISM", 272, 306], ["avian", "ORGANISM", 331, 336], ["H3N1\u223c H3N9 virus", "ORGANISM", 337, 353], ["A/duck", "ORGANISM", 360, 366], ["Zhejiang/5/2011", "ORGANISM", 367, 382], ["A/duck", "ORGANISM", 393, 399], ["Saitama/2/2009", "ORGANISM", 400, 414], ["H3N8", "CANCER", 416, 420], ["H3", "PROTEIN", 13, 15], ["human", "SPECIES", 196, 201], ["H3N2 virus", "SPECIES", 202, 212], ["mammalian H3N8 virus", "SPECIES", 217, 237], ["equine", "SPECIES", 274, 280], ["avian H3N1\u223c H3N9 virus", "SPECIES", 331, 353], ["duck", "SPECIES", 362, 366], ["duck", "SPECIES", 395, 399], ["A/equine/Miami/1/1963 (H3N8)", "SPECIES", 81, 109], ["human H3N2 virus", "SPECIES", 196, 212], ["mammalian H3N8 virus", "SPECIES", 217, 237], ["A/Denmark/22/2011 (H3N2)", "SPECIES", 244, 268], ["A/equine/Yokohama/aq79/2011 (H3N8)", "SPECIES", 272, 306], ["H3N1\u223c H3N9 virus", "SPECIES", 337, 353], ["A/duck/Zhejiang/5/2011 (H3N3)", "SPECIES", 360, 389], ["A/duck/Saitama/2/2009 (H3N8)", "SPECIES", 393, 421], ["six highly conserved glycosites", "PROBLEM", 122, 153], ["seasonal human H3N2 virus", "PROBLEM", 187, 212], ["mammalian H3N8 virus", "PROBLEM", 217, 237], ["H3N2", "PROBLEM", 263, 267], ["H3N9 virus", "PROBLEM", 343, 353], ["A/duck/Saitama", "TEST", 393, 407], ["glycosites", "OBSERVATION", 143, 153]]], ["Over the last four decades, seasonal human H3N2 viruses have gradually acquired additional glycosites within the globular HA1 [37], [40].", [["human", "ORGANISM", 37, 42], ["H3N2 viruses", "ORGANISM", 43, 55], ["human", "SPECIES", 37, 42], ["human H3N2 viruses", "SPECIES", 37, 55], ["seasonal human H3N2 viruses", "PROBLEM", 28, 55], ["gradually acquired additional glycosites", "PROBLEM", 61, 101], ["the globular HA1", "TEST", 109, 125], ["H3N2 viruses", "OBSERVATION", 43, 55], ["globular", "OBSERVATION_MODIFIER", 113, 121]]], ["The occurrence of 294NSS has increased the glycosite numbers to 13 in parts of current HA of H3N2 virus from 2010 (A/Singapore/GP5/2011(H3N2).", [["H3N2 virus", "ORGANISM", 93, 103], ["GP5/2011(H3N2", "ORGANISM", 127, 140], ["H3N2 virus", "SPECIES", 93, 103], ["H3N2 virus", "SPECIES", 93, 103], ["A/Singapore/GP5/2011(H3N2", "SPECIES", 115, 140], ["NSS", "TREATMENT", 21, 24], ["H3N2 virus", "PROBLEM", 93, 103], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["File S6).Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsNot all the glycosites shared the same numbering in one subtype.", [["S6", "PROTEIN", 5, 7], ["HA", "PROBLEM", 38, 40], ["one subtype", "OBSERVATION_MODIFIER", 138, 149]]], ["Most glycosites were influenced by the deletion or insertion of the mutants in the upstream sequence, which is also known as \u201cantigenic drift\u201d [54].", [["glycosites", "GENE_OR_GENE_PRODUCT", 5, 15], ["upstream sequence", "DNA", 83, 100], ["Most glycosites", "PROBLEM", 0, 15], ["the deletion", "PROBLEM", 35, 47]]], ["In the HAs of the H1N1 or H5N1 viruses, some nearby glycosites were determined by \u201cantigenic shift\u201d [55].", [["H5N1 viruses", "ORGANISM", 26, 38], ["glycosites", "GENE_OR_GENE_PRODUCT", 52, 62], ["H5N1 viruses", "SPECIES", 26, 38], ["the H1N1", "PROBLEM", 14, 22], ["H5N1 viruses", "PROBLEM", 26, 38], ["some nearby glycosites", "PROBLEM", 40, 62], ["H1N1", "OBSERVATION", 18, 22], ["H5N1 viruses", "OBSERVATION", 26, 38]]], ["In the H1 subtypes, the 144NVT glycosite from the seasonal H1N1 flu, which were isolated from 1940s to 1980s (e.g., A/Memphis/1/1984 (H1N1)), was replaced by the 142NHT glycosite after the 1990s (e.g., A/California/04/2007 (H1N1)).", [["NVT", "GENE_OR_GENE_PRODUCT", 27, 30], ["seasonal H1N1 flu", "ORGANISM", 50, 67], ["Memphis/1/1984 (H1N1", "ORGANISM", 118, 138], ["144NVT glycosite", "DNA", 24, 40], ["seasonal H1N1 flu", "SPECIES", 50, 67], ["seasonal H1N1 flu", "SPECIES", 50, 67], ["A/Memphis/1/1984 (H1N1)", "SPECIES", 116, 139], ["A/California/04/2007 (H1N1)", "SPECIES", 202, 229], ["the 144NVT glycosite", "PROBLEM", 20, 40], ["the seasonal H1N1 flu", "PROBLEM", 46, 67], ["seasonal", "OBSERVATION_MODIFIER", 50, 58], ["H1N1", "OBSERVATION", 59, 63]]], ["Additionally, no such glycosylation appeared in those H1N1 viruses isolated from swine H1N1 flu (e.g., A/swine/Guangdong/1604/2010 (H1N1)), Spanish flu (e.g., A/South Carolina/1/1918 (H1N1)) and the 2009 influenza pandemic (H1N1) (e.g., A/Mexico city/CIA1/2009 (H1N1)).", [["H1N1 flu", "DISEASE", 87, 95], ["Spanish flu", "DISEASE", 140, 151], ["influenza pandemic", "DISEASE", 204, 222], ["H1N1", "DISEASE", 224, 228], ["H1N1 viruses", "ORGANISM", 54, 66], ["swine H1N1 flu", "ORGANISM", 81, 95], ["A/swine/", "ORGANISM", 103, 111], ["Guangdong/1604/2010 (H1N1)", "ORGANISM", 111, 137], ["South Carolina/1/1918 (H1N1", "ORGANISM", 161, 188], ["swine H1N1 flu", "SPECIES", 81, 95], ["swine", "SPECIES", 105, 110], ["influenza pandemic (H1N1", "SPECIES", 204, 228], ["H1N1 viruses", "SPECIES", 54, 66], ["swine H1N1 flu", "SPECIES", 81, 95], ["A/swine/Guangdong/1604/2010 (H1N1)", "SPECIES", 103, 137], ["Spanish flu", "SPECIES", 140, 151], ["A/South Carolina/1/1918 (H1N1)", "SPECIES", 159, 189], ["A/Mexico city/CIA1/2009 (H1N1)", "SPECIES", 237, 267], ["such glycosylation", "PROBLEM", 17, 35], ["those H1N1 viruses", "PROBLEM", 48, 66], ["swine H1N1 flu", "PROBLEM", 81, 95], ["H1N1", "PROBLEM", 132, 136], ["no", "UNCERTAINTY", 14, 16]]], ["It has been partially shown that vaccination of mice with the 1918 influenza strain protected against subsequent lethal infection by the 2009 virus; however, the 1918 strain did not protect against the seasonal H1N1 flu [56].", [["infection", "DISEASE", 120, 129], ["mice", "ORGANISM", 48, 52], ["1918 influenza strain", "ORGANISM", 62, 83], ["mice", "SPECIES", 48, 52], ["seasonal H1N1 flu", "SPECIES", 202, 219], ["mice", "SPECIES", 48, 52], ["2009 virus", "SPECIES", 137, 147], ["seasonal H1N1 flu", "SPECIES", 202, 219], ["vaccination of mice", "TREATMENT", 33, 52], ["the 1918 influenza strain", "TREATMENT", 58, 83], ["subsequent lethal infection", "PROBLEM", 102, 129]]], ["It is interesting to note that the migration of the 179NKS to 177NLS tracks with these effects.", [["NKS", "ANATOMY", 55, 58], ["NKS", "GENE_OR_GENE_PRODUCT", 55, 58]]], ["Almost all of the 179NKS glycosites identified were centralized in swine-origin influenza viruses (S-OIVs, e.g., A/Swine/Guandong/1604/2010 (H1N1)) and parts of the 2009 influeza pandemic H1N1 virus (e.g., A/Mexico City/014/2009 (H1N1)), while the 177NLS glycosite was mainly found in the swine or human H1N2 viruses (e.g., A/New York/481/2003 (H1N2)) and most seasonal flu viruses (e.g., A/California/04/2007 (H1N1)).", [["influenza viruses", "DISEASE", 80, 97], ["pandemic H1N1 virus", "DISEASE", 179, 198], ["glycosite", "CHEMICAL", 255, 264], ["H1N2 viruses", "DISEASE", 304, 316], ["flu viruses", "DISEASE", 370, 381], ["NKS", "GENE_OR_GENE_PRODUCT", 21, 24], ["swine-origin influenza viruses", "ORGANISM", 67, 97], ["Swine/Guandong/1604/2010 (H1N1", "ORGANISM", 115, 145], ["influeza pandemic H1N1 virus", "ORGANISM", 170, 198], ["Mexico City/014/2009 (H1N1)", "ORGANISM", 208, 235], ["swine", "ORGANISM", 289, 294], ["human H1N2 viruses", "ORGANISM", 298, 316], ["A/New York/481/2003 (H1N2)", "ORGANISM", 324, 350], ["A/California/04/2007 (H1N1", "ORGANISM", 389, 415], ["NKS glycosites", "DNA", 21, 35], ["swine", "SPECIES", 67, 72], ["influeza pandemic H1N1 virus", "SPECIES", 170, 198], ["swine", "SPECIES", 289, 294], ["human", "SPECIES", 298, 303], ["H1N2 viruses", "SPECIES", 304, 316], ["swine-origin influenza viruses", "SPECIES", 67, 97], ["A/Swine/Guandong/1604/2010 (H1N1)", "SPECIES", 113, 146], ["2009 influeza pandemic H1N1 virus", "SPECIES", 165, 198], ["A/Mexico City/014/2009 (H1N1)", "SPECIES", 206, 235], ["swine", "SPECIES", 289, 294], ["human H1N2 viruses", "SPECIES", 298, 316], ["A/New York/481/2003 (H1N2)", "SPECIES", 324, 350], ["seasonal flu viruses", "SPECIES", 361, 381], ["A/California/04/2007 (H1N1)", "SPECIES", 389, 416], ["NKS glycosites", "TEST", 21, 35], ["influenza viruses", "PROBLEM", 80, 97], ["A/Swine/Guandong", "TEST", 113, 129], ["H1N1", "PROBLEM", 141, 145], ["influeza pandemic H1N1 virus", "PROBLEM", 170, 198], ["human H1N2 viruses", "PROBLEM", 298, 316], ["H1N2", "PROBLEM", 345, 349], ["most seasonal flu viruses", "PROBLEM", 356, 381], ["influenza viruses", "OBSERVATION", 80, 97], ["flu viruses", "OBSERVATION", 370, 381]]], ["These date further confirm that the HA of the 2009 influenza pandemic (H1N1) originated from S-OIV, not previous seasonal virus [57].", [["influenza pandemic", "DISEASE", 51, 69], ["2009 influenza pandemic", "ORGANISM", 46, 69], ["S-OIV", "ORGANISM", 93, 98], ["S-OIV", "SPECIES", 93, 98], ["the HA of the 2009 influenza pandemic (H1N1)", "PROBLEM", 32, 76], ["previous seasonal virus", "PROBLEM", 104, 127]]], ["Similar positional conversion of the glycosites in H5N1 caused by \u201cantigenic drift\u201d was the \u201c179NYT/181NNT\u201d.", [["H5N1", "DISEASE", 51, 55], ["H5N1", "ORGANISM", 51, 55], ["the glycosites", "TREATMENT", 33, 47], ["H5N1", "PROBLEM", 51, 55], ["positional conversion", "OBSERVATION", 8, 29], ["H5N1", "OBSERVATION", 51, 55]]], ["The conserved 181NNT glycosites have been replaced by the 179NYT in parts of clade 7 viruses since 2005.", [["NNT", "CHEMICAL", 17, 20], ["179NYT", "PROTEIN", 58, 64], ["NNT glycosites", "TREATMENT", 17, 31]]], ["It reminds us that although these glycosites were adjacent, their N-glycans would shield different antigenic sites, which would provide some suggestions for the development of influenza vaccine.Newly emerging Glycosites of HA appeared in distinctive subclades ::: ResultsMoreover, in the smaller cluster of H7, H10 and H15, one highly conserved glycosite appeared in the long a-helix of HA2 (e.g., 431NWT in A/turkey/Chile/4418/02 (H7N3)).", [["influenza", "DISEASE", 176, 185], ["glycosites", "GENE_OR_GENE_PRODUCT", 34, 44], ["glycosite", "CANCER", 345, 354], ["H7", "PROTEIN", 307, 309], ["H10", "PROTEIN", 311, 314], ["H15", "PROTEIN", 319, 322], ["HA2", "PROTEIN", 387, 390], ["turkey", "SPECIES", 410, 416], ["A/turkey/Chile/4418/02 (H7N3)", "SPECIES", 408, 437], ["these glycosites", "PROBLEM", 28, 44], ["their N-glycans", "TREATMENT", 60, 75], ["influenza vaccine", "TREATMENT", 176, 193], ["HA", "PROBLEM", 223, 225], ["H7", "PROBLEM", 307, 309], ["influenza", "OBSERVATION", 176, 185], ["smaller", "OBSERVATION_MODIFIER", 288, 295], ["cluster", "OBSERVATION_MODIFIER", 296, 303], ["H10", "ANATOMY", 311, 314], ["glycosite", "OBSERVATION", 345, 354], ["long", "OBSERVATION_MODIFIER", 371, 375]]], ["This uncommon glycosite requires further investigation (File S1).The glycosylation of NA is affected by the deletion of the stalk domain ::: ResultsIt can be observed from Figure 1B that N10 is highly divergent from other subtypes [4].", [["NA", "CHEMICAL", 86, 88], ["stalk domain", "PROTEIN", 124, 136], ["N10", "PROTEIN", 187, 190]]], ["The remainder of the current 9 NA subtypes are concentrated into two evolutionary groups: one group was represented by N2 and contains N3, N6, N7, and N9; and another group contains N1, N4, N5, and N8.The glycosylation of NA is affected by the deletion of the stalk domain ::: ResultsThe glycosites of NA can be divided into two types according to the distributed region: two to four highly conserved glycosites are located in the stalk domain in each subtype; two conserved glycosites and most middle-low conserved glycosites are mainly located in the global domain, which are near the tip of NA, the connection of the global and stalk domains, or the antigenic sites.", [["NA", "CHEMICAL", 222, 224], ["NA", "CHEMICAL", 302, 304], ["N2", "CHEMICAL", 119, 121], ["N3", "CHEMICAL", 135, 137], ["N6", "CHEMICAL", 139, 141], ["N7", "CHEMICAL", 143, 145], ["N9", "CHEMICAL", 151, 153], ["N1", "CHEMICAL", 182, 184], ["N4", "CHEMICAL", 186, 188], ["N5", "CHEMICAL", 190, 192], ["N8", "CHEMICAL", 198, 200], ["N5", "CELL", 190, 192], ["N8", "SIMPLE_CHEMICAL", 198, 200], ["NA", "SIMPLE_CHEMICAL", 302, 304], ["glycosites", "GENE_OR_GENE_PRODUCT", 401, 411], ["glycosites", "GENE_OR_GENE_PRODUCT", 516, 526], ["N5", "PROTEIN", 190, 192], ["N8", "PROTEIN", 198, 200], ["stalk domain", "PROTEIN", 260, 272], ["stalk domain", "PROTEIN", 431, 443], ["global domain", "PROTEIN", 553, 566], ["global and stalk domains", "PROTEIN", 620, 644], ["antigenic sites", "PROTEIN", 653, 668], ["N7", "TREATMENT", 143, 145], ["N9", "TREATMENT", 151, 153], ["N5", "TREATMENT", 190, 192], ["N8", "TREATMENT", 198, 200], ["The glycosites of NA", "TREATMENT", 284, 304], ["the antigenic sites", "PROBLEM", 649, 668], ["remainder", "OBSERVATION_MODIFIER", 4, 13], ["glycosites", "OBSERVATION", 401, 411], ["stalk", "ANATOMY_MODIFIER", 431, 436], ["glycosites", "OBSERVATION_MODIFIER", 475, 485], ["most", "OBSERVATION_MODIFIER", 490, 494], ["middle", "OBSERVATION_MODIFIER", 495, 501], ["low conserved", "OBSERVATION_MODIFIER", 502, 515], ["glycosites", "OBSERVATION", 516, 526], ["global domain", "OBSERVATION", 553, 566], ["tip", "OBSERVATION_MODIFIER", 587, 590], ["NA", "OBSERVATION", 594, 596], ["global", "OBSERVATION_MODIFIER", 620, 626], ["stalk", "OBSERVATION_MODIFIER", 631, 636], ["domains", "OBSERVATION_MODIFIER", 637, 644], ["antigenic sites", "OBSERVATION", 653, 668]]], ["The glycosite of 146N is conservative in all NA subtypes (e.g., 146NDT in A/Boston/20/2008(H3N2), 144NGT in A/duck/Taiwan/4201/99(H7N7) or 146NGT in /Viet Nam/1203/2004(H5N1)).", [["146N", "GENE_OR_GENE_PRODUCT", 17, 21], ["Boston/20/2008(H3N2", "ORGANISM", 76, 95], ["A/Boston/20/2008(H3N2)", "SPECIES", 74, 96], ["A/duck/Taiwan/4201/99(H7N7)", "SPECIES", 108, 135], ["Viet Nam/1203/2004(H5N1)", "SPECIES", 150, 174], ["NDT", "TEST", 67, 70], ["H3N2", "PROBLEM", 91, 95], ["NGT", "TREATMENT", 101, 104], ["NGT", "TREATMENT", 142, 145], ["NA subtypes", "OBSERVATION_MODIFIER", 45, 56]]], ["It has been shown that the N-glycan at this glycosite affects NA enzymatic activity, causing a 20-fold decrease in activity [58].", [["NA", "CHEMICAL", 62, 64], ["N", "CHEMICAL", 27, 28], ["N-glycan", "GENE_OR_GENE_PRODUCT", 27, 35], ["glycosite", "SIMPLE_CHEMICAL", 44, 53], ["NA", "SIMPLE_CHEMICAL", 62, 64], ["the N-glycan", "TREATMENT", 23, 35], ["a 20-fold decrease in activity", "PROBLEM", 93, 123], ["20-fold", "OBSERVATION_MODIFIER", 95, 102], ["decrease", "OBSERVATION_MODIFIER", 103, 111]]], ["Similar to the description of HAs, a large number of H1N1, H3N2, H5N1, H7N2 and H9N2 viruses have accumulated numerous glycosites in N1 and N2, especially in the global domain, mainly participating in immune evasion.", [["H5N1", "DISEASE", 65, 69], ["N2", "CHEMICAL", 140, 142], ["H1N1, H3N2", "ORGANISM", 53, 63], ["H5N1, H7N2", "ORGANISM", 65, 75], ["H9N2 viruses", "ORGANISM", 80, 92], ["H3N2", "SPECIES", 59, 63], ["H5N1", "SPECIES", 65, 69], ["H9N2", "SPECIES", 80, 84], ["H7N2", "SPECIES", 71, 75], ["H9N2 viruses", "SPECIES", 80, 92], ["H1N1", "PROBLEM", 53, 57], ["H3N2", "PROBLEM", 59, 63], ["H5N1", "PROBLEM", 65, 69], ["H7N2", "PROBLEM", 71, 75], ["H9N2 viruses", "PROBLEM", 80, 92], ["numerous glycosites in N1 and N2", "PROBLEM", 110, 142], ["immune evasion", "TREATMENT", 201, 215], ["large", "OBSERVATION_MODIFIER", 37, 42], ["H1N1", "OBSERVATION", 53, 57], ["H3N2", "OBSERVATION", 59, 63], ["H9N2 viruses", "OBSERVATION", 80, 92], ["numerous", "OBSERVATION_MODIFIER", 110, 118], ["glycosites", "OBSERVATION_MODIFIER", 119, 129], ["N2", "OBSERVATION_MODIFIER", 140, 142], ["global domain", "ANATOMY", 162, 175], ["immune evasion", "OBSERVATION", 201, 215]]], ["Moreover, one conserved glycosite, 12NTT (Conservative rate: 93%, e.g., A/turkey/Italy/3807/2004 (H7N3)), located in the transmembrane domain in N3 and N10, requires further investigation [59].The glycosylation of NA is affected by the deletion of the stalk domain ::: ResultsThe significance of the conserved glycosites in the stalk domain was providing the N-glycans to avoid the cleavage by host enzyme (e.g., Trypsin) [60], [61].", [["transmembrane", "ANATOMY", 121, 134], ["stalk domain", "ANATOMY", 328, 340], ["NA", "CHEMICAL", 214, 216], ["transmembrane", "CELLULAR_COMPONENT", 121, 134], ["glycosites", "GENE_OR_GENE_PRODUCT", 310, 320], ["Trypsin", "GENE_OR_GENE_PRODUCT", 413, 420], ["transmembrane domain", "PROTEIN", 121, 141], ["N3", "PROTEIN", 145, 147], ["N10", "PROTEIN", 152, 155], ["stalk domain", "PROTEIN", 252, 264], ["stalk domain", "PROTEIN", 328, 340], ["host enzyme", "PROTEIN", 394, 405], ["A/turkey/Italy/3807/2004 (H7N3)", "SPECIES", 72, 103], ["Conservative rate", "TEST", 42, 59], ["further investigation", "TEST", 166, 187], ["the conserved glycosites in the stalk domain", "PROBLEM", 296, 340], ["the N-glycans", "TREATMENT", 355, 368], ["the cleavage", "PROBLEM", 378, 390]]], ["The variance of the glycosites was closely related to the deletion of the stalk domain.", [["stalk domain", "PROTEIN", 74, 86], ["the glycosites", "PROBLEM", 16, 30], ["the deletion of the stalk domain", "PROBLEM", 54, 86]]], ["Although the three-dimensional structure of stalk domain has not been determined yet, it is speculated that the presence of an \u03b1-helix motif in the uncrystallized structure has also been provided by cryoelectron microscopy [62].", [["\u03b1-helix", "GENE_OR_GENE_PRODUCT", 127, 134], ["stalk domain", "PROTEIN", 44, 56], ["\u03b1-helix motif", "PROTEIN", 127, 140], ["an \u03b1-helix motif", "TREATMENT", 124, 140], ["cryoelectron microscopy", "TEST", 199, 222], ["stalk domain", "OBSERVATION", 44, 56]]], ["Wagner et al. believed that a longer stem domain would enhance the replication capacity of the virus, while the deletion of the stem domain would decrease the enzymatic activity of NA [63].", [["NA", "CHEMICAL", 181, 183], ["stem domain", "PROTEIN", 128, 139], ["a longer stem domain", "PROBLEM", 28, 48], ["the virus", "PROBLEM", 91, 100], ["the deletion of the stem domain", "PROBLEM", 108, 139]]], ["Various subtypes had stalk domain deletions of 3 to 24 residues, except for N4, N8, N9 and N10.The glycosylation of NA is affected by the deletion of the stalk domain ::: ResultsThe numbers of deletions were also distinctive across different combinations of IVs and even within one subtype, such as the N2 subtype.", [["NA", "CHEMICAL", 116, 118], ["IVs", "CANCER", 258, 261], ["N4", "PROTEIN", 76, 78], ["N8", "PROTEIN", 80, 82], ["N9", "PROTEIN", 84, 86], ["N10", "PROTEIN", 91, 94], ["stalk domain", "PROTEIN", 154, 166], ["stalk domain deletions", "PROBLEM", 21, 43], ["N4", "TREATMENT", 76, 78], ["N8", "TREATMENT", 80, 82], ["N9", "TREATMENT", 84, 86], ["deletions", "PROBLEM", 193, 202], ["IVs", "TREATMENT", 258, 261], ["the N2 subtype", "PROBLEM", 299, 313], ["stalk domain deletions", "OBSERVATION", 21, 43], ["distinctive", "OBSERVATION_MODIFIER", 213, 224], ["N2 subtype", "OBSERVATION", 303, 313]]], ["Generally, no deletions were found in the NA of the H3N2 virus; deletion of 3 residues and one corresponding glycosite with the pattern \u201cE-R-61N-3-64T-V-H\u201d (meaning 3 residues missing between 61N and 64T, e.g., A/chicken/Zhejiang/611/2011 (H9N2)), appeared in most of the NA subtypes of the H9N2 virus.", [["H3N2 virus", "ORGANISM", 52, 62], ["chicken/Zhejiang/611/2011 (H9N2", "ORGANISM", 213, 244], ["H9N2 virus", "ORGANISM", 291, 301], ["H3N2 virus", "SPECIES", 52, 62], ["chicken", "SPECIES", 213, 220], ["H9N2 virus", "SPECIES", 291, 301], ["H3N2 virus", "SPECIES", 52, 62], ["A/chicken/Zhejiang/611/2011 (H9N2", "SPECIES", 211, 244], ["H9N2 virus", "SPECIES", 291, 301], ["deletions", "PROBLEM", 14, 23], ["the H3N2 virus", "PROBLEM", 48, 62], ["deletion of 3 residues", "PROBLEM", 64, 86], ["the pattern", "TEST", 124, 135], ["e.g.", "TEST", 205, 209], ["A/chicken/Zhejiang", "TEST", 211, 229], ["the H9N2 virus", "PROBLEM", 287, 301], ["no", "UNCERTAINTY", 11, 13], ["H9N2 virus", "OBSERVATION", 291, 301]]], ["A similar deletion of 20 residues and two glycosites (I-E-60R-20-80N-I-I) appeared in most NA subtypes of the H6N2 virus (e.g., A/duck/Fujian/3193/2005 (H6N2)).", [["I-E-60R-20-80N-I-I", "GENE_OR_GENE_PRODUCT", 54, 72], ["H6N2 virus", "ORGANISM", 110, 120], ["A/duck", "ORGANISM", 128, 134], ["Fujian/3193/2005 (H6N2)", "ORGANISM", 135, 158], ["H6N2 virus", "SPECIES", 110, 120], ["A/duck/Fujian/3193/2005 (H6N2)", "SPECIES", 128, 158], ["A similar deletion of 20 residues", "PROBLEM", 0, 33], ["two glycosites", "TEST", 38, 52], ["the H6N2 virus", "PROBLEM", 106, 120], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["deletion", "OBSERVATION", 10, 18], ["20 residues", "OBSERVATION_MODIFIER", 22, 33], ["most NA subtypes", "OBSERVATION_MODIFIER", 86, 102]]], ["The deletion of 16 residues and two glycosites as \u201cC-E-55P-16-72T-T-E\u201d were a distinctive part of the H7N2 virus (e.g., A/unknown/New York/19501-5/2006 (H7N2)).", [["H7N2 virus", "ORGANISM", 102, 112], ["H7N2 virus", "SPECIES", 102, 112], ["A/unknown/New York/19501-5/2006 (H7N2)", "SPECIES", 120, 158], ["The deletion of 16 residues", "PROBLEM", 0, 27], ["two glycosites", "TEST", 32, 46], ["C", "TEST", 51, 52]]], ["Parts of the H5N2 virus were characterized by the deletion of 20 residues and two glycosites (\u201cR-N-62I-20-83G-Y-R\u201d, e.g., A/chicken/Ibaraki/3/2005 (H5N2)).", [["H5N2 virus", "ORGANISM", 13, 23], ["Ibaraki/3/2005 (H5N2", "ORGANISM", 132, 152], ["H5N2 virus", "SPECIES", 13, 23], ["chicken", "SPECIES", 124, 131], ["H5N2 virus", "SPECIES", 13, 23], ["A/chicken/Ibaraki/3/2005 (H5N2)", "SPECIES", 122, 153], ["the H5N2 virus", "TREATMENT", 9, 23], ["glycosites", "TEST", 82, 92], ["e.g.", "TEST", 116, 120], ["A/chicken/Ibaraki", "TEST", 122, 139], ["H5N2 virus", "OBSERVATION", 13, 23]]], ["Moreover, in some avian H2N2 viruses, the deletion of 22 residues resulted in the loss of two glycosites; however, a new glycosite appeared in the newly created sequences (\u201cP-A-47N-22-70N-T-V\u201d, e.g., A/chicken/New York/Sg-00300/1997 (H2N2)).", [["avian H2N2 viruses", "ORGANISM", 18, 36], ["T-V", "GENE_OR_GENE_PRODUCT", 188, 191], ["chicken", "ORGANISM", 202, 209], ["Sg-00300/1997 (H2N2)", "ORGANISM", 219, 239], ["avian H2N2", "SPECIES", 18, 28], ["chicken", "SPECIES", 202, 209], ["H2N2 viruses", "SPECIES", 24, 36], ["A/chicken/New York/Sg-00300/1997 (H2N2)", "SPECIES", 200, 239], ["some avian H2N2 viruses", "PROBLEM", 13, 36], ["the deletion of 22 residues", "PROBLEM", 38, 65], ["the loss of two glycosites", "PROBLEM", 78, 104], ["a new glycosite", "PROBLEM", 115, 130], ["P-A-47N-22-70N", "TEST", 173, 187], ["T", "TEST", 188, 189], ["e.g.", "TEST", 194, 198], ["Sg", "TEST", 219, 221], ["H2N2 viruses", "OBSERVATION", 24, 36], ["loss", "OBSERVATION_MODIFIER", 82, 86]]], ["In all, the diversity of deletions in the stalk domain indicates that the glycosylation pattern of HA and NA has a complex relationship.The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsGlobally, the researchers have been paying attention to the highly pathogenic avian influenza (HPAI) since the first human death caused directly by avian H5N1 virus in 1997.", [["NA", "CHEMICAL", 106, 108], ["avian influenza", "DISEASE", 281, 296], ["HPAI", "DISEASE", 298, 302], ["death", "DISEASE", 326, 331], ["avian H5N1 virus", "DISEASE", 351, 367], ["HA", "GENE_OR_GENE_PRODUCT", 99, 101], ["H5N1 virus", "ORGANISM", 181, 191], ["avian influenza", "ORGANISM", 281, 296], ["human", "ORGANISM", 320, 325], ["avian H5N1 virus", "ORGANISM", 351, 367], ["stalk domain", "PROTEIN", 42, 54], ["H5N1 virus", "SPECIES", 181, 191], ["avian influenza", "SPECIES", 281, 296], ["human", "SPECIES", 320, 325], ["avian H5N1 virus", "SPECIES", 351, 367], ["H5N1 virus", "SPECIES", 181, 191], ["HPAI", "SPECIES", 298, 302], ["human", "SPECIES", 320, 325], ["avian H5N1 virus", "SPECIES", 351, 367], ["deletions in the stalk domain", "PROBLEM", 25, 54], ["HA", "PROBLEM", 99, 101], ["The co-evolutionary glycosite pattern", "TEST", 136, 173], ["the highly pathogenic avian influenza (HPAI", "PROBLEM", 259, 302], ["glycosite pattern", "OBSERVATION", 156, 173], ["H5N1", "OBSERVATION", 181, 185]]], ["It is generally considered that the HPAI viruses were characterized by polybasic residues in the HA0 cleavage site in HA and the deletion of the stalk domain in NA [64].", [["HPAI viruses", "ORGANISM", 36, 48], ["HA0", "GENE_OR_GENE_PRODUCT", 97, 100], ["HA0 cleavage site", "PROTEIN", 97, 114], ["stalk domain", "PROTEIN", 145, 157], ["HPAI viruses", "SPECIES", 36, 48], ["the HPAI viruses", "PROBLEM", 32, 48], ["polybasic residues", "PROBLEM", 71, 89], ["the HA0 cleavage site", "PROBLEM", 93, 114], ["HA", "PROBLEM", 118, 120], ["polybasic residues", "OBSERVATION", 71, 89]]], ["The earliest H5N1 virus, \u201cA/chicken/Scotland/1959 (H5N1)\u201d, had four continuous basic residues in the HA0 cleavage site (compared to 5\u223c6 continuous basic residues in most common H5N1 HAs); the stalked deletion of NA also existed in A/turkey/Ontario/84/1983 (H5N1).", [["NA", "CHEMICAL", 212, 214], ["H5N1 virus", "ORGANISM", 13, 23], ["chicken", "ORGANISM", 28, 35], ["HA0", "GENE_OR_GENE_PRODUCT", 101, 104], ["H5N1 HAs", "ORGANISM", 177, 185], ["A/turkey", "ORGANISM", 231, 239], ["Ontario/84/1983 (H5N1", "ORGANISM", 240, 261], ["HA0 cleavage site", "PROTEIN", 101, 118], ["H5N1 virus", "SPECIES", 13, 23], ["chicken", "SPECIES", 28, 35], ["turkey", "SPECIES", 233, 239], ["H5N1 virus", "SPECIES", 13, 23], ["A/chicken/Scotland/1959 (H5N1)", "SPECIES", 26, 56], ["A/turkey/Ontario/84/1983 (H5N1)", "SPECIES", 231, 262], ["The earliest H5N1 virus", "PROBLEM", 0, 23], ["the HA0 cleavage site", "PROBLEM", 97, 118], ["continuous basic residues", "TREATMENT", 136, 161], ["H5N1 virus", "OBSERVATION", 13, 23], ["residues", "OBSERVATION", 85, 93]]], ["The records of H5N1 virus have increased rapidly since 2003.", [["H5N1 virus", "ORGANISM", 15, 25], ["H5N1 virus", "SPECIES", 15, 25], ["H5N1 virus", "SPECIES", 15, 25], ["H5N1 virus", "PROBLEM", 15, 25], ["H5N1", "OBSERVATION", 15, 19], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["Since then, a number of new clades and subclades have emerged and resulted in various new glycosites (Figure 3A and 3B).", [["various new glycosites", "PROBLEM", 78, 100], ["new", "OBSERVATION_MODIFIER", 24, 27], ["clades", "OBSERVATION", 28, 34]]], ["The percentage of unconserved glycosites in HA also increased and diversified rapidly after 2003, meanwhile the percentage of unconserved glycosites in NA reduced gradually, regardless of those highly-conserved glycosites (Figure 3C and 3D).The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsBoth twelve glycosites were found in the HA and NA of the H5N1 virus, shown in the Tables 1 and 2 and Files S3 and S4.The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsMost H5N1 viruses were grouped into clade 0 before it appeared in Hong Kong again in 2003.", [["NA", "CHEMICAL", 152, 154], ["NA", "CHEMICAL", 356, 358], ["glycosites", "GENE_OR_GENE_PRODUCT", 30, 40], ["HA", "GENE_OR_GENE_PRODUCT", 44, 46], ["NA", "SIMPLE_CHEMICAL", 152, 154], ["H5N1 virus", "ORGANISM", 286, 296], ["H5N1 virus", "ORGANISM", 366, 376], ["H5N1 virus", "ORGANISM", 471, 481], ["H5N1", "ORGANISM", 498, 502], ["unconserved glycosites", "PROTEIN", 18, 40], ["unconserved glycosites", "PROTEIN", 126, 148], ["H5N1 virus", "SPECIES", 286, 296], ["H5N1 virus", "SPECIES", 366, 376], ["H5N1 virus", "SPECIES", 471, 481], ["H5N1 virus", "SPECIES", 286, 296], ["H5N1 virus", "SPECIES", 366, 376], ["H5N1 virus", "SPECIES", 471, 481], ["H5N1 viruses", "SPECIES", 498, 510], ["unconserved glycosites", "PROBLEM", 18, 40], ["HA", "PROBLEM", 44, 46], ["unconserved glycosites", "PROBLEM", 126, 148], ["The co-evolutionary glycosite pattern", "TEST", 241, 278], ["the HA", "PROBLEM", 345, 351], ["the H5N1 virus", "PROBLEM", 362, 376], ["The co-evolutionary glycosite pattern", "TEST", 426, 463], ["Most H5N1 viruses", "PROBLEM", 493, 510], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["unconserved", "OBSERVATION_MODIFIER", 18, 29], ["glycosites", "OBSERVATION", 30, 40], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["diversified", "OBSERVATION_MODIFIER", 66, 77], ["rapidly", "OBSERVATION_MODIFIER", 78, 85], ["NA reduced", "OBSERVATION_MODIFIER", 152, 162], ["glycosite pattern", "OBSERVATION", 261, 278], ["H5N1", "OBSERVATION", 286, 290], ["H5N1", "OBSERVATION", 366, 370], ["S3", "ANATOMY_MODIFIER", 416, 418], ["S4", "ANATOMY", 423, 425], ["glycosite pattern", "OBSERVATION", 446, 463], ["H5N1", "OBSERVATION", 471, 475]]], ["Various patterns of the glycosites in HA and NA had co-existed in these original viruses.", [["HA", "CHEMICAL", 38, 40], ["NA", "CHEMICAL", 45, 47], ["HA", "SIMPLE_CHEMICAL", 38, 40], ["NA", "SIMPLE_CHEMICAL", 45, 47], ["the glycosites", "PROBLEM", 20, 34], ["HA", "PROBLEM", 38, 40], ["NA", "PROBLEM", 45, 47], ["glycosites", "OBSERVATION", 24, 34], ["viruses", "OBSERVATION", 81, 88]]], ["These original NAs contained the known glycosites, including four highly conserved glycosites in the stalk domain and seven in the global domain (except the occasional 341NGT which only appeared in clade 1 and Thailand records during 2004\u223c2010, e.g., A/chicken/Thailand/CU-354/2008 (H5N1)).", [["glycosites", "GENE_OR_GENE_PRODUCT", 39, 49], ["glycosites", "GENE_OR_GENE_PRODUCT", 83, 93], ["chicken", "ORGANISM", 253, 260], ["CU-354/2008 (H5N1", "ORGANISM", 270, 287], ["stalk domain", "PROTEIN", 101, 113], ["global domain", "PROTEIN", 131, 144], ["chicken", "SPECIES", 253, 260], ["A/chicken/Thailand/CU-354/2008 (H5N1)", "SPECIES", 251, 288], ["the known glycosites", "PROBLEM", 29, 49], ["NGT", "TEST", 171, 174], ["glycosites", "OBSERVATION", 39, 49], ["glycosites", "OBSERVATION", 83, 93], ["seven", "OBSERVATION_MODIFIER", 118, 123]]], ["In contrast, six highly conserved glycosites together with 170NST exist widely in clade 0.", [["glycosites", "GENE_OR_GENE_PRODUCT", 34, 44], ["170NST", "DNA", 59, 65]]], ["Since 2003, the WHO has recorded a three-wave epidemic of H5N1, which resulted in hundreds of deaths and huge economic losses [11].", [["H5N1", "DISEASE", 58, 62], ["deaths", "DISEASE", 94, 100], ["H5N1", "ORGANISM", 58, 62], ["H5N1", "PROBLEM", 58, 62], ["huge economic losses", "PROBLEM", 105, 125], ["H5N1", "OBSERVATION", 58, 62], ["huge", "OBSERVATION_MODIFIER", 105, 109], ["economic losses", "OBSERVATION", 110, 125]]], ["Until recently, the glycosite patterns were highly conserved in all the avian clades except for clade 7 (e.g., clade 3, 4, 5, 6, 8 and 9), as shown in Figure 4 and Figure S2.The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsMost currently recorded H5N1 viruses were concentrated in the fourth-order clades.", [["glycosite", "GENE_OR_GENE_PRODUCT", 20, 29], ["H5N1 virus", "ORGANISM", 219, 229], ["H5N1 viruses", "ORGANISM", 265, 277], ["clade 3, 4, 5, 6, 8 and 9", "DNA", 111, 136], ["H5N1 virus", "SPECIES", 219, 229], ["H5N1 virus", "SPECIES", 219, 229], ["the glycosite patterns", "TEST", 16, 38], ["clade", "TEST", 111, 116], ["The co-evolutionary glycosite pattern", "TEST", 174, 211], ["H5N1 viruses", "PROBLEM", 265, 277], ["glycosite pattern", "OBSERVATION", 194, 211], ["H5N1", "OBSERVATION", 219, 223]]], ["During this decade, there have been increasing human infections and new glycosite patterns of HA and NA.", [["infections", "DISEASE", 53, 63], ["NA", "CHEMICAL", 101, 103], ["human", "ORGANISM", 47, 52], ["HA", "SIMPLE_CHEMICAL", 94, 96], ["NA", "MULTI-TISSUE_STRUCTURE", 101, 103], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["increasing human infections", "PROBLEM", 36, 63], ["HA", "PROBLEM", 94, 96], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["human", "OBSERVATION_MODIFIER", 47, 52], ["infections", "OBSERVATION", 53, 63], ["new", "OBSERVATION_MODIFIER", 68, 71], ["glycosite", "OBSERVATION_MODIFIER", 72, 81], ["HA", "OBSERVATION_MODIFIER", 94, 96]]], ["It has been reported that the H5N1 virus of clade 2.2 was involved in the outbreak that occurred among the migratory bird population near Qinghai Lake in 2005.", [["H5N1 virus", "ORGANISM", 30, 40], ["H5N1 virus", "SPECIES", 30, 40], ["H5N1 virus", "SPECIES", 30, 40], ["the H5N1 virus of clade", "PROBLEM", 26, 49], ["H5N1", "OBSERVATION", 30, 34], ["migratory", "OBSERVATION_MODIFIER", 107, 116]]], ["This resulted in a number of deaths of wild birds in Europe [65].", [["deaths", "DISEASE", 29, 35]]], ["In 2006, the H5N1 virus appeared in Africa for the first time, followed by hundreds of mortally infected humans in Egypt, Nigeria and Djibouti [66].", [["H5N1 virus", "ORGANISM", 13, 23], ["humans", "ORGANISM", 105, 111], ["H5N1 virus", "SPECIES", 13, 23], ["humans", "SPECIES", 105, 111], ["H5N1 virus", "SPECIES", 13, 23], ["humans", "SPECIES", 105, 111], ["the H5N1 virus", "PROBLEM", 9, 23], ["infected", "OBSERVATION", 96, 104]]], ["The most recent H5N1 virus isolated from North Africa belongs to clade 2.2.1.1, along with one novel glycosite 88NVS.", [["H5N1 virus", "ORGANISM", 16, 26], ["H5N1 virus", "SPECIES", 16, 26], ["H5N1 virus", "SPECIES", 16, 26], ["The most recent H5N1 virus", "PROBLEM", 0, 26], ["H5N1", "OBSERVATION", 16, 20]]], ["In addition, most viruses in clade 2.2, except for clade 2.2.1.1, lack the 170N glycosite created by the T172A mutation.", [["T172A", "GENE_OR_GENE_PRODUCT", 105, 110], ["170N glycosite", "PROTEIN", 75, 89], ["T172A", "PROTEIN", 105, 110], ["most viruses in clade", "PROBLEM", 13, 34], ["clade", "TEST", 51, 56], ["most", "OBSERVATION_MODIFIER", 13, 17], ["viruses", "OBSERVATION", 18, 25]]], ["Wang et al. concluded that the lack of 170NST would enhance the HA affinity for SA receptors, especially to SA\u03b12-6Gal sialoglycans, which could be one reason for the propensity of clade 2.2.1 to infect humans [67], compared with only three conserved glycosites in the NA of clade 2.2.1.1 (Figure 4, Files S3).The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsParts of the H5N1 virus isolated from China and Vietnam belong to clade 2.3.4, with conserved glycosites in HA, but not in NA.", [["SA receptors", "GENE_OR_GENE_PRODUCT", 80, 92], ["SA\u03b12-6Gal", "GENE_OR_GENE_PRODUCT", 108, 117], ["humans", "ORGANISM", 202, 208], ["H5N1 virus", "ORGANISM", 354, 364], ["H5N1 virus", "ORGANISM", 389, 399], ["SA receptors", "PROTEIN", 80, 92], ["\u03b12", "PROTEIN", 110, 112], ["humans", "SPECIES", 202, 208], ["H5N1 virus", "SPECIES", 354, 364], ["H5N1 virus", "SPECIES", 389, 399], ["humans", "SPECIES", 202, 208], ["H5N1 virus", "SPECIES", 354, 364], ["H5N1 virus", "SPECIES", 389, 399], ["the HA affinity", "PROBLEM", 60, 75], ["SA receptors", "PROBLEM", 80, 92], ["The co-evolutionary glycosite pattern", "TEST", 309, 346], ["the H5N1 virus", "PROBLEM", 385, 399], ["HA", "PROBLEM", 484, 486], ["glycosite pattern", "OBSERVATION", 329, 346], ["H5N1", "OBSERVATION", 354, 358], ["H5N1", "OBSERVATION", 389, 393]]], ["In contrast, another dominant virus from clade 2.3.2 featured the loss of 170NST in HA and stable glycosites in NA.", [["NA", "CHEMICAL", 112, 114], ["NA", "MULTI-TISSUE_STRUCTURE", 112, 114], ["170NST", "PROTEIN", 74, 80], ["another dominant virus", "PROBLEM", 13, 35], ["HA", "PROBLEM", 84, 86], ["dominant", "OBSERVATION_MODIFIER", 21, 29], ["virus", "OBSERVATION", 30, 35], ["loss", "OBSERVATION_MODIFIER", 66, 70], ["stable", "OBSERVATION_MODIFIER", 91, 97], ["glycosites", "OBSERVATION", 98, 108], ["NA", "ANATOMY", 112, 114]]], ["Within the current clade 2.3.2.1, a new glycosite has appeared, \u201c156NSS\u201d, which co-existed with 88NVS near the antigen sites (Figure 5D, Files S3).The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsThe 181NVT glycosite, which is located at the apical \u03b2-folding of HA, is conserved in all human IVs (e.g., A/Anhui/1/2007 (H5N1)).", [["glycosite", "CHEMICAL", 40, 49], ["glycosite", "CANCER", 40, 49], ["H5N1 virus", "ORGANISM", 192, 202], ["NVT", "GENE_OR_GENE_PRODUCT", 221, 224], ["HA", "GENE_OR_GENE_PRODUCT", 280, 282], ["human", "ORGANISM", 304, 309], ["IVs", "CANCER", 310, 313], ["A/Anhui/1/2007 (H5N1)", "ORGANISM", 321, 342], ["88NVS", "PROTEIN", 96, 101], ["antigen sites", "PROTEIN", 111, 124], ["181NVT glycosite", "PROTEIN", 218, 234], ["HA", "PROTEIN", 280, 282], ["H5N1 virus", "SPECIES", 192, 202], ["human", "SPECIES", 304, 309], ["H5N1 virus", "SPECIES", 192, 202], ["human", "SPECIES", 304, 309], ["A/Anhui/1/2007 (H5N1)", "SPECIES", 321, 342], ["a new glycosite", "TEST", 34, 49], ["The co-evolutionary glycosite pattern", "TEST", 147, 184], ["HA", "PROBLEM", 280, 282], ["glycosite pattern", "OBSERVATION", 167, 184], ["H5N1", "OBSERVATION", 192, 196], ["apical", "ANATOMY_MODIFIER", 260, 266], ["\u03b2-folding", "ANATOMY_MODIFIER", 267, 276], ["HA", "OBSERVATION", 280, 282]]], ["Previous statistics have indicated that this glycosite has a lower level of conservation in avian IVs (e.g., A/chicken/Vietnam/NCVD-093/2008 (H5N1)).", [["glycosite", "CHEMICAL", 45, 54], ["glycosite", "GENE_OR_GENE_PRODUCT", 45, 54], ["avian", "ORGANISM", 92, 97], ["IVs", "CANCER", 98, 101], ["chicken", "ORGANISM", 111, 118], ["Vietnam/NCVD-093/2008 (H5N1)", "ORGANISM", 119, 147], ["chicken", "SPECIES", 111, 118], ["A/chicken/Vietnam/NCVD-093/2008 (H5N1)", "SPECIES", 109, 147], ["avian IVs", "TREATMENT", 92, 101], ["A/chicken/Vietnam/NCVD", "TREATMENT", 109, 131]]], ["The results of the molecular dynamics simulation indicated that the \u03b12-3-sialoglycans adopted a straight-like and outward topology structure while the \u03b12-6-sialoglycans were fishhook-like and inward; therefore, we inferred that the that the deficiency of the glycosite would benefit the binding of SA\u03b12-3Gal sialoglycans [68].", [["glycosite", "CHEMICAL", 259, 268], ["\u03b12-3-sialoglycans", "SIMPLE_CHEMICAL", 68, 85], ["\u03b12-6-sialoglycans", "SIMPLE_CHEMICAL", 151, 168], ["glycosite", "SIMPLE_CHEMICAL", 259, 268], ["\u03b12-3-sialoglycans", "PROTEIN", 68, 85], ["\u03b12", "PROTEIN", 151, 153], ["sialoglycans", "PROTEIN", 156, 168], ["\u03b12", "PROTEIN", 300, 302], ["3Gal", "PROTEIN", 303, 307], ["the molecular dynamics simulation", "TEST", 15, 48], ["a straight-like and outward topology structure", "PROBLEM", 94, 140], ["the deficiency of the glycosite", "PROBLEM", 237, 268]]], ["Actually, all the viruses that had deficiencies of the 181N glycosite were isolated from the avian host, which were concentrated in clades 7.1, 7.2 and 2.2.1.1 (Figure 6A, Files S3).The co-evolutionary glycosite pattern in the H5N1 virus ::: ResultsInterestingly, the deletion of the stalk domain in H5N1 NA is variable.", [["181N", "GENE_OR_GENE_PRODUCT", 55, 59], ["H5N1 virus", "ORGANISM", 227, 237], ["H5N1 NA", "ORGANISM", 300, 307], ["181N glycosite", "DNA", 55, 69], ["stalk domain", "PROTEIN", 284, 296], ["H5N1 virus", "SPECIES", 227, 237], ["H5N1 virus", "SPECIES", 227, 237], ["all the viruses", "PROBLEM", 10, 25], ["deficiencies of the 181N glycosite", "PROBLEM", 35, 69], ["The co-evolutionary glycosite pattern", "TEST", 182, 219], ["the stalk domain", "PROBLEM", 280, 296], ["H5N1 NA", "TEST", 300, 307], ["viruses", "OBSERVATION", 18, 25], ["avian host", "OBSERVATION", 93, 103], ["glycosite pattern", "OBSERVATION", 202, 219], ["H5N1", "OBSERVATION", 227, 231], ["H5N1", "OBSERVATION", 300, 304], ["variable", "OBSERVATION_MODIFIER", 311, 319]]], ["As the first human death reported in 1997, most H5N1 viruses that belonged to clade 0 and isolated in Hong Kong were characterized by \u201cN-Q-S-I-54I-18-73N-F-Y\u201d, which remained a glycosite: 50NQS.", [["death", "DISEASE", 19, 24], ["glycosite", "CHEMICAL", 177, 186], ["human", "ORGANISM", 13, 18], ["H5N1 viruses", "ORGANISM", 48, 60], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["H5N1 viruses", "SPECIES", 48, 60], ["most H5N1 viruses", "PROBLEM", 43, 60]]], ["Although previous studies conjectured that the H6N1 virus (e.g., A/Teal/Hong Kong/W312/97 (H6N1)) was the donor of the NA gene in 1997 HPAI virus [69], [70]; however, similar motif could be found even in 1983.", [["H6N1 virus", "ORGANISM", 47, 57], ["A/Teal/Hong Kong/W312/97 (H6N1", "ORGANISM", 65, 95], ["1997 HPAI virus", "ORGANISM", 130, 145], ["NA gene", "DNA", 119, 126], ["HPAI virus", "SPECIES", 135, 145], ["H6N1 virus", "SPECIES", 47, 57], ["A/Teal/Hong Kong/W312/97 (H6N1)", "SPECIES", 65, 96], ["HPAI virus", "SPECIES", 135, 145], ["previous studies", "TEST", 9, 25], ["the H6N1 virus", "PROBLEM", 43, 57], ["the NA gene", "TEST", 115, 126], ["HPAI virus", "TEST", 135, 145]]], ["Since 2000, the most common pattern of \u201cA-E-48P-20-69I-S-N\u201d with four glycosites missing has dominated in the H5N1 NAs (Figure 6B, File S4).DiscussionThere is one kind of glycoprotein that participates in the recognition and membrane fusion in most virus envelopes, such as the spike (S) protein in the SARS virus, the gp160 in HIV and HA in IVs [71], [72].", [["membrane", "ANATOMY", 225, 233], ["SARS", "DISEASE", 303, 307], ["\u201cA-E-48P-20-69I-S-N", "CHEMICAL", 39, 58], ["membrane", "CELLULAR_COMPONENT", 225, 233], ["SARS virus", "ORGANISM", 303, 313], ["gp160", "GENE_OR_GENE_PRODUCT", 319, 324], ["HIV", "ORGANISM", 328, 331], ["glycoprotein", "PROTEIN", 171, 183], ["spike (S) protein", "PROTEIN", 278, 295], ["HIV", "SPECIES", 328, 331], ["SARS virus", "SPECIES", 303, 313], ["HIV", "SPECIES", 328, 331], ["four glycosites missing", "PROBLEM", 65, 88], ["glycoprotein", "TREATMENT", 171, 183], ["membrane fusion", "TREATMENT", 225, 240], ["most virus envelopes", "PROBLEM", 244, 264], ["the spike (S) protein", "PROBLEM", 274, 295], ["the SARS virus", "PROBLEM", 299, 313], ["HIV", "PROBLEM", 328, 331], ["HA", "PROBLEM", 336, 338], ["IVs", "TEST", 342, 345], ["H5N1", "OBSERVATION", 110, 114]]], ["These glycoproteins can bind to one specific glycan structure which is known as the lectin or GBP.", [["lectin", "GENE_OR_GENE_PRODUCT", 84, 90], ["GBP", "GENE_OR_GENE_PRODUCT", 94, 97], ["lectin", "PROTEIN", 84, 90], ["GBP", "PROTEIN", 94, 97], ["GBP", "PROBLEM", 94, 97]]], ["Other viral glycoproteins, such as HN in the Newcastle Disease Virus or NA in IVs, function as the exoglycosidase in the release of virus particles [73].DiscussionThe IVs have an innate capacity for high mutation rates because they are RNA viruses.", [["HN", "GENE_OR_GENE_PRODUCT", 35, 37], ["Newcastle Disease Virus", "ORGANISM", 45, 68], ["exoglycosidase", "GENE_OR_GENE_PRODUCT", 99, 113], ["IVs", "GENE_OR_GENE_PRODUCT", 167, 170], ["viral glycoproteins", "PROTEIN", 6, 25], ["HN", "PROTEIN", 35, 37], ["exoglycosidase", "PROTEIN", 99, 113], ["Newcastle Disease Virus", "SPECIES", 45, 68], ["Other viral glycoproteins", "PROBLEM", 0, 25], ["the Newcastle Disease Virus", "PROBLEM", 41, 68], ["NA in IVs", "TREATMENT", 72, 81], ["the exoglycosidase", "TEST", 95, 113], ["The IVs", "TREATMENT", 163, 170], ["an innate capacity", "TREATMENT", 176, 194], ["high mutation rates", "PROBLEM", 199, 218], ["RNA viruses", "PROBLEM", 236, 247], ["viral glycoproteins", "OBSERVATION", 6, 25]]], ["Humans are under continuous attacks by newly emerging IVs which constantly undergo \u201cantigenic drift\u201d and \u201cantigenic shift\u201d.", [["Humans", "ORGANISM", 0, 6], ["IVs", "CANCER", 54, 57]]], ["Accumulation of substantial sequences and 3D coordinates of IV proteins have provided the ideal tools for the investigation of how mutations affect transfaunation, vaccine design and drug-resistance [74], [75].DiscussionN-glycosylation not only influences the folding and secretion of glycoproteins such as HA and NA but also provides the same glycans (similar to the host's own glycans) to escape the host's immune system.", [["NA", "CHEMICAL", 314, 316], ["IV proteins", "GENE_OR_GENE_PRODUCT", 60, 71], ["HA", "GENE_OR_GENE_PRODUCT", 307, 309], ["NA", "SIMPLE_CHEMICAL", 314, 316], ["immune system", "ANATOMICAL_SYSTEM", 409, 422], ["IV proteins", "PROTEIN", 60, 71], ["substantial sequences", "TEST", 16, 37], ["IV proteins", "TREATMENT", 60, 71], ["the investigation", "TEST", 106, 123], ["how mutations affect transfaunation", "PROBLEM", 127, 162], ["glycosylation", "TREATMENT", 222, 235], ["secretion of glycoproteins", "PROBLEM", 272, 298], ["HA", "PROBLEM", 307, 309], ["substantial", "OBSERVATION_MODIFIER", 16, 27]]], ["As the key modification of biological significance in viral glycoproteins, we found the glycosites in 17 known HA subtypes and 10 known NA subtypes that have complex characteristics.", [["viral glycoproteins", "PROTEIN", 54, 73], ["viral glycoproteins", "PROBLEM", 54, 73], ["the glycosites in 17 known HA subtypes", "PROBLEM", 84, 122], ["known NA subtypes", "PROBLEM", 130, 147], ["viral glycoproteins", "OBSERVATION", 54, 73], ["NA subtypes", "OBSERVATION_MODIFIER", 136, 147], ["complex characteristics", "OBSERVATION_MODIFIER", 158, 181]]], ["In general, two highly conserved glycosites near the HA0 cleavage site and fusion peptide site may maintain the basic function of HA; these sites were seldom absent in the HA subtypes.", [["glycosites", "GENE_OR_GENE_PRODUCT", 33, 43], ["HA0", "GENE_OR_GENE_PRODUCT", 53, 56], ["HA", "GENE_OR_GENE_PRODUCT", 130, 132], ["HA0 cleavage site", "DNA", 53, 70], ["HA", "PROTEIN", 130, 132], ["the HA0 cleavage site", "PROBLEM", 49, 70], ["fusion peptide site", "PROBLEM", 75, 94], ["HA", "PROBLEM", 130, 132], ["glycosites", "OBSERVATION", 33, 43], ["fusion", "OBSERVATION", 75, 81]]], ["More glycosites were identified in the global domain or in the connection of global and stalk domains, along with long-term and large-scale epidemics in several of the subtypes.", [["global and stalk domains", "PROTEIN", 77, 101], ["More glycosites", "PROBLEM", 0, 15], ["global and stalk domains", "PROBLEM", 77, 101], ["long-term and large-scale epidemics", "PROBLEM", 114, 149], ["global", "OBSERVATION_MODIFIER", 77, 83], ["long-term", "OBSERVATION_MODIFIER", 114, 123], ["large", "OBSERVATION_MODIFIER", 128, 133], ["-scale", "OBSERVATION_MODIFIER", 133, 139], ["epidemics", "OBSERVATION", 140, 149], ["subtypes", "OBSERVATION_MODIFIER", 168, 176]]], ["The distributional regularity of the glycosites in the NA subtypes is also complex; two to four glycosites located in the stalk domain are highly conserved in various subtypes, and are affected by the deletion of the stalk domain.", [["stalk domain", "PROTEIN", 122, 134], ["stalk domain", "PROTEIN", 217, 229], ["the glycosites in the NA subtypes", "PROBLEM", 33, 66], ["distributional", "OBSERVATION_MODIFIER", 4, 18], ["regularity", "OBSERVATION_MODIFIER", 19, 29], ["glycosites", "OBSERVATION", 37, 47], ["NA subtypes", "OBSERVATION_MODIFIER", 55, 66], ["complex", "OBSERVATION_MODIFIER", 75, 82], ["stalk", "ANATOMY_MODIFIER", 122, 127], ["highly", "OBSERVATION_MODIFIER", 139, 145], ["conserved", "OBSERVATION_MODIFIER", 146, 155], ["various subtypes", "OBSERVATION_MODIFIER", 159, 175], ["stalk", "OBSERVATION_MODIFIER", 217, 222]]], ["Another highly conserved glycosite was found at the tip of tetramer NA in all subtypes.", [["glycosite", "CANCER", 25, 34], ["tetramer NA", "PROTEIN", 59, 70], ["glycosite", "OBSERVATION", 25, 34], ["tip", "OBSERVATION_MODIFIER", 52, 55], ["tetramer NA", "OBSERVATION", 59, 70], ["all subtypes", "OBSERVATION_MODIFIER", 74, 86]]], ["Other glycosites were found to be mainly concentrated in the global domain, which surrounds the antigenic sites.DiscussionThe HA or NA subtypes exhibited low similarities of amino acid sequences in all subtypes while maintaining identical structures, which revealed that the functions of various HA or NA subtypes remain conserved.", [["amino acid", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 174, 184], ["glycosites", "GENE_OR_GENE_PRODUCT", 6, 16], ["HA", "GENE_OR_GENE_PRODUCT", 126, 128], ["amino acid", "AMINO_ACID", 174, 184], ["HA", "GENE_OR_GENE_PRODUCT", 296, 298], ["global domain", "PROTEIN", 61, 74], ["amino acid sequences", "PROTEIN", 174, 194], ["HA", "PROTEIN", 296, 298], ["Other glycosites", "PROBLEM", 0, 16], ["The HA", "PROBLEM", 122, 128], ["NA subtypes", "PROBLEM", 132, 143], ["amino acid sequences", "PROBLEM", 174, 194], ["various HA", "PROBLEM", 288, 298], ["NA subtypes", "PROBLEM", 302, 313], ["mainly", "OBSERVATION_MODIFIER", 34, 40], ["concentrated", "OBSERVATION_MODIFIER", 41, 53], ["global domain", "OBSERVATION", 61, 74], ["antigenic sites", "OBSERVATION", 96, 111]]], ["Notably, some of the glycosites near the cysteines were found to also be conserved.", [["cysteines", "CHEMICAL", 41, 50], ["glycosites", "GENE_OR_GENE_PRODUCT", 21, 31], ["the glycosites", "PROBLEM", 17, 31]]], ["The cysteines take the main role in stabilizing the tertiary structure; the conservation verifies that cysteines and N-glycans played an important role in the protein folding and quality control.DiscussionWe have further investigated the H5N1 virus to elaborate the collaborative relationship of glycosites in HA and NA.", [["NA", "CHEMICAL", 317, 319], ["cysteines", "CHEMICAL", 4, 13], ["cysteines", "CHEMICAL", 103, 112], ["N", "CHEMICAL", 117, 118], ["N-glycans", "GENE_OR_GENE_PRODUCT", 117, 126], ["H5N1 virus", "ORGANISM", 238, 248], ["HA", "SIMPLE_CHEMICAL", 310, 312], ["H5N1 virus", "SPECIES", 238, 248], ["H5N1 virus", "SPECIES", 238, 248], ["The cysteines", "TREATMENT", 0, 13], ["cysteines and N-glycans", "TREATMENT", 103, 126], ["the protein folding", "TREATMENT", 155, 174], ["the H5N1 virus", "PROBLEM", 234, 248], ["HA", "PROBLEM", 310, 312], ["cysteines", "OBSERVATION", 4, 13], ["main", "OBSERVATION_MODIFIER", 23, 27], ["tertiary structure", "OBSERVATION", 52, 70]]], ["Five highly conserved glycosites in HA had existed before the H5N1 virus first crossed species barriers and infected humans, as well as two additional glycosites, 181NVT and 170NST.", [["glycosites", "CANCER", 22, 32], ["H5N1 virus", "ORGANISM", 62, 72], ["humans", "ORGANISM", 117, 123], ["NVT", "CANCER", 166, 169], ["H5N1 virus", "SPECIES", 62, 72], ["humans", "SPECIES", 117, 123], ["H5N1 virus", "SPECIES", 62, 72], ["humans", "SPECIES", 117, 123], ["HA", "PROBLEM", 36, 38], ["the H5N1 virus", "PROBLEM", 58, 72], ["glycosites", "OBSERVATION", 22, 32], ["infected", "OBSERVATION", 108, 116]]], ["Since 2003, the H5N1 virus has exhibited a rapid evolutionary dynamic.", [["H5N1 virus", "ORGANISM", 16, 26], ["H5N1 virus", "SPECIES", 16, 26], ["H5N1 virus", "SPECIES", 16, 26], ["the H5N1 virus", "PROBLEM", 12, 26], ["rapid", "OBSERVATION_MODIFIER", 43, 48], ["evolutionary dynamic", "OBSERVATION", 49, 69]]], ["Under the selection pressure of different hosts and antigenic drift, the glycosite pattern of current H5N1 viruses in different geographical locations has been distinctive: the HA in clade 2.2.1.1, isolated from Egypt, lacked the 181N glycosite but had added the 88NVS glycosite.", [["H5N1 viruses", "ORGANISM", 102, 114], ["88NVS glycosite", "PROTEIN", 263, 278], ["different hosts", "TREATMENT", 32, 47], ["antigenic drift", "PROBLEM", 52, 67], ["the glycosite pattern", "TREATMENT", 69, 90], ["current H5N1 viruses", "PROBLEM", 94, 114], ["the HA in clade", "PROBLEM", 173, 188], ["antigenic drift", "OBSERVATION", 52, 67], ["H5N1 viruses", "OBSERVATION", 102, 114], ["distinctive", "OBSERVATION_MODIFIER", 160, 171]]], ["In addition, the HA in clade 2.3.2.1, isolated from China or Vietnam, lacked the 170N glycosite but had added the 152N glycosite.", [["152N glycosite", "PROTEIN", 114, 128], ["the HA in clade", "TEST", 13, 28], ["the 152N glycosite", "TREATMENT", 110, 128]]], ["In contrast, as the glycosites in HA became more diverse in the H5N1 virus, the glycosylation in NA was impaired by a decreasing number of glycosites.", [["NA", "CHEMICAL", 97, 99], ["HA", "GENE_OR_GENE_PRODUCT", 34, 36], ["H5N1 virus", "ORGANISM", 64, 74], ["NA", "SIMPLE_CHEMICAL", 97, 99], ["H5N1 virus", "SPECIES", 64, 74], ["H5N1 virus", "SPECIES", 64, 74], ["the glycosites in HA", "PROBLEM", 16, 36], ["the H5N1 virus", "PROBLEM", 60, 74], ["the glycosylation in NA", "PROBLEM", 76, 99], ["a decreasing number of glycosites", "PROBLEM", 116, 149], ["diverse", "OBSERVATION_MODIFIER", 49, 56], ["H5N1", "OBSERVATION", 64, 68], ["decreasing", "OBSERVATION_MODIFIER", 118, 128]]], ["The NAs of current H5N1 viruses lack a stalk domain and the four corresponding glycosites; except the four high conserved glycosites in the global domain, others glycosites have rarely been identified.DiscussionThe envelope glycoproteins, which play a crucial role in virus recognition, invasion and spread.", [["H5N1 viruses", "ORGANISM", 19, 31], ["stalk domain", "PROTEIN", 39, 51], ["global domain", "PROTEIN", 140, 153], ["glycosites", "PROTEIN", 162, 172], ["envelope glycoproteins", "PROTEIN", 215, 237], ["a stalk domain", "PROBLEM", 37, 51], ["The envelope glycoproteins", "TREATMENT", 211, 237], ["invasion", "PROBLEM", 287, 295], ["invasion", "OBSERVATION", 287, 295]]], ["The analysis of the glycosites in HAs and NAs has provided basic information for vaccine design, host selection and changing virulence.", [["HAs", "SIMPLE_CHEMICAL", 34, 37], ["The analysis", "TEST", 0, 12], ["vaccine design", "TREATMENT", 81, 95], ["host selection", "TREATMENT", 97, 111], ["changing virulence", "PROBLEM", 116, 134]]], ["However, infection is a complex process; the alternation of glycosites and glycan shapes may affect the functions of glycoproteins.", [["infection", "DISEASE", 9, 18], ["glycosites", "GENE_OR_GENE_PRODUCT", 60, 70], ["glycoproteins", "PROTEIN", 117, 130], ["infection", "PROBLEM", 9, 18], ["a complex process", "PROBLEM", 22, 39], ["the alternation of glycosites and glycan shapes", "PROBLEM", 41, 88], ["infection", "OBSERVATION", 9, 18], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["process", "OBSERVATION", 32, 39], ["glycan shapes", "OBSERVATION", 75, 88]]], ["In addition, there are other mutations also worthy of further consideration, such as the E627K in the PB2 protein that enhances the avian viral replication capacity in mammalian cells [76], [77].", [["cells", "ANATOMY", 178, 183], ["E627K", "GENE_OR_GENE_PRODUCT", 89, 94], ["mammalian cells", "CELL", 168, 183], ["E627K", "PROTEIN", 89, 94], ["PB2 protein", "PROTEIN", 102, 113], ["mammalian cells", "CELL_TYPE", 168, 183], ["other mutations", "PROBLEM", 23, 38], ["mutations", "OBSERVATION", 29, 38]]], ["Drug resistance is also related to viral proteins, such as the M2 protein [78].", [["M2", "GENE_OR_GENE_PRODUCT", 63, 65], ["viral proteins", "PROTEIN", 35, 49], ["M2 protein", "PROTEIN", 63, 73], ["Drug resistance", "PROBLEM", 0, 15], ["viral proteins", "PROBLEM", 35, 49], ["the M2 protein", "TEST", 59, 73], ["viral proteins", "OBSERVATION", 35, 49]]], ["Thus, to prevent the next influenza pandemics, more research needs to be done.", [["influenza pandemics", "DISEASE", 26, 45], ["the next influenza pandemics", "PROBLEM", 17, 45]]]], "PMC7396067": [], "c887de0008c0f09c7a875a608eec9bfdd678cc21": [["INTRODUCTIONIt is becoming clear that the coronavirus pandemic will have unprecedented economic impacts.", [["coronavirus pandemic", "DISEASE", 42, 62], ["coronavirus", "ORGANISM", 42, 53], ["the coronavirus pandemic", "PROBLEM", 38, 62], ["clear", "OBSERVATION", 27, 32]]], ["The evidence is mounting that the world economy is likely to be hit by a shock similar to that of the Great Depression of the 1930s.", [["shock", "DISEASE", 73, 78], ["Depression", "DISEASE", 108, 118], ["a shock", "PROBLEM", 71, 78], ["the Great Depression", "PROBLEM", 98, 118], ["likely to be", "UNCERTAINTY", 51, 63], ["shock", "OBSERVATION", 73, 78], ["Great", "OBSERVATION_MODIFIER", 102, 107], ["Depression", "OBSERVATION", 108, 118]]], ["In doing so, it aims to highlight emerging economic geographies of the pandemic.", [["the pandemic", "PROBLEM", 67, 79]]], ["More specifically, the paper aims to explore the way in which the concept of 'financial chains' (Sokol 2017a) can be mobilised to understand the current crisis and its winners and losers.INTRODUCTIONWith regard to the first aim (examined in the following section), we argue that the pandemic-induced crisis will exacerbate social inequalities and deepen uneven development at multiple geographical scales.", [["pandemic", "DISEASE", 283, 291], ["the pandemic-induced crisis", "PROBLEM", 279, 306]]], ["The emerging map of winners and losers will most likely further aggravate the existing inequalities in the global economy.", [["global", "OBSERVATION_MODIFIER", 107, 113], ["economy", "OBSERVATION", 114, 121]]], ["In particular, we foresee that the Global North/Global South divide is likely to grow, as will the economic differences within these global regions.", [["likely to", "UNCERTAINTY", 71, 80]]], ["Indeed, within the Global North, the case of Europe highlights complex economic geographies linked to both northsouth and east-west divergence, with further fragmentation likely occurring at sub-national levels.INTRODUCTIONWith regard to our second aim (explored in the third section) we argue that the 'financialisation' perspective in general, and the concept of 'financial chains' in particular, provide useful insights into the crisis and its uneven effects, both for individual economies and at the international political economy level.", [["geographies", "DISEASE", 80, 91], ["further fragmentation", "PROBLEM", 149, 170], ["the crisis", "PROBLEM", 428, 438], ["fragmentation", "OBSERVATION", 157, 170]]], ["We argue that the 'financial chain' approach can shed light on the complex web of flows of value and power relations established/emerging between the prospective winners and losers, while also highlighting the prominent role of debt (and debt-based financial chains) in shaping economic geographies in times of major global crisis.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICIn addition to its significant public health effects, the COVID-19 pandemic (caused by the novel coronavirus SARS-CoV-2) is expected to have unprecedented economic impacts.", [["coronavirus SARS-CoV-2", "ORGANISM", 473, 495], ["major global crisis", "PROBLEM", 311, 330], ["the COVID", "TEST", 430, 439], ["the novel coronavirus SARS", "PROBLEM", 463, 489], ["global crisis", "OBSERVATION", 317, 330], ["significant", "OBSERVATION_MODIFIER", 395, 406]]], ["According to the latest forecast by the IMF, the global economy will face the worst crisis since the Great Depression, surpassing that experienced during the Global Financial Crisis (GFC) (IMF 2020).", [["Depression", "DISEASE", 107, 117], ["the worst crisis", "PROBLEM", 74, 90], ["the Great Depression", "PROBLEM", 97, 117], ["Great", "OBSERVATION_MODIFIER", 101, 106], ["Depression", "OBSERVATION", 107, 117]]], ["We argue that the crisis will (re)produce uneven economic geographies within the global economy at multiple scales while also exacerbating social inequalities.", [["the crisis", "PROBLEM", 14, 24]]], ["We expect that the map of winners and losers will be shaped by the existing socio-spatial inequalities; by the size and nature of the pandemic-induced economic shock inflicted on individual economies; by the ability of individual countries to respond to that shock; and by the ability of different economic sectors, regions, countries and whole macro-regional blocks to recover.", [["pandemic", "DISEASE", 134, 142], ["shock", "DISEASE", 160, 165], ["shock", "DISEASE", 259, 264], ["shock", "PROBLEM", 259, 264], ["whole macro-regional blocks", "TREATMENT", 339, 366], ["size", "OBSERVATION_MODIFIER", 111, 115], ["shock", "OBSERVATION", 259, 264]]], ["Furthermore, economic differences are expected to be exacerbated within these global regions.", [["global", "ANATOMY_MODIFIER", 78, 84], ["regions", "ANATOMY_MODIFIER", 85, 92]]], ["In the Global North, we highlight the case of Europe and its complex economic geographies with regard to its north-south and eastwest divides, both of which may be deepened by the crisis.", [["the crisis", "PROBLEM", 176, 186], ["may be", "UNCERTAINTY", 157, 163], ["crisis", "OBSERVATION", 180, 186]]], ["Further fragmentation is likely to occur at sub-national levels.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICThe winners -The number of economic winners generated by the coronavirus pandemic is likely to be extremely limited and concentrated.", [["coronavirus", "DISEASE", 170, 181], ["coronavirus", "ORGANISM", 170, 181], ["Further fragmentation", "PROBLEM", 0, 21], ["the coronavirus pandemic", "PROBLEM", 166, 190], ["fragmentation", "OBSERVATION", 8, 21], ["is likely", "UNCERTAINTY", 22, 31], ["likely to be", "UNCERTAINTY", 194, 206]]], ["Amid unprecedented stock market collapses -with Wall Street experiencing its fastest bear-market plunge in history (Aslam 2020) -some companies have managed to directly benefit from the health emergency.", [["market collapses", "OBSERVATION", 25, 41]]], ["One example of this is Moderna, a biotech firm based in Cambridge, Massachusetts, whose stock prices soared by 135 per cent upon news that it was making progress in developing a COVID-19 vaccine (Lee 2020) .", [["a COVID-19 vaccine", "TREATMENT", 176, 194]]], ["A number of other biotechnology, pharmaceutical and medical companies have generated substantial profits since the beginning of the crisis.", [["the crisis", "PROBLEM", 128, 138]]], ["According to Forbes reports, St\u00e9phane Bancel, the CEO of Moderna, has become a billionaire overnight after the company announced that it was expected to begin human trials for its COVID-19 vaccine (Tognini 2020) .", [["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["human trials", "TREATMENT", 159, 171], ["its COVID-19 vaccine", "TREATMENT", 176, 196]]], ["Likewise, several other businessmen and businesswomen have benefited from the pandemic, such as Wee Chai Lim, Chairman and Co-Founder at Top Glove Corporation BHD (Malaysia) (Lee & Raghu 2020) ; Zhong Huijuan, the chairwoman of Hansoh Pharmaceutical and her husband, Sun Piaoyang, the chairman of Jiangsu Hengrui Medicine (China), just to name a few (Cuccinello 2020) .", [["BHD", "DISEASE", 159, 162]]], ["More broadly, shareholders/investors of the benefiting companies are among the few economic agents who have made large gains amid the global economic collapse.", [["the global economic collapse", "PROBLEM", 130, 158], ["global", "OBSERVATION_MODIFIER", 134, 140], ["economic", "OBSERVATION_MODIFIER", 141, 149], ["collapse", "OBSERVATION", 150, 158]]], ["We expect that the current crisis will produce a range of similar opportunities across sectors and asset classes (see Fujita 2020; Reuters 2020b; Sharma & Tripathy 2020; Smith & Platt 2020; for emerging examples).EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICThe global economy in crisis -It is becoming increasingly clear that apart from a few isolated sectors and actors (such as those mentioned above) the entire global economy will experience a major downturn.", [["the current crisis", "PROBLEM", 15, 33], ["crisis", "PROBLEM", 280, 286], ["economy", "OBSERVATION_MODIFIER", 269, 276], ["increasingly", "OBSERVATION_MODIFIER", 303, 315], ["clear", "OBSERVATION", 316, 321]]], ["The IMF (2020) predicts that the world economy as a whole will contract sharply -by 3 per cent in 2020 -making the 'Great Lockdown' a bigger economic calamity than the one caused by the 2008 GFC.", [["GFC", "CANCER", 191, 194]]], ["However, we argue that this contraction will not be felt evenly across individual economies (although not necessarily exactly the way the IMF predicts).", [["IMF", "PROTEIN", 138, 141]]], ["Indeed, there are significant differences in the effects of the crisis, in exposure levels and in response capacity between countries and whole macroregions.", [["the crisis", "PROBLEM", 60, 70], ["exposure levels", "TEST", 75, 90], ["whole macroregions", "PROBLEM", 138, 156], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["differences", "OBSERVATION_MODIFIER", 30, 41], ["response capacity", "OBSERVATION", 98, 115]]], ["The combination of these factors will shape the economic geographies of the pandemic -on top of substantial pre-existing inequalities.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICOne of the factors that is hard to predict at the moment is how long individual economies will remain under lockdown.", [["these factors", "PROBLEM", 19, 32], ["the pandemic", "PROBLEM", 72, 84], ["pandemic", "OBSERVATION_MODIFIER", 76, 84], ["substantial", "OBSERVATION_MODIFIER", 96, 107]]], ["The OECD (2020a) forecasts that for each month of containment, there will be a loss of 2 per cent in annual GDP growth, with some sectors, such as tourism and hospitality, experiencing a much larger decline, reaching up to 70 per cent.", [["GDP", "CHEMICAL", 108, 111], ["GDP", "SIMPLE_CHEMICAL", 108, 111], ["a much larger decline", "PROBLEM", 185, 206], ["GDP growth", "OBSERVATION", 108, 118], ["larger", "OBSERVATION_MODIFIER", 192, 198], ["decline", "OBSERVATION", 199, 206]]], ["Big losses are also expected in related sectors, for instance in travel (airlines) and oil-related industries.", [["oil", "ANATOMY", 87, 90], ["oil", "ORGANISM_SUBSTANCE", 87, 90], ["Big losses", "PROBLEM", 0, 10], ["losses", "OBSERVATION", 4, 10]]], ["1) itself admits that there is 'extreme uncertainty around the global growth forecast'.", [["extreme", "OBSERVATION_MODIFIER", 32, 39], ["uncertainty", "OBSERVATION", 40, 51], ["global", "OBSERVATION_MODIFIER", 63, 69], ["growth forecast", "OBSERVATION", 70, 85]]], ["These and other predictions may yet prove to be too optimistic.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICOne of the most striking, and immediately visible, aspects of this economic calamity is a dramatic increase in unemployment.", [["calamity", "DISEASE", 184, 192], ["most striking", "OBSERVATION_MODIFIER", 119, 132], ["dramatic", "OBSERVATION_MODIFIER", 198, 206], ["increase", "OBSERVATION_MODIFIER", 207, 215], ["unemployment", "OBSERVATION", 219, 231]]], ["The speed and the size of the labour market collapse seem unprecedented.", [["the labour market collapse", "PROBLEM", 26, 52], ["size", "OBSERVATION_MODIFIER", 18, 22], ["labour", "OBSERVATION", 30, 36], ["collapse", "OBSERVATION", 44, 52]]], ["Within the first month of the COVID-19 emergency in the US, 22 million workers lost their jobs (DoL 2020), with the unemployment rate nearing 18 per cent (Lambert 2020) , breaking post-War and post-Depression records.", [["Depression", "DISEASE", 198, 208]]], ["In the UK, the Institute for Employment Studies estimated that up to 2 million people lost their jobs within the first month of the crisis, with unemployment jumping from 3.9 per cent to 7.5 per cent, already surpassing the peak of the last recession (Wilson et al. 2020) .", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["Employment Studies", "TEST", 29, 47]]], ["It is likely that these figures will grow further, disproportionately hitting low-pay and precarious workers, and driving social inequality to new highs.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICThe realisation that this crisis is threatening the entire economic edifice has led to some extraordinary policy responses (see .", [["this crisis", "PROBLEM", 219, 230], ["is likely", "UNCERTAINTY", 3, 12]]], ["Both the US and the UK, perhaps the two most neo-liberalised/financialised 1 among the advanced countries, have responded with massive fiscal interventions.", [["massive fiscal interventions", "TREATMENT", 127, 155]]], ["The US Government's US$2.1 trillion rescue package seems to be the biggest economic stimulus in history (see also Buiter 2020) .", [["The US", "TEST", 0, 6], ["trillion rescue package", "TREATMENT", 27, 50]]], ["The UK, meanwhile, is spending some 7.5 per cent of GDP on coping mechanisms (Inman 2020) .", [["GDP", "CHEMICAL", 52, 55], ["GDP", "CHEMICAL", 52, 55], ["GDP", "SIMPLE_CHEMICAL", 52, 55]]], ["In addition to such unprecedented fiscal interventions, we have also witnessed a dramatic mobilisation of monetary policy instruments.", [["such unprecedented fiscal interventions", "TREATMENT", 15, 54], ["a dramatic mobilisation of monetary policy instruments", "TREATMENT", 79, 133]]], ["Indeed, this massive government spending has been matched by colossal interventions from central banks.", [["colossal interventions", "TREATMENT", 61, 83], ["massive", "OBSERVATION_MODIFIER", 13, 20], ["central banks", "OBSERVATION", 89, 102]]], ["Apart from slashing interest rates, both the Fed and the Bank of England have been injecting liquidity into financial markets though quantitative easing (QE) and extending credit lines to their governments in order to cover their extraordinary expenditure (Giles & Georgiadis 2020; Marte 2020) .", [["extending credit lines", "TREATMENT", 162, 184]]], ["It is likely that, without such actions, financial markets would have collapsed completely -demonstrating just how central the central banks really are in sustaining contemporary financialised economies and their 'financial chains' (see Figure 1 and the third section).EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICThere are, of course, major issues related to money-creation programmes such as QE.", [["major issues", "PROBLEM", 336, 348], ["creation programmes", "TREATMENT", 366, 385], ["is likely", "UNCERTAINTY", 3, 12], ["central banks", "OBSERVATION", 127, 140]]], ["The monetary interventions by the Fed and other central banks certainly helped to contain the previous crisis of 2008.", [["The monetary interventions", "TREATMENT", 0, 26]]], ["However, it did so by helping to build an unprecedented pile of debt that is now weighting on the whole global economy, making it a lot more vulnerable to the pandemic-induced economic shock (see also below).", [["pandemic", "DISEASE", 159, 167], ["shock", "DISEASE", 185, 190], ["the pandemic-induced economic shock", "PROBLEM", 155, 190], ["economic shock", "OBSERVATION", 176, 190]]], ["Much of this debt has been created on the back of QE and ultra-loose monetary policy applied by the Fed in the aftermath of the 2008 crisis (see Plender 2020 ).", [["ultra-loose monetary policy", "TREATMENT", 57, 84]]], ["The problem is that a large portion of this debt keeps alive the so-called 'zombie' banks and companies that are extremely vulnerable to the slightest economic shock (Plender 2020) .", [["shock", "DISEASE", 160, 165], ["the slightest economic shock", "PROBLEM", 137, 165], ["large", "OBSERVATION_MODIFIER", 22, 27]]], ["The issue of debt is further amplified at the global level.", [["debt", "OBSERVATION", 13, 17]]], ["At the end of 2019, total world debt reached US$253 trillion, equivalent to 322 per cent of global GDP, the highest ever recorded level (IIF 2020a).", [["global GDP", "TEST", 92, 102]]], ["The levels of debt are particularly worrying for the Global South, to which we now turn.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICThe Global South -The coronavirus pandemic poses a number of serious threats to developing and emerging countries (DECs) in the Global South.", [["coronavirus pandemic", "DISEASE", 155, 175], ["coronavirus", "ORGANISM", 155, 166], ["coronavirus pandemic", "OBSERVATION", 155, 175]]], ["The quarantine measures applied in many of these countries to contain COVID-19 contagion have led to serious economic collapses, sharp rises in unemployment and a significant reduction in state revenues (UNCTAD 2020).", [["The quarantine measures", "TREATMENT", 0, 23], ["COVID", "TEST", 70, 75], ["serious economic collapses", "PROBLEM", 101, 127], ["sharp rises", "PROBLEM", 129, 140], ["quarantine", "OBSERVATION", 4, 14], ["serious", "OBSERVATION_MODIFIER", 101, 108], ["economic", "OBSERVATION_MODIFIER", 109, 117], ["collapses", "OBSERVATION", 118, 127], ["sharp", "OBSERVATION_MODIFIER", 129, 134], ["rises", "OBSERVATION_MODIFIER", 135, 140], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["reduction", "OBSERVATION_MODIFIER", 175, 184]]], ["This creates an additional challenge because, unlike the developed economies of the Global North, many DECs have much weaker fiscal capacity to implement large stimulus packages (or to apply effective monetary policies).", [["DECs", "CANCER", 103, 107], ["large stimulus packages", "TREATMENT", 154, 177]]], ["The situation will be even worse for those depending on self-employment or informal work -which represent a large part of labour in Latin America, Asia and Africa, and cannot be carried out remotely (ILO 2020).", [["large", "OBSERVATION_MODIFIER", 108, 113]]], ["The collapse of the informal economy may not be accurately captured in official statistics (or IMF predictions).", [["collapse", "OBSERVATION", 4, 12], ["may not be", "UNCERTAINTY", 37, 47]]], ["The crisis is likely to hit the weakest sections of society the hardest.", [["The crisis", "PROBLEM", 0, 10], ["crisis", "OBSERVATION", 4, 10], ["likely to", "UNCERTAINTY", 14, 23]]], ["By the time the pandemic is over, half the world's population may be living in poverty (Oxfam Note: chain 1: labour value / wages; chain 2: personal taxes / welfare payments; chain 3: bank lending to households / debt repayments by households; chain 4: investments by households / returns; chain 5: bank lending to firms / debt repayments by firms; chain 6: corporate taxes / state subsidies and bailouts; chain 7: investments / returns; chain 8: government borrowing from banks / repayments; chain 9: government borrowing from the central bank / repayments (or monetary financing); chain 10: government borrowing from financial markets / repayments; chain 11: bank borrowing from the central bank / repayments; chain 12: bank investments and borrowing via financial markets; chain 13: central bank interventions on financial markets (e.g. quantitative easing) Source: Adapted from Sokol (2020).", [["central bank interventions", "TREATMENT", 786, 812], ["financial markets", "TREATMENT", 816, 833]]], ["The global economic slowdown expected for 2020 and beyond will significantly reduce the demand for exports from DECs.", [["DECs", "CELL_TYPE", 112, 116], ["global", "OBSERVATION_MODIFIER", 4, 10], ["economic", "OBSERVATION_MODIFIER", 11, 19], ["slowdown", "OBSERVATION_MODIFIER", 20, 28]]], ["Moreover, the decline in export volume will be accompanied by sharp falls in energy and commodity prices, which still make up most of the goods that many countries from the Global South export.", [["the decline in export volume", "PROBLEM", 10, 38], ["sharp falls in energy", "PROBLEM", 62, 83], ["sharp", "OBSERVATION_MODIFIER", 62, 67], ["falls", "OBSERVATION", 68, 73]]], ["Moreover, other contributing items in their current accounts, such as remittances, are likely to decline as well.", [["likely to", "UNCERTAINTY", 87, 96]]], ["Thus, the fall in hard currency inflows will put further pressure on the exchange rates, while many countries in Latin America and other developing regions have already experienced devaluations (see below).", [["the fall", "PROBLEM", 6, 14], ["further pressure", "TREATMENT", 49, 65], ["the exchange rates", "TREATMENT", 69, 87]]], ["This means not only that their exports will fall in volume and value, but also that the terms of trade vis-\u00e0-vis the advanced economies will deteriorate dramatically, producing a relative impoverishment of these economies in the international markets.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICWe argue that, on top of this, a major source of weakness for developing economies in the pandemic crisis will be their financial position.", [["weakness", "PROBLEM", 345, 353], ["developing economies", "PROBLEM", 358, 378], ["the pandemic crisis", "PROBLEM", 382, 401], ["impoverishment", "OBSERVATION_MODIFIER", 188, 202], ["weakness", "OBSERVATION", 345, 353]]], ["Over the past decade, the global liquidity promoted by central banks in the Global North (such as the Fed's policies mentioned above) has contributed to a systematic build-up of financial and debt vulnerabilities in countries of the Global South.", [["global", "OBSERVATION_MODIFIER", 26, 32], ["liquidity", "OBSERVATION", 33, 42], ["central banks", "OBSERVATION", 55, 68]]], ["The pandemic has triggered a flight to safety that caused record capital outflows from DECs.", [["DECs", "CELL_TYPE", 87, 91], ["capital outflows", "OBSERVATION", 65, 81]]], ["According to the International Institute of Finance, in March 2020 alone, Emerging Markets securities suffered around US$83.3 billion in outflows (IIF 2020b), which is more than three times the portfolio outflows experienced by the same countries during the GFC of 2008.", [["the GFC", "TEST", 254, 261]]], ["In turn, these capital flights have already triggered widening spreads and large currency depreciations.EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICA critical vulnerability for developing and emerging economies relates to debt.", [["widening spreads", "PROBLEM", 54, 70], ["large currency depreciations", "PROBLEM", 75, 103], ["widening", "OBSERVATION_MODIFIER", 54, 62], ["spreads", "OBSERVATION_MODIFIER", 63, 70], ["large", "OBSERVATION_MODIFIER", 75, 80], ["currency depreciations", "OBSERVATION", 81, 103]]], ["Total debt in DECs reached a record US$55 trillion after the 'largest, fastest, and most broad-based' debt wave in half a century (World Bank 2019; Ayhan Kose et al. 2020), with the debt-to-GDP ratio surging by 54 percentage points between 2010 and 2018 to a record high of 168 per cent.", [["GDP", "CHEMICAL", 190, 193], ["GDP", "SIMPLE_CHEMICAL", 190, 193], ["GDP ratio", "TEST", 190, 199]]], ["The total external debt of DECs reached 26 per cent of GDP in 2018, but if China is excluded, the external debt stood at 35 per cent of GDP.", [["DECs", "DISEASE", 27, 31], ["GDP", "CHEMICAL", 55, 58], ["GDP", "CHEMICAL", 136, 139], ["GDP", "CHEMICAL", 55, 58], ["GDP", "CHEMICAL", 136, 139], ["GDP", "SIMPLE_CHEMICAL", 55, 58], ["GDP", "SIMPLE_CHEMICAL", 136, 139], ["The total external debt of DECs", "TREATMENT", 0, 31]]], ["This means that both the public and private sectors in DECs will face increasing pressure on debt service in the coming years, especially those denominated in foreign currencies, in a context in which rolling over that debt seems unlikely.", [["increasing", "OBSERVATION_MODIFIER", 70, 80], ["pressure", "OBSERVATION", 81, 89], ["foreign currencies", "OBSERVATION", 159, 177], ["seems unlikely", "UNCERTAINTY", 224, 238]]], ["This situation, coupled with the declining export earnings, widening spreads and sharp currency devaluations mentioned above, will seriously jeopardise DECs' ability to repay their debts and pay for the imports necessary to keep their economies running.", [["widening spreads", "PROBLEM", 60, 76], ["sharp currency devaluations", "PROBLEM", 81, 108], ["widening", "OBSERVATION_MODIFIER", 60, 68], ["spreads", "OBSERVATION_MODIFIER", 69, 76], ["sharp", "OBSERVATION_MODIFIER", 81, 86]]], ["Furthermore, as suggested by Joseph Stiglitz (2020), many DEC governments will face a dilemma between paying off their external debts or using these funds to fight the domestic health and economic effects of Covid-19.", [["DEC", "CHEMICAL", 58, 61], ["Covid", "TEST", 208, 213]]], ["There is a serious danger that the situation could descend into a major global debt crisis (see also Ghosh 2020; Roos 2020).EMERGING ECONOMIC GEOGRAPHIES OF THE PANDEMICIt remains to be seen what winners and losers such a scenario will produce but, unless some global rescue efforts are put in place, the crisis is likely to hit the weakest economies the hardest.", [["the crisis", "PROBLEM", 301, 311], ["serious", "OBSERVATION_MODIFIER", 11, 18], ["debt crisis", "OBSERVATION", 79, 90]]], ["It also remains to be seen how China and India, the two biggest emerging economies and both intimately connected to the fortunes of the global economy, will withstand the global downturn.", [["economies", "OBSERVATION", 73, 82], ["global", "OBSERVATION_MODIFIER", 136, 142], ["economy", "OBSERVATION", 143, 150]]], ["Taking into consideration the factors discussed above, it looks likely that the broad gap between the Global North and Global South will widen.", [["the broad gap", "PROBLEM", 76, 89], ["Global", "OBSERVATION_MODIFIER", 102, 108], ["North", "OBSERVATION_MODIFIER", 109, 114]]], ["This can be illustrated by the case of Europe, which we examine in turn.Economic geographies of pandemic Europe-Europe provides a fascinating example within the Global North of how economic geographies of the pandemic will be shaped by pre-existing inequalities; by the intensity of the pandemic-induced economic shock inflicted on individual economies; by the ability of individual countries to respond to that shock; and by their ability to stage an economic recovery.", [["pandemic", "DISEASE", 287, 295], ["shock", "DISEASE", 313, 318], ["shock", "DISEASE", 412, 417]]], ["But the fact is that significant economic differences between the 'core' (Germany, Belgium, the Netherlands, etc.) and the southern 'periphery' (Portugal, Spain, Italy, Greece) remain despite decades of European integration.", [["European integration", "TREATMENT", 203, 223], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["economic", "OBSERVATION_MODIFIER", 33, 41]]], ["The Global Financial Crisis of 2008 and the subsequent sovereign debt crisis in Europe have brutally exposed, and further deepened, these differences.", [["the subsequent sovereign debt crisis", "PROBLEM", 40, 76], ["Global", "OBSERVATION_MODIFIER", 4, 10], ["Financial Crisis", "OBSERVATION", 11, 27], ["debt crisis", "OBSERVATION", 65, 76]]], ["EU-imposed austerity may have stabilised the eurozone and allowed the core to recover, but it left the southern periphery weaker and more vulnerable.", [["eurozone", "CHEMICAL", 45, 53], ["eurozone", "CHEMICAL", 45, 53], ["eurozone", "SIMPLE_CHEMICAL", 45, 53], ["the eurozone", "TREATMENT", 41, 53]]], ["Indeed, in 2019 Germany's output was approximately 15 per cent higher than in 2007; Belgium's was 13.5 per cent higher and the Netherlands' was up by 12 per cent (World Bank 2020).", [["Germany's output", "TEST", 16, 32], ["Belgium's", "TEST", 84, 93]]], ["By contrast, the Italian GDP in 2019 was nearly 6 per cent lower than in 2007 and the Greek GDP was, astonishingly, nearly 25 per cent lower, while the 2019 outputs of Spain and Portugal were only about 4.5 per cent and 2.5 per cent above their respective pre-crisis levels (World Bank 2020).", [["GDP", "CHEMICAL", 25, 28], ["GDP", "CHEMICAL", 92, 95], ["the Italian GDP", "TEST", 13, 28]]], ["The contrasts in sovereign debt levels between the north and the south are equally stark.", [["sovereign debt", "OBSERVATION", 17, 31], ["north", "OBSERVATION_MODIFIER", 51, 56]]], ["Germany's sovereign debt-to-GDP ratio stands at approximately 62 per cent and that of the Netherlands at 52 per cent.", [["Germany's sovereign debt", "TEST", 0, 24], ["GDP ratio", "TEST", 28, 37]]], ["Meanwhile, Italy's sovereign debt burden is equivalent to almost 135 per cent of its GDP and Greece's exceeds 185 per cent of GDP.", [["GDP", "CHEMICAL", 85, 88], ["GDP", "CHEMICAL", 126, 129], ["GDP", "CHEMICAL", 126, 129], ["GDP", "SIMPLE_CHEMICAL", 85, 88], ["GDP", "SIMPLE_CHEMICAL", 126, 129], ["Italy's sovereign debt burden", "PROBLEM", 11, 40], ["its GDP", "TEST", 81, 88], ["Greece's", "TEST", 93, 101]]], ["The Italian and the Greek banking sectors are also among the most fragile in Europe, with high ratios of non-performing loans (Reuters 2020a ).", [["most fragile", "OBSERVATION_MODIFIER", 61, 73]]], ["Greece, Spain and Italy have the highest unemployment rates in the EU, reaching 16 per cent, 14 per cent and 10 per cent, respectively, in contrast to Germany's 3.2 per cent and the Netherland's 2.9 per cent (Eurostat 2020) .Economic geographies of pandemic EuropeAll these differences are about to be dramatically exacerbated by the crisis.", [["the crisis", "PROBLEM", 330, 340]]], ["Extending the analogy made by Roos (2020) in connection to Italy, it is a 'cruel irony' that the southern periphery, being the weakest economically, was also hardest hit by the coronavirus.", [["coronavirus", "ORGANISM", 177, 188], ["the coronavirus", "PROBLEM", 173, 188]]], ["The IMF forecasts that unemployment rates are expected to increase significantly in 2020, peaking at over 20 per cent in Spain and Greece, about 14 per cent in Portugal, and 13 per cent in Italy, compared to 4 per cent in Germany (IMF 2020).Economic geographies of pandemic EuropeIt is expected that the eurozone as a whole will be hit hard by the crisis, with the block's GDP falling by as much as 7.5 per cent in 2020 (IMF 2020).", [["eurozone", "CHEMICAL", 304, 312], ["eurozone", "CHEMICAL", 304, 312], ["GDP", "SIMPLE_CHEMICAL", 373, 376], ["IMF", "PROTEIN", 4, 7], ["the block's GDP", "TREATMENT", 361, 376]]], ["However, it is widely expected that the fall in the southern periphery will be more pronounced, while its subsequent recovery will be weaker (see also M\u00fcnchau 2020) .", [["the fall", "PROBLEM", 36, 44], ["fall", "OBSERVATION", 40, 44], ["more pronounced", "OBSERVATION_MODIFIER", 79, 94]]], ["Thus, the uneven economic impact of the crisis combined with the uneven recovery, playing out on an already uneven terrain, will drive the northsouth divide to new levels.Economic geographies of pandemic EuropeIn the absence of a strong EU-wide supporting mechanism (such as 'eurobonds' 4 ), the diverging economic fortunes of the southern periphery can have unpredictable consequences.", [["the crisis", "PROBLEM", 36, 46], ["unpredictable consequences", "PROBLEM", 359, 385], ["uneven", "OBSERVATION_MODIFIER", 10, 16], ["economic", "OBSERVATION_MODIFIER", 17, 25], ["crisis", "OBSERVATION", 40, 46]]], ["For example, Italy's falling GDP combined with rising debt could push its debt-to-GDP ratio from the current 135 per cent to between 160 per cent and 180 per cent, raising doubts about Italy's solvency and potentially leading to a default (M\u00fcnchau 2020) .", [["GDP", "CHEMICAL", 29, 32], ["GDP", "CHEMICAL", 29, 32], ["GDP", "CHEMICAL", 82, 85], ["GDP", "SIMPLE_CHEMICAL", 29, 32], ["GDP", "SIMPLE_CHEMICAL", 82, 85], ["Italy's falling GDP", "PROBLEM", 13, 32], ["rising debt", "PROBLEM", 47, 58], ["GDP ratio", "TEST", 82, 91]]], ["The prospect of a disintegration of the EU is of crucial concern to member states in the 'eastern' periphery.Economic geographies of pandemic EuropeEast-Central European dimension -It is worth remembering that one of the key reasons for post-socialist countries in East-Central Europe to join the EU was to catch-up economically with their Western European counterparts.", [["' periphery", "CELLULAR_COMPONENT", 97, 108]]], ["Deep 'transition' recessions in the early 1990s that followed the collapse of state-socialism have meant that the economic divide between the Western and Eastern halves of Europe has actually grown larger, as have differences within the East itself.", [["Deep 'transition' recessions", "PROBLEM", 0, 28], ["transition' recessions", "OBSERVATION", 6, 28], ["collapse", "OBSERVATION", 66, 74], ["grown", "OBSERVATION_MODIFIER", 192, 197], ["larger", "OBSERVATION_MODIFIER", 198, 204]]], ["Through the combination of old historical legacies and uneven effects of transformation processes, Central and Eastern Europe has established itself as a European 'super-periphery' while itself internally displaying increasing divergence of economic fortunes (Sokol 2001) .", [["old historical legacies", "TREATMENT", 27, 50], ["transformation processes", "PROBLEM", 73, 97], ["Central", "OBSERVATION_MODIFIER", 99, 106], ["increasing", "OBSERVATION_MODIFIER", 216, 226], ["divergence", "OBSERVATION_MODIFIER", 227, 237]]], ["From the 'varieties of capitalism' perspective, the economies of East-Central Europe (ECE) have been described as 'dependent market economies' (N\u00f6lke & Vliegenthart 2009 )their productive capacity became dominated by Western European FDI and their financial systems became heavily dependent on Western European banking groups.", [["Central Europe (ECE", "TREATMENT", 70, 89], ["heavily dependent", "PROBLEM", 273, 290]]], ["The economic fortunes of the entire region have thus became inextricably linked to those of Western Europe.", [["economic", "OBSERVATION_MODIFIER", 4, 12]]], ["Part of this boom was related to increasing financialisation, not least through the Western banks that were instrumental in rapidly expanding credit across the region, on the back of newly created 'financial chains' (Sokol 2017b) .Economic geographies of pandemic EuropeHowever, for many people and places, all this came to a rather abrupt end when the GFC hit in 2008.", [["people", "ORGANISM", 288, 294], ["people", "SPECIES", 288, 294], ["increasing financialisation", "PROBLEM", 33, 60], ["increasing", "OBSERVATION_MODIFIER", 33, 43], ["financialisation", "OBSERVATION", 44, 60]]], ["The economic damage caused by the crisis was enormous (e.g. see Smith & Swain 2010) , in many cases wiping out any gains made in the previous decade.Economic geographies of pandemic EuropeThe impacts, however, were unevenly distributed, as was the recovery.", [["The economic damage", "PROBLEM", 0, 19], ["the crisis", "PROBLEM", 30, 40], ["pandemic Europe", "TREATMENT", 173, 188], ["economic", "OBSERVATION_MODIFIER", 4, 12], ["damage", "OBSERVATION", 13, 19], ["impacts", "OBSERVATION_MODIFIER", 192, 199], ["unevenly", "OBSERVATION_MODIFIER", 215, 223], ["distributed", "OBSERVATION_MODIFIER", 224, 235]]], ["Poland, for example, emerged as the only country in the entire European Union to avoid a recession, while Baltic countries experienced deep falls and took nearly a decade to get back to pre-crisis level (Pataccini & Eamets 2019; Pataccini 2020) .", [["a recession", "PROBLEM", 87, 98], ["deep falls", "PROBLEM", 135, 145]]], ["For many ECE countries, even the best performing ones, the prospects of fully converging to GDP levels of Western Europe appear as distant as ever.Economic geographies of pandemic EuropeFollowing the 'transition' recession of the 1990s and the GFC of 2008, the pandemic-induced crisis of 2020 will be the third major economic calamity in as many decades and perhaps the biggest one yet.", [["pandemic", "DISEASE", 261, 269], ["GDP", "SIMPLE_CHEMICAL", 92, 95], ["GDP levels", "TEST", 92, 102], ["pandemic", "PROBLEM", 171, 179], ["the 'transition' recession", "TREATMENT", 196, 222], ["the GFC", "TEST", 240, 247]]], ["Indeed, the impact could be explosive.", [["explosive", "OBSERVATION_MODIFIER", 28, 37]]], ["Economically, the crisis will be playing out on an already uneven economic terrain and is likely to have uneven impacts.", [["the crisis", "PROBLEM", 14, 24]]], ["The exact contours are hard to predict at this time -but much will depend on the way in which economic and financial links with Western Europe will unfold.", [["contours", "OBSERVATION_MODIFIER", 10, 18]]], ["This leads us to consider the operation of the financial system and its uneven impacts under the conditions of financialisation.CRISES, FINANCIALISATION AND FINANCIAL CHAINSFinancialisation and financial chains -Financialisation, a shorthand for the growing pow-\u00a9 2020 The Authors.", [["the operation of the financial system", "TREATMENT", 26, 63]]], ["Tijdschrift voor Economische en Sociale Geografie published by John Wiley & Sons Ltd on behalf of Royal Dutch Geographical Society / Koninklijk Nederlands Aardrijkskundig er of finance over societies and economies, has been recognised as the key feature of contemporary capitalism.", [["capitalism", "OBSERVATION", 270, 280]]], ["Financial chains could be defined as 'channels of value transfer (between people and places) and as social relations that shape socio-economic processes and attendant economic geographies' (Sokol 2017a, p.", [["people", "SPECIES", 74, 80]]], ["The pandemic-induced crisis is a perfect opportunity to explore the operation of financial chains and their role in creating economic winners and losers.CRISES, FINANCIALISATION AND FINANCIAL CHAINSCrisis and financial chains in a financialised economy - Figure 1 represents a simplified illustration of the web of financial chains in an abstract financialised economy.", [["the operation of financial chains", "TREATMENT", 64, 97]]], ["A main feature of financialised capitalism is precisely the growing power of financial markets.", [["main", "OBSERVATION_MODIFIER", 2, 6], ["financialised", "OBSERVATION_MODIFIER", 18, 31], ["capitalism", "OBSERVATION", 32, 42], ["growing", "OBSERVATION_MODIFIER", 60, 67], ["power", "OBSERVATION_MODIFIER", 68, 73], ["financial markets", "OBSERVATION", 77, 94]]], ["As critics (e.g. Pettifor 2014) argue, this is at the expense of the productive economy (often also referred to as the 'real economy'), while also making the system more susceptible to crises.", [["crises", "PROBLEM", 185, 191], ["productive", "OBSERVATION_MODIFIER", 69, 79], ["economy", "OBSERVATION", 80, 87]]], ["The current crisis did not start as a financial crisis, but it may end up as one.", [["a financial crisis", "PROBLEM", 36, 54]]], ["The pandemic-induced shutdown of the economy creates a major disruption at the heart of the productive economy: households (workers) under lockdown can neither produce nor consume.", [["heart", "ANATOMY", 79, 84], ["heart", "ORGAN", 79, 84], ["a major disruption", "PROBLEM", 53, 71], ["shutdown", "OBSERVATION_MODIFIER", 21, 29], ["major", "OBSERVATION_MODIFIER", 55, 60], ["disruption", "OBSERVATION", 61, 71], ["heart", "ANATOMY", 79, 84], ["productive", "OBSERVATION_MODIFIER", 92, 102], ["economy", "OBSERVATION_MODIFIER", 103, 110]]], ["The critical value chain of the 'real economy' between firms and households (chain 1) is thus being disrupted, creating a tsunami of knock-on effects for the rest of the economic system: personal taxes (chain 2); debt repayments by households (chain 3); debt repayments by firms (chain 5); corporate taxes (chain 6); dividends to investors via financial markets (chain 7); etc. (see Figure 1 ).", [["chain", "OBSERVATION_MODIFIER", 19, 24]]], ["Traditionally, in times of crisis, the state would try to borrow from financial markets (chain 10) via government bonds to finance its growing budget deficit.", [["crisis", "PROBLEM", 27, 33], ["crisis", "OBSERVATION", 27, 33]]], ["In this way the financial markets and attendant debt-based financial chains will further exacerbate existing economic disparities and will shape the map of winners and losers (see also below).CRISES, FINANCIALISATION AND FINANCIAL CHAINSThere is only one player that can potentially alter the above dynamics for any given economy: the central bank (Figure 1 ).", [["attendant debt-based financial chains", "TREATMENT", 38, 75]]], ["This crisis has demonstrated yet again just how central the central banks really are for the financialised economy and its survival (see also Lapavitsas & Mendieta-Mu\u00f1oz 2016) .", [["This crisis", "PROBLEM", 0, 11], ["central banks", "OBSERVATION", 60, 73]]], ["Apart from setting interest rates (thus influencing the cost of debt for all participants), the central bank can directly intervene in the financial markets (chain 13), for example through quantitative easing.", [["participants", "SPECIES", 77, 89]]], ["It remains to be seen to what extent major central banks will adopt such unconventional policies.", [["central banks", "OBSERVATION", 43, 56]]], ["5 What is increasingly clear, however, is that central bank actions have significant implications for the international political economy, to which we now turn.CRISES, FINANCIALISATION AND FINANCIAL CHAINSCrises, financial chains and the international political economy -There are several issues related to central bank interventions that deserve attention as they have implications for the emerging economic geographies of the pandemic.", [["several issues", "PROBLEM", 281, 295], ["central bank interventions", "TREATMENT", 307, 333], ["increasingly", "OBSERVATION_MODIFIER", 10, 22], ["clear", "OBSERVATION", 23, 28]]], ["Indeed, some central banks appear to have unlimited 'firing power', while interventions by other central banks look more like 'fire-fighting'.", [["central banks", "OBSERVATION", 13, 26]]], ["The latter group of central banks could be mostly found in the Global South or in the peripheries of the Global North (for instance in East-Central Europe).", [["central banks", "OBSERVATION", 20, 33], ["peripheries", "ANATOMY_MODIFIER", 86, 97]]], ["Their capacity to support their domestic economies in times of crisis is somewhat limited, affecting any post-crisis recovery.CRISES, FINANCIALISATION AND FINANCIAL CHAINSSecond, even the most robust interventions by the most powerful central banks in the Global North (such as those undertaken by the Fed) do not actually 'resolve' the crisis.", [["crisis", "PROBLEM", 63, 69], ["the crisis", "PROBLEM", 333, 343]]], ["6 From the 'financial chains' perspective, this basically creates new debtbased financial chains that stretch value flows (and the power relations that go with them) in time.", [["new debtbased financial chains", "PROBLEM", 66, 96], ["new", "OBSERVATION_MODIFIER", 66, 69]]], ["Third, such interventions by central banks have significant impacts beyond their domestic economies.", [["such interventions", "TREATMENT", 7, 25], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["impacts", "OBSERVATION_MODIFIER", 60, 67], ["domestic economies", "OBSERVATION", 81, 99]]], ["Indeed, the newly created debt spills over into a wider international political economy (see below).", [["debt spills", "OBSERVATION", 26, 37]]], ["In other words, such debt-based financial chains (with attendant value flows and power relations) are stretched in space, across international borders.CRISES, FINANCIALISATION AND FINANCIAL CHAINSAll of these three aspects are now in play during the pandemic-induced crisis and will shape the emerging map of winners and losers.", [["such debt-based financial chains", "PROBLEM", 16, 48], ["attendant value flows", "TREATMENT", 55, 76]]], ["The problem with this, as already alluded to above, is that it only creates another wall of debt -on top of that created after the last crisis.", [["wall", "ANATOMY", 84, 88], ["the last crisis", "PROBLEM", 127, 142], ["debt", "OBSERVATION", 92, 96]]], ["Indeed, it has been estimated that some US$11 trillion has been injected into the economy via QE between 2008 and 2018 in the US, Japan and the eurozone alone, and that the total figure may be US$15 trillion, that is, about 20 per cent of the global GDP, making central banks key bond holders (see Fernandez et al. 2018) .", [["GDP", "CHEMICAL", 250, 253], ["GDP", "SIMPLE_CHEMICAL", 250, 253], ["the eurozone alone", "TREATMENT", 140, 158]]], ["So, yet again, the crisis will not actually be 'resolved', only pushed further into the future.", [["the crisis", "PROBLEM", 15, 25]]], ["Indeed, there is a good body of evidence (Lim et al. 2014; Caldentey 2017; Fernandez et al. 2018) (2019) warned of serious risks created by the largest wave of debt accumulation in the countries of the Global South in the last 50 years.", [["debt accumulation", "PROBLEM", 160, 177], ["good", "OBSERVATION_MODIFIER", 19, 23], ["largest", "OBSERVATION_MODIFIER", 144, 151], ["debt accumulation", "OBSERVATION", 160, 177]]], ["In other words, the Global South was already in an extremely vulnerable position, even before the coronavirus pandemic hit (see also Ghosh 2020; Roos 2020).", [["coronavirus", "DISEASE", 98, 109], ["the coronavirus pandemic hit", "PROBLEM", 94, 122]]], ["Financialisation is a crucial feature of these movements, not only because it promotes the liberalisation and deregulation of capital mobility on a global scale (Epstein 2005) , but also because it enables the realisation of profit even without being related to the creation of surplus value (Lapavitsas 2013; Lapavitsas & Mendieta-Mu\u00f1oz 2016) .CRISES, FINANCIALISATION AND FINANCIAL CHAINSThis outflow of capital from the economies of the Global South will further complicate their already problematic financial position.", [["capital mobility", "OBSERVATION", 126, 142]]], ["The debt that Global South economies have accumulated since the last crisis has been built on financial chains that systematically transfer value to advanced economies, while it has also substantially increased the Global South's vulnerability to external shocks.", [["external shocks", "TREATMENT", 247, 262], ["Global", "OBSERVATION_MODIFIER", 14, 20], ["South", "OBSERVATION_MODIFIER", 21, 26], ["economies", "OBSERVATION", 27, 36], ["increased", "OBSERVATION_MODIFIER", 201, 210], ["external shocks", "OBSERVATION", 247, 262]]], ["The shock produced by the pandemic could trigger a 'debt deluge' (Ghosh 2020; Roos 2020) , putting the Global South's economies on the brink of an unprecedented debt crisis.CRISES, FINANCIALISATION AND FINANCIAL CHAINSAll this highlights the point that unfolding processes of financialisation (and their effects) must be understood in a very geographical way.", [["shock", "DISEASE", 4, 9], ["The shock", "PROBLEM", 0, 9], ["unfolding processes of financialisation", "PROBLEM", 253, 292], ["shock", "OBSERVATION", 4, 9], ["debt crisis", "OBSERVATION", 161, 172]]], ["Building on a notion introduced by Fernandez and Aalbers (2019) who see subordinated financialisation in the Global South as a contemporary form of uneven and combined development, we argue that inserting financial chains into the analysis may help to further elucidate the emerging economic geographies in crisis times.", [["the analysis", "TEST", 227, 239]]], ["First, we have attempted to sketch out the emerging economic geographies of the coronavirus pandemic, highlighting possible winners and losers.", [["coronavirus pandemic", "DISEASE", 80, 100], ["coronavirus", "ORGANISM", 80, 91], ["the coronavirus pandemic", "PROBLEM", 76, 100], ["coronavirus", "ANATOMY", 80, 91]]], ["Second, we have aimed to explore the links between these emerging economic geographies and the processes of 'financialisation' (Aalbers 2016) , while drawing on the concept of 'financial chains' (Sokol 2017a) .CONCLUDING REMARKSWith regard to our first aim, we have argued that the pandemic-induced crisis will exacerbate social inequalities and deepen uneven development at multiple geographical scales.", [["the pandemic-induced crisis", "PROBLEM", 278, 305]]], ["The emerging map of winners and losers will most likely be conditioned by the existing imbalances in the global economy.", [["imbalances", "OBSERVATION", 87, 97], ["global", "OBSERVATION_MODIFIER", 105, 111], ["economy", "OBSERVATION", 112, 119]]], ["In particular, we foresee that the Global North/Global South divide is likely to be exacerbated, with the Global South potentially facing unprecedented debt crisis.", [["likely to be", "UNCERTAINTY", 71, 83], ["exacerbated", "OBSERVATION", 84, 95]]], ["Major disruptions to international financial chains can be expected (unless some coordinated global action is taken).", [["Major disruptions to international financial chains", "PROBLEM", 0, 51]]], ["Simultaneously, it is most likely that the economic differences within both the Global North and the Global South will grow.", [["most likely", "UNCERTAINTY", 22, 33], ["economic", "OBSERVATION_MODIFIER", 43, 51], ["Global", "OBSERVATION_MODIFIER", 80, 86], ["North", "OBSERVATION_MODIFIER", 87, 92]]], ["Taking Europe as an example, we have highlighted the fact that the pandemic-induced crisis is likely to dramatically deepen the disparities between the northern 'core' and the southern 'periphery' and between the west and the east, as well as within the east.", [["pandemic", "DISEASE", 67, 75]]], ["Further fragmentation is likely to occur at sub-national levels unless bold policies are implemented to counter this.CONCLUDING REMARKSWith regard to our second aim we have argued that the 'financialisation' perspective in general, and the concept of 'financial chains' in particular, provide useful insights into the crisis and its effects.", [["Further fragmentation", "PROBLEM", 0, 21], ["fragmentation", "OBSERVATION", 8, 21], ["is likely", "UNCERTAINTY", 22, 31]]], ["Indeed, the 'financial chains' approach helps to highlight the interdependencies between various economic actors, including 'contagion' mechanisms of the current crisis both within individual economies and at the international political economy level.", [["the 'financial chains' approach", "TREATMENT", 8, 39], ["the current crisis", "PROBLEM", 150, 168]]], ["It also draws attention to the centrality of debt and the role of debt-based financial chains which are likely to be created, disrupted or transformed by the current crisis.", [["debt-based financial chains", "PROBLEM", 66, 93], ["financial chains", "OBSERVATION", 77, 93], ["likely to be", "UNCERTAINTY", 104, 116]]], ["In turn, these financial chains will play an active role in shaping economic geographies at a time of major global crisis. nrese arch.eu).", [["major global crisis", "PROBLEM", 102, 121], ["active", "OBSERVATION_MODIFIER", 45, 51], ["global crisis", "OBSERVATION", 108, 121], ["arch", "ANATOMY", 129, 133]]], ["All remaining mistakes are our own.", [["remaining", "OBSERVATION_MODIFIER", 4, 13], ["mistakes", "OBSERVATION", 14, 22]]]], "PMC7313501": [["Oligonucleotide (DNA/RNA) delivery systemsMany industry leaders believe an efficient nanoparticle delivery system is the key to mount an effective DNA/RNA vaccine response.", [["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["Oligonucleotide (DNA/RNA) delivery systems", "TREATMENT", 0, 42], ["an efficient nanoparticle delivery system", "TREATMENT", 72, 113], ["an effective DNA/RNA vaccine", "TREATMENT", 134, 162]]], ["Any ideal delivery system needs to demonstrate a combination of high loading capacity, controlled release with extended half-life, no leakage, no interference with the stability of the therapeutic molecule, and a straightforward and consistent manufacturing process.", [["Any ideal delivery system", "TREATMENT", 0, 25], ["high loading capacity", "PROBLEM", 64, 85], ["leakage", "PROBLEM", 134, 141], ["loading capacity", "OBSERVATION", 69, 85], ["no", "UNCERTAINTY", 131, 133], ["leakage", "OBSERVATION", 134, 141], ["manufacturing process", "OBSERVATION", 244, 265]]], ["Good biocompatibility, low toxicity, and biodegradability, as well as a clear understanding of the mode of action of the delivery system, are also desirable factors.Adeno-associated virus (AAV) and lentivirus-based vaccinesThe pressure to find and administer a COVID-19 vaccine has sparked interest in finding a safe and effective viral delivery system, or most likely, more than one delivery system.", [["toxicity", "DISEASE", 27, 35], ["COVID-19", "CHEMICAL", 261, 269], ["Adeno-associated virus", "ORGANISM", 165, 187], ["AAV", "ORGANISM", 189, 192], ["lentivirus", "ORGANISM", 198, 208], ["Adeno-associated virus", "SPECIES", 165, 187], ["AAV", "SPECIES", 189, 192], ["lentivirus", "SPECIES", 198, 208], ["low toxicity", "PROBLEM", 23, 35], ["the delivery system", "TREATMENT", 117, 136], ["Adeno-associated virus (AAV)", "TREATMENT", 165, 193], ["lentivirus-based vaccines", "TREATMENT", 198, 223], ["The pressure", "TEST", 223, 235], ["a COVID-19 vaccine", "TREATMENT", 259, 277], ["a safe and effective viral delivery system", "TREATMENT", 310, 352], ["biocompatibility", "OBSERVATION_MODIFIER", 5, 21], ["low toxicity", "OBSERVATION_MODIFIER", 23, 35], ["virus", "OBSERVATION", 182, 187], ["pressure", "OBSERVATION_MODIFIER", 227, 235], ["most likely", "UNCERTAINTY", 357, 368]]], ["Of those 89, the seven front runners (in clinical stage) are predominantly nucleic acid vaccines using non-replicating viral vectors (such as adeno-associated virus or lentivirus) for the vaccine delivery.Adeno-associated virus (AAV) and lentivirus-based vaccinesMany companies developing COVID-19 vaccines are using viral vectors to ensure effective delivery of the vaccine.", [["nucleic acid", "CHEMICAL", 75, 87], ["nucleic acid", "SIMPLE_CHEMICAL", 75, 87], ["adeno-associated virus", "ORGANISM", 142, 164], ["lentivirus", "ORGANISM", 168, 178], ["Adeno-associated virus", "ORGANISM", 205, 227], ["AAV", "ORGANISM", 229, 232], ["lentivirus", "ORGANISM", 238, 248], ["lentivirus", "SPECIES", 168, 178], ["AAV", "SPECIES", 229, 232], ["lentivirus", "SPECIES", 238, 248], ["nucleic acid vaccines", "TREATMENT", 75, 96], ["non-replicating viral vectors", "TREATMENT", 103, 132], ["adeno-associated virus or lentivirus", "TREATMENT", 142, 178], ["the vaccine delivery", "TREATMENT", 184, 204], ["Adeno-associated virus (AAV)", "PROBLEM", 205, 233], ["lentivirus-based vaccines", "TREATMENT", 238, 263], ["COVID-19 vaccines", "TREATMENT", 289, 306], ["viral vectors", "TREATMENT", 317, 330], ["effective delivery of the vaccine", "TREATMENT", 341, 374], ["predominantly", "OBSERVATION_MODIFIER", 61, 74], ["nucleic acid", "OBSERVATION", 75, 87], ["virus", "OBSERVATION", 222, 227]]], ["However, production of the viral vectors can be a cumbersome and challenging process and any improvement to that process could result in more vaccines being available faster.", [["the viral vectors", "PROBLEM", 23, 40], ["a cumbersome and challenging process", "PROBLEM", 48, 84], ["viral vectors", "OBSERVATION", 27, 40]]], ["The viral vector-producing cells need to be transfected with multiple plasmids carrying various viral genes and the \u2018payload\u2019, the vaccine.ElectroporationAmong the clinical candidates for COVID-19 vaccine delivery systems is an experimental DNA vaccine that uses electroporation, which is the process of applying a high-voltage electrical pulse to a living cell, causing temporary permeability of the cell membrane, through which a foreign material such as DNA may pass.ElectroporationHowever, researchers noted that \u201ca primary drawback of electroporation is pain and discomfort at the application site compared with conventional injections\u201d [2].", [["cells", "ANATOMY", 27, 32], ["plasmids", "ANATOMY", 70, 78], ["cell", "ANATOMY", 357, 361], ["cell membrane", "ANATOMY", 401, 414], ["COVID-19", "CHEMICAL", 188, 196], ["pain", "DISEASE", 559, 563], ["cells", "CELL", 27, 32], ["COVID-19", "SIMPLE_CHEMICAL", 188, 196], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["cell", "CELL", 357, 361], ["cell membrane", "CELLULAR_COMPONENT", 401, 414], ["DNA", "CELLULAR_COMPONENT", 457, 460], ["plasmids", "DNA", 70, 78], ["viral genes", "DNA", 96, 107], ["The viral vector", "TREATMENT", 0, 16], ["producing cells", "PROBLEM", 17, 32], ["multiple plasmids", "TREATMENT", 61, 78], ["various viral genes", "TREATMENT", 88, 107], ["the \u2018payload", "TREATMENT", 112, 124], ["the vaccine", "TREATMENT", 127, 138], ["COVID-19 vaccine delivery systems", "TREATMENT", 188, 221], ["an experimental DNA vaccine", "TREATMENT", 225, 252], ["electroporation", "TREATMENT", 263, 278], ["a high-voltage electrical pulse", "TREATMENT", 313, 344], ["temporary permeability of the cell membrane", "PROBLEM", 371, 414], ["a foreign material", "TREATMENT", 430, 448], ["pain", "PROBLEM", 559, 563], ["discomfort at the application site", "PROBLEM", 568, 602], ["conventional injections", "TREATMENT", 617, 640], ["viral vector", "OBSERVATION", 4, 16], ["temporary permeability", "OBSERVATION", 371, 393], ["cell membrane", "OBSERVATION", 401, 414]]], ["There were also reaction reports of involuntary muscle contraction and mild to severe asymptomatic increases in CPK (creatine phosphokinase) levels in the blood of six participants.", [["muscle", "ANATOMY", 48, 54], ["blood", "ANATOMY", 155, 160], ["involuntary muscle contraction", "DISEASE", 36, 66], ["creatine", "CHEMICAL", 117, 125], ["creatine", "CHEMICAL", 117, 125], ["muscle", "ORGAN", 48, 54], ["CPK", "GENE_OR_GENE_PRODUCT", 112, 115], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 117, 139], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["CPK", "PROTEIN", 112, 115], ["creatine phosphokinase", "PROTEIN", 117, 139], ["participants", "SPECIES", 168, 180], ["involuntary muscle contraction", "PROBLEM", 36, 66], ["mild to severe asymptomatic increases in CPK (creatine phosphokinase) levels", "PROBLEM", 71, 147], ["involuntary muscle contraction", "OBSERVATION", 36, 66], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["asymptomatic", "OBSERVATION_MODIFIER", 86, 98], ["increases", "OBSERVATION_MODIFIER", 99, 108]]], ["The researchers acknowledged that \u201cThe electroporation procedure has been shown to carry some potential of transient muscle damage in animal models, evident as increased numbers of fibres with central nucleoli and damaged myofibrillar bundles\u201d [3].", [["muscle", "ANATOMY", 117, 123], ["fibres", "ANATOMY", 181, 187], ["nucleoli", "ANATOMY", 201, 209], ["myofibrillar bundles", "ANATOMY", 222, 242], ["muscle damage", "DISEASE", 117, 130], ["muscle", "ORGAN", 117, 123], ["fibres", "TISSUE", 181, 187], ["nucleoli", "CELLULAR_COMPONENT", 201, 209], ["myofibrillar bundles", "CELLULAR_COMPONENT", 222, 242], ["The electroporation procedure", "TREATMENT", 35, 64], ["transient muscle damage in animal models", "PROBLEM", 107, 147], ["increased numbers of fibres", "PROBLEM", 160, 187], ["central nucleoli", "PROBLEM", 193, 209], ["transient", "OBSERVATION_MODIFIER", 107, 116], ["muscle", "ANATOMY", 117, 123], ["damage", "OBSERVATION", 124, 130], ["increased", "OBSERVATION_MODIFIER", 160, 169], ["central nucleoli", "OBSERVATION", 193, 209], ["myofibrillar bundles", "OBSERVATION", 222, 242]]], ["In addition, the equipment required together with the training of medical staff in its use will preclude widespread adoption of electroporation as a mass vaccination methodology.Lipid nanoparticle (LNP) systemsLiposomal encapsulation of drugs with bioavailability issues was a proven approach in small molecule pharma, and it was apparent to biopharma R&D scientists that LNPs could meet the basic requirements of an RNA/DNA delivery system too, namely to protect nucleic acid from in vivo digestion as it travels to the target.", [["Lipid nanoparticle", "CHEMICAL", 178, 196], ["LNP", "CHEMICAL", 198, 201], ["nucleic acid", "CHEMICAL", 464, 476], ["Lipid nanoparticle", "SIMPLE_CHEMICAL", 178, 196], ["LNP", "SIMPLE_CHEMICAL", 198, 201], ["systemsLiposomal", "SIMPLE_CHEMICAL", 203, 219], ["LNPs", "SIMPLE_CHEMICAL", 372, 376], ["DNA", "CELLULAR_COMPONENT", 421, 424], ["nucleic acid", "SIMPLE_CHEMICAL", 464, 476], ["electroporation", "TREATMENT", 128, 143], ["a mass vaccination methodology", "TREATMENT", 147, 177], ["Lipid nanoparticle (LNP) systemsLiposomal encapsulation of drugs", "TREATMENT", 178, 242], ["bioavailability issues", "PROBLEM", 248, 270], ["an RNA/DNA delivery system", "TREATMENT", 414, 440], ["small", "OBSERVATION_MODIFIER", 296, 301], ["molecule pharma", "OBSERVATION", 302, 317]]], ["Additionally, LNPs can be produced with catatonic outer membranes to allow cell entry.Lipid nanoparticle (LNP) systemsHowever, solid LNPs [4] have some significant disadvantages to be overcome, including cell toxicity; stimulating the release of systemic inflammatory cytokines; possible accumulation in the liver and spleen, with the resulting possibility of hepato-toxicity; low drug payload for hydrophilic molecules; and the potential of the reticuloendothelial system (RES) as a major route of clearance if liposomes are administered systemically.", [["outer membranes", "ANATOMY", 50, 65], ["cell", "ANATOMY", 75, 79], ["cell", "ANATOMY", 204, 208], ["liver", "ANATOMY", 308, 313], ["spleen", "ANATOMY", 318, 324], ["reticuloendothelial system", "ANATOMY", 446, 472], ["catatonic", "DISEASE", 40, 49], ["Lipid nanoparticle", "CHEMICAL", 86, 104], ["toxicity", "DISEASE", 209, 217], ["toxicity", "DISEASE", 367, 375], ["LNPs", "SIMPLE_CHEMICAL", 14, 18], ["outer membranes", "CELLULAR_COMPONENT", 50, 65], ["cell", "CELL", 75, 79], ["Lipid nanoparticle", "SIMPLE_CHEMICAL", 86, 104], ["LNP", "SIMPLE_CHEMICAL", 106, 109], ["cell", "CELL", 204, 208], ["liver", "ORGAN", 308, 313], ["spleen", "ORGAN", 318, 324], ["reticuloendothelial system", "MULTI-TISSUE_STRUCTURE", 446, 472], ["RES", "ANATOMICAL_SYSTEM", 474, 477], ["liposomes", "SIMPLE_CHEMICAL", 512, 521], ["LNPs", "PROTEIN", 14, 18], ["systemic inflammatory cytokines", "PROTEIN", 246, 277], ["catatonic outer membranes", "TREATMENT", 40, 65], ["Lipid nanoparticle (LNP) systems", "TREATMENT", 86, 118], ["some significant disadvantages", "PROBLEM", 147, 177], ["cell toxicity", "PROBLEM", 204, 217], ["systemic inflammatory cytokines", "PROBLEM", 246, 277], ["accumulation in the liver and spleen", "PROBLEM", 288, 324], ["hepato-toxicity", "PROBLEM", 360, 375], ["low drug payload", "TREATMENT", 377, 393], ["hydrophilic molecules", "PROBLEM", 398, 419], ["liposomes", "TREATMENT", 512, 521], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["disadvantages", "OBSERVATION", 164, 177], ["systemic", "OBSERVATION_MODIFIER", 246, 254], ["inflammatory", "OBSERVATION", 255, 267], ["liver", "ANATOMY", 308, 313], ["spleen", "ANATOMY", 318, 324], ["reticuloendothelial system", "ANATOMY", 446, 472]]], ["The challenge is delivering enough nucleic acid into the cells without unwanted side effects.", [["cells", "ANATOMY", 57, 62], ["nucleic acid", "CHEMICAL", 35, 47], ["cells", "CELL", 57, 62], ["The challenge", "TREATMENT", 0, 13], ["nucleic acid into the cells", "TREATMENT", 35, 62], ["unwanted side effects", "PROBLEM", 71, 92]]], ["This level of variation in performance has led scientists to consider alternatives to LNPs.Nanosilica for DNA and RNA deliveryWidely used in many different pharmaceutical and food situations, silica and has been proven to be safe in these various uses.", [["Nanosilica", "CHEMICAL", 91, 101], ["silica", "CHEMICAL", 192, 198], ["Nanosilica", "CHEMICAL", 91, 101], ["silica", "CHEMICAL", 192, 198], ["LNPs", "SIMPLE_CHEMICAL", 86, 90], ["Nanosilica", "SIMPLE_CHEMICAL", 91, 101], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["silica", "SIMPLE_CHEMICAL", 192, 198], ["LNPs", "TREATMENT", 86, 90], ["Nanosilica", "TREATMENT", 91, 101], ["DNA", "PROBLEM", 106, 109], ["RNA delivery", "TREATMENT", 114, 126]]], ["As scientists looked to alternative carriers that could be adapted to encapsulate and protect nucleic acids, mesoporous silica nanoparticles (MSNs) \u2013 silica-based nanostructured materials with excellent biocompatibility and chemical stability \u2013 emerged as a suitable candidate 5, 6.", [["nucleic acids", "CHEMICAL", 94, 107], ["mesoporous silica nanoparticles", "CHEMICAL", 109, 140], ["MSNs", "CHEMICAL", 142, 146], ["silica", "CHEMICAL", 150, 156], ["silica", "CHEMICAL", 120, 126], ["silica", "CHEMICAL", 150, 156], ["nucleic acids", "SIMPLE_CHEMICAL", 94, 107], ["mesoporous silica nanoparticles", "SIMPLE_CHEMICAL", 109, 140], ["MSNs", "SIMPLE_CHEMICAL", 142, 146], ["silica", "SIMPLE_CHEMICAL", 150, 156], ["nucleic acids", "TEST", 94, 107], ["mesoporous silica nanoparticles", "TREATMENT", 109, 140], ["silica-based nanostructured materials", "TREATMENT", 150, 187], ["chemical stability", "OBSERVATION", 224, 242]]], ["In particular, nanoparticulate silica can be re-engineered to bind oligonucleotides of a range of sizes including DNA, RNA and SiRNA.Nanosilica for DNA and RNA deliveryN4 Pharma is developing a novel silica nanoparticle technology for the delivery of vaccines and drugs, with a particular focus on supporting the development of cancer treatments and viral vaccines based on mRNA and pDNA.", [["cancer", "ANATOMY", 328, 334], ["silica", "CHEMICAL", 31, 37], ["Nanosilica", "CHEMICAL", 133, 143], ["silica nanoparticle", "CHEMICAL", 200, 219], ["cancer", "DISEASE", 328, 334], ["silica", "CHEMICAL", 31, 37], ["Nanosilica", "CHEMICAL", 133, 143], ["silica", "CHEMICAL", 200, 206], ["nanoparticulate silica", "SIMPLE_CHEMICAL", 15, 37], ["DNA", "CELLULAR_COMPONENT", 114, 117], ["SiRNA", "GENE_OR_GENE_PRODUCT", 127, 132], ["Nanosilica", "SIMPLE_CHEMICAL", 133, 143], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["cancer", "CANCER", 328, 334], ["pDNA", "GENE_OR_GENE_PRODUCT", 383, 387], ["RNA", "RNA", 119, 122], ["SiRNA", "PROTEIN", 127, 132], ["mRNA", "RNA", 374, 378], ["nanoparticulate silica", "TREATMENT", 15, 37], ["DNA, RNA and SiRNA", "PROBLEM", 114, 132], ["Nanosilica", "TREATMENT", 133, 143], ["DNA", "PROBLEM", 148, 151], ["RNA delivery", "TREATMENT", 156, 168], ["a novel silica nanoparticle technology", "TREATMENT", 192, 230], ["the delivery of vaccines", "TREATMENT", 235, 259], ["drugs", "TREATMENT", 264, 269], ["cancer treatments", "TREATMENT", 328, 345], ["viral vaccines", "TREATMENT", 350, 364], ["nanoparticulate silica", "OBSERVATION", 15, 37], ["sizes", "OBSERVATION_MODIFIER", 98, 103], ["SiRNA", "ANATOMY", 127, 132], ["cancer", "OBSERVATION", 328, 334]]], ["The original technology, licensed from researchers at the University of Queensland (UQ) in Australia, was developed as a nanosilica system for the delivery of a hepatitis B vaccine that would reduce the number of doses per day from three to one.Nanosilica for DNA and RNA deliveryBuilding on this experience, the founders of N4 Pharma licensed the UQ technology and jointly developed a novel silica nanoparticle specifically designed for nucleic acid delivery has an irregular (spiky) surface structure \u2013 functionalised by coupling with polyethyleneimine (PEI).", [["surface", "ANATOMY", 485, 492], ["hepatitis B", "DISEASE", 161, 172], ["Nanosilica", "CHEMICAL", 245, 255], ["silica nanoparticle", "CHEMICAL", 392, 411], ["nucleic acid", "CHEMICAL", 438, 450], ["polyethyleneimine", "CHEMICAL", 537, 554], ["PEI", "CHEMICAL", 556, 559], ["Nanosilica", "CHEMICAL", 245, 255], ["silica", "CHEMICAL", 392, 398], ["polyethyleneimine", "CHEMICAL", 537, 554], ["PEI", "CHEMICAL", 556, 559], ["hepatitis B", "ORGANISM", 161, 172], ["Nanosilica", "SIMPLE_CHEMICAL", 245, 255], ["DNA", "CELLULAR_COMPONENT", 260, 263], ["silica nanoparticle", "SIMPLE_CHEMICAL", 392, 411], ["nucleic acid", "SIMPLE_CHEMICAL", 438, 450], ["polyethyleneimine", "SIMPLE_CHEMICAL", 537, 554], ["PEI", "SIMPLE_CHEMICAL", 556, 559], ["hepatitis B", "SPECIES", 161, 172], ["a nanosilica system", "TREATMENT", 119, 138], ["a hepatitis B vaccine", "TREATMENT", 159, 180], ["Nanosilica", "TREATMENT", 245, 255], ["DNA", "PROBLEM", 260, 263], ["RNA delivery", "TREATMENT", 268, 280], ["a novel silica nanoparticle", "TREATMENT", 384, 411], ["nucleic acid delivery", "TREATMENT", 438, 459], ["an irregular (spiky) surface structure", "PROBLEM", 464, 502], ["polyethyleneimine (PEI", "TREATMENT", 537, 559], ["irregular", "OBSERVATION_MODIFIER", 467, 476]]], ["This surface simply and effectively traps and protects nucleic acids (such as mRNA/pDNA) from nuclease enzymes as it travels to the cells.", [["surface", "ANATOMY", 5, 12], ["cells", "ANATOMY", 132, 137], ["nucleic acids", "CHEMICAL", 55, 68], ["surface", "CELLULAR_COMPONENT", 5, 12], ["nucleic acids", "SIMPLE_CHEMICAL", 55, 68], ["pDNA", "GENE_OR_GENE_PRODUCT", 83, 87], ["cells", "CELL", 132, 137], ["mRNA", "RNA", 78, 82], ["pDNA", "PROTEIN", 83, 87], ["nuclease enzymes", "PROTEIN", 94, 110], ["nucleic acids", "TREATMENT", 55, 68], ["mRNA/pDNA", "TREATMENT", 78, 87], ["nuclease enzymes", "TEST", 94, 110]]], ["Once inside the cell, the DNA/RNA is released and will result in synthesis of the foreign/target protein which will activate the immune system, leading to both a cellular and humoral immune response.", [["cell", "ANATOMY", 16, 20], ["immune system", "ANATOMY", 129, 142], ["cellular", "ANATOMY", 162, 170], ["cell", "CELL", 16, 20], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["cellular", "CELL", 162, 170], ["DNA/RNA", "RNA", 26, 33], ["foreign/target protein", "PROTEIN", 82, 104], ["the DNA/RNA", "PROBLEM", 22, 33], ["the foreign/target protein", "PROBLEM", 78, 104], ["a cellular and humoral immune response", "PROBLEM", 160, 198], ["humoral immune response", "OBSERVATION", 175, 198]]], ["The cellular response (T cells) can sense and kill infected cells and the humoral response (antibodies) will bind to the virus and (1) neutralise its capability to bind to the target cell and (2) be increasingly cleared by phagocytic mechanisms.Nanosilica for DNA and RNA deliveryThe new delivery system is called Nuvec\u00ae.", [["cellular", "ANATOMY", 4, 12], ["T cells", "ANATOMY", 23, 30], ["cells", "ANATOMY", 60, 65], ["cell", "ANATOMY", 183, 187], ["Nanosilica", "CHEMICAL", 245, 255], ["Nanosilica", "CHEMICAL", 245, 255], ["cellular", "CELL", 4, 12], ["T cells", "CELL", 23, 30], ["cells", "CELL", 60, 65], ["cell", "CELL", 183, 187], ["Nanosilica", "SIMPLE_CHEMICAL", 245, 255], ["DNA", "CELLULAR_COMPONENT", 260, 263], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 314, 320], ["T cells", "CELL_TYPE", 23, 30], ["infected cells", "CELL_TYPE", 51, 65], ["antibodies", "PROTEIN", 92, 102], ["kill infected cells", "PROBLEM", 46, 65], ["Nanosilica", "TREATMENT", 245, 255], ["DNA", "PROBLEM", 260, 263], ["RNA delivery", "TREATMENT", 268, 280], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["response", "OBSERVATION_MODIFIER", 13, 21], ["new", "OBSERVATION_MODIFIER", 284, 287]]], ["Figure 1shows the end-to-end mode of action for Nuvec\u00ae as it delivers DNA/RNA to antigen presenting cells: the Nuvec\u00ae particle carrying the DNA/RNA attaches to the cell membrane, by charge attraction, and is taken up into the cell via general and dynamin endocytosis.", [["cells", "ANATOMY", 100, 105], ["cell membrane", "ANATOMY", 164, 177], ["cell", "ANATOMY", 226, 230], ["Nuvec\u00ae", "CHEMICAL", 48, 54], ["Nuvec\u00ae", "CHEMICAL", 48, 54], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 48, 54], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["cells", "CELL", 100, 105], ["Nuvec\u00ae", "GENE_OR_GENE_PRODUCT", 111, 117], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["cell membrane", "CELLULAR_COMPONENT", 164, 177], ["cell", "CELL", 226, 230], ["dynamin", "GENE_OR_GENE_PRODUCT", 247, 254], ["Nuvec\u00ae", "PROTEIN", 48, 54], ["antigen presenting cells", "CELL_TYPE", 81, 105], ["dynamin", "PROTEIN", 247, 254], ["Nuvec\u00ae", "TREATMENT", 48, 54], ["DNA/RNA", "PROBLEM", 70, 77], ["the Nuvec\u00ae particle", "TREATMENT", 107, 126], ["the DNA/RNA attaches", "PROBLEM", 136, 156], ["cell membrane", "OBSERVATION", 164, 177], ["dynamin endocytosis", "OBSERVATION", 247, 266]]], ["Once inside the endosome, the association of DNA with Nuvec changes as a consequence of the acidic environment of the endosome, releasing some DNA/RNA.Nanosilica for DNA and RNA deliveryA crucial feature of Nuvec\u00ae is that, compared to lipid-based delivery systems, it does not disrupt the cell membrane as it enters the cell and does not exhibit inflammatory response at the site of injection or any unwanted systemic side-effects.", [["endosome", "ANATOMY", 16, 24], ["endosome", "ANATOMY", 118, 126], ["cell membrane", "ANATOMY", 289, 302], ["cell", "ANATOMY", 320, 324], ["Nanosilica", "CHEMICAL", 151, 161], ["Nanosilica", "CHEMICAL", 151, 161], ["endosome", "CELLULAR_COMPONENT", 16, 24], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["Nuvec", "GENE_OR_GENE_PRODUCT", 54, 59], ["endosome", "CELLULAR_COMPONENT", 118, 126], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["Nanosilica", "SIMPLE_CHEMICAL", 151, 161], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 207, 213], ["lipid", "SIMPLE_CHEMICAL", 235, 240], ["cell membrane", "CELLULAR_COMPONENT", 289, 302], ["cell", "CELL", 320, 324], ["Nuvec", "PROTEIN", 54, 59], ["DNA/RNA", "RNA", 143, 150], ["DNA", "PROBLEM", 45, 48], ["Nuvec changes", "PROBLEM", 54, 67], ["some DNA/RNA", "PROBLEM", 138, 150], ["Nanosilica", "TREATMENT", 151, 161], ["DNA", "PROBLEM", 166, 169], ["RNA delivery", "TREATMENT", 174, 186], ["lipid-based delivery systems", "TREATMENT", 235, 263], ["inflammatory response", "PROBLEM", 346, 367], ["injection", "TREATMENT", 383, 392], ["RNA", "OBSERVATION", 147, 150], ["cell membrane", "OBSERVATION", 289, 302], ["inflammatory", "OBSERVATION_MODIFIER", 346, 358]]], ["A series of studies have supported the safety, efficacy and mode of action of Nuvec\u00ae and the particle is being used in late stage pre-clinical studies.Nanosilica for DNA and RNA deliveryIn addition, Nuvec\u00ae\u2019s capability to bind more than one plasmid has the potential to assist viral vector delivery.", [["plasmid", "ANATOMY", 241, 248], ["Nuvec\u00ae", "CHEMICAL", 78, 84], ["Nanosilica", "CHEMICAL", 151, 161], ["Nuvec\u00ae", "CHEMICAL", 199, 205], ["Nuvec\u00ae", "CHEMICAL", 78, 84], ["Nanosilica", "CHEMICAL", 151, 161], ["Nuvec\u00ae", "CHEMICAL", 199, 205], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 78, 84], ["Nanosilica", "SIMPLE_CHEMICAL", 151, 161], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 199, 205], ["Nuvec\u00ae", "PROTEIN", 199, 205], ["A series of studies", "TEST", 0, 19], ["Nuvec\u00ae", "TREATMENT", 78, 84], ["Nanosilica", "TREATMENT", 151, 161], ["DNA", "PROBLEM", 166, 169], ["RNA delivery", "TREATMENT", 174, 186], ["Nuvec\u00ae\u2019s capability", "TREATMENT", 199, 218], ["viral vector delivery", "TREATMENT", 277, 298]]], ["This ensures that in a multi-plasmid transfection approach, each cell will be exposed to all plasmids at the same time and can lead to less plasmid necessary to achieve the same transfection efficacy.", [["cell", "ANATOMY", 65, 69], ["plasmids", "ANATOMY", 93, 101], ["plasmid", "ANATOMY", 140, 147], ["cell", "CELL", 65, 69], ["plasmids", "DNA", 93, 101], ["a multi-plasmid transfection approach", "TREATMENT", 21, 58], ["all plasmids", "TREATMENT", 89, 101]]], ["Also during in vivo delivery of the vaccine, Nuvec\u00ae and the viral vector can work synergistically to deliver the payload.Nanosilica for DNA and RNA deliveryNuvec\u00ae\u2019s particle will be sensed and picked up by macrophages and antigen-presenting cells.", [["macrophages", "ANATOMY", 206, 217], ["antigen-presenting cells", "ANATOMY", 222, 246], ["Nuvec\u00ae", "CHEMICAL", 45, 51], ["Nanosilica", "CHEMICAL", 121, 131], ["Nanosilica", "CHEMICAL", 121, 131], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 45, 51], ["Nanosilica", "SIMPLE_CHEMICAL", 121, 131], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["Nuvec\u00ae", "SIMPLE_CHEMICAL", 156, 162], ["macrophages", "CELL", 206, 217], ["cells", "CELL", 241, 246], ["macrophages", "CELL_TYPE", 206, 217], ["antigen-presenting cells", "CELL_TYPE", 222, 246], ["the vaccine", "TREATMENT", 32, 43], ["Nuvec\u00ae", "TREATMENT", 45, 51], ["the viral vector", "TREATMENT", 56, 72], ["the payload", "TREATMENT", 109, 120], ["Nanosilica", "TREATMENT", 121, 131], ["DNA", "PROBLEM", 136, 139], ["RNA delivery", "TREATMENT", 144, 156], ["Nuvec\u00ae\u2019s particle", "TREATMENT", 156, 173]]], ["The presence of PEI will facilitate the endosomal disruption and release of nucleic acid but also presents a danger signal that will up regulate surface markers and hence attract immune cells and boost the immune response.Delivering the vaccineThe global urgency of the COVID-19 pandemic has brought more than 25 years of research into nucleic acid-based vaccines and therapeutics into the limelight.", [["endosomal", "ANATOMY", 40, 49], ["surface", "ANATOMY", 145, 152], ["immune cells", "ANATOMY", 179, 191], ["PEI", "CHEMICAL", 16, 19], ["nucleic acid", "CHEMICAL", 76, 88], ["nucleic acid", "CHEMICAL", 336, 348], ["PEI", "CHEMICAL", 16, 19], ["PEI", "SIMPLE_CHEMICAL", 16, 19], ["endosomal", "CELLULAR_COMPONENT", 40, 49], ["nucleic acid", "SIMPLE_CHEMICAL", 76, 88], ["immune cells", "CELL", 179, 191], ["nucleic acid", "SIMPLE_CHEMICAL", 336, 348], ["surface markers", "PROTEIN", 145, 160], ["immune cells", "CELL_TYPE", 179, 191], ["PEI", "TREATMENT", 16, 19], ["the endosomal disruption", "PROBLEM", 36, 60], ["nucleic acid", "PROBLEM", 76, 88], ["a danger signal", "PROBLEM", 107, 122], ["immune cells", "TREATMENT", 179, 191], ["the vaccine", "TREATMENT", 233, 244], ["the COVID", "TEST", 266, 275], ["nucleic acid-based vaccines", "TREATMENT", 336, 363], ["therapeutics", "TREATMENT", 368, 380], ["PEI", "OBSERVATION", 16, 19], ["endosomal disruption", "OBSERVATION", 40, 60], ["global", "OBSERVATION_MODIFIER", 248, 254], ["urgency", "OBSERVATION", 255, 262]]], ["The pharmaceutical industry, government agencies and WHO are working hard to find a COVID-19 vaccine.", [["a COVID-19 vaccine", "TREATMENT", 82, 100]]], ["As researchers search for their ideal delivery platforms, safe and effective alternatives to established technologies \u2013 including emerging technologies like such as Nuvec\u00ae \u2013 can be considered.", [["Nuvec\u00ae", "SIMPLE_CHEMICAL", 165, 171]]]], "PMC6531852": [["IntroductionRecent advances with incretin-based drugs have opened new avenues in the management of diabetes.", [["diabetes", "DISEASE", 99, 107], ["incretin", "SIMPLE_CHEMICAL", 33, 41], ["incretin-based drugs", "TREATMENT", 33, 53], ["diabetes", "PROBLEM", 99, 107], ["diabetes", "OBSERVATION", 99, 107]]], ["In the clinic, we can prescribe two types of incretin-based drugs: glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors.", [["dipeptidyl peptidase-4", "CHEMICAL", 124, 146], ["incretin-based drugs", "SIMPLE_CHEMICAL", 45, 65], ["glucagon-like peptide 1 receptor agonists", "GENE_OR_GENE_PRODUCT", 67, 108], ["GLP-1RAs", "SIMPLE_CHEMICAL", 110, 118], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 124, 146], ["DPP-4", "GENE_OR_GENE_PRODUCT", 148, 153], ["incretin-based drugs", "TREATMENT", 45, 65], ["glucagon", "TREATMENT", 67, 75], ["peptide 1 receptor agonists", "TREATMENT", 81, 108], ["GLP", "TEST", 110, 113], ["dipeptidyl peptidase", "TREATMENT", 124, 144]]], ["GLP-1 is produced from intestinal L-cells by proteolytical processing from proglucagon (ProG) and immediately degraded by DPP-4; its half-life is approximately 2 min.", [["intestinal L-cells", "ANATOMY", 23, 41], ["DPP-4", "CHEMICAL", 122, 127], ["GLP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["intestinal L-cells", "CELL", 23, 41], ["proglucagon", "GENE_OR_GENE_PRODUCT", 75, 86], ["ProG", "GENE_OR_GENE_PRODUCT", 88, 92], ["DPP-4", "GENE_OR_GENE_PRODUCT", 122, 127], ["GLP-1", "PROTEIN", 0, 5], ["intestinal L-cells", "CELL_TYPE", 23, 41], ["proglucagon", "PROTEIN", 75, 86], ["ProG", "PROTEIN", 88, 92], ["DPP", "PROTEIN", 122, 125], ["GLP", "TEST", 0, 3], ["intestinal L-cells", "TREATMENT", 23, 41], ["proglucagon (ProG)", "TREATMENT", 75, 93], ["DPP", "TEST", 122, 125], ["intestinal", "ANATOMY", 23, 33], ["L", "ANATOMY_MODIFIER", 34, 35], ["-cells", "ANATOMY", 35, 41]]], ["GLP-1RAs have been developed to avoid DPP-4-mediated cleavage of GLP-1 by introducing a mutation in the amino acid residue that DPP-4 targets.", [["amino acid", "CHEMICAL", 104, 114], ["amino acid", "CHEMICAL", 104, 114], ["GLP-1RAs", "GENE_OR_GENE_PRODUCT", 0, 8], ["DPP-4", "GENE_OR_GENE_PRODUCT", 38, 43], ["GLP-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["amino acid", "AMINO_ACID", 104, 114], ["DPP-4", "GENE_OR_GENE_PRODUCT", 128, 133], ["GLP-1RAs", "PROTEIN", 0, 8], ["DPP-4", "PROTEIN", 38, 43], ["GLP-1", "PROTEIN", 65, 70], ["DPP-4 targets", "PROTEIN", 128, 141], ["GLP", "TEST", 0, 3], ["DPP", "TEST", 38, 41], ["a mutation", "PROBLEM", 86, 96], ["the amino acid residue", "TREATMENT", 100, 122], ["DPP", "TEST", 128, 131]]], ["Exenatide (Exendin-4), a 39-amino-acid polypeptide isolated from the venom of the Gila monster lizard with 50% homology to human GLP-1, has been used in the clinic.", [["venom", "ANATOMY", 69, 74], ["Exenatide", "CHEMICAL", 0, 9], ["Exendin-4", "CHEMICAL", 11, 20], ["39-amino-acid", "CHEMICAL", 25, 38], ["Exenatide", "CHEMICAL", 0, 9], ["Exendin-4", "CHEMICAL", 11, 20], ["39-amino-acid", "CHEMICAL", 25, 38], ["Exenatide", "SIMPLE_CHEMICAL", 0, 9], ["Exendin-4", "SIMPLE_CHEMICAL", 11, 20], ["39-amino-acid", "SIMPLE_CHEMICAL", 25, 38], ["venom", "ORGANISM_SUBSTANCE", 69, 74], ["Gila monster", "ORGANISM", 82, 94], ["lizard", "ORGANISM", 95, 101], ["human", "ORGANISM", 123, 128], ["GLP-1", "GENE_OR_GENE_PRODUCT", 129, 134], ["Gila monster lizard", "SPECIES", 82, 101], ["human", "SPECIES", 123, 128], ["Gila monster lizard", "SPECIES", 82, 101], ["human", "SPECIES", 123, 128], ["Exenatide (Exendin", "TREATMENT", 0, 18], ["amino-acid polypeptide", "TREATMENT", 28, 50]]], ["Alternatively, to extend the half-life of endogenous GLP-1, DPP-4 inhibitors are prescribed.", [["GLP-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["DPP-4", "GENE_OR_GENE_PRODUCT", 60, 65], ["endogenous GLP", "TEST", 42, 56], ["DPP-4 inhibitors", "TREATMENT", 60, 76]]], ["Recent clinical trials (Marso et al., 2016, 2017; Rosenstock et al., 2019) investigating the safety and efficacy of incretin-based drugs have provided diverse interpretations and provocative intellectual curiosities regarding the biology of incretin hormones and incretin-based drugs, specifically focusing on pleiotropic effects.IntroductionAutophagy, the cellular mechanism that promotes cell survival during nutrient depletion, may also be relevant under basal or nutrient excess conditions.", [["cellular", "ANATOMY", 357, 365], ["cell", "ANATOMY", 390, 394], ["incretin", "SIMPLE_CHEMICAL", 116, 124], ["incretin hormones", "GENE_OR_GENE_PRODUCT", 241, 258], ["incretin", "SIMPLE_CHEMICAL", 263, 271], ["cellular", "CELL", 357, 365], ["cell", "CELL", 390, 394], ["incretin-based drugs", "TREATMENT", 116, 136], ["provocative intellectual curiosities", "PROBLEM", 179, 215], ["incretin hormones", "TREATMENT", 241, 258], ["incretin-based drugs", "TREATMENT", 263, 283], ["IntroductionAutophagy", "TREATMENT", 330, 351], ["nutrient depletion", "TREATMENT", 411, 429], ["cell survival", "OBSERVATION", 390, 403], ["nutrient depletion", "OBSERVATION", 411, 429]]], ["This cellular process is specified by the formation of autophagosomes, by which cytosolic components are captured and fused with lysosomes to promote the degradation and/or recycling of its contents.", [["cellular", "ANATOMY", 5, 13], ["autophagosomes", "ANATOMY", 55, 69], ["cytosolic components", "ANATOMY", 80, 100], ["lysosomes", "ANATOMY", 129, 138], ["cellular", "CELL", 5, 13], ["autophagosomes", "CELLULAR_COMPONENT", 55, 69], ["lysosomes", "CELLULAR_COMPONENT", 129, 138], ["autophagosomes", "PROBLEM", 55, 69], ["lysosomes", "TREATMENT", 129, 138], ["the degradation", "PROBLEM", 150, 165], ["cellular process", "OBSERVATION", 5, 21], ["autophagosomes", "OBSERVATION", 55, 69]]], ["The autophagic process consists of four stages: initiation, nucleation, elongation, and fusion/degradation (Codogno et al., 2011).", [["elongation, and fusion/degradation", "PROBLEM", 72, 106], ["autophagic process", "OBSERVATION", 4, 22], ["four stages", "OBSERVATION_MODIFIER", 35, 46], ["elongation", "OBSERVATION_MODIFIER", 72, 82]]], ["During nutrient depletion, autophagy can provide essential components for energy production and biosynthesis.", [["nutrient depletion", "TREATMENT", 7, 25], ["autophagy", "PROBLEM", 27, 36], ["energy production", "PROBLEM", 74, 91], ["biosynthesis", "TREATMENT", 96, 108], ["nutrient depletion", "OBSERVATION", 7, 25]]], ["However, it also acts in a similar manner by recycling damaged organelles, unnecessary proteins, and foreign substances for the quality maintenance of these intracellular components (Ueno and Komatsu, 2017).", [["organelles", "ANATOMY", 63, 73], ["intracellular", "ANATOMY", 157, 170], ["organelles", "CELLULAR_COMPONENT", 63, 73], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["unnecessary proteins", "PROBLEM", 75, 95], ["foreign substances", "TREATMENT", 101, 119], ["foreign substances", "OBSERVATION", 101, 119], ["intracellular components", "OBSERVATION", 157, 181]]], ["In circumstances of nutrient excess, autophagy plays important roles in eliminating unfolded proteins and toxic aggregates and facilitating endoplasmic reticulum (ER) homeostasis.", [["endoplasmic reticulum", "ANATOMY", 140, 161], ["ER", "ANATOMY", 163, 165], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 140, 161], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["unfolded proteins", "PROTEIN", 84, 101], ["nutrient excess", "PROBLEM", 20, 35], ["unfolded proteins", "PROBLEM", 84, 101], ["toxic aggregates", "PROBLEM", 106, 122], ["nutrient excess", "OBSERVATION", 20, 35], ["toxic aggregates", "OBSERVATION", 106, 122], ["endoplasmic reticulum", "OBSERVATION", 140, 161]]], ["The detailed mechanisms and biology of autophagy are summarized in subsequent sections of this issue.IntroductionAutophagy defects in certain diseases have been the subject of extensive research.", [["sections", "ANATOMY", 78, 86], ["IntroductionAutophagy defects", "DISEASE", 101, 130], ["IntroductionAutophagy defects in certain diseases", "PROBLEM", 101, 150], ["defects", "OBSERVATION", 123, 130], ["certain diseases", "OBSERVATION", 134, 150], ["extensive", "OBSERVATION_MODIFIER", 176, 185]]], ["In addition, liver autophagy defects have been shown to occur with several metabolic diseases, such as obesity, steatosis, and type 2 diabetes (Ueno and Komatsu, 2017).", [["liver", "ANATOMY", 13, 18], ["metabolic diseases", "DISEASE", 75, 93], ["obesity", "DISEASE", 103, 110], ["steatosis", "DISEASE", 112, 121], ["type 2 diabetes", "DISEASE", 127, 142], ["liver", "ORGAN", 13, 18], ["liver autophagy defects", "PROBLEM", 13, 36], ["several metabolic diseases", "PROBLEM", 67, 93], ["obesity", "PROBLEM", 103, 110], ["steatosis", "PROBLEM", 112, 121], ["type 2 diabetes", "PROBLEM", 127, 142], ["liver", "ANATOMY", 13, 18], ["autophagy defects", "OBSERVATION", 19, 36], ["several", "OBSERVATION_MODIFIER", 67, 74], ["metabolic diseases", "OBSERVATION", 75, 93], ["obesity", "OBSERVATION", 103, 110], ["steatosis", "OBSERVATION", 112, 121], ["diabetes", "OBSERVATION", 134, 142]]], ["Early work in liver research indicates a link in the regulation between gastrointestinal hormones and liver autophagy (Ueno and Komatsu, 2017).", [["liver", "ANATOMY", 14, 19], ["gastrointestinal", "ANATOMY", 72, 88], ["liver", "ANATOMY", 102, 107], ["liver", "ORGAN", 14, 19], ["gastrointestinal", "ORGAN", 72, 88], ["liver", "ORGAN", 102, 107], ["Early work in liver research", "PROBLEM", 0, 28], ["liver", "ANATOMY", 14, 19], ["gastrointestinal hormones", "ANATOMY", 72, 97], ["liver", "ANATOMY", 102, 107]]], ["Interestingly, incretin hormones and DPP-4 inhibitors have been associated with the amelioration of steatosis (Rowlands et al., 2018; Zheng et al., 2018).", [["steatosis", "DISEASE", 100, 109], ["incretin hormones", "GENE_OR_GENE_PRODUCT", 15, 32], ["DPP-4", "GENE_OR_GENE_PRODUCT", 37, 42], ["incretin hormones", "TREATMENT", 15, 32], ["DPP-4 inhibitors", "TREATMENT", 37, 53], ["steatosis", "PROBLEM", 100, 109], ["steatosis", "OBSERVATION", 100, 109]]], ["These drugs have been shown to induce autophagy in various cell types (Murase et al., 2015; Rowlands et al., 2018; Zheng et al., 2018).IntroductionIn this review, we investigated the potential involvement of autophagy induction by GLP-1 and incretin-based dugs.", [["cell", "ANATOMY", 59, 63], ["cell", "CELL", 59, 63], ["GLP-1", "GENE_OR_GENE_PRODUCT", 231, 236], ["incretin-based dugs", "SIMPLE_CHEMICAL", 241, 260], ["These drugs", "TREATMENT", 0, 11], ["autophagy induction", "TREATMENT", 208, 227], ["GLP", "TEST", 231, 234], ["incretin-based dugs", "TREATMENT", 241, 260], ["various cell", "OBSERVATION_MODIFIER", 51, 63]]], ["In addition, we focused on glucagon, a known polypeptide that regulates glucose levels and a classic molecule that induces autophagy.Glucagon and GLP-1 Synthesis From ProglucagonGLP-1 is produced from proteolytic cleavage of the precursor polypeptide pProG (Muller et al., 2017).", [["glucagon", "CHEMICAL", 27, 35], ["glucose", "CHEMICAL", 72, 79], ["Glucagon", "CHEMICAL", 133, 141], ["glucose", "CHEMICAL", 72, 79], ["glucagon", "GENE_OR_GENE_PRODUCT", 27, 35], ["glucose", "SIMPLE_CHEMICAL", 72, 79], ["Glucagon", "GENE_OR_GENE_PRODUCT", 133, 141], ["GLP-1", "GENE_OR_GENE_PRODUCT", 146, 151], ["ProglucagonGLP-1", "GENE_OR_GENE_PRODUCT", 167, 183], ["glucagon", "TREATMENT", 27, 35], ["a known polypeptide", "TREATMENT", 37, 56], ["glucose levels", "TEST", 72, 86], ["a classic molecule", "PROBLEM", 91, 109], ["autophagy", "PROBLEM", 123, 132], ["Glucagon", "TEST", 133, 141], ["GLP", "TEST", 146, 149], ["ProglucagonGLP", "TEST", 167, 181], ["the precursor polypeptide", "TREATMENT", 225, 250], ["glucose levels", "OBSERVATION", 72, 86]]], ["The pProG gene (Gcg) is expressed in a specific population of enteroendocrine cells (L-cells) in the intestinal mucosa, islet cells in the pancreas, and some neurons within the nucleus of the solitary tract (NTS) (Han et al., 1986; Jin et al., 1988).", [["enteroendocrine cells", "ANATOMY", 62, 83], ["L-cells", "ANATOMY", 85, 92], ["intestinal mucosa", "ANATOMY", 101, 118], ["islet cells", "ANATOMY", 120, 131], ["pancreas", "ANATOMY", 139, 147], ["neurons", "ANATOMY", 158, 165], ["nucleus", "ANATOMY", 177, 184], ["solitary tract", "ANATOMY", 192, 206], ["NTS", "ANATOMY", 208, 211], ["pProG", "GENE_OR_GENE_PRODUCT", 4, 9], ["Gcg", "GENE_OR_GENE_PRODUCT", 16, 19], ["enteroendocrine cells", "CELL", 62, 83], ["L-cells", "CELL", 85, 92], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 101, 118], ["islet cells", "CELL", 120, 131], ["pancreas", "ORGAN", 139, 147], ["neurons", "CELL", 158, 165], ["nucleus", "CELLULAR_COMPONENT", 177, 184], ["solitary tract", "ORGAN", 192, 206], ["NTS", "MULTI-TISSUE_STRUCTURE", 208, 211], ["pProG gene", "DNA", 4, 14], ["Gcg", "DNA", 16, 19], ["enteroendocrine cells", "CELL_TYPE", 62, 83], ["L-cells", "CELL_TYPE", 85, 92], ["islet cells", "CELL_TYPE", 120, 131], ["islet cells in the pancreas", "PROBLEM", 120, 147], ["enteroendocrine cells", "OBSERVATION", 62, 83], ["intestinal mucosa", "ANATOMY", 101, 118], ["islet cells", "OBSERVATION", 120, 131], ["pancreas", "ANATOMY", 139, 147], ["nucleus", "ANATOMY_MODIFIER", 177, 184], ["solitary tract", "ANATOMY", 192, 206]]], ["Regulation of the Gcg transcription process is not completely known and distinct pattern of mRNA expression has been reported in intestinal endocrine cells and in pancreatic islet \u03b1-cells (Jin, 2008; Yi et al., 2008; Chiang et al., 2012; Muller et al., 2017).", [["intestinal endocrine cells", "ANATOMY", 129, 155], ["pancreatic islet \u03b1-cells", "ANATOMY", 163, 187], ["Gcg", "GENE_OR_GENE_PRODUCT", 18, 21], ["intestinal endocrine cells", "CELL", 129, 155], ["pancreatic islet \u03b1-cells", "CELL", 163, 187], ["Gcg", "DNA", 18, 21], ["mRNA", "RNA", 92, 96], ["intestinal endocrine cells", "CELL_TYPE", 129, 155], ["the Gcg transcription process", "PROBLEM", 14, 43], ["mRNA expression", "PROBLEM", 92, 107], ["Gcg transcription", "OBSERVATION", 18, 35], ["not completely", "UNCERTAINTY", 47, 61], ["mRNA expression", "OBSERVATION", 92, 107], ["intestinal", "ANATOMY", 129, 139], ["endocrine cells", "OBSERVATION", 140, 155], ["pancreatic islet", "ANATOMY", 163, 179]]], ["In addition to such unique transcriptional control in each cell type, posttranslational processing of prohormone plays an important role in the major cell types producing ProG peptides.", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 150, 154], ["cell type", "CELL", 59, 68], ["prohormone", "GENE_OR_GENE_PRODUCT", 102, 112], ["cell", "CELL", 150, 154], ["ProG peptides", "GENE_OR_GENE_PRODUCT", 171, 184], ["such unique transcriptional control", "TREATMENT", 15, 50], ["posttranslational processing of prohormone", "TREATMENT", 70, 112], ["ProG peptides", "TREATMENT", 171, 184]]], ["In addition to glucagon and GLP-1, glucagon-like peptide-2 (GLP-2), oxyntomodulin, glicentin, glicentin-related pancreatic polypeptide (GRPP), and major proglucagon fragment (MPGF) are synthesized from ProG; however, the specific biological function of some of these fragments has not been identified (Figure 1).", [["fragments", "ANATOMY", 267, 276], ["glucagon", "CHEMICAL", 15, 23], ["glicentin", "CHEMICAL", 83, 92], ["glicentin", "CHEMICAL", 94, 103], ["glucagon", "GENE_OR_GENE_PRODUCT", 15, 23], ["GLP-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["glucagon-like peptide-2", "GENE_OR_GENE_PRODUCT", 35, 58], ["GLP-2", "GENE_OR_GENE_PRODUCT", 60, 65], ["oxyntomodulin", "GENE_OR_GENE_PRODUCT", 68, 81], ["glicentin", "SIMPLE_CHEMICAL", 83, 92], ["glicentin-related pancreatic polypeptide", "GENE_OR_GENE_PRODUCT", 94, 134], ["GRPP", "GENE_OR_GENE_PRODUCT", 136, 140], ["proglucagon fragment", "GENE_OR_GENE_PRODUCT", 153, 173], ["MPGF", "GENE_OR_GENE_PRODUCT", 175, 179], ["ProG", "GENE_OR_GENE_PRODUCT", 202, 206], ["glicentin", "PROTEIN", 83, 92], ["glicentin", "PROTEIN", 94, 103], ["pancreatic polypeptide", "PROTEIN", 112, 134], ["GRPP", "PROTEIN", 136, 140], ["major proglucagon fragment", "PROTEIN", 147, 173], ["MPGF", "PROTEIN", 175, 179], ["ProG", "PROTEIN", 202, 206], ["glucagon", "TEST", 15, 23], ["GLP", "TEST", 28, 31], ["glucagon", "TEST", 35, 43], ["peptide", "TEST", 49, 56], ["GLP", "TEST", 60, 63], ["oxyntomodulin", "TREATMENT", 68, 81], ["glicentin", "TREATMENT", 83, 92], ["glicentin", "TREATMENT", 94, 103], ["pancreatic polypeptide (GRPP)", "TREATMENT", 112, 141], ["major proglucagon fragment", "PROBLEM", 147, 173], ["these fragments", "PROBLEM", 261, 276], ["pancreatic", "ANATOMY", 112, 122], ["proglucagon fragment", "OBSERVATION", 153, 173], ["fragments", "OBSERVATION", 267, 276]]], ["Such posttranslational regulation of these ProG peptides in their respective cell types relies on tissue-specific posttranslational modification by prohormone convertases (PCs).", [["cell", "ANATOMY", 77, 81], ["tissue", "ANATOMY", 98, 104], ["ProG peptides", "GENE_OR_GENE_PRODUCT", 43, 56], ["cell", "CELL", 77, 81], ["tissue", "TISSUE", 98, 104], ["prohormone convertases", "PROTEIN", 148, 170], ["these ProG peptides", "TREATMENT", 37, 56], ["cell types", "OBSERVATION", 77, 87]]], ["In intestinal L-cells and neurons of the NTS, a predominance of PC1/3 expression, GLP-1, oxyntomodulin, and GLP-2 are seen as physiologically relevant (Tucker et al., 1996; Larsen et al., 1997; Vrang et al., 2007); in pancreatic \u03b1-cells, high PC2 levels are responsible for the predominant glucagon synthesis (Figure 1) (Holst et al., 1994).", [["intestinal L-cells", "ANATOMY", 3, 21], ["neurons", "ANATOMY", 26, 33], ["NTS", "ANATOMY", 41, 44], ["pancreatic \u03b1-cells", "ANATOMY", 218, 236], ["intestinal L-cells", "CELL", 3, 21], ["neurons", "CELL", 26, 33], ["NTS", "CELL", 41, 44], ["PC1", "GENE_OR_GENE_PRODUCT", 64, 67], ["3", "GENE_OR_GENE_PRODUCT", 68, 69], ["GLP-1", "GENE_OR_GENE_PRODUCT", 82, 87], ["oxyntomodulin", "GENE_OR_GENE_PRODUCT", 89, 102], ["GLP-2", "GENE_OR_GENE_PRODUCT", 108, 113], ["pancreatic \u03b1-cells", "CANCER", 218, 236], ["PC2", "GENE_OR_GENE_PRODUCT", 243, 246], ["glucagon", "SIMPLE_CHEMICAL", 290, 298], ["intestinal L-cells", "CELL_TYPE", 3, 21], ["PC1", "PROTEIN", 64, 67], ["GLP-1", "PROTEIN", 82, 87], ["oxyntomodulin", "PROTEIN", 89, 102], ["pancreatic \u03b1-cells", "CELL_TYPE", 218, 236], ["PC2", "PROTEIN", 243, 246], ["PC1", "TEST", 64, 67], ["GLP", "TEST", 82, 85], ["oxyntomodulin", "TEST", 89, 102], ["GLP", "TEST", 108, 111], ["high PC2 levels", "PROBLEM", 238, 253], ["the predominant glucagon synthesis", "PROBLEM", 274, 308], ["intestinal", "ANATOMY", 3, 13], ["L", "ANATOMY_MODIFIER", 14, 15], ["-cells", "ANATOMY", 15, 21], ["neurons", "ANATOMY_MODIFIER", 26, 33], ["NTS", "ANATOMY", 41, 44], ["pancreatic", "ANATOMY", 218, 228]]], ["PC2 is also expressed in the brain but does not colocalize with Gcg.", [["brain", "ANATOMY", 29, 34], ["PC2", "GENE_OR_GENE_PRODUCT", 0, 3], ["brain", "ORGAN", 29, 34], ["Gcg", "GENE_OR_GENE_PRODUCT", 64, 67], ["PC2", "PROTEIN", 0, 3], ["Gcg", "PROTEIN", 64, 67], ["PC2", "TEST", 0, 3], ["brain", "ANATOMY", 29, 34]]], ["Additionally, PC1/3 is expressed in \u03b1-cells but at lower levels than PC2, and the ratio of GLP-1 to glucagon expressed in islet cells has been shown to be increased during the progression of diabetes (O\u2019Malley et al., 2014).", [["\u03b1-cells", "ANATOMY", 36, 43], ["islet cells", "ANATOMY", 122, 133], ["diabetes", "DISEASE", 191, 199], ["PC1/3", "GENE_OR_GENE_PRODUCT", 14, 19], ["\u03b1-cells", "CELL", 36, 43], ["PC2", "GENE_OR_GENE_PRODUCT", 69, 72], ["GLP-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["glucagon", "GENE_OR_GENE_PRODUCT", 100, 108], ["islet cells", "CELL", 122, 133], ["PC1", "PROTEIN", 14, 17], ["\u03b1-cells", "CELL_TYPE", 36, 43], ["PC2", "PROTEIN", 69, 72], ["GLP-1", "PROTEIN", 91, 96], ["islet cells", "CELL_TYPE", 122, 133], ["PC1", "TEST", 14, 17], ["PC2", "TEST", 69, 72], ["GLP", "TEST", 91, 94], ["glucagon", "TEST", 100, 108], ["islet cells", "PROBLEM", 122, 133], ["diabetes", "PROBLEM", 191, 199], ["islet cells", "OBSERVATION", 122, 133], ["shown to be", "UNCERTAINTY", 143, 154], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["progression", "OBSERVATION_MODIFIER", 176, 187], ["diabetes", "OBSERVATION", 191, 199]]], ["Gcg expression and ProG levels are relatively lower in the proximal gut and higher in the distal part, with the highest expression in the colon (Bryant and Bloom, 1979).Glucagon and AutophagyThe association between autophagy and glucagon was reported approximately 50 years ago.", [["proximal gut", "ANATOMY", 59, 71], ["distal part", "ANATOMY", 90, 101], ["colon", "ANATOMY", 138, 143], ["Glucagon", "CHEMICAL", 169, 177], ["glucagon", "CHEMICAL", 229, 237], ["Gcg", "GENE_OR_GENE_PRODUCT", 0, 3], ["ProG", "GENE_OR_GENE_PRODUCT", 19, 23], ["gut", "ORGAN", 68, 71], ["colon", "ORGAN", 138, 143], ["Glucagon", "GENE_OR_GENE_PRODUCT", 169, 177], ["glucagon", "GENE_OR_GENE_PRODUCT", 229, 237], ["Gcg", "PROTEIN", 0, 3], ["ProG", "PROTEIN", 19, 23], ["Gcg expression", "TEST", 0, 14], ["ProG levels", "TEST", 19, 30], ["Glucagon", "TREATMENT", 169, 177], ["Autophagy", "TREATMENT", 182, 191], ["glucagon", "TREATMENT", 229, 237], ["relatively", "OBSERVATION_MODIFIER", 35, 45], ["lower", "OBSERVATION_MODIFIER", 46, 51], ["proximal", "ANATOMY_MODIFIER", 59, 67], ["gut", "ANATOMY", 68, 71], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["distal", "ANATOMY_MODIFIER", 90, 96], ["highest", "OBSERVATION_MODIFIER", 112, 119], ["expression", "OBSERVATION", 120, 130], ["colon", "ANATOMY", 138, 143], ["Autophagy", "OBSERVATION", 182, 191]]], ["In 1955, Christian de Duve reported on acid phosphatase-positive sac-like particles in rat liver cytoplasm (De Duve et al., 1955).", [["sac-like particles", "ANATOMY", 65, 83], ["liver cytoplasm", "ANATOMY", 91, 106], ["rat", "ORGANISM", 87, 90], ["liver cytoplasm", "ORGANISM_SUBSTANCE", 91, 106], ["acid phosphatase", "PROTEIN", 39, 55], ["rat", "SPECIES", 87, 90], ["rat", "SPECIES", 87, 90], ["acid phosphatase", "TEST", 39, 55], ["positive sac", "PROBLEM", 56, 68], ["sac", "ANATOMY", 65, 68], ["liver", "ANATOMY", 91, 96]]], ["Electron microscopy analysis revealed that such particles are surrounded by a lipoprotein membrane (Novikoff et al., 1956) and later showed acid hydrolases in these organelles, which were subsequently named lysosomes.Glucagon and AutophagySecreted glucagon is recognized by the glucagon receptor (a G protein-coupled receptor) on the hepatocyte, subsequently adenyl cyclase-mediated productions of the second messenger cAMP was stimulated.", [["lipoprotein membrane", "ANATOMY", 78, 98], ["organelles", "ANATOMY", 165, 175], ["lysosomes", "ANATOMY", 207, 216], ["hepatocyte", "ANATOMY", 334, 344], ["Glucagon", "CHEMICAL", 217, 225], ["glucagon", "CHEMICAL", 248, 256], ["cAMP", "CHEMICAL", 419, 423], ["adenyl", "CHEMICAL", 359, 365], ["cAMP", "CHEMICAL", 419, 423], ["lipoprotein membrane", "CELLULAR_COMPONENT", 78, 98], ["organelles", "CELLULAR_COMPONENT", 165, 175], ["lysosomes", "CELLULAR_COMPONENT", 207, 216], ["Glucagon", "GENE_OR_GENE_PRODUCT", 217, 225], ["glucagon", "GENE_OR_GENE_PRODUCT", 248, 256], ["glucagon receptor", "GENE_OR_GENE_PRODUCT", 278, 295], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 299, 325], ["hepatocyte", "CELL", 334, 344], ["adenyl cyclase", "GENE_OR_GENE_PRODUCT", 359, 373], ["cAMP", "SIMPLE_CHEMICAL", 419, 423], ["acid hydrolases", "PROTEIN", 140, 155], ["glucagon receptor", "PROTEIN", 278, 295], ["G protein-coupled receptor", "PROTEIN", 299, 325], ["adenyl cyclase", "PROTEIN", 359, 373], ["Electron microscopy analysis", "TEST", 0, 28], ["such particles", "PROBLEM", 43, 57], ["a lipoprotein membrane", "TEST", 76, 98], ["acid hydrolases in these organelles", "PROBLEM", 140, 175], ["Glucagon", "TREATMENT", 217, 225], ["AutophagySecreted glucagon", "TREATMENT", 230, 256], ["a G protein-coupled receptor)", "TREATMENT", 297, 326], ["the hepatocyte", "TEST", 330, 344], ["adenyl cyclase", "TREATMENT", 359, 373], ["the second messenger cAMP", "TREATMENT", 398, 423], ["lipoprotein membrane", "OBSERVATION", 78, 98], ["hepatocyte", "ANATOMY", 334, 344]]], ["Rise in the intracellular level of cAMP activates protein kinase A (PKA) and inhibits salt-inducible kinases (SIK).", [["intracellular", "ANATOMY", 12, 25], ["cAMP", "CHEMICAL", 35, 39], ["cAMP", "CHEMICAL", 35, 39], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["cAMP", "SIMPLE_CHEMICAL", 35, 39], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 50, 66], ["PKA", "GENE_OR_GENE_PRODUCT", 68, 71], ["salt-inducible kinases", "GENE_OR_GENE_PRODUCT", 86, 108], ["SIK", "GENE_OR_GENE_PRODUCT", 110, 113], ["protein kinase A", "PROTEIN", 50, 66], ["PKA", "PROTEIN", 68, 71], ["salt-inducible kinases", "PROTEIN", 86, 108], ["SIK", "PROTEIN", 110, 113], ["cAMP activates protein kinase", "TEST", 35, 64], ["A (PKA)", "TEST", 65, 72], ["salt", "TEST", 86, 90]]], ["PKA phosphorylates Ser133 of cyclic AMP-responsive element-binding protein (CREB) and SIK dephosphorylates Ser171 of CREB-regulated transcription co-activator (CRTC).", [["AMP", "CHEMICAL", 36, 39], ["cyclic AMP", "CHEMICAL", 29, 39], ["PKA", "GENE_OR_GENE_PRODUCT", 0, 3], ["Ser133", "AMINO_ACID", 19, 25], ["cyclic AMP-responsive element-binding protein", "GENE_OR_GENE_PRODUCT", 29, 74], ["CREB", "GENE_OR_GENE_PRODUCT", 76, 80], ["SIK", "GENE_OR_GENE_PRODUCT", 86, 89], ["Ser171", "GENE_OR_GENE_PRODUCT", 107, 113], ["CREB-regulated transcription co-activator", "GENE_OR_GENE_PRODUCT", 117, 158], ["CRTC", "GENE_OR_GENE_PRODUCT", 160, 164], ["PKA", "PROTEIN", 0, 3], ["cyclic AMP-responsive element-binding protein", "PROTEIN", 29, 74], ["CREB", "PROTEIN", 76, 80], ["SIK", "PROTEIN", 86, 89], ["Ser171", "PROTEIN", 107, 113], ["CREB", "PROTEIN", 117, 121], ["transcription co-activator", "PROTEIN", 132, 158], ["CRTC", "PROTEIN", 160, 164], ["PKA phosphorylates", "TEST", 0, 18], ["cyclic AMP-responsive element", "TEST", 29, 58], ["binding protein", "TEST", 59, 74], ["CREB", "TEST", 76, 80], ["SIK dephosphorylates", "TEST", 86, 106], ["CREB", "TEST", 117, 121]]], ["Ser133-phosphorylated CREB together with CRTC upregulates CREB target genes such as the gluconeogenesis-related genes PGC1\u03b1, nuclear receptor subfamily 4 group A member 1 (NR4A1) and TFEB which regulates gene expressions of autophagy proteins (Ueno and Komatsu, 2017).Glucagon and AutophagyIn 1962, seminal work by Ashford and Porter (1962) found that glucagon administration increased the autophagy in liver.", [["liver", "ANATOMY", 403, 408], ["Glucagon", "CHEMICAL", 268, 276], ["glucagon", "CHEMICAL", 352, 360], ["Ser133", "GENE_OR_GENE_PRODUCT", 0, 6], ["CREB", "GENE_OR_GENE_PRODUCT", 22, 26], ["CRTC", "GENE_OR_GENE_PRODUCT", 41, 45], ["CREB", "GENE_OR_GENE_PRODUCT", 58, 62], ["PGC1\u03b1", "GENE_OR_GENE_PRODUCT", 118, 123], ["nuclear receptor subfamily 4 group A member 1", "GENE_OR_GENE_PRODUCT", 125, 170], ["NR4A1", "GENE_OR_GENE_PRODUCT", 172, 177], ["TFEB", "GENE_OR_GENE_PRODUCT", 183, 187], ["Glucagon", "GENE_OR_GENE_PRODUCT", 268, 276], ["glucagon", "GENE_OR_GENE_PRODUCT", 352, 360], ["liver", "ORGAN", 403, 408], ["Ser133", "PROTEIN", 0, 6], ["CREB", "PROTEIN", 22, 26], ["CRTC", "PROTEIN", 41, 45], ["CREB target genes", "DNA", 58, 75], ["gluconeogenesis-related genes", "DNA", 88, 117], ["PGC1\u03b1", "DNA", 118, 123], ["nuclear receptor subfamily 4 group A member 1", "PROTEIN", 125, 170], ["NR4A1", "PROTEIN", 172, 177], ["TFEB", "PROTEIN", 183, 187], ["autophagy proteins", "PROTEIN", 224, 242], ["Ser133", "TEST", 0, 6], ["phosphorylated CREB", "TEST", 7, 26], ["CRTC upregulates CREB target genes", "PROBLEM", 41, 75], ["the gluconeogenesis", "TEST", 84, 103], ["Glucagon", "TREATMENT", 268, 276], ["glucagon administration", "TREATMENT", 352, 375], ["liver", "ANATOMY", 403, 408]]], ["Subsequently, the role of glucagon in hepatocyte autophagy induction was confirmed in vivo by studies in rats (Arstila and Trump, 1968; Guder et al., 1970; Deter, 1971).", [["hepatocyte", "ANATOMY", 38, 48], ["glucagon", "CHEMICAL", 26, 34], ["glucagon", "GENE_OR_GENE_PRODUCT", 26, 34], ["hepatocyte", "CELL", 38, 48], ["rats", "ORGANISM", 105, 109], ["rats", "SPECIES", 105, 109], ["glucagon", "TREATMENT", 26, 34], ["hepatocyte autophagy induction", "TREATMENT", 38, 68]]], ["Such effects of glucagon on the autophagy are likely tissue specific manner (Mortimore and Poso, 1987).", [["tissue", "ANATOMY", 53, 59], ["glucagon", "CHEMICAL", 16, 24], ["glucagon", "GENE_OR_GENE_PRODUCT", 16, 24], ["tissue", "TISSUE", 53, 59], ["glucagon", "TREATMENT", 16, 24], ["likely", "UNCERTAINTY", 46, 52]]], ["Glucagon could induce autophagy by increasing the size and number of autophagic vacuoles (Guder et al., 1970; Deter, 1971; Shelburne et al., 1973); in addition, glucagon enhanced the fragility of hepatic lysosomes both mechanically and osmotically and altered sedimentation properties (Deter and De Duve, 1967).", [["autophagic vacuoles", "ANATOMY", 69, 88], ["hepatic lysosomes", "ANATOMY", 196, 213], ["Glucagon", "CHEMICAL", 0, 8], ["glucagon", "CHEMICAL", 161, 169], ["Glucagon", "GENE_OR_GENE_PRODUCT", 0, 8], ["autophagic vacuoles", "CELLULAR_COMPONENT", 69, 88], ["glucagon", "GENE_OR_GENE_PRODUCT", 161, 169], ["hepatic lysosomes", "MULTI-TISSUE_STRUCTURE", 196, 213], ["Glucagon", "TREATMENT", 0, 8], ["autophagy", "PROBLEM", 22, 31], ["glucagon", "TREATMENT", 161, 169], ["hepatic lysosomes", "PROBLEM", 196, 213], ["altered sedimentation properties", "PROBLEM", 252, 284], ["increasing", "OBSERVATION_MODIFIER", 35, 45], ["size", "OBSERVATION_MODIFIER", 50, 54], ["autophagic vacuoles", "OBSERVATION", 69, 88], ["hepatic", "ANATOMY", 196, 203], ["lysosomes", "OBSERVATION", 204, 213]]], ["Such effects of glucagon on the hepatic lysosome appeared 30 min after intraperitoneal administration of glucagon, peaked for 15\u201330 min, and disappeared after approximately 4 h (Deter and De Duve, 1967).", [["hepatic lysosome", "ANATOMY", 32, 48], ["intraperitoneal", "ANATOMY", 71, 86], ["glucagon", "CHEMICAL", 16, 24], ["glucagon", "CHEMICAL", 105, 113], ["glucagon", "GENE_OR_GENE_PRODUCT", 16, 24], ["hepatic lysosome", "MULTI-TISSUE_STRUCTURE", 32, 48], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 86], ["glucagon", "GENE_OR_GENE_PRODUCT", 105, 113], ["glucagon", "TREATMENT", 16, 24], ["intraperitoneal administration of glucagon", "TREATMENT", 71, 113], ["hepatic", "ANATOMY", 32, 39]]], ["The number of hepatic lysosomes increased under conditions associated with an increase in endogenous glucagon levels, such as starvation (Guder et al., 1970), hypoglycemia induced by phlorizin (Becker and CornwallJr., 1971), or type 1 diabetes (Amherdt et al., 1974).", [["hepatic lysosomes", "ANATOMY", 14, 31], ["glucagon", "CHEMICAL", 101, 109], ["hypoglycemia", "DISEASE", 159, 171], ["phlorizin", "CHEMICAL", 183, 192], ["type 1 diabetes", "DISEASE", 228, 243], ["phlorizin", "CHEMICAL", 183, 192], ["hepatic lysosomes", "MULTI-TISSUE_STRUCTURE", 14, 31], ["glucagon", "GENE_OR_GENE_PRODUCT", 101, 109], ["phlorizin", "SIMPLE_CHEMICAL", 183, 192], ["hepatic lysosomes", "PROBLEM", 14, 31], ["an increase in endogenous glucagon levels", "PROBLEM", 75, 116], ["hypoglycemia", "PROBLEM", 159, 171], ["type 1 diabetes", "PROBLEM", 228, 243], ["hepatic", "ANATOMY", 14, 21], ["lysosomes increased", "OBSERVATION", 22, 41], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["endogenous glucagon levels", "OBSERVATION", 90, 116]]], ["Supporting these findings, a significant correlation between the parameters of hepatic lysosomal volume density and plasma glucagon was observed in rats with type 1 diabetes induced by streptozotocin, and insulin intervention in these rats led to suppression of glucose and glucagon levels (Amherdt et al., 1974).", [["hepatic lysosomal", "ANATOMY", 79, 96], ["plasma", "ANATOMY", 116, 122], ["glucagon", "CHEMICAL", 123, 131], ["type 1 diabetes", "DISEASE", 158, 173], ["streptozotocin", "CHEMICAL", 185, 199], ["glucose", "CHEMICAL", 262, 269], ["glucagon", "CHEMICAL", 274, 282], ["streptozotocin", "CHEMICAL", 185, 199], ["glucose", "CHEMICAL", 262, 269], ["hepatic lysosomal", "MULTI-TISSUE_STRUCTURE", 79, 96], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["glucagon", "GENE_OR_GENE_PRODUCT", 123, 131], ["rats", "ORGANISM", 148, 152], ["streptozotocin", "SIMPLE_CHEMICAL", 185, 199], ["insulin", "GENE_OR_GENE_PRODUCT", 205, 212], ["rats", "ORGANISM", 235, 239], ["glucose", "SIMPLE_CHEMICAL", 262, 269], ["glucagon", "SIMPLE_CHEMICAL", 274, 282], ["rats", "SPECIES", 148, 152], ["rats", "SPECIES", 235, 239], ["hepatic lysosomal volume density", "TEST", 79, 111], ["plasma glucagon", "TEST", 116, 131], ["type 1 diabetes", "PROBLEM", 158, 173], ["streptozotocin", "TREATMENT", 185, 199], ["insulin intervention", "TREATMENT", 205, 225], ["glucose", "TEST", 262, 269], ["glucagon levels", "TEST", 274, 289], ["hepatic", "ANATOMY", 79, 86], ["lysosomal", "OBSERVATION", 87, 96], ["volume density", "OBSERVATION", 97, 111]]], ["In addition, pancreatic transplantation normalized liver autophagy levels in rats with streptozotocin-induced diabetes by restoring insulin and glucagon levels (Brekke et al., 1983).", [["pancreatic", "ANATOMY", 13, 23], ["liver", "ANATOMY", 51, 56], ["streptozotocin", "CHEMICAL", 87, 101], ["diabetes", "DISEASE", 110, 118], ["glucagon", "CHEMICAL", 144, 152], ["streptozotocin", "CHEMICAL", 87, 101], ["pancreatic", "ORGAN", 13, 23], ["liver", "ORGAN", 51, 56], ["rats", "ORGANISM", 77, 81], ["streptozotocin", "SIMPLE_CHEMICAL", 87, 101], ["insulin", "GENE_OR_GENE_PRODUCT", 132, 139], ["glucagon", "GENE_OR_GENE_PRODUCT", 144, 152], ["rats", "SPECIES", 77, 81], ["pancreatic transplantation", "TREATMENT", 13, 39], ["streptozotocin", "TREATMENT", 87, 101], ["diabetes", "PROBLEM", 110, 118], ["restoring insulin", "TREATMENT", 122, 139], ["glucagon levels", "TEST", 144, 159], ["pancreatic", "ANATOMY", 13, 23], ["transplantation", "OBSERVATION", 24, 39], ["liver", "ANATOMY", 51, 56], ["autophagy levels", "OBSERVATION", 57, 73]]], ["Glucagon is relevant to glucagon-mediated glycogenolysis; glycogen granules are selectively enveloped by autophagosomes for catabolism into glucose.", [["glycogen granules", "ANATOMY", 58, 75], ["autophagosomes", "ANATOMY", 105, 119], ["Glucagon", "CHEMICAL", 0, 8], ["glycogen", "CHEMICAL", 58, 66], ["glucose", "CHEMICAL", 140, 147], ["glucose", "CHEMICAL", 140, 147], ["Glucagon", "GENE_OR_GENE_PRODUCT", 0, 8], ["glucagon", "GENE_OR_GENE_PRODUCT", 24, 32], ["glycogen", "SIMPLE_CHEMICAL", 58, 66], ["granules", "ORGANISM_SUBSTANCE", 67, 75], ["autophagosomes", "CELLULAR_COMPONENT", 105, 119], ["glucose", "SIMPLE_CHEMICAL", 140, 147], ["Glucagon", "TREATMENT", 0, 8], ["glucagon-mediated glycogenolysis", "TREATMENT", 24, 56], ["glycogen granules", "TREATMENT", 58, 75], ["catabolism into glucose", "TEST", 124, 147]]], ["This special type of autophagy is termed glycophagy.GLP-1-Related AutophagyGLP-1RA has been shown to suppress glucagon levels (Mentis et al., 2011).", [["AutophagyGLP-1RA", "CHEMICAL", 66, 82], ["GLP-1", "GENE_OR_GENE_PRODUCT", 52, 57], ["AutophagyGLP-1RA", "GENE_OR_GENE_PRODUCT", 66, 82], ["glucagon", "GENE_OR_GENE_PRODUCT", 110, 118], ["AutophagyGLP-1RA", "PROTEIN", 66, 82], ["GLP", "TEST", 52, 55], ["AutophagyGLP", "TEST", 66, 78], ["glucagon levels", "TEST", 110, 125]]], ["Even though tissue diversity effects of glucagon on the autophagy induction, the liver is the established target organ for glucagon-induced autophagy; therefore, from this point of view, GLP-1 signaling could be relevant to inhibiting autophagy induction in liver.", [["tissue", "ANATOMY", 12, 18], ["liver", "ANATOMY", 81, 86], ["organ", "ANATOMY", 113, 118], ["liver", "ANATOMY", 258, 263], ["glucagon", "CHEMICAL", 40, 48], ["glucagon", "CHEMICAL", 123, 131], ["tissue", "TISSUE", 12, 18], ["glucagon", "GENE_OR_GENE_PRODUCT", 40, 48], ["liver", "ORGAN", 81, 86], ["organ", "ORGAN", 113, 118], ["glucagon", "GENE_OR_GENE_PRODUCT", 123, 131], ["GLP-1", "GENE_OR_GENE_PRODUCT", 187, 192], ["liver", "ORGAN", 258, 263], ["glucagon", "TREATMENT", 40, 48], ["the autophagy induction", "TREATMENT", 52, 75], ["glucagon", "TEST", 123, 131], ["GLP", "TEST", 187, 190], ["liver", "ANATOMY", 81, 86], ["liver", "ANATOMY", 258, 263]]], ["Recently, however, GLP-1 has also been implicated in the induction of autophagy in the liver (He et al., 2016) and in \u03b2 cells (Zummo et al., 2017; Arden, 2018) as well.GLP-1-Related AutophagyGLP-1 can protect \u03b2 cells from insults induced by chronic exposure to excess nutrients via induction of autophagosomal-lysosomal fusion (Zummo et al., 2017; Arden, 2018).", [["liver", "ANATOMY", 87, 92], ["\u03b2 cells", "ANATOMY", 118, 125], ["\u03b2 cells", "ANATOMY", 209, 216], ["autophagosomal", "ANATOMY", 295, 309], ["lysosomal", "ANATOMY", 310, 319], ["GLP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["liver", "ORGAN", 87, 92], ["\u03b2 cells", "CELL", 118, 125], ["GLP-1", "GENE_OR_GENE_PRODUCT", 168, 173], ["AutophagyGLP-1", "GENE_OR_GENE_PRODUCT", 182, 196], ["\u03b2 cells", "CELL", 209, 216], ["autophagosomal", "CELLULAR_COMPONENT", 295, 309], ["lysosomal", "CELLULAR_COMPONENT", 310, 319], ["GLP-1", "PROTEIN", 19, 24], ["\u03b2 cells", "CELL_TYPE", 118, 125], ["\u03b2 cells", "CELL_TYPE", 209, 216], ["GLP", "TEST", 19, 22], ["GLP", "TEST", 168, 171], ["AutophagyGLP", "PROBLEM", 182, 194], ["excess nutrients", "TREATMENT", 261, 277], ["autophagosomal-lysosomal fusion", "TREATMENT", 295, 326], ["liver", "ANATOMY", 87, 92], ["chronic", "OBSERVATION_MODIFIER", 241, 248], ["lysosomal fusion", "OBSERVATION", 310, 326]]], ["Exendin-4, an agonistic polypeptide for human GLP-1R derived from the venom of the Gila monster lizard, has also been shown to enhance lysosomal function in \u03b2-cells, improve autophagosome clearance and protect against islet injury in a rat model of tacrolimus-induced diabetes (Lim et al., 2016).", [["venom", "ANATOMY", 70, 75], ["lysosomal", "ANATOMY", 135, 144], ["\u03b2-cells", "ANATOMY", 157, 164], ["autophagosome", "ANATOMY", 174, 187], ["islet", "ANATOMY", 218, 223], ["Exendin-4", "CHEMICAL", 0, 9], ["islet injury", "DISEASE", 218, 230], ["tacrolimus", "CHEMICAL", 249, 259], ["diabetes", "DISEASE", 268, 276], ["tacrolimus", "CHEMICAL", 249, 259], ["Exendin-4", "GENE_OR_GENE_PRODUCT", 0, 9], ["human", "ORGANISM", 40, 45], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 46, 52], ["venom", "ORGANISM_SUBSTANCE", 70, 75], ["Gila monster", "ORGANISM", 83, 95], ["lizard", "ORGANISM", 96, 102], ["lysosomal", "CELLULAR_COMPONENT", 135, 144], ["\u03b2-cells", "CELL", 157, 164], ["autophagosome", "CELLULAR_COMPONENT", 174, 187], ["islet", "MULTI-TISSUE_STRUCTURE", 218, 223], ["rat", "ORGANISM", 236, 239], ["tacrolimus", "SIMPLE_CHEMICAL", 249, 259], ["human GLP-1R", "PROTEIN", 40, 52], ["\u03b2-cells", "CELL_TYPE", 157, 164], ["human", "SPECIES", 40, 45], ["Gila monster lizard", "SPECIES", 83, 102], ["rat", "SPECIES", 236, 239], ["human", "SPECIES", 40, 45], ["Gila monster lizard", "SPECIES", 83, 102], ["rat", "SPECIES", 236, 239], ["Exendin", "TEST", 0, 7], ["an agonistic polypeptide", "TREATMENT", 11, 35], ["human GLP", "TEST", 40, 49], ["autophagosome clearance", "TEST", 174, 197], ["islet injury", "PROBLEM", 218, 230], ["tacrolimus", "TREATMENT", 249, 259], ["induced diabetes", "PROBLEM", 260, 276]]], ["Indeed, in this study, \u03b2 cells from rats administered Exendin-4 showed a reduction in the number of autophagosomes (Lim et al., 2016).", [["\u03b2 cells", "ANATOMY", 23, 30], ["autophagosomes", "ANATOMY", 100, 114], ["Exendin-4", "CHEMICAL", 54, 63], ["\u03b2 cells", "CELL", 23, 30], ["rats", "ORGANISM", 36, 40], ["Exendin-4", "GENE_OR_GENE_PRODUCT", 54, 63], ["autophagosomes", "CELLULAR_COMPONENT", 100, 114], ["\u03b2 cells", "CELL_TYPE", 23, 30], ["rats", "SPECIES", 36, 40], ["this study", "TEST", 11, 21], ["Exendin", "TEST", 54, 61], ["a reduction", "PROBLEM", 71, 82], ["reduction", "OBSERVATION_MODIFIER", 73, 82]]], ["Therefore, in certain environments, contrary to the hypothesis of the antiglucagon and antiautophagic signaling effects of GLP-1, GLP-1 receptor signaling could be relevant to the accelerated effects on autophagosomal-lysosomal fusion and the positive mediation of autophagic flux.", [["autophagosomal", "ANATOMY", 203, 217], ["lysosomal", "ANATOMY", 218, 227], ["antiglucagon", "SIMPLE_CHEMICAL", 70, 82], ["GLP-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["GLP-1 receptor", "GENE_OR_GENE_PRODUCT", 130, 144], ["autophagosomal", "CELLULAR_COMPONENT", 203, 217], ["lysosomal", "CELLULAR_COMPONENT", 218, 227], ["GLP-1 receptor", "PROTEIN", 130, 144], ["the antiglucagon", "TREATMENT", 66, 82], ["GLP", "TEST", 123, 126], ["GLP", "TEST", 130, 133], ["the accelerated effects", "PROBLEM", 176, 199], ["autophagosomal-lysosomal fusion", "TREATMENT", 203, 234], ["autophagic flux", "PROBLEM", 265, 280], ["lysosomal fusion", "OBSERVATION", 218, 234], ["autophagic flux", "OBSERVATION", 265, 280]]], ["However, the role of GLP-1 in \u03b2-cell autophagy is complex and likely dependent on stress conditions.", [["\u03b2-cell", "ANATOMY", 30, 36], ["GLP-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["\u03b2-cell", "CELL", 30, 36], ["GLP-1", "PROTEIN", 21, 26], ["GLP", "TEST", 21, 24], ["stress conditions", "PROBLEM", 82, 99]]], ["In a rat model fed with high levels of fructose, GLP-1 analog intervention induced notable inhibition of \u03b2 cell autophagy and enhanced \u03b2 cell mass and function (Maiztegui et al., 2017).", [["\u03b2 cell", "ANATOMY", 105, 111], ["\u03b2 cell", "ANATOMY", 135, 141], ["fructose", "CHEMICAL", 39, 47], ["fructose", "CHEMICAL", 39, 47], ["rat", "ORGANISM", 5, 8], ["fructose", "SIMPLE_CHEMICAL", 39, 47], ["GLP-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["\u03b2 cell", "CELL", 105, 111], ["\u03b2 cell", "CELL", 135, 141], ["rat", "SPECIES", 5, 8], ["rat", "SPECIES", 5, 8], ["high levels of fructose", "PROBLEM", 24, 47], ["GLP", "TEST", 49, 52], ["1 analog intervention", "TREATMENT", 53, 74], ["\u03b2 cell autophagy", "PROBLEM", 105, 121], ["enhanced \u03b2 cell mass", "PROBLEM", 126, 146], ["\u03b2 cell autophagy", "OBSERVATION", 105, 121], ["\u03b2 cell mass", "OBSERVATION", 135, 146]]], ["The detailed molecular regulation of the autophagy system in \u03b2 cells via GLP-1 receptor signaling requires further investigation.GLP-1-Related AutophagyThe liver is the potential target organ for GLP-1-induced autophagy (He et al., 2016).", [["\u03b2 cells", "ANATOMY", 61, 68], ["liver", "ANATOMY", 156, 161], ["organ", "ANATOMY", 186, 191], ["\u03b2 cells", "CELL", 61, 68], ["GLP-1 receptor", "GENE_OR_GENE_PRODUCT", 73, 87], ["GLP-1", "GENE_OR_GENE_PRODUCT", 129, 134], ["liver", "ORGAN", 156, 161], ["organ", "ORGAN", 186, 191], ["GLP-1", "GENE_OR_GENE_PRODUCT", 196, 201], ["\u03b2 cells", "CELL_TYPE", 61, 68], ["GLP-1 receptor", "PROTEIN", 73, 87], ["GLP", "TEST", 73, 76], ["further investigation", "TEST", 107, 128], ["GLP", "TEST", 129, 132], ["GLP", "TEST", 196, 199], ["liver", "ANATOMY", 156, 161]]], ["Among the organs, the level of GLP-1 in the liver is highest because of transport through the hepatic portal vein from the gut.", [["organs", "ANATOMY", 10, 16], ["liver", "ANATOMY", 44, 49], ["hepatic portal vein", "ANATOMY", 94, 113], ["gut", "ANATOMY", 123, 126], ["organs", "ORGAN", 10, 16], ["GLP-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["liver", "ORGAN", 44, 49], ["hepatic portal vein", "MULTI-TISSUE_STRUCTURE", 94, 113], ["gut", "ORGANISM_SUBDIVISION", 123, 126], ["GLP-1", "PROTEIN", 31, 36], ["GLP", "TEST", 31, 34], ["organs", "ANATOMY", 10, 16], ["liver", "ANATOMY", 44, 49], ["highest", "OBSERVATION", 53, 60], ["hepatic", "ANATOMY", 94, 101], ["portal vein", "ANATOMY", 102, 113], ["gut", "ANATOMY", 123, 126]]], ["Intervention of GLP-1 or its analogs could ameliorate several aspects of liver injury (D\u2019Alessio et al., 2004; Cantini et al., 2016) and influence hepatic gluconeogenesis, glycogen synthesis, and glycolysis (Figure 2).", [["liver", "ANATOMY", 73, 78], ["hepatic", "ANATOMY", 147, 154], ["liver injury", "DISEASE", 73, 85], ["glycogen", "CHEMICAL", 172, 180], ["GLP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["liver", "ORGAN", 73, 78], ["hepatic", "MULTI-TISSUE_STRUCTURE", 147, 154], ["glycogen", "SIMPLE_CHEMICAL", 172, 180], ["GLP", "TEST", 16, 19], ["its analogs", "PROBLEM", 25, 36], ["liver injury", "PROBLEM", 73, 85], ["influence hepatic gluconeogenesis", "PROBLEM", 137, 170], ["glycogen synthesis", "TREATMENT", 172, 190], ["liver", "ANATOMY", 73, 78], ["injury", "OBSERVATION", 79, 85], ["hepatic", "ANATOMY", 147, 154]]], ["For the effects of GLP-1, its receptor GLP-1R is essential; the presence of GLP-1R is controversial in hepatocytes and the focus of intense discussion.", [["hepatocytes", "ANATOMY", 103, 114], ["GLP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 39, 45], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 76, 82], ["hepatocytes", "CELL", 103, 114], ["GLP-1", "PROTEIN", 19, 24], ["GLP-1R", "PROTEIN", 39, 45], ["GLP-1R", "PROTEIN", 76, 82], ["hepatocytes", "CELL_TYPE", 103, 114], ["GLP", "TEST", 19, 22], ["its receptor GLP", "TEST", 26, 42], ["GLP", "TEST", 76, 79], ["controversial in hepatocytes", "PROBLEM", 86, 114], ["hepatocytes", "ANATOMY", 103, 114]]], ["Protein expression of GLP-1R has been reported in transformed human hepatocyte cell lines, Hep-G2, HuH7, and primary human hepatocytes (Gupta et al., 2010).", [["hepatocyte cell lines", "ANATOMY", 68, 89], ["Hep-G2", "ANATOMY", 91, 97], ["HuH7", "ANATOMY", 99, 103], ["hepatocytes", "ANATOMY", 123, 134], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 22, 28], ["human", "ORGANISM", 62, 67], ["hepatocyte cell lines", "CELL", 68, 89], ["Hep-G2", "CELL", 91, 97], ["HuH7", "CELL", 99, 103], ["human", "ORGANISM", 117, 122], ["hepatocytes", "CELL", 123, 134], ["GLP-1R", "PROTEIN", 22, 28], ["transformed human hepatocyte cell lines", "CELL_LINE", 50, 89], ["Hep-G2", "CELL_LINE", 91, 97], ["HuH7", "CELL_LINE", 99, 103], ["primary human hepatocytes", "CELL_TYPE", 109, 134], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 117, 122], ["GLP", "TEST", 22, 25], ["Hep", "TEST", 91, 94], ["HuH7", "TEST", 99, 103], ["hepatocyte cell lines", "OBSERVATION", 68, 89], ["human hepatocytes", "ANATOMY", 117, 134]]], ["Even though there is confirmation of GLP-1R expression on hepatocytes, research has suggested that some effects of GLP-1 are indeed GLP-1R-independent events (Bullock et al., 1996; Flock et al., 2007; Aviv et al., 2009; Tomas et al., 2010).", [["hepatocytes", "ANATOMY", 58, 69], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 37, 43], ["hepatocytes", "CELL", 58, 69], ["GLP-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 132, 138], ["GLP-1R", "PROTEIN", 37, 43], ["hepatocytes", "CELL_TYPE", 58, 69], ["GLP", "TEST", 37, 40], ["GLP", "TEST", 115, 118], ["hepatocytes", "ANATOMY", 58, 69]]], ["An alternative possible explanation could be based on the GLP-1 degradation products, such as GLP-1 9-36, GLP-1 28-36, or GLP-1 32-36.", [["GLP-1 9-36, GLP-1 28-36", "CHEMICAL", 94, 117], ["GLP-1 32-36", "CHEMICAL", 122, 133], ["GLP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["GLP-1 9-36", "SIMPLE_CHEMICAL", 94, 104], ["GLP-1 28-36", "SIMPLE_CHEMICAL", 106, 117], ["GLP-1 32-36", "SIMPLE_CHEMICAL", 122, 133], ["GLP-1 degradation products", "PROTEIN", 58, 84], ["the GLP", "TEST", 54, 61], ["GLP", "TEST", 94, 97], ["GLP", "TEST", 106, 109], ["GLP", "TEST", 122, 125]]], ["Studies have indicated that both GLP-1 28\u201336 and GLP-1 32\u201336 are cell-penetrating peptides that do not require a GLP-1R (Elahi et al., 2014).", [["cell", "ANATOMY", 65, 69], ["GLP-1 32\u201336", "CHEMICAL", 49, 60], ["GLP-1 28\u201336", "GENE_OR_GENE_PRODUCT", 33, 44], ["GLP-1 32\u201336", "GENE_OR_GENE_PRODUCT", 49, 60], ["cell", "CELL", 65, 69], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 113, 119], ["GLP", "TEST", 33, 36], ["GLP", "TEST", 49, 52], ["cell-penetrating peptides", "PROBLEM", 65, 90], ["a GLP", "TEST", 111, 116]]], ["GLP-1(32\u201336) amide, a novel pentapeptide cleavage product of GLP-1, modulates whole-body glucose metabolism in dogs (Elahi et al., 2014).", [["body", "ANATOMY", 84, 88], ["GLP-1(32\u201336) amide", "CHEMICAL", 0, 18], ["glucose", "CHEMICAL", 89, 96], ["amide", "CHEMICAL", 13, 18], ["glucose", "CHEMICAL", 89, 96], ["GLP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["32\u201336) amide", "SIMPLE_CHEMICAL", 6, 18], ["GLP-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["glucose", "SIMPLE_CHEMICAL", 89, 96], ["dogs", "ORGANISM", 111, 115], ["GLP-1", "PROTEIN", 61, 66], ["dogs", "SPECIES", 111, 115], ["GLP", "TEST", 0, 3], ["a novel pentapeptide cleavage product", "TREATMENT", 20, 57], ["GLP", "TEST", 61, 64]]], ["GLP1-derived nonapeptide GLP1(28\u201336) amide preserves pancreatic \u03b2 cells from glucolipotoxicity (Liu et al., 2012) and activates PKA and Wnt signaling [reviewed in (Jin and Weng, 2016)].", [["pancreatic \u03b2 cells", "ANATOMY", 53, 71], ["GLP1", "CHEMICAL", 25, 29], ["28\u201336) amide", "CHEMICAL", 30, 42], ["amide", "CHEMICAL", 37, 42], ["GLP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["28\u201336) amide", "SIMPLE_CHEMICAL", 30, 42], ["pancreatic \u03b2 cells", "CELL", 53, 71], ["PKA", "GENE_OR_GENE_PRODUCT", 128, 131], ["Wnt", "GENE_OR_GENE_PRODUCT", 136, 139], ["GLP1", "PROTEIN", 0, 4], ["pancreatic \u03b2 cells", "CELL_TYPE", 53, 71], ["PKA", "PROTEIN", 128, 131], ["GLP1", "TEST", 0, 4], ["derived nonapeptide GLP1", "TEST", 5, 29], ["pancreatic \u03b2 cells", "PROBLEM", 53, 71], ["glucolipotoxicity", "PROBLEM", 77, 94], ["pancreatic", "ANATOMY", 53, 63]]], ["The beneficial effects of GLP-1 fragments were reported to include kidney protective effects in db/db mice with diabetes (Moellmann et al., 2018).", [["kidney", "ANATOMY", 67, 73], ["diabetes", "DISEASE", 112, 120], ["GLP-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["kidney", "ORGAN", 67, 73], ["db/db mice", "ORGANISM", 96, 106], ["mice", "SPECIES", 102, 106], ["db/db mice", "SPECIES", 96, 106], ["GLP-1 fragments", "PROBLEM", 26, 41], ["diabetes", "PROBLEM", 112, 120], ["kidney", "ANATOMY", 67, 73], ["protective", "OBSERVATION", 74, 84]]], ["Whether such GLP-1 derived fragments are relevant for the GLP-1-induced liver autophagy induction is not known and required further investigation.GLP-1-Related AutophagyA series of experiments provided evidence that a GLP-1 agonist ameliorated hepatic steatosis and metabolic defects.", [["liver", "ANATOMY", 72, 77], ["hepatic", "ANATOMY", 244, 251], ["steatosis", "DISEASE", 252, 261], ["metabolic defects", "DISEASE", 266, 283], ["GLP-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["GLP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["liver", "ORGAN", 72, 77], ["GLP-1", "GENE_OR_GENE_PRODUCT", 146, 151], ["GLP-1", "GENE_OR_GENE_PRODUCT", 218, 223], ["hepatic", "ORGAN", 244, 251], ["GLP-1 derived fragments", "DNA", 13, 36], ["such GLP-1 derived fragments", "PROBLEM", 8, 36], ["the GLP", "TEST", 54, 61], ["further investigation", "TEST", 124, 145], ["GLP", "TEST", 146, 149], ["a GLP", "TEST", 216, 221], ["hepatic steatosis", "PROBLEM", 244, 261], ["metabolic defects", "PROBLEM", 266, 283], ["liver", "ANATOMY", 72, 77], ["autophagy", "OBSERVATION", 78, 87], ["hepatic", "ANATOMY", 244, 251], ["steatosis", "OBSERVATION", 252, 261], ["metabolic defects", "OBSERVATION", 266, 283]]], ["Such antisteatotic and metabolic effects of GLP-1 on the liver could involve AMPK activation and suppression of the mTOR pathway.", [["liver", "ANATOMY", 57, 62], ["GLP-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["liver", "ORGAN", 57, 62], ["AMPK", "GENE_OR_GENE_PRODUCT", 77, 81], ["mTOR", "GENE_OR_GENE_PRODUCT", 116, 120], ["GLP-1", "PROTEIN", 44, 49], ["AMPK", "PROTEIN", 77, 81], ["mTOR", "PROTEIN", 116, 120], ["GLP", "TEST", 44, 47], ["AMPK activation", "TREATMENT", 77, 92], ["the mTOR pathway", "TREATMENT", 112, 128], ["metabolic effects", "OBSERVATION", 23, 40], ["liver", "ANATOMY", 57, 62], ["AMPK activation", "OBSERVATION", 77, 92]]], ["Liraglutide has been shown to halt the progression of steatosis and is associated with the induction of autophagy via activation of AMPK and suppression of mTOR pathways (He et al., 2016).", [["Liraglutide", "CHEMICAL", 0, 11], ["steatosis", "DISEASE", 54, 63], ["Liraglutide", "CHEMICAL", 0, 11], ["Liraglutide", "SIMPLE_CHEMICAL", 0, 11], ["AMPK", "GENE_OR_GENE_PRODUCT", 132, 136], ["mTOR", "GENE_OR_GENE_PRODUCT", 156, 160], ["AMPK", "PROTEIN", 132, 136], ["mTOR", "PROTEIN", 156, 160], ["Liraglutide", "TREATMENT", 0, 11], ["steatosis", "PROBLEM", 54, 63], ["autophagy", "TREATMENT", 104, 113], ["activation of AMPK", "TREATMENT", 118, 136], ["suppression of mTOR pathways", "TREATMENT", 141, 169], ["progression", "OBSERVATION_MODIFIER", 39, 50], ["steatosis", "OBSERVATION", 54, 63]]], ["By activating both macro- and chaperone-mediated autophagy, GLP-1 could protect hepatocytes from fatty acid-related apoptosis by suppressing a dysfunctional ER stress response.", [["hepatocytes", "ANATOMY", 80, 91], ["GLP-1", "GENE_OR_GENE_PRODUCT", 60, 65], ["hepatocytes", "CELL", 80, 91], ["ER", "GENE_OR_GENE_PRODUCT", 157, 159], ["GLP-1", "PROTEIN", 60, 65], ["hepatocytes", "CELL_TYPE", 80, 91], ["ER", "PROTEIN", 157, 159], ["GLP", "TEST", 60, 63], ["hepatocytes", "PROBLEM", 80, 91], ["fatty acid-related apoptosis", "PROBLEM", 97, 125], ["a dysfunctional ER stress response", "PROBLEM", 141, 175], ["hepatocytes", "ANATOMY", 80, 91], ["fatty acid-related apoptosis", "OBSERVATION", 97, 125], ["stress response", "OBSERVATION", 160, 175]]], ["GLP-1 therapies have been shown to relieve the burden on the ER, reduce ER stress, and decrease subsequent hepatocyte apoptosis (Sharma et al., 2011).GLP-1-Related AutophagyThe alternative explanation of autophagy induction by GLP-1 could be associated with suppression of oxidative stress.", [["ER", "ANATOMY", 61, 63], ["hepatocyte", "ANATOMY", 107, 117], ["GLP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["hepatocyte", "CELL", 107, 117], ["GLP-1", "GENE_OR_GENE_PRODUCT", 150, 155], ["GLP-1", "GENE_OR_GENE_PRODUCT", 227, 232], ["ER", "PROTEIN", 61, 63], ["ER", "PROTEIN", 72, 74], ["GLP-1", "PROTEIN", 150, 155], ["GLP-1", "PROTEIN", 227, 232], ["GLP", "TEST", 0, 3], ["ER stress", "PROBLEM", 72, 81], ["decrease subsequent hepatocyte apoptosis", "PROBLEM", 87, 127], ["GLP", "TEST", 150, 153], ["Autophagy", "PROBLEM", 164, 173], ["autophagy induction", "TREATMENT", 204, 223], ["oxidative stress", "PROBLEM", 273, 289], ["hepatocyte apoptosis", "OBSERVATION", 107, 127], ["Autophagy", "OBSERVATION", 164, 173], ["oxidative stress", "OBSERVATION", 273, 289]]], ["GLP-1 agonists have been shown to reduce oxidative stress in diverse preclinical studies.", [["GLP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["GLP", "TEST", 0, 3], ["oxidative stress", "PROBLEM", 41, 57], ["diverse preclinical studies", "TEST", 61, 88]]], ["When the endogenous antioxidant system cannot remove free radicals appropriately, oxidative stress, the accumulation of such free radicals, accelerates a variety of disease conditions, such as diabetes and its complications, cancer, and neuronal disorders.", [["cancer", "ANATOMY", 225, 231], ["neuronal", "ANATOMY", 237, 245], ["diabetes", "DISEASE", 193, 201], ["cancer", "DISEASE", 225, 231], ["neuronal disorders", "DISEASE", 237, 255], ["cancer", "CANCER", 225, 231], ["neuronal", "CELL", 237, 245], ["oxidative stress", "PROBLEM", 82, 98], ["such free radicals", "PROBLEM", 120, 138], ["disease conditions", "PROBLEM", 165, 183], ["diabetes", "PROBLEM", 193, 201], ["its complications", "PROBLEM", 206, 223], ["cancer", "PROBLEM", 225, 231], ["neuronal disorders", "PROBLEM", 237, 255], ["free radicals", "OBSERVATION", 125, 138], ["variety", "OBSERVATION_MODIFIER", 154, 161], ["disease", "OBSERVATION", 165, 172], ["cancer", "OBSERVATION", 225, 231], ["neuronal disorders", "OBSERVATION", 237, 255]]], ["Cellular defense systems for combatting reactive oxygen species (ROS) rely on the presence of antioxidants that scavenge ROS or induce genes involved in cytoprotection to neutralize ROS (Kaspar et al., 2009; Ma, 2013).", [["Cellular", "ANATOMY", 0, 8], ["oxygen", "CHEMICAL", 49, 55], ["ROS", "CHEMICAL", 65, 68], ["ROS", "CHEMICAL", 121, 124], ["ROS", "CHEMICAL", 182, 185], ["oxygen", "CHEMICAL", 49, 55], ["reactive oxygen species", "SIMPLE_CHEMICAL", 40, 63], ["ROS", "SIMPLE_CHEMICAL", 65, 68], ["ROS", "SIMPLE_CHEMICAL", 121, 124], ["ROS", "SIMPLE_CHEMICAL", 182, 185], ["Cellular defense systems", "PROBLEM", 0, 24], ["combatting reactive oxygen species", "PROBLEM", 29, 63], ["antioxidants", "TREATMENT", 94, 106], ["scavenge ROS", "PROBLEM", 112, 124], ["reactive", "OBSERVATION_MODIFIER", 40, 48], ["oxygen species", "OBSERVATION", 49, 63]]], ["The nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor is a master regulator of redox balance and is responsible for the transcription of various antioxidant and detoxification genes by binding to antioxidant response elements (AREs) (Kaspar et al., 2009; Ma, 2013).", [["nuclear factor erythroid 2-related factor 2", "GENE_OR_GENE_PRODUCT", 4, 47], ["Nrf2", "GENE_OR_GENE_PRODUCT", 49, 53], ["nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor", "PROTEIN", 4, 75], ["detoxification genes", "DNA", 183, 203], ["antioxidant response elements", "DNA", 218, 247], ["AREs", "DNA", 249, 253], ["The nuclear factor erythroid", "TEST", 0, 28]]], ["GLP-1 agonists have been shown to induce Nrf2 in \u03b2 cells (Oh and Jun, 2017).GLP-1-Related AutophagyWhen cells are exposed to oxidative stress, SQSTM1, known as the ubiquitin-binding protein p62 and an autophagosome cargo protein, is phosphorylated at Ser349.", [["\u03b2 cells", "ANATOMY", 49, 56], ["AutophagyWhen cells", "ANATOMY", 90, 109], ["autophagosome", "ANATOMY", 201, 214], ["GLP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nrf2", "GENE_OR_GENE_PRODUCT", 41, 45], ["\u03b2 cells", "CELL", 49, 56], ["Jun", "GENE_OR_GENE_PRODUCT", 65, 68], ["GLP-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["AutophagyWhen cells", "CELL", 90, 109], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 143, 149], ["p62", "GENE_OR_GENE_PRODUCT", 190, 193], ["autophagosome", "CELLULAR_COMPONENT", 201, 214], ["Ser349", "AMINO_ACID", 251, 257], ["Nrf2", "PROTEIN", 41, 45], ["\u03b2 cells", "CELL_TYPE", 49, 56], ["GLP-1", "PROTEIN", 76, 81], ["AutophagyWhen cells", "CELL_LINE", 90, 109], ["SQSTM1", "PROTEIN", 143, 149], ["ubiquitin-binding protein", "PROTEIN", 164, 189], ["p62", "PROTEIN", 190, 193], ["autophagosome cargo protein", "PROTEIN", 201, 228], ["Ser349", "PROTEIN", 251, 257], ["GLP", "TEST", 0, 3], ["GLP", "TEST", 76, 79], ["AutophagyWhen cells", "PROBLEM", 90, 109], ["oxidative stress", "PROBLEM", 125, 141], ["the ubiquitin-binding protein p62", "TEST", 160, 193], ["an autophagosome cargo protein", "TEST", 198, 228]]], ["Phosphorylated form of SQSTM1 physically interacted with KEAP1, an adaptor of the ubiquitin ligase complex for Nrf2, with high affinity (Ueno and Komatsu, 2017).", [["SQSTM1", "GENE_OR_GENE_PRODUCT", 23, 29], ["KEAP1", "GENE_OR_GENE_PRODUCT", 57, 62], ["Nrf2", "GENE_OR_GENE_PRODUCT", 111, 115], ["SQSTM1", "PROTEIN", 23, 29], ["KEAP1", "PROTEIN", 57, 62], ["ubiquitin ligase complex", "PROTEIN", 82, 106], ["Nrf2", "PROTEIN", 111, 115], ["the ubiquitin ligase complex", "TREATMENT", 78, 106]]], ["The interaction between SQSTM1 and KEAP1 results in the suppression of KEAP1-driven ubiquitination of Nrf2; phosphorylated SQSTM1 and KEAP1 complexes are selectively degraded by autophagy (Ueno and Komatsu, 2017).", [["SQSTM1", "GENE_OR_GENE_PRODUCT", 24, 30], ["KEAP1", "GENE_OR_GENE_PRODUCT", 35, 40], ["KEAP1", "GENE_OR_GENE_PRODUCT", 71, 76], ["Nrf2", "GENE_OR_GENE_PRODUCT", 102, 106], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 123, 129], ["KEAP1", "GENE_OR_GENE_PRODUCT", 134, 139], ["SQSTM1", "PROTEIN", 24, 30], ["KEAP1", "PROTEIN", 35, 40], ["KEAP1", "PROTEIN", 71, 76], ["Nrf2", "PROTEIN", 102, 106], ["SQSTM1", "PROTEIN", 123, 129], ["KEAP1 complexes", "PROTEIN", 134, 149], ["SQSTM1", "TEST", 24, 30], ["KEAP1", "TEST", 71, 76], ["phosphorylated SQSTM1", "TEST", 108, 129], ["KEAP1 complexes", "TEST", 134, 149]]], ["Thereafter, Nrf2 is stabilized, translocates into the nucleus, and induces the expression of various essential cytoprotective genes, such as NAD(P)H dehydrogenase quinone 1, glutathione S-transferase, glutamate-cysteine ligase catalytic subunit and heme oxygenase 1 (Jain et al., 2010; Komatsu et al., 2010; Lau et al., 2010; Taguchi et al., 2012; Ichimura et al., 2013).", [["nucleus", "ANATOMY", 54, 61], ["NAD", "CHEMICAL", 141, 144], ["glutathione", "CHEMICAL", 174, 185], ["glutamate", "CHEMICAL", 201, 210], ["NAD(P)H", "CHEMICAL", 141, 148], ["quinone", "CHEMICAL", 163, 170], ["glutathione", "CHEMICAL", 174, 185], ["S-", "CHEMICAL", 186, 188], ["glutamate", "CHEMICAL", 201, 210], ["cysteine", "CHEMICAL", 211, 219], ["Nrf2", "GENE_OR_GENE_PRODUCT", 12, 16], ["nucleus", "CELLULAR_COMPONENT", 54, 61], ["NAD(P)H dehydrogenase quinone 1", "GENE_OR_GENE_PRODUCT", 141, 172], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 174, 199], ["glutamate-cysteine ligase", "GENE_OR_GENE_PRODUCT", 201, 226], ["heme oxygenase 1", "GENE_OR_GENE_PRODUCT", 249, 265], ["Nrf2", "PROTEIN", 12, 16], ["cytoprotective genes", "DNA", 111, 131], ["NAD(P)H dehydrogenase quinone 1", "PROTEIN", 141, 172], ["glutathione S-transferase", "PROTEIN", 174, 199], ["glutamate-cysteine ligase catalytic subunit", "PROTEIN", 201, 244], ["heme oxygenase 1", "PROTEIN", 249, 265], ["Nrf2", "TREATMENT", 12, 16], ["NAD(P)H dehydrogenase quinone", "TREATMENT", 141, 170], ["glutathione S-transferase", "TREATMENT", 174, 199], ["glutamate-cysteine ligase catalytic subunit", "TREATMENT", 201, 244], ["heme oxygenase", "TREATMENT", 249, 263], ["stabilized", "OBSERVATION", 20, 30], ["nucleus", "ANATOMY", 54, 61], ["cytoprotective genes", "OBSERVATION", 111, 131]]], ["Sestrin 2, also known as an intracellular leucine sensor that negatively regulates mTORC1 signaling, binds with the SQSTM1 and KEAP1 complexes and functions as a scaffold protein for the SQSTM1-mediated autophagy of KEAP1 (Bae et al., 2013).", [["intracellular", "ANATOMY", 28, 41], ["leucine", "CHEMICAL", 42, 49], ["leucine", "CHEMICAL", 42, 49], ["Sestrin 2", "GENE_OR_GENE_PRODUCT", 0, 9], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["leucine", "AMINO_ACID", 42, 49], ["mTORC1", "GENE_OR_GENE_PRODUCT", 83, 89], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 116, 122], ["KEAP1", "GENE_OR_GENE_PRODUCT", 127, 132], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 187, 193], ["KEAP1", "GENE_OR_GENE_PRODUCT", 216, 221], ["Sestrin 2", "PROTEIN", 0, 9], ["mTORC1", "PROTEIN", 83, 89], ["SQSTM1", "PROTEIN", 116, 122], ["KEAP1 complexes", "PROTEIN", 127, 142], ["SQSTM1", "PROTEIN", 187, 193], ["an intracellular leucine sensor", "TEST", 25, 56], ["the SQSTM1", "TEST", 112, 122], ["KEAP1 complexes", "TEST", 127, 142], ["a scaffold protein", "TEST", 160, 178], ["the SQSTM1", "TEST", 183, 193]]], ["Sestrin 2 is also induced under conditions of stress (Yang et al., 2014); Nrf2 activation might be regulated by selective autophagy under metabolic stress.", [["Sestrin 2", "GENE_OR_GENE_PRODUCT", 0, 9], ["Nrf2", "GENE_OR_GENE_PRODUCT", 74, 78], ["Sestrin 2", "PROTEIN", 0, 9], ["Nrf2", "PROTEIN", 74, 78], ["Nrf2 activation", "TREATMENT", 74, 89], ["metabolic stress", "OBSERVATION", 138, 154]]], ["Therefore, GLP-1-induced Nfr2 activation could be relevant to GLP-1-induced autophagy, but further study is needed.", [["GLP-1", "GENE_OR_GENE_PRODUCT", 11, 16], ["Nfr2", "GENE_OR_GENE_PRODUCT", 25, 29], ["GLP-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["Nfr2", "PROTEIN", 25, 29], ["GLP", "TEST", 11, 14], ["Nfr2 activation", "PROBLEM", 25, 40], ["GLP", "TEST", 62, 65], ["induced autophagy", "PROBLEM", 68, 85], ["further study", "TEST", 91, 104]]], ["The association between GLP-1 and sestrin 2 has yet to be confirmed.DPP-4 Inhibitors-Induced AutophagyDPP-4, a member of the serine peptidase/prolyl oligopeptidase gene family, was first found as a T cell differentiation antigen (CD26) and also as cell surface aminopeptidase.", [["T cell", "ANATOMY", 198, 204], ["cell surface", "ANATOMY", 248, 260], ["serine", "CHEMICAL", 125, 131], ["prolyl", "CHEMICAL", 142, 148], ["GLP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["sestrin 2", "GENE_OR_GENE_PRODUCT", 34, 43], ["DPP-4", "GENE_OR_GENE_PRODUCT", 68, 73], ["AutophagyDPP-4", "GENE_OR_GENE_PRODUCT", 93, 107], ["prolyl oligopeptidase", "GENE_OR_GENE_PRODUCT", 142, 163], ["T cell differentiation antigen", "GENE_OR_GENE_PRODUCT", 198, 228], ["CD26", "GENE_OR_GENE_PRODUCT", 230, 234], ["cell surface aminopeptidase", "GENE_OR_GENE_PRODUCT", 248, 275], ["GLP-1", "PROTEIN", 24, 29], ["sestrin 2", "PROTEIN", 34, 43], ["Induced AutophagyDPP-4", "PROTEIN", 85, 107], ["serine peptidase", "PROTEIN", 125, 141], ["prolyl oligopeptidase gene family", "PROTEIN", 142, 175], ["T cell differentiation antigen", "PROTEIN", 198, 228], ["CD26", "PROTEIN", 230, 234], ["cell surface aminopeptidase", "PROTEIN", 248, 275], ["GLP", "TEST", 24, 27], ["DPP", "TEST", 68, 71], ["Inhibitors", "TEST", 74, 84], ["AutophagyDPP", "TEST", 93, 105], ["the serine peptidase/prolyl oligopeptidase gene family", "TREATMENT", 121, 175], ["a T cell differentiation antigen", "PROBLEM", 196, 228]]], ["DPP-4 displays numerous biological functions, such as protease activity, interaction with adenosine deaminase and the extracellular matrix proteins, co-receptor activity mediating viral entry, and regulation of intracellular signals (Kameoka et al., 1993; Kahne et al., 1999; Lambeir et al., 2003; Lopez-Otin and Matrisian, 2007; Lu et al., 2013).", [["extracellular matrix", "ANATOMY", 118, 138], ["intracellular", "ANATOMY", 211, 224], ["DPP-4", "CHEMICAL", 0, 5], ["adenosine", "CHEMICAL", 90, 99], ["adenosine", "CHEMICAL", 90, 99], ["DPP-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["adenosine deaminase", "GENE_OR_GENE_PRODUCT", 90, 109], ["extracellular matrix", "CELLULAR_COMPONENT", 118, 138], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 211, 224], ["DPP-4", "PROTEIN", 0, 5], ["protease", "PROTEIN", 54, 62], ["adenosine deaminase", "PROTEIN", 90, 109], ["extracellular matrix proteins", "PROTEIN", 118, 147], ["DPP", "TEST", 0, 3], ["numerous biological functions", "PROBLEM", 15, 44], ["adenosine deaminase", "TREATMENT", 90, 109], ["the extracellular matrix proteins", "TREATMENT", 114, 147], ["numerous", "OBSERVATION_MODIFIER", 15, 23], ["biological functions", "OBSERVATION", 24, 44]]], ["Furthermore, the complexities of the biological functions of DPP-4 are indeed multiplying with diverse bioactive substrates of DPP-4, thus emphasizing the elegant role of DPP-4 in the biochemical tuning of multiple cell type and tissues.", [["cell type", "ANATOMY", 215, 224], ["tissues", "ANATOMY", 229, 236], ["DPP-4", "GENE_OR_GENE_PRODUCT", 61, 66], ["DPP-4", "GENE_OR_GENE_PRODUCT", 127, 132], ["DPP-4", "GENE_OR_GENE_PRODUCT", 171, 176], ["cell type", "CELL", 215, 224], ["tissues", "TISSUE", 229, 236], ["DPP-4", "PROTEIN", 61, 66], ["DPP-4", "PROTEIN", 127, 132], ["DPP-4", "PROTEIN", 171, 176], ["DPP", "TEST", 61, 64], ["DPP", "TEST", 127, 130], ["DPP", "TEST", 171, 174], ["multiple cell type", "OBSERVATION", 206, 224], ["tissues", "ANATOMY", 229, 236]]], ["DPP-4 inhibitors exhibited multiple organ protective potential (Kroller-Schon et al., 2012; Itou et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2018; Ye et al., 2018; Enz et al., 2019; Hollande et al., 2019; Yang et al., 2019).DPP-4 Inhibitors-Induced AutophagySome preclinical studies have shown a potential link between DPP-4 inhibition and autophagy induction.", [["organ", "ANATOMY", 36, 41], ["cancer", "ANATOMY", 193, 199], ["cancer", "DISEASE", 193, 199], ["DPP-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["organ", "ORGAN", 36, 41], ["cancer", "CANCER", 193, 199], ["DPP-4", "GENE_OR_GENE_PRODUCT", 309, 314], ["DPP-4", "GENE_OR_GENE_PRODUCT", 404, 409], ["DPP-4", "PROTEIN", 404, 409], ["DPP", "TEST", 0, 3], ["DPP", "TEST", 309, 312], ["AutophagySome preclinical studies", "TEST", 334, 367], ["DPP", "TEST", 404, 407], ["autophagy induction", "TREATMENT", 425, 444], ["cancer", "OBSERVATION", 193, 199]]], ["In leptin-deficient ob/ob mice, sitagliptin at 50 mg/kg daily for 4 weeks ameliorated weight gain, metabolic disorders, and steatosis in the liver as well as insulin sensitivity.", [["liver", "ANATOMY", 141, 146], ["sitagliptin", "CHEMICAL", 32, 43], ["weight gain", "DISEASE", 86, 97], ["metabolic disorders", "DISEASE", 99, 118], ["steatosis", "DISEASE", 124, 133], ["sitagliptin", "CHEMICAL", 32, 43], ["leptin", "GENE_OR_GENE_PRODUCT", 3, 9], ["sitagliptin", "SIMPLE_CHEMICAL", 32, 43], ["liver", "ORGAN", 141, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 158, 165], ["leptin", "PROTEIN", 3, 9], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["sitagliptin", "TREATMENT", 32, 43], ["weight gain", "PROBLEM", 86, 97], ["metabolic disorders", "PROBLEM", 99, 118], ["steatosis in the liver", "PROBLEM", 124, 146], ["insulin sensitivity", "TEST", 158, 177], ["metabolic disorders", "OBSERVATION", 99, 118], ["steatosis", "OBSERVATION", 124, 133], ["liver", "ANATOMY", 141, 146]]], ["In this study, sitagliptin increased AMPK phosphorylation and decreased mTOR phosphorylation associated with the restoration of ATG5 and Beclin 1 messenger RNA expression that was suppressed in ob/ob mice.", [["sitagliptin", "CHEMICAL", 15, 26], ["sitagliptin", "CHEMICAL", 15, 26], ["sitagliptin", "SIMPLE_CHEMICAL", 15, 26], ["AMPK", "GENE_OR_GENE_PRODUCT", 37, 41], ["mTOR", "GENE_OR_GENE_PRODUCT", 72, 76], ["ATG5", "GENE_OR_GENE_PRODUCT", 128, 132], ["Beclin 1", "GENE_OR_GENE_PRODUCT", 137, 145], ["ob/ob mice", "ORGANISM", 194, 204], ["AMPK", "PROTEIN", 37, 41], ["mTOR", "PROTEIN", 72, 76], ["ATG5", "PROTEIN", 128, 132], ["Beclin 1", "PROTEIN", 137, 145], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 200, 204], ["this study", "TEST", 3, 13], ["sitagliptin increased AMPK phosphorylation", "TREATMENT", 15, 57], ["decreased mTOR phosphorylation", "TREATMENT", 62, 92], ["ATG5", "TREATMENT", 128, 132], ["Beclin", "TREATMENT", 137, 143]]], ["In addition, the relative level of LC3-II/LC3-I was significantly diminished in ob/ob mice and was restored to the basal level by sitagliptin (Zheng et al., 2018).", [["sitagliptin", "CHEMICAL", 130, 141], ["sitagliptin", "CHEMICAL", 130, 141], ["LC3-II", "GENE_OR_GENE_PRODUCT", 35, 41], ["LC3-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["ob/ob mice", "ORGANISM", 80, 90], ["sitagliptin", "SIMPLE_CHEMICAL", 130, 141], ["LC3", "PROTEIN", 35, 38], ["LC3-I", "PROTEIN", 42, 47], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["significantly diminished", "PROBLEM", 52, 76], ["sitagliptin", "TREATMENT", 130, 141], ["LC3", "OBSERVATION", 35, 38], ["significantly", "OBSERVATION_MODIFIER", 52, 65], ["diminished", "OBSERVATION", 66, 76], ["ob mice", "ANATOMY", 83, 90], ["basal", "ANATOMY_MODIFIER", 115, 120]]], ["Another report showed that autophagic responses were significantly diminished in OLETF rats after experimental myocardial infarction associated with a deficiency in AMPK/ULK-1 activation, Akt/mTOR/S6 signaling, and increased Beclin-1-Bcl-2 interaction, which are key molecular events for suppressing autophagy.", [["autophagic", "ANATOMY", 27, 37], ["myocardial", "ANATOMY", 111, 121], ["myocardial infarction", "DISEASE", 111, 132], ["OLETF rats", "ORGANISM", 81, 91], ["myocardial", "MULTI-TISSUE_STRUCTURE", 111, 121], ["AMPK", "GENE_OR_GENE_PRODUCT", 165, 169], ["ULK-1", "GENE_OR_GENE_PRODUCT", 170, 175], ["Akt", "GENE_OR_GENE_PRODUCT", 188, 191], ["mTOR", "GENE_OR_GENE_PRODUCT", 192, 196], ["S6", "GENE_OR_GENE_PRODUCT", 197, 199], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 225, 233], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 234, 239], ["AMPK", "PROTEIN", 165, 169], ["ULK", "PROTEIN", 170, 173], ["Akt", "PROTEIN", 188, 191], ["mTOR", "PROTEIN", 192, 196], ["S6", "PROTEIN", 197, 199], ["Beclin", "PROTEIN", 225, 231], ["Bcl-2", "PROTEIN", 234, 239], ["rats", "SPECIES", 87, 91], ["autophagic responses", "PROBLEM", 27, 47], ["significantly diminished", "PROBLEM", 53, 77], ["experimental myocardial infarction", "PROBLEM", 98, 132], ["a deficiency", "PROBLEM", 149, 161], ["AMPK", "TEST", 165, 169], ["ULK", "TEST", 170, 173], ["Akt/mTOR", "TEST", 188, 196], ["S6 signaling", "PROBLEM", 197, 209], ["increased Beclin", "PROBLEM", 215, 231], ["suppressing autophagy", "PROBLEM", 288, 309], ["diminished", "OBSERVATION_MODIFIER", 67, 77], ["myocardial", "ANATOMY", 111, 121], ["infarction", "OBSERVATION", 122, 132]]], ["Intervention with the DPP-4 inhibitor vildagliptin inhibited the Beclin-1-Bcl-2 interaction and enhanced both LC3-II protein and autophagosomes in the non-infarcted region in OLETF rats without normalization of either AMPK/ULK-1 or mTOR/S6 signaling.", [["autophagosomes", "ANATOMY", 129, 143], ["vildagliptin", "CHEMICAL", 38, 50], ["vildagliptin", "CHEMICAL", 38, 50], ["DPP-4", "GENE_OR_GENE_PRODUCT", 22, 27], ["vildagliptin", "SIMPLE_CHEMICAL", 38, 50], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 65, 73], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 74, 79], ["LC3-II", "GENE_OR_GENE_PRODUCT", 110, 116], ["autophagosomes", "CELLULAR_COMPONENT", 129, 143], ["OLETF rats", "ORGANISM", 175, 185], ["AMPK", "GENE_OR_GENE_PRODUCT", 218, 222], ["ULK-1", "GENE_OR_GENE_PRODUCT", 223, 228], ["mTOR", "GENE_OR_GENE_PRODUCT", 232, 236], ["S6", "GENE_OR_GENE_PRODUCT", 237, 239], ["Beclin-1", "PROTEIN", 65, 73], ["Bcl-2", "PROTEIN", 74, 79], ["LC3-II protein", "PROTEIN", 110, 124], ["AMPK", "PROTEIN", 218, 222], ["ULK", "PROTEIN", 223, 226], ["mTOR", "PROTEIN", 232, 236], ["S6", "PROTEIN", 237, 239], ["rats", "SPECIES", 181, 185], ["Intervention", "TREATMENT", 0, 12], ["the DPP", "TEST", 18, 25], ["vildagliptin", "TEST", 38, 50], ["the Beclin", "TEST", 61, 71], ["AMPK", "TEST", 218, 222], ["ULK", "TEST", 223, 226], ["mTOR/S6 signaling", "PROBLEM", 232, 249], ["non-infarcted", "ANATOMY_MODIFIER", 151, 164], ["region", "ANATOMY_MODIFIER", 165, 171]]], ["Such effects of vildagliptin on heart autophagy are associated with an 80% survival rate in OLETF rats; chloroquine, an autophagy inhibitor, diminished these beneficial effects of vildagliptin (Murase et al., 2015).DPP-4 Inhibitors-Induced AutophagyReports have indicated that DPP-4 inhibitors could be associated with the induction of autophagy; however, the underlying mechanisms by which DPP-4 inhibition is related to autophagy induction are not absolutely clear.", [["heart", "ANATOMY", 32, 37], ["vildagliptin", "CHEMICAL", 16, 28], ["chloroquine", "CHEMICAL", 104, 115], ["vildagliptin", "CHEMICAL", 180, 192], ["vildagliptin", "CHEMICAL", 16, 28], ["chloroquine", "CHEMICAL", 104, 115], ["vildagliptin", "CHEMICAL", 180, 192], ["vildagliptin", "SIMPLE_CHEMICAL", 16, 28], ["heart", "ORGAN", 32, 37], ["OLETF rats", "ORGANISM", 92, 102], ["chloroquine", "SIMPLE_CHEMICAL", 104, 115], ["vildagliptin", "SIMPLE_CHEMICAL", 180, 192], ["DPP-4", "GENE_OR_GENE_PRODUCT", 215, 220], ["DPP-4", "GENE_OR_GENE_PRODUCT", 277, 282], ["DPP-4", "GENE_OR_GENE_PRODUCT", 391, 396], ["DPP-4", "PROTEIN", 391, 396], ["rats", "SPECIES", 98, 102], ["vildagliptin", "TREATMENT", 16, 28], ["heart autophagy", "PROBLEM", 32, 47], ["chloroquine", "TREATMENT", 104, 115], ["an autophagy inhibitor", "TREATMENT", 117, 139], ["vildagliptin", "TREATMENT", 180, 192], ["DPP", "TEST", 215, 218], ["DPP-4 inhibitors", "TREATMENT", 277, 293], ["autophagy", "PROBLEM", 336, 345], ["DPP", "TEST", 391, 394], ["autophagy induction", "TREATMENT", 422, 441], ["heart", "ANATOMY", 32, 37]]], ["It may involve an increase in levels of GLP-1 by DPP-4 inhibitor treatment.", [["DPP-4 inhibitor", "CHEMICAL", 49, 64], ["GLP-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["DPP-4", "GENE_OR_GENE_PRODUCT", 49, 54], ["GLP-1", "PROTEIN", 40, 45], ["an increase in levels of GLP", "PROBLEM", 15, 43], ["DPP", "TEST", 49, 52], ["inhibitor treatment", "TREATMENT", 55, 74], ["increase", "OBSERVATION_MODIFIER", 18, 26]]], ["DPP-4 inhibitor enhanced insulin secretion and induction of autophagy signals in the islets of high-fat-fed mice; such effects of DPP-4 inhibition on autophagy signaling were completely abolished by GLP-1R antagonist exendin 9-39 coadministration (Liu et al., 2016).DPP-4 and Extracellular Matrix Interaction: Relevance to Autophagy SuppressionOther than GLP-1 induction, the pleiotropic effects of a DPP-4 inhibitor may be relevant to the mechanisms of autophagy induction by DPP-4 inhibition.DPP-4 and Extracellular Matrix Interaction: Relevance to Autophagy SuppressionThe interaction with the extracellular matrix is an important determinant of cell fate.", [["islets", "ANATOMY", 85, 91], ["extracellular matrix", "ANATOMY", 597, 617], ["cell", "ANATOMY", 649, 653], ["exendin 9-39", "CHEMICAL", 217, 229], ["exendin 9-39", "CHEMICAL", 217, 229], ["DPP-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["insulin", "GENE_OR_GENE_PRODUCT", 25, 32], ["islets", "MULTI-TISSUE_STRUCTURE", 85, 91], ["high-fat", "TISSUE", 95, 103], ["mice", "ORGANISM", 108, 112], ["DPP-4", "GENE_OR_GENE_PRODUCT", 130, 135], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 199, 205], ["exendin 9-39", "SIMPLE_CHEMICAL", 217, 229], ["DPP-4", "GENE_OR_GENE_PRODUCT", 266, 271], ["GLP-1", "GENE_OR_GENE_PRODUCT", 355, 360], ["DPP-4", "GENE_OR_GENE_PRODUCT", 401, 406], ["DPP-4", "GENE_OR_GENE_PRODUCT", 477, 482], ["DPP-4", "GENE_OR_GENE_PRODUCT", 494, 499], ["extracellular matrix", "CELLULAR_COMPONENT", 597, 617], ["cell", "CELL", 649, 653], ["DPP-4", "PROTEIN", 130, 135], ["DPP-4", "PROTEIN", 266, 271], ["DPP-4", "PROTEIN", 477, 482], ["DPP-4", "PROTEIN", 494, 499], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["DPP", "TEST", 0, 3], ["inhibitor enhanced insulin secretion", "TREATMENT", 6, 42], ["autophagy signals", "TEST", 60, 77], ["DPP", "TEST", 130, 133], ["autophagy signaling", "PROBLEM", 150, 169], ["GLP", "TEST", 199, 202], ["1R antagonist exendin", "TREATMENT", 203, 224], ["DPP", "TEST", 266, 269], ["Autophagy SuppressionOther", "TREATMENT", 323, 349], ["a DPP-4 inhibitor", "TREATMENT", 399, 416], ["autophagy induction", "TREATMENT", 454, 473], ["DPP", "TEST", 494, 497], ["Autophagy Suppression", "TREATMENT", 551, 572], ["the extracellular matrix", "TREATMENT", 593, 617]]], ["Integrins are glycoproteins that play vital roles in cell\u2013cell or cell\u2013matrix interactions through \u03b1\u03b2 heterodimers.", [["cell\u2013cell", "ANATOMY", 53, 62], ["cell\u2013matrix", "ANATOMY", 66, 77], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["cell\u2013cell", "CELL", 53, 62], ["cell\u2013matrix", "GENE_OR_GENE_PRODUCT", 66, 77], ["\u03b1\u03b2 heterodimers", "GENE_OR_GENE_PRODUCT", 99, 114], ["Integrins", "PROTEIN", 0, 9], ["\u03b1\u03b2 heterodimers", "PROTEIN", 99, 114], ["glycoproteins", "TREATMENT", 14, 27]]], ["Eighteen \u03b1 and eight \u03b2 subunits of integrins are known, and each of them displays diverse ligand binding and signaling properties (Pozzi and Zent, 2011).", [["\u03b1", "GENE_OR_GENE_PRODUCT", 9, 10], ["integrins", "GENE_OR_GENE_PRODUCT", 35, 44], ["\u03b1", "PROTEIN", 9, 10], ["\u03b2 subunits", "PROTEIN", 21, 31], ["integrins", "PROTEIN", 35, 44], ["diverse", "OBSERVATION_MODIFIER", 82, 89], ["ligand binding", "OBSERVATION", 90, 104]]], ["Integrin subunits consist of an extracellular domain that is important for their ligand binding properties and contains a transmembrane domain and a short cytoplasmic tail, which could interact with diverse cytosolic and transmembrane proteins by consisting a focal adhesion complex (with the exception of \u03b24) (Pozzi and Zent, 2003).", [["extracellular", "ANATOMY", 32, 45], ["transmembrane", "ANATOMY", 122, 135], ["cytoplasmic tail", "ANATOMY", 155, 171], ["cytosolic", "ANATOMY", 207, 216], ["transmembrane", "ANATOMY", 221, 234], ["Integrin", "GENE_OR_GENE_PRODUCT", 0, 8], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["cytoplasmic tail", "CELLULAR_COMPONENT", 155, 171], ["cytosolic", "CELLULAR_COMPONENT", 207, 216], ["transmembrane", "CELLULAR_COMPONENT", 221, 234], ["focal adhesion complex", "GENE_OR_GENE_PRODUCT", 260, 282], ["\u03b24", "GENE_OR_GENE_PRODUCT", 306, 308], ["Integrin subunits", "PROTEIN", 0, 17], ["extracellular domain", "PROTEIN", 32, 52], ["transmembrane domain", "PROTEIN", 122, 142], ["cytoplasmic tail", "PROTEIN", 155, 171], ["cytosolic and transmembrane proteins", "PROTEIN", 207, 243], ["focal adhesion complex", "PROTEIN", 260, 282], ["\u03b24", "PROTEIN", 306, 308], ["Integrin subunits", "TREATMENT", 0, 17], ["an extracellular domain", "TREATMENT", 29, 52], ["a transmembrane domain", "PROBLEM", 120, 142], ["a short cytoplasmic tail", "PROBLEM", 147, 171], ["diverse cytosolic and transmembrane proteins", "PROBLEM", 199, 243], ["a focal adhesion complex", "PROBLEM", 258, 282], ["extracellular domain", "OBSERVATION", 32, 52], ["focal", "OBSERVATION_MODIFIER", 260, 265], ["adhesion", "OBSERVATION", 266, 274]]], ["Integrins display physical interaction with several extracellular matrix (ECM) glycoproteins (such as collagens, fibronectins, and laminins) and cellular receptors (Plow et al., 2000; Hynes, 2002).", [["extracellular matrix", "ANATOMY", 52, 72], ["ECM", "ANATOMY", 74, 77], ["cellular", "ANATOMY", 145, 153], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["extracellular matrix", "CELLULAR_COMPONENT", 52, 72], ["ECM", "CELLULAR_COMPONENT", 74, 77], ["collagens", "GENE_OR_GENE_PRODUCT", 102, 111], ["fibronectins", "GENE_OR_GENE_PRODUCT", 113, 125], ["laminins", "GENE_OR_GENE_PRODUCT", 131, 139], ["cellular", "CELL", 145, 153], ["Integrins", "PROTEIN", 0, 9], ["extracellular matrix (ECM) glycoproteins", "PROTEIN", 52, 92], ["collagens", "PROTEIN", 102, 111], ["fibronectins", "PROTEIN", 113, 125], ["laminins", "PROTEIN", 131, 139], ["cellular receptors", "PROTEIN", 145, 163], ["several extracellular matrix (ECM) glycoproteins", "TREATMENT", 44, 92], ["collagens, fibronectins", "TREATMENT", 102, 125]]], ["Integrins are essential molecules in actin cytoskeleton remodeling and in regulating cell signals that regulate biological and cellular functions (Park et al., 2015).", [["cytoskeleton", "ANATOMY", 43, 55], ["cell", "ANATOMY", 85, 89], ["cellular", "ANATOMY", 127, 135], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["actin", "GENE_OR_GENE_PRODUCT", 37, 42], ["cytoskeleton", "CELLULAR_COMPONENT", 43, 55], ["cell", "CELL", 85, 89], ["cellular", "CELL", 127, 135], ["Integrins", "PROTEIN", 0, 9], ["actin", "PROTEIN", 37, 42], ["actin cytoskeleton remodeling", "PROBLEM", 37, 66], ["essential", "OBSERVATION_MODIFIER", 14, 23], ["molecules", "OBSERVATION_MODIFIER", 24, 33], ["actin cytoskeleton remodeling", "OBSERVATION", 37, 66], ["regulating cell signals", "OBSERVATION", 74, 97]]], ["Integrins display intracellular signaling through ligand binding (\u201coutside-in\u201d signaling) (Ratnikov et al., 2005).", [["intracellular", "ANATOMY", 18, 31], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["Integrins", "PROTEIN", 0, 9], ["intracellular signaling through ligand binding", "PROBLEM", 18, 64], ["intracellular signaling", "OBSERVATION", 18, 41]]], ["Alternatively, integrins can alter their high- to low-affinity conformations, facilitating specific ligand binding (\u201cinside-out\u201d signaling) (Luo et al., 2007).", [["integrins", "GENE_OR_GENE_PRODUCT", 15, 24], ["integrins", "PROTEIN", 15, 24]]], ["The activation status of integrin relies on the cell type.", [["cell", "ANATOMY", 48, 52], ["integrin", "GENE_OR_GENE_PRODUCT", 25, 33], ["cell type", "CELL", 48, 57], ["integrin", "PROTEIN", 25, 33]]], ["In most cells that adhere to the basement membrane, integrins are activated; in contrast, integrins are inactive in circulating platelets or leukocytes until they are induced by platelet aggregation or stimulated by an inflammatory response.", [["cells", "ANATOMY", 8, 13], ["basement membrane", "ANATOMY", 33, 50], ["platelets", "ANATOMY", 128, 137], ["leukocytes", "ANATOMY", 141, 151], ["platelet", "ANATOMY", 178, 186], ["platelet aggregation", "DISEASE", 178, 198], ["cells", "CELL", 8, 13], ["basement membrane", "CELLULAR_COMPONENT", 33, 50], ["integrins", "GENE_OR_GENE_PRODUCT", 52, 61], ["integrins", "GENE_OR_GENE_PRODUCT", 90, 99], ["platelets", "CELL", 128, 137], ["leukocytes", "CELL", 141, 151], ["platelet", "CELL", 178, 186], ["integrins", "PROTEIN", 52, 61], ["integrins", "PROTEIN", 90, 99], ["circulating platelets", "CELL_TYPE", 116, 137], ["leukocytes", "CELL_TYPE", 141, 151], ["leukocytes", "PROBLEM", 141, 151], ["platelet aggregation", "PROBLEM", 178, 198], ["an inflammatory response", "PROBLEM", 216, 240], ["most cells", "OBSERVATION_MODIFIER", 3, 13], ["inactive", "OBSERVATION_MODIFIER", 104, 112], ["inflammatory response", "OBSERVATION", 219, 240]]], ["Integrins contain neither a catalytic site nor kinase activity but play a role as a bridge between the ECM and actin cytoskeleton.", [["ECM", "ANATOMY", 103, 106], ["cytoskeleton", "ANATOMY", 117, 129], ["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["ECM", "CELLULAR_COMPONENT", 103, 106], ["actin", "GENE_OR_GENE_PRODUCT", 111, 116], ["cytoskeleton", "CELLULAR_COMPONENT", 117, 129], ["Integrins", "PROTEIN", 0, 9], ["catalytic site", "PROTEIN", 28, 42], ["ECM", "PROTEIN", 103, 106], ["actin", "PROTEIN", 111, 116], ["Integrins", "TREATMENT", 0, 9], ["a catalytic site", "PROBLEM", 26, 42], ["kinase activity", "OBSERVATION", 47, 62], ["actin cytoskeleton", "OBSERVATION", 111, 129]]], ["Such interaction between the ECM and the actin cytoskeleton through integrins allows integrins to maintain cytoskeletal organization, cell motility and intracellular-signaling pathways such as cell survival, cell shape, cell proliferation, and angiogenesis (Arnaout et al., 2007; Luo et al., 2007).DPP-4 and Extracellular Matrix Interaction: Relevance to Autophagy SuppressionIndeed, DPP-4 is the molecule that interacts with the key integrin, integrin \u03b21 (Figure 3), which can form a heterodimer with at least 11 \u03b1-subunits.", [["ECM", "ANATOMY", 29, 32], ["cytoskeleton", "ANATOMY", 47, 59], ["cytoskeletal", "ANATOMY", 107, 119], ["cell", "ANATOMY", 134, 138], ["intracellular", "ANATOMY", 152, 165], ["cell", "ANATOMY", 193, 197], ["cell", "ANATOMY", 208, 212], ["cell", "ANATOMY", 220, 224], ["ECM", "CELLULAR_COMPONENT", 29, 32], ["actin", "GENE_OR_GENE_PRODUCT", 41, 46], ["cytoskeleton", "CELLULAR_COMPONENT", 47, 59], ["integrins", "GENE_OR_GENE_PRODUCT", 68, 77], ["integrins", "GENE_OR_GENE_PRODUCT", 85, 94], ["cytoskeletal", "CELLULAR_COMPONENT", 107, 119], ["cell", "CELL", 134, 138], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["cell", "CELL", 193, 197], ["cell", "CELL", 208, 212], ["cell", "CELL", 220, 224], ["DPP-4", "GENE_OR_GENE_PRODUCT", 298, 303], ["DPP-4", "GENE_OR_GENE_PRODUCT", 384, 389], ["integrin", "GENE_OR_GENE_PRODUCT", 434, 442], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 444, 455], ["Figure 3", "GENE_OR_GENE_PRODUCT", 457, 465], ["ECM", "PROTEIN", 29, 32], ["actin", "PROTEIN", 41, 46], ["integrins", "PROTEIN", 68, 77], ["integrins", "PROTEIN", 85, 94], ["DPP-4", "PROTEIN", 298, 303], ["DPP-4", "PROTEIN", 384, 389], ["integrin", "PROTEIN", 434, 442], ["integrin \u03b21", "PROTEIN", 444, 455], ["Figure 3", "PROTEIN", 457, 465], ["heterodimer", "PROTEIN", 485, 496], ["\u03b1", "PROTEIN", 514, 515], ["cell motility", "TEST", 134, 147], ["cell survival", "TREATMENT", 193, 206], ["cell proliferation", "PROBLEM", 220, 238], ["DPP", "TEST", 298, 301], ["Autophagy", "TREATMENT", 355, 364], ["DPP", "TEST", 384, 387], ["cytoskeletal organization", "OBSERVATION", 107, 132], ["cell motility", "OBSERVATION", 134, 147], ["cell shape", "OBSERVATION", 208, 218], ["cell proliferation", "OBSERVATION", 220, 238]]], ["Integrin \u03b21 has the biological function of a \u201chub integrin\u201d and acts as a receptor for specific ECM components, revealed in kidney epithelial cells (Glynne et al., 2001) or in T cell lymphoma (Elias et al., 2014).", [["ECM components", "ANATOMY", 96, 110], ["kidney epithelial cells", "ANATOMY", 124, 147], ["T cell lymphoma", "ANATOMY", 176, 191], ["T cell lymphoma", "DISEASE", 176, 191], ["Integrin \u03b21", "GENE_OR_GENE_PRODUCT", 0, 11], ["integrin", "GENE_OR_GENE_PRODUCT", 50, 58], ["ECM components", "CELLULAR_COMPONENT", 96, 110], ["kidney epithelial cells", "CELL", 124, 147], ["T cell lymphoma", "CANCER", 176, 191], ["Integrin \u03b21", "PROTEIN", 0, 11], ["integrin", "PROTEIN", 50, 58], ["ECM components", "PROTEIN", 96, 110], ["kidney epithelial cells", "CELL_TYPE", 124, 147], ["a \u201chub integrin\u201d", "TREATMENT", 43, 59], ["specific ECM components", "TEST", 87, 110], ["kidney epithelial cells", "PROBLEM", 124, 147], ["T cell lymphoma", "PROBLEM", 176, 191], ["kidney", "ANATOMY", 124, 130], ["epithelial cells", "OBSERVATION", 131, 147], ["T cell lymphoma", "OBSERVATION", 176, 191]]], ["The loss of membrane-bound DPP-4 has been associated with suppression of the phosphorylation of integrin \u03b21 S785, which plays a key role in the cellular adhesion of integrin \u03b21 to the ECM (Sato et al., 2005).", [["membrane", "ANATOMY", 12, 20], ["cellular", "ANATOMY", 144, 152], ["ECM", "ANATOMY", 184, 187], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["DPP-4", "GENE_OR_GENE_PRODUCT", 27, 32], ["integrin \u03b21 S785", "GENE_OR_GENE_PRODUCT", 96, 112], ["cellular", "CELL", 144, 152], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 165, 176], ["ECM", "CELLULAR_COMPONENT", 184, 187], ["DPP-4", "PROTEIN", 27, 32], ["integrin \u03b21", "PROTEIN", 96, 107], ["S785", "PROTEIN", 108, 112], ["integrin \u03b21", "PROTEIN", 165, 176], ["ECM", "PROTEIN", 184, 187], ["The loss of membrane-bound DPP", "PROBLEM", 0, 30], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["membrane", "OBSERVATION_MODIFIER", 12, 20], ["cellular adhesion", "OBSERVATION", 144, 161]]], ["We have shown that the DPP-4 inhibitor linagliptin suppressed the interaction between DPP-4 and integrin \u03b21, subsequently inhibiting the endothelial to mesenchymal transition program (Shi et al., 2015; Kanasaki, 2016), the fibrogenic programs associated with the inhibition of autophagy (Singh et al., 2015).", [["endothelial", "ANATOMY", 137, 148], ["mesenchymal", "ANATOMY", 152, 163], ["linagliptin", "CHEMICAL", 39, 50], ["linagliptin", "CHEMICAL", 39, 50], ["DPP-4", "GENE_OR_GENE_PRODUCT", 23, 28], ["linagliptin", "SIMPLE_CHEMICAL", 39, 50], ["DPP-4", "GENE_OR_GENE_PRODUCT", 86, 91], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 96, 107], ["endothelial", "CELL", 137, 148], ["mesenchymal", "CELL", 152, 163], ["DPP-4", "PROTEIN", 86, 91], ["integrin \u03b21", "PROTEIN", 96, 107], ["the DPP-4 inhibitor linagliptin", "TREATMENT", 19, 50], ["DPP", "TEST", 86, 89], ["the fibrogenic programs", "TREATMENT", 219, 242], ["fibrogenic", "OBSERVATION", 223, 233]]], ["Interestingly, in addition to the biological importance of integrin \u03b21 on the suppression of autophagy, the autophagy pathway targets integrin \u03b21 during nutrient starvation (Vlahakis and Debnath, 2017).", [["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 59, 70], ["integrin \u03b21", "GENE_OR_GENE_PRODUCT", 134, 145], ["integrin \u03b21", "PROTEIN", 59, 70], ["integrin \u03b21", "PROTEIN", 134, 145]]], ["Autophagy degrades focal adhesion proteins and promotes turnover of those molecules (Vlahakis and Debnath, 2017).", [["focal adhesion proteins", "GENE_OR_GENE_PRODUCT", 19, 42], ["focal adhesion proteins", "PROTEIN", 19, 42], ["focal adhesion proteins", "PROBLEM", 19, 42], ["focal", "OBSERVATION_MODIFIER", 19, 24], ["adhesion proteins", "OBSERVATION", 25, 42], ["turnover", "OBSERVATION_MODIFIER", 56, 64]]], ["Additionally, integrin-mediated cell adhesion to the ECM has been shown to protect cells from anoikis, the apoptosis induced by the lack of correct cell/ECM attachment.", [["cell", "ANATOMY", 32, 36], ["ECM", "ANATOMY", 53, 56], ["cells", "ANATOMY", 83, 88], ["cell", "ANATOMY", 148, 152], ["ECM", "ANATOMY", 153, 156], ["integrin", "GENE_OR_GENE_PRODUCT", 14, 22], ["cell", "CELL", 32, 36], ["ECM", "CELLULAR_COMPONENT", 53, 56], ["cells", "CELL", 83, 88], ["cell", "CELL", 148, 152], ["ECM", "CELLULAR_COMPONENT", 153, 156], ["integrin", "PROTEIN", 14, 22], ["ECM", "PROTEIN", 53, 56], ["integrin-mediated cell adhesion", "TREATMENT", 14, 45], ["anoikis", "PROBLEM", 94, 101], ["the apoptosis", "PROBLEM", 103, 116], ["correct cell/ECM attachment", "TREATMENT", 140, 167], ["cell adhesion", "OBSERVATION", 32, 45], ["anoikis", "OBSERVATION", 94, 101], ["correct cell", "OBSERVATION", 140, 152], ["ECM attachment", "OBSERVATION", 153, 167]]], ["Once integrin-mediated interaction with the ECM is lost, cells induce autophagy for survival (Figure 3).", [["ECM", "ANATOMY", 44, 47], ["cells", "ANATOMY", 57, 62], ["ECM", "CELLULAR_COMPONENT", 44, 47], ["cells", "CELL", 57, 62], ["ECM", "PROTEIN", 44, 47]]], ["Autophagy induction has been shown to promote the survival of epithelial cells and adjustments in the absence of cell\u2013matrix contact, resulting in the anoikis resistance (Yang et al., 2013; Chen et al., 2017; Talukdar et al., 2018) (Figure 3).", [["epithelial cells", "ANATOMY", 62, 78], ["anoikis", "DISEASE", 151, 158], ["epithelial cells", "CELL", 62, 78], ["epithelial cells", "CELL_TYPE", 62, 78], ["Autophagy induction", "TREATMENT", 0, 19], ["epithelial cells", "PROBLEM", 62, 78], ["the anoikis resistance", "PROBLEM", 147, 169], ["epithelial cells", "OBSERVATION", 62, 78], ["anoikis resistance", "OBSERVATION", 151, 169]]], ["After autophagy was inhibited by either RNA interference or harboring of oncogenes, cells lost their ability to combat anoikis (Figure 3).Glucagon ::: Perspective: Bariatric Surgery and Autophagy InductionIn the stomach, gastric emptying is regulated by gastric content and neural and hormonal influences and is altered after bariatric surgery as described earlier.", [["cells", "ANATOMY", 84, 89], ["stomach", "ANATOMY", 212, 219], ["gastric", "ANATOMY", 221, 228], ["gastric", "ANATOMY", 254, 261], ["neural", "ANATOMY", 274, 280], ["Glucagon", "CHEMICAL", 138, 146], ["cells", "CELL", 84, 89], ["Glucagon", "GENE_OR_GENE_PRODUCT", 138, 146], ["stomach", "ORGAN", 212, 219], ["gastric", "ORGAN", 221, 228], ["gastric", "MULTI-TISSUE_STRUCTURE", 254, 261], ["oncogenes", "DNA", 73, 82], ["autophagy", "PROBLEM", 6, 15], ["harboring of oncogenes", "PROBLEM", 60, 82], ["Glucagon", "TREATMENT", 138, 146], ["Bariatric Surgery", "TREATMENT", 164, 181], ["Autophagy", "TREATMENT", 186, 195], ["gastric emptying", "TREATMENT", 221, 237], ["gastric content and neural and hormonal influences", "PROBLEM", 254, 304], ["bariatric surgery", "TREATMENT", 326, 343], ["Bariatric Surgery", "OBSERVATION", 164, 181], ["stomach", "ANATOMY", 212, 219], ["gastric", "ANATOMY", 221, 228], ["emptying", "OBSERVATION", 229, 237], ["gastric", "ANATOMY", 254, 261], ["content", "OBSERVATION", 262, 269], ["neural", "ANATOMY_MODIFIER", 274, 280], ["hormonal influences", "OBSERVATION", 285, 304], ["altered", "OBSERVATION_MODIFIER", 312, 319], ["bariatric surgery", "OBSERVATION", 326, 343]]], ["Accelerated gastric emptying time for liquids but slower gastric emptying time for solids have been reported after RYGB (Horowitz et al., 1982).", [["gastric", "ANATOMY", 12, 19], ["gastric", "ANATOMY", 57, 64], ["gastric", "ORGAN", 12, 19], ["gastric", "ORGAN", 57, 64], ["Accelerated gastric emptying", "TREATMENT", 0, 28], ["liquids", "TREATMENT", 38, 45], ["gastric", "ANATOMY", 12, 19], ["emptying", "OBSERVATION", 20, 28], ["gastric", "ANATOMY", 57, 64]]], ["Kotler et al. (1985) reported faster intestinal transit time and increased enteroglucagon levels in patients with greater weight loss compared to weight-stable patients.", [["intestinal", "ANATOMY", 37, 47], ["weight loss", "DISEASE", 122, 133], ["intestinal", "ORGAN", 37, 47], ["enteroglucagon", "SIMPLE_CHEMICAL", 75, 89], ["patients", "ORGANISM", 100, 108], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 160, 168], ["faster intestinal transit time", "PROBLEM", 30, 60], ["increased enteroglucagon levels", "PROBLEM", 65, 96], ["greater weight loss", "PROBLEM", 114, 133], ["weight", "TEST", 146, 152], ["intestinal", "ANATOMY", 37, 47], ["enteroglucagon levels", "OBSERVATION", 75, 96], ["stable", "OBSERVATION_MODIFIER", 153, 159]]], ["The term \u201centeroglucagon\u201d in this report did not necessarily include \u201cglucagon\u201d because of cross reaction with several glucagon sequence-containing polypeptides at the time of this report.", [["glucagon", "CHEMICAL", 70, 78], ["enteroglucagon", "SIMPLE_CHEMICAL", 10, 24], ["glucagon", "SIMPLE_CHEMICAL", 70, 78], ["glucagon", "GENE_OR_GENE_PRODUCT", 119, 127], ["glucagon", "TREATMENT", 70, 78], ["cross reaction", "PROBLEM", 91, 105], ["several glucagon sequence", "TREATMENT", 111, 136], ["polypeptides", "TREATMENT", 148, 160]]], ["The presence of extrapancreatic glucagon secretion in humans has been the focus of intense discussion for years, and even though evidence was conflicting, some investigators reported that glucagon responses after total pancreatectomy were present in animals (Sutherland and De Duve, 1948; Matsuyama and Foa, 1974; Vranic et al., 1974; Muller et al., 1978; Doi et al., 1979; Gotoh et al., 1989) and humans (Unger et al., 1966; Barnes and Bloom, 1976; Villanueva et al., 1976; Boden et al., 1980; Karesen et al., 1980; Sudo et al., 1980; Dammann et al., 1981; Holst et al., 1983; Yasui, 1983; Polonsky et al., 1984; Bajorunas et al., 1986a,b; Ohtsuka et al., 1986; Tanjoh et al., 2003).", [["extrapancreatic", "ANATOMY", 16, 31], ["glucagon", "CHEMICAL", 32, 40], ["glucagon", "CHEMICAL", 188, 196], ["extrapancreatic", "ORGAN", 16, 31], ["glucagon", "GENE_OR_GENE_PRODUCT", 32, 40], ["humans", "ORGANISM", 54, 60], ["glucagon", "GENE_OR_GENE_PRODUCT", 188, 196], ["humans", "ORGANISM", 398, 404], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 398, 404], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 398, 404], ["extrapancreatic glucagon secretion", "PROBLEM", 16, 50], ["glucagon responses", "TREATMENT", 188, 206], ["total pancreatectomy", "TREATMENT", 213, 233], ["extrapancreatic", "ANATOMY", 16, 31], ["glucagon secretion", "OBSERVATION", 32, 50], ["pancreatectomy", "OBSERVATION", 219, 233]]], ["The most challenging point was that until recently, analytical methods for glucagon have not been sufficiently sensitive or specific to justify decisive statements about the absence or presence of extrapancreatic fully processed 29\u2013amino acid glucagon (Tanjoh et al., 2003).", [["extrapancreatic", "ANATOMY", 197, 212], ["glucagon", "CHEMICAL", 75, 83], ["29\u2013amino acid", "CHEMICAL", 229, 242], ["glucagon", "CHEMICAL", 243, 251], ["29\u2013amino acid", "CHEMICAL", 229, 242], ["glucagon", "GENE_OR_GENE_PRODUCT", 75, 83], ["extrapancreatic", "ORGAN", 197, 212], ["29\u2013amino acid glucagon", "SIMPLE_CHEMICAL", 229, 251], ["glucagon", "TREATMENT", 75, 83], ["extrapancreatic", "ANATOMY", 197, 212]]], ["Recently, sandwich enzyme-linked immunosorbent assays (ELISA) utilizing a combination of C- and N-terminal antiglucagon antibodies have been emerged.", [["C", "CHEMICAL", 89, 90], ["N", "CHEMICAL", 96, 97], ["C", "SIMPLE_CHEMICAL", 89, 90], ["C- and N-terminal antiglucagon antibodies", "PROTEIN", 89, 130], ["sandwich enzyme", "TEST", 10, 25], ["immunosorbent assays", "TEST", 33, 53], ["C- and N-terminal antiglucagon antibodies", "TREATMENT", 89, 130]]], ["Such ELISA system theoretically could eliminate cross-reactivity with truncated or elongated forms of glucagon containing polypeptides (Wewer Albrechtsen et al., 2014).", [["glucagon", "CHEMICAL", 102, 110], ["glucagon", "GENE_OR_GENE_PRODUCT", 102, 110], ["cross-reactivity", "PROBLEM", 48, 64], ["glucagon containing polypeptides", "TREATMENT", 102, 134]]], ["Lund et al. (2016) studied patients who underwent total pancreatectomy and analyzed plasma glucagon levels.", [["plasma", "ANATOMY", 84, 90], ["glucagon", "CHEMICAL", 91, 99], ["patients", "ORGANISM", 27, 35], ["plasma", "ORGANISM_SUBSTANCE", 84, 90], ["glucagon", "GENE_OR_GENE_PRODUCT", 91, 99], ["patients", "SPECIES", 27, 35], ["total pancreatectomy", "TREATMENT", 50, 70], ["plasma glucagon levels", "TEST", 84, 106], ["pancreatectomy", "OBSERVATION", 56, 70]]], ["As expected, the gastrointestinal anatomy was remarkably changed, including the removal of the pyloric sphincter and duodenum after total pancreatectomy.", [["gastrointestinal", "ANATOMY", 17, 33], ["pyloric sphincter", "ANATOMY", 95, 112], ["duodenum", "ANATOMY", 117, 125], ["gastrointestinal", "ORGAN", 17, 33], ["pyloric sphincter", "MULTI-TISSUE_STRUCTURE", 95, 112], ["duodenum", "ORGAN", 117, 125], ["the removal of the pyloric sphincter", "TREATMENT", 76, 112], ["total pancreatectomy", "TREATMENT", 132, 152], ["gastrointestinal", "ANATOMY", 17, 33], ["anatomy", "OBSERVATION", 34, 41], ["pyloric sphincter", "ANATOMY", 95, 112], ["duodenum", "ANATOMY", 117, 125], ["total", "OBSERVATION_MODIFIER", 132, 137], ["pancreatectomy", "OBSERVATION", 138, 152]]], ["Therefore, following the ingestion of a meal, nutrients are rerouted and delivered directly from the stomach to the jejunum in a manner similar to bariatric surgery as previously described.", [["stomach", "ANATOMY", 101, 108], ["jejunum", "ANATOMY", 116, 123], ["stomach", "ORGAN", 101, 108], ["jejunum", "ORGAN", 116, 123], ["nutrients", "TREATMENT", 46, 55], ["bariatric surgery", "TREATMENT", 147, 164], ["stomach", "ANATOMY", 101, 108], ["jejunum", "ANATOMY", 116, 123], ["bariatric surgery", "OBSERVATION", 147, 164]]], ["The unique point of the study by Lund et al. (2016) is that they utilized not only novel sandwich enzyme-linked immunosorbent assays of plasma glucagon but also mass spectrometry-based proteomics to confirm 29-amino acid circulatory glucagon levels in patients without a pancreas.", [["plasma", "ANATOMY", 136, 142], ["pancreas", "ANATOMY", 271, 279], ["glucagon", "CHEMICAL", 143, 151], ["29-amino acid", "CHEMICAL", 207, 220], ["glucagon", "CHEMICAL", 233, 241], ["29-amino acid", "CHEMICAL", 207, 220], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["glucagon", "SIMPLE_CHEMICAL", 143, 151], ["amino acid", "AMINO_ACID", 210, 220], ["glucagon", "GENE_OR_GENE_PRODUCT", 233, 241], ["patients", "ORGANISM", 252, 260], ["pancreas", "ORGAN", 271, 279], ["patients", "SPECIES", 252, 260], ["the study", "TEST", 20, 29], ["novel sandwich enzyme", "TEST", 83, 104], ["immunosorbent assays", "TEST", 112, 132], ["plasma glucagon", "TEST", 136, 151], ["mass spectrometry", "TEST", 161, 178], ["based proteomics", "TEST", 179, 195], ["amino acid circulatory glucagon levels", "TEST", 210, 248], ["pancreas", "ANATOMY", 271, 279]]], ["Basal glucagon levels in these patients exhibited a lower trend, and glucose challenge of the gastrointestinal tract exerted significant hyperglucagonemia in these patients.", [["gastrointestinal tract", "ANATOMY", 94, 116], ["glucagon", "CHEMICAL", 6, 14], ["glucose", "CHEMICAL", 69, 76], ["hyperglucagonemia", "DISEASE", 137, 154], ["glucose", "CHEMICAL", 69, 76], ["glucagon", "GENE_OR_GENE_PRODUCT", 6, 14], ["patients", "ORGANISM", 31, 39], ["glucose", "SIMPLE_CHEMICAL", 69, 76], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 94, 116], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 164, 172], ["Basal glucagon levels", "TEST", 0, 21], ["a lower trend", "PROBLEM", 50, 63], ["glucose challenge", "TEST", 69, 86], ["the gastrointestinal tract", "PROBLEM", 90, 116], ["significant hyperglucagonemia", "PROBLEM", 125, 154], ["lower", "OBSERVATION_MODIFIER", 52, 57], ["trend", "OBSERVATION_MODIFIER", 58, 63], ["gastrointestinal tract", "ANATOMY", 94, 116], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["hyperglucagonemia", "OBSERVATION", 137, 154]]], ["Lund et al. (2016) also confirm that the intravenous glucose infusion attenuated plasma glucagon levels, and directs focus on the gastrointestinal tract.", [["intravenous", "ANATOMY", 41, 52], ["plasma", "ANATOMY", 81, 87], ["gastrointestinal tract", "ANATOMY", 130, 152], ["glucose", "CHEMICAL", 53, 60], ["glucagon", "CHEMICAL", 88, 96], ["glucose", "CHEMICAL", 53, 60], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 52], ["glucose", "SIMPLE_CHEMICAL", 53, 60], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["glucagon", "SIMPLE_CHEMICAL", 88, 96], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 130, 152], ["the intravenous glucose infusion", "TREATMENT", 37, 69], ["plasma glucagon levels", "TEST", 81, 103], ["directs focus on the gastrointestinal tract", "PROBLEM", 109, 152], ["gastrointestinal tract", "ANATOMY", 130, 152]]], ["Unfortunately, there is no direct evidence indicated the hyperglucagonemia after bariatric surgery yet, but higher glucagon release within the first 2 h and higher trend of peak level of glucagon in post RYGB patients when compared to SG or neither operation group has been recently reported (Svane et al., 2019).", [["hyperglucagonemia", "DISEASE", 57, 74], ["glucagon", "CHEMICAL", 187, 195], ["glucagon", "GENE_OR_GENE_PRODUCT", 115, 123], ["glucagon", "GENE_OR_GENE_PRODUCT", 187, 195], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["the hyperglucagonemia", "PROBLEM", 53, 74], ["bariatric surgery", "TREATMENT", 81, 98], ["higher glucagon release", "PROBLEM", 108, 131], ["glucagon", "TREATMENT", 187, 195], ["no direct evidence indicated", "UNCERTAINTY", 24, 52], ["hyperglucagonemia", "OBSERVATION", 57, 74]]], ["These findings suggest that alteration in glucagon secretion or possibly hyperglucagonemia could be induced by bariatric surgery and be relevant in systemic physiological alterations, including autophagy (Figure 4).", [["hyperglucagonemia", "DISEASE", 73, 90], ["glucagon", "GENE_OR_GENE_PRODUCT", 42, 50], ["alteration in glucagon secretion", "PROBLEM", 28, 60], ["hyperglucagonemia", "PROBLEM", 73, 90], ["bariatric surgery", "TREATMENT", 111, 128], ["systemic physiological alterations", "PROBLEM", 148, 182], ["glucagon secretion", "OBSERVATION", 42, 60], ["possibly", "UNCERTAINTY", 64, 72], ["hyperglucagonemia", "OBSERVATION", 73, 90]]], ["Subsequently such induction of autophagy could influence on the health in individuals with obesity but also in lean and in malnourished patients after gastrectomy.", [["obesity", "DISEASE", 91, 98], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["autophagy", "PROBLEM", 31, 40], ["obesity", "PROBLEM", 91, 98], ["gastrectomy", "TREATMENT", 151, 162], ["obesity", "OBSERVATION", 91, 98], ["gastrectomy", "OBSERVATION", 151, 162]]], ["Further research would be required in this field.GLP-1 ::: Perspective: Bariatric Surgery and Autophagy InductionThe potential contribution of GLP-1 to the pathobiological alteration that occurs after bariatric surgery was seen in adverse outcomes of bariatric surgery.", [["GLP-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["GLP-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["GLP-1", "PROTEIN", 143, 148], ["Bariatric Surgery", "TREATMENT", 72, 89], ["Autophagy", "TREATMENT", 94, 103], ["GLP", "TEST", 143, 146], ["the pathobiological alteration", "PROBLEM", 152, 182], ["bariatric surgery", "TREATMENT", 201, 218], ["bariatric surgery", "TREATMENT", 251, 268], ["alteration", "OBSERVATION", 172, 182], ["bariatric surgery", "OBSERVATION", 251, 268]]], ["Late dumping syndrome, a well-known hypoglycemic event, occurs 2\u20133 h after a meal, after gastric surgery, and as a complication after surgery for obesity as well.", [["gastric", "ANATOMY", 89, 96], ["dumping syndrome", "DISEASE", 5, 21], ["hypoglycemic", "DISEASE", 36, 48], ["obesity", "DISEASE", 146, 153], ["gastric", "ORGAN", 89, 96], ["Late dumping syndrome", "PROBLEM", 0, 21], ["hypoglycemic event", "PROBLEM", 36, 54], ["gastric surgery", "TREATMENT", 89, 104], ["surgery", "TREATMENT", 134, 141], ["obesity", "PROBLEM", 146, 153], ["dumping syndrome", "OBSERVATION", 5, 21], ["gastric", "ANATOMY", 89, 96], ["surgery", "OBSERVATION", 97, 104], ["obesity", "OBSERVATION", 146, 153]]], ["The underlying cause of late dumping syndrome is not completely understood, but in general, it is hypothesized that postoperative elevation of incretin hormone, especially GLP-1 levels, leads to pancreatic \u03b2-cell hypertrophy (Figure 4).", [["pancreatic \u03b2-cell", "ANATOMY", 195, 212], ["dumping syndrome", "DISEASE", 29, 45], ["pancreatic \u03b2-cell hypertrophy", "DISEASE", 195, 224], ["incretin hormone", "GENE_OR_GENE_PRODUCT", 143, 159], ["GLP-1", "GENE_OR_GENE_PRODUCT", 172, 177], ["pancreatic \u03b2-cell", "CELL", 195, 212], ["late dumping syndrome", "PROBLEM", 24, 45], ["postoperative elevation of incretin hormone", "PROBLEM", 116, 159], ["GLP", "TEST", 172, 175], ["pancreatic \u03b2-cell hypertrophy", "PROBLEM", 195, 224], ["late", "OBSERVATION_MODIFIER", 24, 28], ["dumping syndrome", "OBSERVATION", 29, 45], ["incretin hormone", "OBSERVATION", 143, 159], ["pancreatic", "ANATOMY", 195, 205], ["\u03b2-cell hypertrophy", "OBSERVATION", 206, 224]]], ["Such \u03b2-cell hypertrophy stimulates insulin secretion and hypoglycemic symptoms.", [["\u03b2-cell", "ANATOMY", 5, 11], ["hypertrophy", "DISEASE", 12, 23], ["hypoglycemic", "DISEASE", 57, 69], ["\u03b2-cell", "CELL", 5, 11], ["insulin", "GENE_OR_GENE_PRODUCT", 35, 42], ["Such \u03b2-cell hypertrophy", "PROBLEM", 0, 23], ["insulin secretion", "PROBLEM", 35, 52], ["hypoglycemic symptoms", "PROBLEM", 57, 78], ["cell hypertrophy", "OBSERVATION", 7, 23], ["insulin secretion", "OBSERVATION", 35, 52]]], ["These theories are supported by the observation that hyperinsulinemic hypoglycemia most frequently occurred in patients who underwent resection of parts of the stomach, in which the gastrojejunostomy bypasses the pylorus.", [["stomach", "ANATOMY", 160, 167], ["pylorus", "ANATOMY", 213, 220], ["hyperinsulinemic hypoglycemia", "DISEASE", 53, 82], ["patients", "ORGANISM", 111, 119], ["stomach", "ORGAN", 160, 167], ["pylorus", "MULTI-TISSUE_STRUCTURE", 213, 220], ["patients", "SPECIES", 111, 119], ["hyperinsulinemic hypoglycemia", "PROBLEM", 53, 82], ["resection of parts of the stomach", "TREATMENT", 134, 167], ["the gastrojejunostomy bypasses the pylorus", "TREATMENT", 178, 220], ["resection", "OBSERVATION", 134, 143], ["parts", "ANATOMY_MODIFIER", 147, 152], ["stomach", "ANATOMY", 160, 167], ["gastrojejunostomy", "OBSERVATION", 182, 199], ["pylorus", "ANATOMY", 213, 220]]], ["Therefore, induced levels of GLP-1 during an oral glucose or meal test have been consistently reported after RYGB (Yi et al., 2008), BPD (Jin and Weng, 2016), and SG (Moellmann et al., 2018) (Figure 4).", [["oral", "ANATOMY", 45, 49], ["glucose", "CHEMICAL", 50, 57], ["BPD", "DISEASE", 133, 136], ["glucose", "CHEMICAL", 50, 57], ["GLP-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["oral", "ORGANISM_SUBDIVISION", 45, 49], ["glucose", "SIMPLE_CHEMICAL", 50, 57], ["GLP-1", "PROTEIN", 29, 34], ["GLP", "TEST", 29, 32], ["an oral glucose", "TEST", 42, 57], ["meal test", "TEST", 61, 70], ["RYGB", "TEST", 109, 113], ["BPD", "TEST", 133, 136], ["SG", "TEST", 163, 165]]], ["Even though none of these theories have been mechanistically proven during a hypoglycemic event, an increase in GLP-1 could be associated with hepatic autophagy.", [["hepatic", "ANATOMY", 143, 150], ["hypoglycemic", "DISEASE", 77, 89], ["GLP-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["hepatic", "ORGAN", 143, 150], ["GLP-1", "PROTEIN", 112, 117], ["a hypoglycemic event", "PROBLEM", 75, 95], ["an increase in GLP", "PROBLEM", 97, 115], ["hepatic autophagy", "PROBLEM", 143, 160], ["increase", "OBSERVATION_MODIFIER", 100, 108], ["hepatic", "ANATOMY", 143, 150], ["autophagy", "OBSERVATION", 151, 160]]], ["He et al. (2015) reported that in a study of rats with obesity and diabetes, RYGB led to significant induction of autophagy in the liver, restored autophagy levels in the liver and was associated with reducing the level of hepatic lipids.", [["liver", "ANATOMY", 131, 136], ["liver", "ANATOMY", 171, 176], ["hepatic", "ANATOMY", 223, 230], ["obesity", "DISEASE", 55, 62], ["diabetes", "DISEASE", 67, 75], ["RYGB", "CHEMICAL", 77, 81], ["rats", "ORGANISM", 45, 49], ["liver", "ORGAN", 131, 136], ["liver", "ORGAN", 171, 176], ["hepatic lipids", "TISSUE", 223, 237], ["rats", "SPECIES", 45, 49], ["a study", "TEST", 34, 41], ["obesity", "PROBLEM", 55, 62], ["diabetes", "PROBLEM", 67, 75], ["RYGB", "TREATMENT", 77, 81], ["autophagy in the liver", "PROBLEM", 114, 136], ["hepatic lipids", "TREATMENT", 223, 237], ["obesity", "OBSERVATION", 55, 62], ["diabetes", "OBSERVATION", 67, 75], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["autophagy", "OBSERVATION", 114, 123], ["liver", "ANATOMY", 131, 136], ["autophagy levels", "OBSERVATION", 147, 163], ["liver", "ANATOMY", 171, 176], ["hepatic", "ANATOMY", 223, 230], ["lipids", "OBSERVATION", 231, 237]]], ["Increased autophagy in the liver after RYGB was well correlated with plasma GLP-1 levels (He et al., 2015).", [["liver", "ANATOMY", 27, 32], ["plasma", "ANATOMY", 69, 75], ["liver", "ORGAN", 27, 32], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["GLP-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["Increased autophagy in the liver", "PROBLEM", 0, 32], ["RYGB", "TREATMENT", 39, 43], ["plasma GLP", "TEST", 69, 79], ["autophagy", "OBSERVATION", 10, 19], ["liver", "ANATOMY", 27, 32], ["RYGB", "OBSERVATION", 39, 43]]], ["Therefore, induction of GLP-1 after bariatric surgery would also lead to significant stimulation of autophagy (Figure 4).ConclusionIn this review, we focused on glucagon/GLP-1 and associated drugs in the physiology of autophagy.", [["glucagon", "CHEMICAL", 161, 169], ["GLP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["glucagon", "GENE_OR_GENE_PRODUCT", 161, 169], ["GLP-1", "GENE_OR_GENE_PRODUCT", 170, 175], ["GLP-1", "PROTEIN", 24, 29], ["GLP", "TEST", 24, 27], ["bariatric surgery", "TREATMENT", 36, 53], ["significant stimulation of autophagy", "PROBLEM", 73, 109], ["glucagon/GLP", "TREATMENT", 161, 173]]], ["We propose that changes in the gastrointestinal tract that induces food to bypass the intestine would be relevant to the induction of autophagy via secretion of GLP-1 and/or glucagon.Author ContributionsKK concept, design, and major contribution to writing the manuscript.", [["gastrointestinal tract", "ANATOMY", 31, 53], ["intestine", "ANATOMY", 86, 95], ["glucagon", "CHEMICAL", 174, 182], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 31, 53], ["intestine", "ORGAN", 86, 95], ["GLP-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["glucagon", "GENE_OR_GENE_PRODUCT", 174, 182], ["changes in the gastrointestinal tract", "PROBLEM", 16, 53], ["bypass", "TREATMENT", 75, 81], ["GLP", "TEST", 161, 164], ["glucagon", "TREATMENT", 174, 182], ["gastrointestinal tract", "ANATOMY", 31, 53], ["intestine", "ANATOMY", 86, 95]]], ["DK intellectual input in the projects.Conflict of Interest StatementKK is under a consultancy agreement with Boehringer Ingelheim.", [["DK intellectual input", "PROBLEM", 0, 21], ["intellectual input", "OBSERVATION", 3, 21]]]], "a1104051dbb2b39a6a23d64dfdd49f784ea34676": [["Severe acute respiratory syndrome (SARS) emerged in November 2002 and claimed about 800 lives worldwide (1) .", [["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33]]], ["Although no reoccurrence has yet been reported, SARS continues to be of great concern because no vaccine or clinical drug is currently available.", [["SARS", "DISEASE", 48, 52], ["reoccurrence", "PROBLEM", 12, 24], ["SARS", "PROBLEM", 48, 52], ["vaccine", "TREATMENT", 97, 104], ["clinical drug", "TREATMENT", 108, 121], ["no", "UNCERTAINTY", 9, 11], ["reoccurrence", "OBSERVATION", 12, 24]]], ["SARS was caused by a novel coronavirus, SARS coronavirus (SARS CoV).", [["SARS", "DISEASE", 0, 4], ["SARS coronavirus", "DISEASE", 40, 56], ["SARS", "DISEASE", 58, 62], ["coronavirus", "ORGANISM", 27, 38], ["SARS coronavirus", "ORGANISM", 40, 56], ["SARS CoV", "ORGANISM", 58, 66], ["coronavirus", "SPECIES", 27, 38], ["SARS coronavirus", "SPECIES", 40, 56], ["SARS coronavirus", "SPECIES", 40, 56], ["SARS CoV", "SPECIES", 58, 66], ["SARS", "PROBLEM", 0, 4], ["a novel coronavirus", "PROBLEM", 19, 38], ["SARS coronavirus", "PROBLEM", 40, 56]]], ["The virus is a (+) sense single-stranded RNA virus with a genome containing 29,727 nucleotides (2,3) which consist of four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (4) .", [["membrane", "ANATOMY", 169, 177], ["nucleotides", "CHEMICAL", 83, 94], ["membrane", "CELLULAR_COMPONENT", 169, 177], ["structural proteins", "PROTEIN", 123, 142], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 144, 181], ["The virus", "PROBLEM", 0, 9], ["a (+) sense single-stranded RNA virus", "PROBLEM", 13, 50], ["nucleotides", "TEST", 83, 94], ["spike (S), envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 144, 203], ["virus", "OBSERVATION", 4, 9]]], ["Similar to other coronaviruses, the S and N proteins are highly expressed during viral infection and are a useful target for immune detection (5, 6) .", [["viral infection", "DISEASE", 81, 96], ["S and N proteins", "PROTEIN", 36, 52], ["the S and N proteins", "TEST", 32, 52], ["viral infection", "PROBLEM", 81, 96], ["immune detection", "TEST", 125, 141], ["coronaviruses", "OBSERVATION", 17, 30], ["viral infection", "OBSERVATION", 81, 96]]], ["The SARS CoV N protein is of particular interest because it can be a potential target for vaccine development (7) as well as a diagnostic marker for SARS CoV infection (8, 9) .", [["SARS CoV infection", "DISEASE", 149, 167], ["SARS CoV", "ORGANISM", 149, 157], ["SARS CoV N protein", "PROTEIN", 4, 22], ["SARS CoV", "SPECIES", 4, 12], ["SARS CoV", "SPECIES", 149, 157], ["The SARS CoV N protein", "PROBLEM", 0, 22], ["vaccine development", "TREATMENT", 90, 109], ["a diagnostic marker", "TEST", 125, 144], ["SARS CoV infection", "PROBLEM", 149, 167]]], ["The N protein has been shown to stimulate immune responses in the host, indicating that it has strong antigenicity.", [["N protein", "PROTEIN", 4, 13], ["The N protein", "TEST", 0, 13], ["strong", "OBSERVATION_MODIFIER", 95, 101], ["antigenicity", "OBSERVATION", 102, 114]]], ["Moreover, it is expressed predominantly during the early stage of viral infection (10) and thus is an attractive target for diagnostics.", [["viral infection", "DISEASE", 66, 81], ["viral infection", "PROBLEM", 66, 81], ["predominantly", "OBSERVATION_MODIFIER", 26, 39], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["infection", "OBSERVATION", 72, 81]]], ["It has also been reported that the convalescent sera from SARS patients strongly reacted with the N protein.", [["sera", "ANATOMY", 48, 52], ["SARS", "DISEASE", 58, 62], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["patients", "ORGANISM", 63, 71], ["N protein", "PROTEIN", 98, 107], ["patients", "SPECIES", 63, 71], ["the convalescent sera", "PROBLEM", 31, 52], ["the N protein", "TREATMENT", 94, 107]]]]}